CONTENTS

GENERAL INFORMATION ........................................................................... ii

LIVE PRECONFERENCE SESSIONS ............................................................. 1

LIVE PLENARY, ORAL ABSTRACT, AND INTERACTIVE SESSIONS BY DAY .................................................................................. 7

POSTER SESSIONS BY DAY ........................................................................ 32
  POSTER SESSIONS DAY 1 ........................................................................ 32
  POSTER SESSIONS DAY 2 ........................................................................ 59
  POSTER SESSIONS DAY 3 ........................................................................ 89

POSTER SESSIONS BY CATEGORY ................................................................ 120

LIVE SYMPOSIA SESSIONS BY DAY ............................................................ 124
  SYMPOSIA SESSIONS DAY 1 ................................................................. 124
  SYMPOSIA SESSIONS DAY 2 ................................................................. 126
  SYMPOSIA SESSIONS DAY 3 ................................................................. 129

ABSTRACT PROCESS ................................................................................... 132

INDEX OF STUDIES RELATED TO WOMEN ........................................... 134

INDEX OF PRESENTING AUTHORS ......................................................... 140

SCHEDULE AT A GLANCE ........................................................................... INSIDE BACK COVER
GENERAL INFORMATION

CONTINUING MEDICAL EDUCATION
For information, visit the CROI Continuing Medical Education webpage.

FUNDING AND GRANT SUPPORT
For information, visit the CROI Funding and Grant Support webpage.

CROI FOUNDATION
The CROI Foundation is a 501(c)(3) not-for-profit professional organization that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the annual Conference on Retroviruses and Opportunistic Infections.

To view the current CROI Foundation Board Members and their roles and responsibilities, visit the CROI Foundation webpage.

IAS–USA
The International Antiviral (formerly AIDS) Society–USA (IAS–USA) serves as the Conference Organizer for the logistical planning and organization for CROI in partnership with the CROI Foundation and Program Committee. The mission of the IAS–USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

To access primary educational and informational programs sponsored by the IAS–USA, visit the IAS–USA website.
SCIENTIFIC PROGRAM COMMITTEE
To view current members, visit the CROI Scientific Program Committee webpage.

COMMUNITY LIAISON SUBCOMMITTEE
To view the current members, visit the CROI Community Liaison Subcommittee webpage.

FORMER MEMBERS
To view former members, visit the Former Members of the CROI Scientific Program Committee webpage.

EXTERNAL REVIEWERS
To view current external reviewers, visit the CROI External Reviewers webpage.

SCHOLARSHIP AWARDEES
To view CROI 2022 New Investigator, International Investigator, and Community Scholarship recipients, visit the Scholarship Recipient webpage.

AFFILIATED OR PROXIMATE ACTIVITIES
For information, visit the CROI Affiliated or Proximate Activities webpage.

EMBARGO AND PRESS RELEASE POLICIES
For information, visit the CROI Embargo and Press Release Policies webpage.
LIVE PRECONFERENCE SESSIONS

SATURDAY, FEBRUARY 12, 2022

Workshop-1  SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES
8:30 AM MT - 12:30 PM MT

Target Audience: This workshop is directed to new investigators and trainees (e.g., postdoctoral fellows, physician fellows, undergraduate students, and graduate students). Attendance is mandatory for all scholarship recipients, but the workshop is open to all CROI attendees.

Level of Knowledge: It is assumed that participants have been conducting active research in the field for fewer than 3 years.

Objectives: At the completion of the session, participants will be able to:

- Describe the current state of the art of selected areas of HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions, in terms of basic, epidemiologic, and clinical research
- List the leading research themes being presented at CROI 2022
- Navigate CROI 2022, maximize the knowledge gained, and interact with research colleagues
- Clarify their individual research interests in relation to the priorities discussed at the workshop and at CROI 2022 overall

Conveners
Nicolas Chomont, Université de Montréal, Montreal, Canada
Serena S. Spudich, Yale University, New Haven, CT, USA

1  SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES
8:30  SESSION DEDICATION AND WELCOME
John W. Mellors, University of Pittsburgh, Pittsburgh, PA, USA

8:35  ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2
Theodora Hatziioannou, Rockefeller University, New York, NY, USA

9:10  ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY
Penny Moore, University of the Witwatersrand, Johannesburg, South Africa

9:45  BREAK

9:55  ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC
Carlos del Rio, Emory University, Atlanta, GA, USA

10:30  ADVANCES IN BIOMEDICAL PREVENTION OF HIV
Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

11:05  BREAK
11:15  ADVANCES IN HIV CURE WITH CLINICAL PERSPECTIVES  
Peter W. Hunt, University of California San Francisco, San Francisco, CA, USA

11:50  LIVE QUESTIONS AND ANSWERS
**OPENING SESSION**

**8:30 AM MT - 10:45 AM MT**

**Description:** The Opening Session is directed to all CROI participants: researchers and clinicians in HIV, hepatitis viruses, SARS-CoV-2, and other viral infections and their related conditions, as well as new investigators, community educators, and research trainees (eg, postdoctoral fellows, physician fellows’ undergraduate students, and graduate students).

**8:30**  
**CHAIR’S WELCOME TO CROI 2022**  
Elaine J. Abrams  
*ICAP at Columbia University, New York, NY, USA*  
**CROI 2022 Chair**

James A. Hoxie  
*University of Pennsylvania, Philadelphia, PA, USA*  
**CROI 2022 Vice Chair**

Landon Myer  
*University of Cape Town, Cape Town, South Africa*  
**CROI 2022 Vice Chair**

The Martin Delaney Presentation is designed annually by the CROI Community Liaison Subcommittee and held annually in honor of pioneering HIV/AIDS activist Martin Delaney (1945–2009). It recognizes the important contributions of community advocacy and engagement in research.

**8:40**  
**INTRODUCTION OF THE MARTIN DELANEY PRESENTATION**  
Ntando D. Yola, *University of Cape Town, Cape Town, South Africa*

**2 WE’RE STILL HERE: HIV, AGING, AND THE INVISIBLE GENERATION**

**8:45**  
Marc Thompson, *PrEPster, London, UK*

The Bernard Fields Lecture, named in tribute to the exemplary work of the esteemed microbiologist and virologist Bernard Fields (1938–1995), is given during the Opening Session, usually by a basic scientist recognized for their important and relevant contributions to the fields of virology and viral pathogenesis.

**9:10**  
**INTRODUCTION OF THE BERNARD FIELDS LECTURE**  
James A. Hoxie, *University of Pennsylvania, Philadelphia, PA, USA*

**3 VACCINE STRATEGIES FOR HIV-1 AND COVID-19**

**9:15**  
Dan H. Barouch, *Beth Israel Deaconess Medical Center, Boston, MA, USA*
The N’Galy-Mann Lecture recognizes an HIV/AIDS researcher for their important and relevant work in the fields of epidemiology or clinical research. The lecture is named in honor of Drs Bosenge N’Galy and Jonathan Mann for their crucial, pioneering work in HIV science and care in Africa.

9:40  **INTRODUCTION OF THE N’GALY-MANN LECTURE**  
Landon Myer, University of Cape Town, Cape Town, South Africa

4  **HIV PREVENTION IN VULNERABLE POPULATIONS: GENERATING EVIDENCE TO REDUCE INEQUALITIES**  
Beatriz Grinsztejn, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

A special moderated discussion with the 19th Director of the Centers for Disease Control and Prevention will focus on the US response to the COVID-19 pandemic.

10:15  **THE COVID-19 EPIDEMIC IN THE UNITED STATES: A DISCUSSION WITH DR ROCHELLE P. WALENSKY**

Moderator  
Elaine J. Abrams, ICAP at Columbia University, New York, NY, USA

Rochelle P. Walensky, Centers for Disease Control and Prevention, Atlanta, GA, USA

---

**Workshop-2  FRONTIERS IN LABORATORY TECHNOLOGIES**

**Target Audience:** This session is directed to scientists, clinicians, funders, stakeholders, students, and members of the community at large, who are interested in understanding the impact of novel laboratory technologies.

**Level of Knowledge:** It is assumed that the participants are familiar with the main technologic and data analysis approaches used in research.

**Objectives:** At the completion of the session, participants will be able to:

- Describe the power of protein visualization for mapping protein function, defining sites of vulnerability, and developing drugs or vaccines
- List the emerging technologies used to track and predict viral evolution, their impact on virulence, infectivity, and escape from vaccine immunity
- Describe the overlap in artificial intelligence techniques involved in tracking epidemics as well as developing new therapeutics

**Conveners**  
Galit Alter, Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA  
Frank Kirchhoff, Ulm University Medical Center, Ulm, Germany

5  **POPULATION-LEVEL VIRAL SEQUENCING**

11:00  
Tulio de Oliveira, University of KwaZulu-Natal, Durban, South Africa

11:20  **LIVE QUESTIONS AND ANSWERS**
Opening Day
CROI 2022

Sunday

6 11:30 DEEP MUTATIONAL SCANNING TO INTERPRET VIRAL EVOLUTION
Jesse Bloom, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

7 11:50 LIVE QUESTIONS AND ANSWERS

8 12:00 AI-INSPIRED MONOCLONAL THERAPEUTIC ANTIBODY DESIGN
Regina Barzilay, Massachusetts Institute of Technology, Cambridge, MA, USA

9 12:20 LIVE QUESTIONS AND ANSWERS

10 12:30 SINGLE-CELL PROTEOMICS
Nikolai Slavov, Northeastern University, Boston, MA, USA

11 12:50 LIVE QUESTIONS AND ANSWERS

Workshop-3  CASE-BASED LIVER WORKSHOP  11:00 AM MT - 1:00 PM MT

Target Audience: This session is directed to physicians and researchers interested in obtaining a contemporary understanding of key issues in viral hepatitis and liver disease in people with and without HIV infection.

Level of Knowledge: It is assumed that the participants are familiar with the major viral causes of hepatitis and other key issues related to liver disease in people with and without HIV infection.

Objectives: At the completion of the session, participants will be able to:
• Identify individuals at risk for hepatitis C virus reinfection
• Describe how the hepatitis viruses are transmitted
• Describe testing strategies in high-risk vulnerable populations
• List the current treatment strategies for recently acquired hepatitis C virus infection

Conveners
David Wyles, Denver Health Medical Center, Denver, CO, USA
Marina B. Klein, McGill University Health Centre, Montreal, Canada

9 11:00 LIVER STEATOSIS IN PERSONS LIVING WITH HIV
Maud Lemoine, Imperial College London, London, UK

10 11:25 LIVE QUESTIONS AND ANSWERS

11 11:30 GETTING HEPATITIS C AGAIN
Maria Prins, Public Health Service of Amsterdam, Amsterdam, Netherlands

11 11:52 CONTROVERSIES IN HEPATITIS B
Chloe L. Thio, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

12 12:15 THE ORIGINAL DELTA VIRUS OR D LIKE THE DEVIL
Markus Cornberg, Medizinische Hochschule Hannover, Hannover, Germany

12 12:37 LIVE QUESTIONS AND ANSWERS
Target Audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies.

Level of Knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and epidemiologic studies of HIV or SARS-CoV-2.

Objectives: At the completion of the session, participants will be able to:
- List some of the reasons for disparate results between different COVID-19 studies
- Describe how analyses can be used to identify correlates of vaccine efficacy
- Discuss the underlying principles behind test-negative study designs and other study designs of vaccine effectiveness

Conveners
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA
Richard E. Chaisson, The Johns Hopkins University, Baltimore, MD, USA

13 STUDYING COVID TREATMENT OUTCOMES: WHY DISPARATE RESULTS?
11:00 Eric J. Rubin, New England Journal of Medicine, Boston, MA, USA
11:25 LIVE QUESTIONS AND ANSWERS
14 ANALYSIS APPROACHES TO CORRELATES OF VACCINE EFFICACY
11:30 Peter Gilbert, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
11:55 LIVE QUESTIONS AND ANSWERS
15 ASSESSING VACCINE EFFICACY IN THE REAL WORLD
12:00 Sheena G. Sullivan, University of Melbourne, Melbourne, Australia
12:25 LIVE QUESTIONS AND ANSWERS AND PANEL DISCUSSION
CONFERENCE DAYS

MONDAY, FEBRUARY 14, 2022

Session Hosts
Guido Silvestri, Emory University, Atlanta, GA, USA
Hermione Lyall, Imperial College Healthcare NHS Trust, London, UK

Plenary Session-1  MONDAY PLENARY SESSION
8:30 AM MT - 9:30 AM MT

8:30 WELCOME AND DAILY ROADMAP
James A. Hoxie, University of Pennsylvania, Philadelphia, PA, USA

16 HIV NONHUMAN PRIMATE MODELS FOR STUDIES OF VIRUS PATHOGENESIS, PERSISTENCE, AND CURE
Michaela Müller-Trutwin, Institut Pasteur, Paris, France

17 CHILDREN EXPOSED TO HIV, BUT UNINFECTED: EVIDENCE FOR ACTION
Andrew J. Prendergast, Queen Mary University of London, London, UK

Oral Abstract Session-1  TARGETS AND BARRIERS TO VIRAL INFECTION
9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators
John M. Coffin, Tufts University, Boston, MA, USA
Theodora Hatziioannou, The Rockefeller University, New York, NY, USA

9:45 INTRODUCTIONS
18 HIV INFECTION OF BRAIN ORGANOID MICROGLIA INDUCES INFLAMMATION AND NEURONAL DEATH
Weili Kong, Gang Zhang, Peter Sohn, Roland Schwarzer, Guorui Xie, Julie Frouard, Mauricio Montano, Nadia Roan, Li Gan, Warner Greene

19 MACROPHAGES ARE THE PRIMARY SOURCE OF VIRUS IN SEMEN IN ACUTELY INFECTED MACAQUES
Christine M. Fennessey, Catherine Brands, Simona Florea, Laura Newman, Leslie Lipkey, William Bosche, Randy Fast, Jeffrey D. Lifson, Brandon Keele, Claire Deleage

20 CyTOF-Lec REVEALS GLYCAN FEATURES DEFINING CELLS DIFFERENTIALLY SUSCEPTIBLE TO HIV
Tongcui Ma, Matthew McGregor, Leila B. Giron, Mohamed Abdel-Mohsen, Nadia Roan

21 MONOMERIC HIV-1 ENVELOPE CYTOPLASMIC TAILS ARE SUFFICIENT FOR Gag LATTICE RETENTION
Nicholas S. Groves, Yuta Hikichi, Merissa Bruns, Eric O. Freed, Schuyler van Engelenburg

CME
10:22 LIVE QUESTIONS AND ANSWERS

10:40 INTRODUCTIONS

22 RAPALOGS DOWNMODULATE INTRINSIC IMMUNITY AND PROMOTE CELL ENTRY OF SARS-CoV-2
Guoli Shi, Abhilash I. Chiramel, Saliha Majdoul, Kin Kui Lai, Swagata Kar, Sonja M. Best, Alex A. Compton

23 IFITM DEPENDENCY OF SARS-CoV-2 VARIANTS OF CONCERN
Rayhane Nchioua, Caterina Prelli Bozzo, Annika Schundfaber, Fabian Zech, Manfred Frick, Konstantin Sparrer, Frank Kirchhoff

24 INTERFERON RESISTANCE OF EMERGING SARS-CoV-2 VARIANTS
Kejun Guo, Bradley S. Barrett, Kaylee Mickens, Eszter Vladar, James Morrison, Kim J. Hasenkrug, Eric M. Poeschla, Mario L. Santiago

25 TYPE-I INTERFERON MODULATION IN VIVO BLOCKS SARS-CoV-2 REPLICATION AND INFLAMMATION
Timothy Hoang, Elise G. Viox, Amit Upadhyay, Maria Pino, Arun Boddapati, Gregory Tharp, Zachary Strongin, Thomas H. Vanderford, Monica Vaccari, Jacob Estes, Daniel C. Douek, Gideon Schreiber, Steven Bosinger, Mirko Paiardi

26 SARS-CoV-2 SPIKE BINDS FIBRINOGEN-INDUCING ABNORMAL INFLAMMATORY BLOOD CLOTS

11:25 LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-2 MATERNAL AND CHILD HEALTH: NEW INSIGHTS INTO HEPATITIS, SARS-CoV-2, AND HIV
9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators
Elaine J. Abrams, Columbia University, New York, NY, USA
Landon Myer, University of Cape Town, Cape Town, South Africa

9:45 INTRODUCTIONS

27 UNIVERSAL HEPATITIS C VIRUS SCREENING IN PREGNANCY: THE JUICE IS WORTH THE SQUEEZE
Catherine A. Chappell, Samantha M. Mayo, John A. Grosko, Leslie A. Meyn, Scott Henzler, Naudia Jonassaint, Sharon L. Hillier

28 HBIG-FREE STRATEGY TO PREVENT HBV MOTHER-TO-CHILD TRANSMISSION: ANRS TA PROHM STUDY
Olivier Segeral, Bunnet Dim, Christine Durier, Sovann Nhoeung, Kearena Chhim, Chantana Yay, Sothy Pech, Buntohun Nem, Kay Huot, Chanlinha Vong, Julia Guillebaud, Rattana Kim, Samsorphea Chhun, Laurence Borand, for the ANRS 12345 TA PROHM Study Group

29 THE IMPACT OF COVID-19 ON ADVERSE BIRTH OUTCOMES IN BOTSWANA BY HIV STATUS
Maya Jackson-Gibson, Modiegi Diseko, Ellen Caniglia, Gloria Mayondo, Judith Mabuta, Rebecca Luckett, Sikhulile Moyo, Pamela F. Smith-Lawrence, Mogomotsi S. Matshaba, Mosepele Mosepele, Mompati Mmalane, Shahin Lockman, Joseph Makhema, Rebecca Zash, Roger L. Shapiro
30 10:14 GROWTH OF INFANTS WITH PERINATAL EXPOSURE TO MATERNAL DTG VS EFV AND TDF VS TAF
Lynda Stranix-Chibanda, Lauren Ziemba, Sean Brummer, Benjamin Johnston, Tapiwa G. Mbengeranwa, Haseena Cassim, Gerhard Theron, Sherika Hanley, Maxensia Owor, Katie McCarthy, Nahida Chakhtoura, Patrick Jean-Philippe, Lameck Chimula, Shahin Lockman, for the IMPAACT 2010/VESTED Study Team and Investigators

10:22 LIVE QUESTIONS AND ANSWERS

31 10:45 TWO-YEAR VIROLOGIC OUTCOMES OF VERY EARLY ART FOR INFANTS IN THE IMPAACT P1115 STUDY
Deborah Persaud, Ellen G. Chadwick, Bryan S. Nelson, Camlin Tierney, Mark F. Cotton, Anne Coletti, Diane Costello, Nicol Nicodimus, Lynda Stranix-Chibanda, Adeodara R. Kekitiinwa, Christina Reding, Sai Majji, Patrick Jean-Philippe, Yvonne Bryson, for the IMPAACT P1115 Study Team

32 10:53 TREATMENT WITH BROADLY NEUTRALIZING ANTIBODIES IN CHILDREN WITH HIV IN BOTSWANA
Roger L. Shapiro, Kenneth Maswabi, Gbolahan Ajibola, Michael Hughes, Molly Pretorius Holme, Kathleen M. Powis, Sikkhulile Moyo, Bryan S. Nelson, Marina Caskey, Lucio Gama, Patrick Jean-Philippe, Dwight E. Yin, Edmund Capparelli, Daniel Kuritzkes, Mathias Lichterfeld

33 11:01 IMPACT OF POINT-OF-CARE HIV VIRAL LOAD TESTING IN KENyan CHILDREN: A RANDOMIZED TRIAL

11:09 LIVE QUESTIONS AND ANSWERS

----

Oral Abstract Session-3 MALIGNANCIES AND COMORBIDITIES: AN INCREASING BURDEN 9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators
Judith S. Currier, University of California Los Angeles, Los Angeles, CA, USA
Peter W. Hunt, University of California San Francisco, San Francisco, CA, USA

9:45 INTRODUCTIONS

34 9:50 GEOGRAPHICAL DIFFERENCES IN FUNCTIONAL IMPAIRMENT OF PEOPLE WITH HIV
Kristine Erlandson, Kathleen Fitch, Sara McCallum, Heather J. Ribaudo, Edgar T. Overton, Gerald S. Bloomfield, Todd Brown, Carl J. Fichtenbaum, Sara Bares, Judith A. Aberg, Pamela S. Douglas, Laura Moran, Vidya Mave, Steven Grinspoon

35 9:58 ANTICHOLINERGIC MEDICATIONS ASSOCIATED WITH FALLS AND FRAILTY IN PEOPLE WITH HIV
Jessica Doctor, Alan Winston, Jaime Vera, Frank A. Post, Marta Boffito, Patrick Mallon, Jane Anderson, Margarita Durkina, Ian Williams, Margaret Johnson, Manolis Bagkeris, Memory Zachikonye, Caroline Sabin, for the POPPY Study
36  INFLAMMATION AND KYNURENINE PATHWAY LINKED TO TYPE 2 DIABETES AND FAT FIBROSIS IN HIV
10:06  

37  GUT MICROBIOTA, PLASMA METABOLOMICS, ANDATHEROSCLEROSIS IN HIV INFECTION
10:14  

10:22  LIVE QUESTIONS AND ANSWERS

10:40  INTRODUCTIONS

38  MACROPHAGE ARTERIAL INFILTRATION RELATES TO PLAQUE TYPE AND IMMUNE ACTIVATION IN HIV
10:45  
Mabel Toribio, Moses Wilks, Sandeep Hedgire, Michael T. Lu, Madeline Cetlin, Melissa Wang, Iad Alhallak, Kevin S. White, Zoey K. Wallis, Takara Stanley, Georges El-Fakhri, Patrick Autissier, Markella V. Zanni, Kenneth Williams, Steven Grinspoon

39  TRENDS IN MYOCARDIAL INFARCTION RISK BY HIV STATUS IN TWO US HEALTHCARE SYSTEMS
10:53  
Michael J. Silverberg, Asya Lyass, Leo Hurley, Rachel Ehrbar, Taylor Mahoney, Leila Borowsky, Wei He, Jorge Plutzky, Daniel Klein, Joseph M. Massaro, Ralph B. D’Agostino Sr, Virginia A. Triant

40  NONSMALL CELL LUNG CARCINOMA IN PLWH HARBORS IMMUNOREGULATORY TUMOR MICROENVIRONMENT
11:01  
Syim Salahuddin, Ramsey Yusuf, Shruti Desai, Kishu Ranjan, Jianlei Gu, Daimei Tang, Yong Kong, Hongyu Zhao, Yuval Kluger, Kurt Schalper, Brinda Emu

41  HPV GENOTYPING IN STUDY OF ADJUNCTIVE VACCINE FOR TREATMENT OF CERVICAL DYSPLASIA
11:09  
Grant Ellsworth, Yvonne Perner, Mathilda Claaseen, Avril J. Swarts, Vuyokazi Jeziile, Iolanda Mabugu, Bridgette Goeieman, Sophie Williams, Mark Faesen, Pamela Michelow, Wolfgang Freiser, Timothy Wilkin, Cynthia S. Firnhaber

42  ANGIOGENIC FACTORS IN RNA-SEQ OF SKIN AND GASTROINTESTINAL KAPOSI SARCOMA LESIONS
11:17  
Ramya Ramaswami, Takanobu Tagawa, Anna Serquina, Guruswamy Mahesh, Xiaofan Li, Vishal Koparde, Kathryn Lurain, Ralph Mangusan, Anaida Widell, Irene Ekwede, Laurie T. Krug, Robert Yarchoan, Joseph Ziegelbauer

11:25  LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-4 EVOLVING EPIDEMIOLOGY OF HIV AND SARS-CoV-2
9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA
James A. McIntyre, Anova Health Institute, Johannesburg, South Africa
9:45  INTRODUCTIONS

43  ESTIMATING THE LIFETIME RISK OF A DIAGNOSIS OF HIV INFECTION IN THE UNITED STATES
Sonia Singh, Xiaohong Hu, Kristen Hess

44  LARGE HIV CLUSTERS AMONG MEN WHO HAVE SEX WITH MEN IN THE UNITED STATES
Stephen Perez, Nivedha Panneer, Anne Marie France, Kathryn Curran, Alexandra M. Oster

45  HIV-1 DIAGNOSES IN NORTH CAROLINA, 2018-21: INCIDENT INFECTIONS AND DRUG RESISTANCE

46  SARS-CoV-2 PREVALENCE IN CHILDREN AND ADULTS IN 15 US COMMUNITIES: THE COMPASS STUDY
Jessica E. Justman, Timothy M. Skalland, Ayana Moore, Christopher Amos, Mark Marzinke, Colleen F. Kelley, Rebecca M. Singer, Yael Hirsch-Moverman, Susanne Dobleciki-Lewis, David Metzger, Elizabeth Barranco, Ken Ho, Margaret M. Powers-Fletcher, Patricia J. Kissinger, for the CoVPN 5002 COMPASS Study Team

10:22  LIVE QUESTIONS AND ANSWERS

10:40  INTRODUCTIONS

47  SAFETY AND EFFECTIVENESS OF THE Ad26.COV2.S VACCINE IN SOUTH AFRICA

48  COVID-19 BOOSTER VACCINE EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION
Jing Sun, Qulu Zheng, Alfred J. Anzalone, Alison G. Abraham, Jomol Mathew, Nasia Safdar, Jessica Y. Islam, Amy L. Olex, Roslyn B. Mannon, Christopher G. Chute, Rena Patel, Gregory D. Kirk, for the National COVID Cohort Collaborative

49  INFECTIOUSNESS OF BREAKTHROUGH INFECTIONS AFTER VACCINATION AND NATURAL INFECTION
Laith J. Abu-Raddad, Hiam Chaimaitelley, for the National Study Group for COVID-19 Epidemiology in Qatar

50  COVID-19 VACCINATION RATES IN A GLOBAL HIV COHORT
Evelynne S. Fulda, Kathleen Fitch, Edgar T. Overton, Markella V. Zanni, Judith A. Aberg, Judith S. Currier, Michael T. Lu, Carlos Malvestutto, Carl J. Fichtenbaum, Esteban Martinez, Triin Uemleja, Pamela S. Douglas, Heather J. Ribaudo, Steven Grinspoon, for the REPRIEVE Trial

11:17  LIVE QUESTIONS AND ANSWERS
Description: This session is intended to be engaging, lively, interactive, and scientifically fun. The session will include 5 rapid-fire presentations, followed by discussions and interactions with the moderators, experts, and audience.

Target Audience: This session is directed to researchers, clinicians, and translational scientists interested in why some vaccines have been successful and why some viruses have presented challenges to the development of effective vaccines.

Level of Knowledge: It is assumed that the participants are familiar with the importance of vaccine development and use and their infectious targets.

Objectives: At the completion of the session, participants will be able to:
• Explain how effective vaccines against SARS-CoV-2 were developed so quickly
• Describe why the most effective viral vaccine (ie, for human papillomavirus infection) achieves its success, especially against mucosal infection
• Describe the mechanisms by which certain important viruses (herpes simplex virus, influenza virus, and HIV) pose different impediments to the development of effective vaccines

Moderators
Douglas D. Richman, University of California
San Diego, San Diego, CA, USA
Guido Silvestri, Emory University, Atlanta, GA, USA

12:00  SESSION OVERVIEW
12:05  UNIQUE CHALLENGES OF VACCINATING DURING A PANDEMIC
      John P. Moore, Weill Cornell Medicine, New York, NY, USA

12:10  HPV VACCINE: A SUCCESSFUL MODEL OF VACCINE-INDUCED MUCOSAL ANTIVIRAL IMMUNE RESPONSE
      Margaret A. Stanley, University of Cambridge, Cambridge, UK

12:15  FLU VACCINES: THE GLASS HALF-FULL
      Florian Krammer, Columbia University, New York, NY, USA

12:20  HERPES VIRUSES: VIRUSES THAT EVADE VACCINE-INDUCED HOST-IMMUNE RESPONSES
      Betsy Herold, Albert Einstein College of Medicine, New York, NY, USA

12:25  HIV-1: THE ULTIMATE CHALLENGE FOR VACCINE DEVELOPMENT
      Alexandra Trkola, University of Zurich, Zurich, Switzerland

12:30  LIVE PANEL DISCUSSION
Interactive Session-2  COVID-19 TREATMENT: CONSENSUS AND CONTROVERSIES
12:00 PM MT - 1:00 PM MT

Description: This session is intended to be engaging, lively, interactive, and scientifically fun. The session will include case presentations with discussion from the expert panel, followed by discussions and interactions with the moderators, experts, and audience.

Target Audience: This session is directed to clinicians interested in the care of persons with COVID-19.

Level of Knowledge: It is assumed that the participants are familiar with the clinical expression of SARS-CoV-2 and general medical principles and practices.

Objectives: At the completion of the session, participants will be able to:
- Compare the therapeutics recommended by international guidelines for the management of serious COVID-19
- Compare the treatment of COVID-19 in pregnant women with nonpregnant adults
- Compare the treatment of COVID-19 in persons with HIV or otherwise immunocompromised with those without apparent immunologic deficits
- List the treatments available for persons with mild or moderate COVID-19

Moderators
Rajesh T. Gandhi, Massachusetts General Hospital, Boston, MA, USA
Annie Luetkemeyer, University of California San Francisco, San Francisco, CA, USA

Panelists
Ghady Haidar, University of Pittsburgh, Pittsburgh, PA, USA
Laura Riley, Weill Cornell Medicine, New York, NY, USA
David Lye, National Centre for Infectious Diseases, Singapore, Singapore
Sandra Wagner-Cardoso, Instituto de Pesquisa Clinica Evandro Chagos, Rio de Janeiro, Brazil

- CASE 1: AN IMMUNOCOMPROMISED PATIENT WITH HIV AND COVID-19
- CASE 2: A PREGNANT WOMAN WITH MODERATE TO SEVERE COVID-19
- CASE 3: A FULLY VACCINATED AND BOOSTED PATIENT WHO IS OPEN TO COVID-19 PrEP
12:00 PM MT - 1:00 PM MT

Description: This session is intended to be an engaging, lively, interactive, and scientifically fun discussion on the issue of mandating vaccinations for COVID-19. The session includes 3 presentations of 10 minutes each, followed by a discussion by the expert panel and responses to questions from the audience.

Target Audience: This session is directed at researchers, clinicians, translational scientists, and policymakers interested in the issue of mandated COVID-19 vaccination.

Level of Knowledge: It is assumed that the participants are familiar with COVID-19 vaccines and most may be working in environments where vaccination is or is not mandatory.

Objectives: At the completion of the session, participants will be able to:
- Describe the history of vaccine mandates
- Explain the causes of vaccine hesitancy and concern among members of some under-represented minority groups and solutions for overcoming this challenge
- Identify barriers to vaccine mandates and solutions for this problem

Moderators
Adaora Adimora, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Carlos del Rio, Emory University, Atlanta, GA, USA

12:00 VACCINE MANDATES: HISTORY IN THE UNITED STATES AND OTHER COUNTRIES
Ruth Macklin, Albert Einstein College of Medicine, New York, NY, USA

12:10 VACCINE HESITANCY AMONG MEMBERS OF RACIAL AND ETHNIC MINORITY GROUPS
Matifadza Hlatshwayo Davis, City of St Louis Department of Health, Saint Louis, MO, USA

12:20 LEGAL AND POLITICAL ISSUES RELATED TO VACCINE MANDATES IN THE US, AND SOLUTIONS FOR OVERCOMING THEM
Lawrence O. Gostin, Georgetown University, Washington, DC, USA

12:30 LIVE PANEL DISCUSSION
## TUESDAY, FEBRUARY 15, 2022

### Plenary Session-2  TUESDAY PLENARY SESSION

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM MT - 9:30 AM MT</td>
<td><strong>WELCOME AND DAILY ROADMAP</strong>&lt;br&gt;<strong>Landon Myer, University of Cape Town, Cape Town, South Africa</strong></td>
</tr>
<tr>
<td>8:40 AM MT</td>
<td><strong>NEW INSIGHTS INTO HIV RNA BIOLOGY</strong>&lt;br&gt;<strong>Michael Summers, University of Maryland Baltimore County, Baltimore, MD, USA</strong></td>
</tr>
<tr>
<td>9:05 AM MT</td>
<td><strong>UNDERSTANDING THE EPIDEMIOLOGY OF COVID-19: A GLOBAL PERSPECTIVE</strong>&lt;br&gt;<strong>Muge Cevik, University of St Andrews, St Andrews, UK</strong></td>
</tr>
</tbody>
</table>

### Oral Abstract Session-5  HIV RESERVOIRS AND CURE STRATEGIES

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45 AM MT - 11:45 AM MT</td>
<td><strong>INTRODUCTIONS</strong>&lt;br&gt;<strong>Jesper D. Gunst, Marie H. Pahus, Miriam Rosás-Umbert, Thomas Benfield, Henrik Nielsen, Isik S. Johansen, Rajesh Mohey, Lars Østergaard, Mariane H. Schleimann, Martin Tolstrup, Julie Fox, Michel Nussenzweig, Marina Caskey, Sarah Fidler, Ole Søgaard</strong></td>
</tr>
<tr>
<td>9:50 AM MT</td>
<td><strong>THE IMPACT OF 3BNC117 AND ROMIDEPSIN TREATMENT AT ART INITIATION ON HIV-1 PERSISTENCE</strong></td>
</tr>
<tr>
<td>9:58 AM MT</td>
<td><strong>THERAPEUTIC EFFICACY OF COMBINED ACTIVE AND PASSIVE IMMUNIZATION IN SHIV+ MACAQUES</strong>&lt;br&gt;<strong>Victoria E. Walker-Sperling, Noe B. Mercado, Abishek Chandrashekar, Erica N. Borducchi, Jinyan Liu, Joseph P. Nkolola, Mark G. Lewis, Romas Gelezuniene, Merlin Robb, Nelson L. Michael, Maria G. Pau, Hanneke Schuitemaker, Janet Siliciano, Robert Siliciano, Dan Barouch</strong></td>
</tr>
<tr>
<td>10:06 AM MT</td>
<td><strong>AZD5582 PLUS SIV mAbs TO REDUCE TISSUE RESERVOIRS IN ART-SUPPRESSED MACAQUES</strong>&lt;br&gt;<strong>Amir Dashti, Sophia Sukkestad, Anna M. Horner, Margaret A. Neja, Nils Schoof, Maud Mavigner, Jeffrey D. Litson, Shane D. Falcinelli, Hannah King, Rosemarie D. Mason, Richard M. Dunham, David M. Margolis, Mario R. Roederer, Guido Silvestri, Ann Chahroudi</strong></td>
</tr>
</tbody>
</table>
65  HIV-1 REMISSION WITH CCR5∆32∆32 HAPLO-CORD TRANSPLANT IN A US WOMAN: IMPAACT P1107
10:14  JingMei Hsu, Koen Van Besien, Marshall J. Glesby, Anne Coletti, Savita G. Pahwa, Meredith Warshaw, Amanda Golner, Frederic Bone, Nicole Tobin, Marcie Riches, John W. Mellors, Renee Browning, Deborah Persaud, Yvonne Bryson, for the IMPAACT P1107 Study Team
10:22  LIVE QUESTIONS AND ANSWERS
10:40  INTRODUCTIONS
66  UNBIASED AND MULTIOMIC ASSESSMENT OF HIV-1–INFECTED CELLS AT SINGLE-CELL RESOLUTION
10:45  Vincent H. Wu, Son Nguyen, Perla Mariana Del Rio Estrada, Fernanda Torres-Ruiz, Yara A. Luna-Villalobos, Santiago Ávila-Rios, Gustavo Reyes-Teran, Katharine J. Bar, Laura A. Vella, Michael Betts
10:53  EXPANSION AND EXTENSIVE RECIRCULATION OF HIV-INFECTED CELLS IN MULTIPLE ORGANS
Caroline Dufour, Maria Julia Ruiz, Amélie Pagliuzzi, Amélie Cattin, Tomas Raul Wiche Salinas, Syim Salahuddin, Stephanie Burke Schinkel, Cecilia Theresa Costiniuk, Mohammad-Ali Jenabian, Petronela Ancuta, Jean-Pierre Routy, Eric A. Cohen, Christopher Power, Jonathan B. Angel, Nicolas Chomont
67  SELECTION OF INTACT HIV-1 PROVIRUSES IN DEEP LATENCY DURING LONG-TERM ART
11:01  Kyra W. Seiger, Xiaodong Lian, Elizabeth Parsons, Cé Gao, Gregory T. Gladkov, Joshua M. Chevalier, Michael M. Lederman, Deborah K. Mcmahon, Ronald J. Bosch, Jeffrey M. Jacobson, Rajesh T. Gandhi, Michael J. Peluso, Steven G. Deeks, Xu Yu, Mathias Lichterfeld
68  SINGLE-CELL MULTIOMICS REVEALS HIV-1 PERSISTENCE IN EXPANDED CYTOTOXIC T-CELL CLONES
11:09  Jack A. Collora, Runxia Liu, Neal Ravindra, Delia M. Pinto-Santini, Siavash Pasalar, Carmela Ganoza, Javier R. Lama, Ricardo Alfaro, Serena S. Spudich, Karam Mounzer, Pablo Tebas, Luis J. Montaner, David Van Dijk, Ann C. Duerr, Ya-Chi Ho
70  DELAYED VIRAL REBOUND FOLLOWING ANTIBODY ADMINISTRATION IN INFANT MACAQUES
11:17  Jenna S. Powers, Katherine M. Bricker, Brianna Williams, Danielle Oliver, Veronica Obregon-Perko, Dormarie E. Rivera Rodriguez, Sophia Sukkestad, Amir Dashti, Rosemarie D. Mason, Mario R. Roederer, Ann Chahroudi
11:25  LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-6  TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HEPATITIS
9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators
Constance A. Benson, University of California San Diego, San Diego, CA, USA
David L. Thomas, The Johns Hopkins School of Medicine, Baltimore, MD, USA

9:45  INTRODUCTIONS
71  NOVEL qPCR APPROACH REVEALS DYNAMICS OF HBsAg DERIVED FROM INTEGRATED HBV (iDNA)
9:50  Tanner Grudda, Hyon S. Hwang, Mark S. Sulkowski, Maraake Taddese, Richard Sterling, Ashwin Balagopal, Chloe L. Thio
72  MODELING IMPACT OF THE COVID-19 PANDEMIC ON HEPATITIS C VIRUS ELIMINATION IN THE US
  9:58  
  Ricardo E. Flores Ortega, Martin Hoenigl, Jaskaran S. Cheema, Nancy Reau, Natasha Martin

73  EFFECT OF DIRECT-ACTING ANTIVIRALS ON HCV INCIDENCE AMONG PEOPLE LIVING WITH HIV
  10:06  
  Daniela K. van Santen, Rachel Sacks-Davis, Marc Van der Valk, Mark Stoove, Andri Rauch, Inna Jarrin, Karine Lacombe, Linda Wittkop, Gail Matthews, Joseph Doyle, Marina B. Klein, Maria Prins, Tim Spelman, Margaret Hellard, for the InCHEHC Collaboration

74  VORICONAZOLE OR AMPHOTERICIN B DEOXYCHOLATE: WHICH IS THE PREFERRED INDUCTION THERAPY
  10:14  
  Yihong Zhou, Yuanyuan Qin, Yanqiu Lu, Jing Yuan, Jinming Nie, Min Liu, Qun Tian, Ke Lan, Guoqiang Zhou, Yingmei Qin, Kaiyin He, Jianhua Yu, Jun Liu, Vijay Harypursat, Yaokai Chen
  10:22  LIVE QUESTIONS AND ANSWERS

75  CLUSTER RCT OF A MID-LEVEL MANAGER INTERVENTION TO PROMOTE IPT UPTAKE IN UGANDA
  10:45  
  Elijah Kakande, Canice Christian, Laura B. Balzer, Joshua R. Nugent, William Dilesio, Derek Rast, Jane Kabami, Jason Johnson Peretz, Carol S. Camlin, Starley R. Shade, Elvin H. Geng, Dalsone Kwarishiima, Moses R. Kamya, Diane V. Havlir, Gabriel Chamie

76  RANDOMIZED CONTROLLED TRIAL OF ADJUNCTIVE ROSUVASTATIN FOR TUBERCULOSIS TREATMENT
  10:53  
  Gail B. Cross, Intan Permata Sari, Cissy Kityo, Yogesh Pokharkar, Han-Nguyen Thi, Quyet Do, Emmanuel Gutierrez, Victoria Dalay, Vincent M. Jr, Henry Mugerwa, Ka-Lip Chew, Nicholas Paton, for the ROSETTA Trial Team

77  PK OF DOSE-ADJUSTED EMERGENCY CONTRACEPTION WITH RIFAMPICIN THERAPY IN ACTG A5375
  11:01  
  Rosie Mngqibisa, Laura M. Smeaton, Maxine Olefsky, Anthony T. Podany, Elizabeth Barr, Pablo Belaunzaranz, Sharlaa Badal-Faesen, Evans Kachale, Cecelia Kanyama, Marije Van Schalkwyk, Elizabeth Woolley, Susan E. Cohn, Catherine Godfrey, Kimberly K. Scarsi, for the AIDS Clinical Trials Group A5375 Study Team

78  DTG PK IN PEOPLE WITH HIV RECEIVING DAILY 1HP FOR LATENT TB TREATMENT (ACTG A5372)
  11:09  
  Marjorie Z. Imperial, Annie Luetkemeyer, Rodney Dawson, Yoninah Cramer, Sue Rosenkranz, Susan Swindells, Irina Gelmanova, Anchalee Avihingsanon, Roberto C. Arduino, Wadzanal Samaneka, Kelly Dooley, Rada Savic, Anthony T. Podany, for the ACTG A5372 Protocol Team

79  TB-PRACTECAL RESULTS: 24 WEEK ALL-ORAL REGIMENS FOR RIFAMPICIN RESISTANT TUBERCULOSIS
  11:17  
  Bern-Thomas Nyang’wa, Emil Kazounis, Ilaria Motta, Matthew Dodd, Katherine Fielding, Catherine Berry, for the TB-PRACTECAL Team
  11:25  LIVE QUESTIONS AND ANSWERS
Oral Abstract Session-7  HIV PREVENTION: FROM THE BENCH TO POPULATION  
9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators
Sharon L. Hillier, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Jean-Michel Molina, University of Paris, Paris, France

9:45  INTRODUCTIONS

80  LONG-ACTING INJECTABLE FOR PREVENTION OF HIV AND UNPLANNED PREGNANCY
Isabella Young, Aryani Pallerla, Panita Maturavongsadit, Alka Prasher, Roopali Shrivastava, Stephanie Montgomery, Amanda Schauer, Mackenzie L. Cottrell, Angela Kashuba, Soumya R. Benhabour

81  PHASE I STUDY OF COMBINATION ANTI-HIV NEUTRALIZING ANTIBODIES IN HIV-NEGATIVE ADULTS
Magdalena E. Sobieszczynyk, Sharon Mannheimer, Yunda Huang, Carmen Paez, Theresa Gamble, Deborah A. Theodore, Wairimu Chege, Margaret Yacovone, Chenchen Yu, Lily Zhang, Jack Hptinstall, Kelly E. Seaton, Georgia Tomaras, David Montefiori, for the HVTN 130/HPTN 089 Study Team

82  PHASE I PK, SAFETY, AND ACCEPTABILITY STUDY OF A 90-DAY TENOFOVIR VAGINAL RING
Albert Liu, Holly Gundacker, Barbra A. Richardson, Beatrice Chen, Craig Hoesley, Ariane Van der Straten, May Beamer, Jennifer Robinson, Cindy Jacobson, Rachel Scheckter, Katherine Bunge, Andrea Thurman, Gustavo Doncel, Jeanna Piper, Mark Marzinke

83  ISLATRAVIR DISTRIBUTION IN MUCOSAL TISSUES, PBMC, & PLASMA AFTER MONTHLY ORAL DOSING
Craig W. Hendrix, Sharon L. Hillier, Linda-Gail Bekker, Sharlaa Badal-Faesen, Sharon A. Riddler, Edward J. Fuchs, Pippa J. Macdonald, Stacey Edick, Rebeca M. Plank, Cynthia M. Chavez-Eng, Barbara Evans, Xiaowei Zang, Ryan Vargo, Michael N. Robertson, Munjal Patel

10:22  LIVE QUESTIONS AND ANSWERS

84  THE BIDIRECTIONAL EFFECTS OF HORMONE THERAPY AND PrEP IN TRANSGENDER INDIVIDUALS

85  PHASE IIA TRIAL OF ISLATRAVIR QM FOR HIV PrEP: WEEK 24 METABOLIC AND RENAL OUTCOMES
Pippa J. Macdonald, Sharon A. Riddler, Sharlaa Badal-Faesen, Howard Schwartz, Johannes Lombaard, Yoseph Caraco, Avivit Peer, Ciaran McMullan, Keith D. Kaufman, Brenda Homony, Katherine Nedrow, Valerie Teal, Michael N. Robertson, Rebeca M. Plank

86  COUNTERFACTUAL ESTIMATION OF CAB-LA EFFICACY AGAINST PLACEBO USING EXTERNAL TRIALS
Deborah Donnell, Fei Gao, James Hughes, Brett Hanscom, Lawrence Corey, Myron S. Cohen, Snlathda Edupuganti, Nyaradzo M. Mgodi, Helen V. Rees, Jared Baeten, Glenda E. Gray, Linda-Gail Bekker, Mina C. Hosseinipour, Sinead Delany-Moretlwe
87  DIFFERENT HIV PROTECTION FOR TRADITIONAL AND MEDICAL CIRCUMCISION IN HPTN 071 (PopART)
11:09
Kidist B. Zewdie, Michael Pickles, Sian Floyd, Sarah Fidler, Helen Ayles, Peter Bock, Graeme Hoddinot, Nomthla Mandla, Ephraim Sakala, Kwame Shanagle, Musonda Simwanga, Estelle M. Piwowar-Manning, Richard Hayes, Deborah Donnell

88  CHOICE AND ADHERENCE TO DAPIVIRINE RING OR ORAL PrEP BY YOUNG AFRICAN WOMEN IN REACH
11:17

11:25  LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-8  GLOBAL PERSPECTIVES ON HIV TESTING, TREATMENT, AND PREVENTION
9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators
Jonathan Mermin, Centers for Disease Control and Prevention, Atlanta, GA, USA
Landon Myer, University of Cape Town, Cape Town, South Africa

9:45  INTRODUCTIONS
89  TRENDS IN HIV TESTING AND LINKAGE TO HIV TREATMENT IN 41 COUNTRIES: 2016-2021
9:50
Bakary Drammeh, Anindya K. De, Amy Medley, Randy Yee, Shazad Ahmed, Helen Dale, Arielle Lasry, Vincent J. Wong, Michael Grillo, Emanny Sanchez, David A. Miller, Tiffiny Aholou, Shahul Ebrahim, Stephanie Behel

9:58  DETECTING RECENT HIV INFECTIONS IN OUTPATIENT DEPARTMENTS: A MULTI-COUNTRY ANALYSIS
9:58
Suzue Saito, Lenhle D. Nsibandze, Samkelo Simelane, Dumile Sibandze, Vusie Lokotfwako, Munyaradzi Pasipamire, Peter Fonjungo, Aime Mboyo, Tania L. Chissambou, Mugyenyi Asimwe, Appolinaire Tiam, Thlomola Mphothleng, Keisha Jackson, Michael Martin, Stephanie Behel

10:06  HIV AND VIREMIA PREVALENCE IN NONMIGRATING MEMBERS OF MIGRANT HOUSEHOLDS IN UGANDA
10:06
Ruth Young, Joseph Ssekasanyu, Fred Nalugoda, Joseph Kagaayi, Robert Ssekubugu, Godfrey Kigozi, Steven J. Reynolds, Lisa J. Nelson, Maria Wawer, Bareng A. Nonjane, Larry W. Chang, Caitlin E. Kennedy, Ligia Paina, David Serwadda, M. Kate Grabowski

10:14  THE IMPACT OF FREE ANTIRETROVIRAL THERAPY FOR NONCITIZEN PREGNANT WOMEN IN BOTSWANA
10:14
Christina Fennell, Daniel J. Escudero, Rebecca Zash, Modiegi Diseko, Gloria Mayondi, Judith Mabuta, Tumalano Sekoto, Tendani Gaolathe, Mompati Mmalane, Shahin Lockman, Joseph Makhema, Roger L. Shapiro

10:22  LIVE QUESTIONS AND ANSWERS
10:40  INTRODUCTIONS
93 10:45 DO INCENTIVE VOUCHERS IMPROVE HIV TREATMENT OUTCOMES AMONG KEY POPULATIONS IN INDIA?
Sunil S. Solomon, Allison M. McFall, Aylur K. Sririkrishnan, Vasudevan C. Kesavan, Rifa Khan, Anand Santhanam, Saravanan Shanmugam, Paneerselvam Nandagopal, David C. Celentano, Shruti H. Mehta, Gregory M. Lucas

94 10:53 THE COOPERATIVE RE-ENGAGEMENT CONTROLLED TRIAL: DURABLE VIRAL SUPPRESSION ASSESSMENT
Jesse O’Shea, Robyn Fanfair, George Khalil, Tiffany Williams, Kathleen Brady, Alfred DeMaria, Heidi Jenkins, Liisa Randall, Nasima Camp, Crystal Lucas, Marianne Buchelli, Taraz Samandari, Paul Weidle

96 11:01 UPDATED EFFICACY, SAFETY, AND CASE STUDIES IN HPTN 083: CAB-LA VS TDF/FTC FOR PrEP
Raphael J. Landovitz, Deborah Donnell, Ha Tran, Esper G. Kallas, Manya Magnus, Mark Marzinke, Susan Eshleman, Brett Hanscom, Adeola Adeyeye, James F. Rooney, Alex R. Rinehart, Myron S. Cohen, Marybeth McCauley, Beatriz Grinsztejn, for the HPTN 083 Study Team

95 11:09 CAB-LA PrEP: EARLY DETECTION OF HIV INFECTION MAY REDUCE InSTI RESISTANCE RISK
Susan Eshleman, Jessica M. Fogel, Elias K. Halvas, John W. Mellors, Estelle M. Piwowar-Manning, Alex R. Rinehart, Marybeth McCauley, Adeola Adeyeye, Juan C. Hinojosa, Robinson Cabello, Keren Middelkoop, Myron S. Cohen, Beatriz Grinsztejn, Raphael J. Landovitz, for the HPTN 083 Study Team

97 11:17 INTRODUCTIONS

98 9:45 SYMPTOM DURATION IN COVID-19 CONVALESCENT PATIENTS: REGIONAL & CLINICAL ASSOCIATIONS
Jorge A. Gallardo-Cartagena, Juan J. Montenegro-Idrogo, Sue Li, Jiani Hu, Abhishek B. Amin, Portia Hunidzairua, Paul Goepfert, Megan Jones, Vicky Kim, Robert De La Grecca, Azwi Takalani, Simbarashe Takuva, Lawrence Corey, Shelly Karuna, for the HVTN 405/HPTN 1901 Study Team

99 9:50 POST-ACUTE SEQUELAE OF SARS-CoV-2: CLINICAL CONDITION COMPARISON IN A MATCHED COHORT

100 10:06 INFLAMMATION, EXERCISE CAPACITY, CHRONOTROPY, AND SYMPTOMS IN POST-ACUTE COVID-19
Matthew S. Durstenfeld, Michael J. Peluso, Punta Kaveti, Christopher Hill, Danny Li, Erica Sander, Shreya Swaminathan, Victor M. Arechiga, Victor Zepeda, Yoojin Lee, Mandar Aras, Donald J. Grandis, Carlin S. Long, Steven G. Deeks, Priscilla Hsue
100 10:14 SALIVA, NASAL & TEAR PK OF EIDD-1931 IN PATIENTS WITH COVID-19 RECEIVING MOLNUPIRAVIR
Richard FitzGerald, Laura Dickinson, Laura Else, Thomas Fletcher, Colin Hale, Aliieu Amara, Lauren Walker, Sujan D. Penchala, Rebecca Lyon, Victoria Shaw, Helen Reynolds, Wendy P. Painter, Sean Ewings, Gareth Griffiths, Saye Khoo

10:22 10:40 LIVE QUESTIONS AND ANSWERS INTRODUCTIONS

101 10:45 PHASE III TRIAL OF MOLNUPIRAVIR IN ADULTS WITH MILD SARS-CoV-2 INFECTION IN INDIA
Nagalingeswaran Kumarasamy, Bibhuti Saha, Atul Jindal, Veer Bahadur Singh, Naveen Chander Reddy Podduturi, Shubhadeep Sinha, Sreenivasa Chary Srimadamasu

102 10:53 INTRAMUSCULAR SOTROVIMAB IS NONINFERIOR TO INTRAVENOUS SOTROVIMAB FOR COVID-19

103 11:01 EFFECT OF SEROSTATUS ON THE EFFICACY OF SOTROVIMAB IN PREVENTING COVID-19 PROGRESSION
Anil Gupta, Elias Sarkis, Andrea L. Cathcart, Elizabeth Alexander, Wendy W. Yeh, Megan Smithey, Nicola Scott, Andrew Skingsley, Helen Watson, Melissa Aldinger, Adrienne E. Shapiro

104 11:09 CASIRIVIMAB AND IMDEVIMAB COMBINATION PROVIDES LONG-TERM PROTECTION AGAINST COVID-19

105 11:17 CAMOSTAT IS NOT EFFECTIVE FOR MILD-MODERATE COVID-19 IN A PHASE II TRIAL OF ACTIV-2
Nikolaus Jilg, Kara W. Chew, Mark Giganti, Eric S. Daar, David A. Wohl, Arzhang Cyrus Javan, Amy Kantor, Atasi Jana, Philip A. Hart, Joseph J. Eron, Judith S. Currier, Michael Hughes, Davey M. Smith, Jonathan Li, for the ACTIV-2/A5401 Study Team

11:25 LIVE QUESTIONS AND ANSWERS

Interactive Session-4 LONG COVID: FROM BENCH TO BEDSIDE AND BEYOND
Description: This session is intended to be engaging, lively, interactive, and scientifically fun. The session will include a 10-minute overview, 3 rapid-fire presentations of 5 minutes each, and interactions with the moderators, experts, and audience.
Target Audience: This session is directed to clinical and basic scientists interested in understanding the mechanisms of postacute sequelae of SARS-CoV-2 infection, or long COVID.
Level of Knowledge: It is assumed that the participants are familiar with the fundamental aspects of viral infection and the immune response to it.
Objectives: At the completion of the session, participants will be able to:
- Describe the symptoms and clinical consequences of long COVID
- Describe the challenges associated with research to understand the virologic and immunologic basis of this condition
- Identify potential strategies being considered for treatment

Moderators
Galit Alter, Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Karine Lacombe, Sorbonne Université, Paris, France

12:00 PUTTING LONG COVID IN CONTEXT
Steven G. Deeks, University of California San Francisco, San Francisco, CA, USA

12:10 THEMES IN NEUROLOGY
Avindra Nath, National Institutes of Health, Bethesda, MD, USA

12:15 THEMES IN VIROLOGY
Susan R. Weiss, University of Pennsylvania, Philadelphia, PA, USA

12:20 THEMES IN IMMUNOLOGY
Akiko Iwasaki, Yale University, New Haven, CT, USA

12:25 LIVE PANEL DISCUSSION
Interactive Session-5 WHAT WILL IT TAKE TO INCREASE PEP AND PrEP USE FOR ADOLESCENT GIRLS AND YOUNG WOMEN AT RISK?
12:00 PM MT - 1:00 PM MT

Description: This session will discuss the status of scale-up of risk-informed use of preexposure prophylaxis (PrEP) in adolescent girls and young women, focusing on the challenges faced as well as learning lessons from successful experiences. Expanded opportunities for postexposure prophylaxis (PEP) use will also be discussed. This session is intended to be engaging, lively, interactive, and scientifically fun. Moderators will introduce the session, followed by rapid-fire presentations and discussion, and end with responses to questions from the audience.

Target Audience: This session is directed to policymakers and implementers, clinicians, epidemiologists, and researchers with an interest in HIV prevention.

Level of Knowledge: It is assumed that the participants are familiar with the HIV field and, in particular, with PrEP and PEP to prevent HIV acquisition.

Objectives: At the completion of the session, participants will be able to:
- Describe the challenges with achieving appropriate, risk-informed PrEP use in adolescent girls and young women
- List some potential solutions and how they might be implemented
- Describe the potential role of greater use of PEP
Moderators
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA
Moses R. Kamya, Makerere University College of Health Sciences, Kampala, Uganda

12:00 SESSION OVERVIEW

12:05 GLOBAL PrEP UPTAKE IN ADOLESCENT GIRLS AND YOUNG WOMEN
Rachel Baggaley, World Health Organization, Geneva, Switzerland

12:10 EXPERIENCE WITH OFFERING PEP ALONGSIDE PrEP
James Ayieko, Kenya Medical Research Institute, Nairobi, Kenya

12:15 PrEP IMPLEMENTATION IN ADOLESCENT GIRLS AND YOUNG WOMEN
Nicolette Naidoo, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa

12:20 PrEP IMPLEMENTATION IN YOUNG SEX WORKERS IN ZIMBABWE
Primrose Matambanadzo, Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe

12:25 LIVE PANEL DISCUSSION

Special Session ANAL CANCER PREVENTION AND MANAGEMENT 1:15 PM MT - 2:00 PM MT

Moderator
Ronald Mitsuyasu, University of California Los Angeles, Los Angeles, CA, USA

1:15 WELCOME AND SESSION OVERVIEW

106 TREATMENT OF ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS TO PREVENT ANAL CANCER
Joel Palefsky, Jeannette Lee, Teresa Darragh, Stephen Goldstone, Naomi Jay, Hillary Dunlevy, Timothy Wilkin, Isabella Rosa-Cunha, Abigail Arons, Julia Pugliese, Gary Bucher, Lisa Flowers, Rebecca Levine, Michael Berry-Lawhorn, for the ANCHOR Investigators Group

1:37 LIVE QUESTIONS AND ANSWERS AND PANEL DISCUSSION

Panelists
Elizabeth Chiao, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
David Henry, University of Pennsylvania, Philadelphia, PA, USA
Richard Little, National Cancer Institute, Bethesda, MD, USA
WEDNESDAY, FEBRUARY 16, 2022

Plenary Session-3 WEDNESDAY PLENARY SESSION
8:30 AM MT - 9:30 AM MT

Session Hosts
Joseph J. Eron, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA

8:30 WELCOME AND DAILY ROADMAP
Elaine J. Abrams, ICAP at Columbia University, New York, NY, USA

116 NEW ANTIRETROVIRALS AND THE FUTURE OF HIV TREATMENT AND PREVENTION
8:40 Chloe L. Orkin, Queen Mary University of London, London, UK

117 PAST AND FUTURE OF HIV VACCINES
9:05 Mark Feinberg, International AIDS Vaccine Initiative, Amsterdam, Netherlands

Oral Abstract Session-10 IMMUNE RESPONSES TO HIV AND SARS-CoV-2 IN TREATMENT, PREVENTION, AND PATHOGENESIS
9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators
Galit Alter, Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Richard A. Koup, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

9:45 INTRODUCTIONS

118 INFLAMMASOMES AND IL-1β: AN INNATE IMMUNE AXIS IN CD4+ T CELLS DRIVING HIV INFECTION
9:50 Jeffrey A. Tomalka, Khader Ghneim, Margaret Costanzo, Susan Pereira Ribeiro, Nelson L. Michael, Merlin Robb, Michael Eller, Rafick-Pierre Sékaly

119 RAPID LOSS OF CD4+ T CELLS BY PYROPTOSIS IN ACUTELY SIV-INFECTED RHESUS MACAQUES
9:58 Xuan He, Malika M. Boudries, John D. Ventura, Erica N. Borducchi, Abishek Chandrashekar, Michelle Lifton, Jinyan Liu, Dan Barouch

120 EXPERIMENTAL MICROBIAL DYSBIOSIS ENHANCES RECTAL SIV ACQUISITION IN RHESUS MACAQUES
10:06 Alexandra Ortiz, Phillip Baker, Charlotte Langner, Jennifer Simpson, Jacob Flynn, Carly E. Starke, Carol Vinton, Brandon Keele, Jason Brenchley

121 PHASE IIB EFFICACY TRIAL OF MOSAIC HIV-1 VACCINE REGIMEN IN AFRICAN WOMEN: IMBOKODO
10:14 Glenda E. Gray, Kathy Mngadi, Ludo Lavreys, Alex Luedtke, Steven Nijs, Daniel Stieh, Michal Juraska, Ollivier Hyrien, Edith Swann, Georgia Tomaras, Julie McElrath, Maria G. Pau, Susan P. Buchbinder, Frank Tomaka, for the Imbokodo Study Group

10:22 LIVE QUESTIONS AND ANSWERS
10:40 INTRODUCTIONS
122 ADMINISTRATION OF 3BNC117 AT ART INITIATION INDUCES LONG-TERM HIV CD8 T-CELL IMMUNITY

10:45 Miriam Rosás-Umbert, Jesper D. Gunst, Rikke Olesen, Marina Caskey, Michel Nussenzweig, Martin Tolstrup, Ole Søgaard

123 CD8+ LYMPHOCYTES MODULATE STEMNESS AND SURVIVAL PATHWAYS IN HIV-INFECTED CD4+ T CELLS

10:53 Lavinia Franchitti, Ashish A. Sharma, Jack Yoon, Erick R. White, Hong Wang, Maura Statz, Abigail Willemsen, Rafick-Pierre Sékaly, Mirko Paiardini, Guido Silvestri, Deanna Kulp

124 HIGH NEUTRALIZING CONVALESCENT PLASMA RESULTS IN RAPID CLEARANCE OF SARS-CoV-2


125 SARS-CoV-2 ANTIBODY RESPONSES IN INDIVIDUALS FOLLOWING mRNA BOOSTER VACCINATION


11:17 LIVE QUESTIONS AND ANSWERS


9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators

Dennis L. Kolson, University of Pennsylvania, Philadelphia, PA, USA

Serena S. Spudich, Yale University, New Haven, CT, USA

9:45 INTRODUCTIONS

126 HIV-1 RNA TRANSCRIPTS IN CSF CD4+ T CELLS, NOT MONOCYTES, ARE LINKED TO BRAIN INJURY

9:50 Kazuo Suzuki, John Zaunders, Thomas Gates, Angelique Levert, Shannen Butterfly, Zhixin Liu, Takaomi Ishida, Chin-Shiou Huang, Caroline Rae, Lauriane Jugé, Lucette A. Cysique, Bruce Brew

127 PBR28 PET IMAGING IN PEOPLE WHO STARTED ART DURING ACUTE VERSUS CHRONIC HIV INFECTION

9:58 Jasmini Alagaratnam, Jaime Vera, Zhen Fan, John Thornhill, Jonathan Underwood, David Owen, Paul Edison, Sarah Fidler, Alan Winston

128 LONGITUDINAL MODELING OF EARLY HIV BURDEN IN THE CENTRAL NERVOUS SYSTEM


129 CD4+ DEPLETION RESULTS IN ROBUST CNS REBOUND AND LARGER MACROPHAGE RESERVOIRS

10:14 Rebecca T. Veenhuis, Celina Abreu, Edna Ferreira, Janaysha Ratliff, Suzanne Queen, Erin Shirk, Joseph Mankowski, Lucio Gama, Janice Clements

10:22 LIVE QUESTIONS AND ANSWERS

10:40 INTRODUCTIONS
130 10:45 NEUROSYMPTOMATIC HIV-1 CSF ESCAPE ASSOCIATES WITH REPLICATION IN CNS CD4+ T CELLS
Laura Kincer, Ameet N. Dravid, Paola Cinque, Mattia Trunfio, Andrea Calcagno, Serena S. Spudich, Magnus Gisslen, Richard Price, Sarah B. Joseph

131 10:53 SARS-CoV-2 CSF N-ANTIGEN DETECTION IS ASSOCIATED WITH CNS INFLAMMATION IN NEUROCVID
Arvid Eden, Anna Grahn, Daniel Bremler, Pradeepthi Bathala, Dietmar Fuchs, Johanna Gostner, Salvia Mishagian, Navaratnam Manjula, Staffan Nilsson, Michael Schöll, George Sigal, Erika Stentoft, Martin Stengelin, Henrik Zetterberg, Magnus Gisslen

132 11:01 IS THERE A ROLE OF NOVEL ART REGIMENS IN THE DECLINING PREVALENCE OF HAND?
Ilaria Mastrorosa, Anna Clelia Brita, Annalisa Mondi, Giulia Del Duca, Patrizia Lorenzini, Alessandra Vergori, Valentina Mazzotta, Roberta Gagliardini, Marta Camici, Rita Bellagamba, Federico De Zottis, Marisa Fusto, Stefania Cicalini, Andrea Antinori, Carmela Pinnetti

133 11:09 ACTG A5324: A RANDOMIZED TRIAL OF ART INTENSIFICATION FOR COGNITIVE IMPAIRMENT IN PWH
Scott L. Letendre, Jhoanna Roa, Huichao Chen, Ashley McKhann, Christina M. Marra, Eric S. Daar, Peter W. Hunt, Thomas Campbell, Shobha Swaminathan, Belinda Ha, Beverly Alston-Smith, Robert Paul, Serena S. Spudich, for the A5324 Study Team

11:17 LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-12  HIV ANTIVIRALS AND OUTCOMES 9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators
Joseph J. Eron, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Angela Kashuba, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

9:45 INTRODUCTIONS

134 9:50 IMPROVING INTESTINAL BARRIER USING GLP-2 AGONIST REDUCES ARTERIAL INFLAMMATION IN PWH
Caroline E. Diggins, Shibani Mukerji, Douglas S. Kwon, Charles F. Saylor, Lediya Cheru, Jae Sim, Meaghan Flagg, Bjorn Corleis, Emily Rudmann, Shady Abohashem, Ahmed Tawakol, Janet Lo

135 9:58 DOLUTEGRAVIR WITH RECYCLED nRTIs IS NONINFERIOR TO PI-BASED ART: VISEND TRIAL
Lloyd B. Mulenga, Sombo Fwoloshi, Aggrey Mweemba, Mpanji Siwingwa, Suluiani Sivile, Davies Kampamba, Danielle C. Engamba, Nyuma Mbewe, Henry Phiri, Aaron Shibemba, Bryony Simons, C. William Wester, Lameck Chirwa, Andrew Hill, for the VISEND Study Team

136 10:06 A RANDOMIZED TRIAL OF SWITCHING TREATMENT-EXPERIENCED ADULTS FROM PI/r TO DTG
Loice A. Ombajo, Jeremy Penner, Joseph Nkuranga, Jared Mecha, Margaret Mburu, Collins Odhiambbo, Florentius Ndinya, Rukia Aksam, Richard Njenga, Simon Wahome, Peter Muiruri, Catherine Ngugi, Anton Pozniak
137  NUCLEOSIDES AND DARUNAVIR/DOLUTEGRAVIR IN AFRICA (NADIA) TRIAL: OUTCOMES AT 96 WEEKS
10:14  Nicholas Paton, Joseph Musaazi, Cissy Kityo, Stephen I. Walimbwa, Apolo Balyegisawa, Anne Hoppe, Arvind Kaimal, Grace Mirembe, Gilbert Ategeka, Henry Mugerwa, Margaret Borok, Abraham Siika, Barbara Castelnuovo, Andrew D. Kambugu, for the Nucleosides and Darunavir/Dolutegravir in Africa (NADIA) Trial Team

10:22  LIVE QUESTIONS AND ANSWERS

10:40  INTRODUCTIONS

138  LENACAPAVIR AS PART OF A COMBINATION REGIMEN IN TREATMENT NAIVE PWH: WEEK 54 RESULTS
10:45  Samir Gupta, James Sims, Cynthia Brinson, Frederick A. Cruickshank, Godson Oguchi, Javier Morales, Theo Hodge, Craig Dietz, Angela S. Liu, Laurie VanderVeen, Hadas Dvory-Sobol, Martin Rhee, Jared Baeten, Ellen Koenig

10:53  VIRAL ESCAPE DURING TRIPLET BROADLY NEUTRALIZING ANTIBODY THERAPY AGAINST HIV-1

11:01  PHASE I STUDY OF LONG-ACTING 3BNC117 AND 10-1074 IN VIREMATIC ADULTS LIVING WITH HIV
11:01  Marina Caskey, Katrina Millard, Martina Turroja, Christian Gaebler, Erin Logue, Caroline S. Jiang, Leah Todd, Jacqueline D. Reeves, Christos Petropoulos, Timothy Wilkin, Pablo Tebas, Michel Nussenzweig

11:09  LIVE QUESTIONS AND ANSWERS

Oral Abstract Session-13  SHIFTING PARADIGMS IN HIV TESTING
9:45 AM MT - 11:45 AM MT

Oral Abstract Moderators
Wafaa M. El-Sadr, Columbia University, New York, NY, USA
Andrew N. Phillips, University College London, London, UK

9:45  INTRODUCTIONS

141  PREVALENCE OF SYPHILIS AND HIV/SYPHILIS COINFECTION IN 5 SUB-SAHARAN COUNTRIES
9:50  Rose Killian, Mansoor Farahani, Giles Reid, Godfrey Musuka, Samuel Biraro, Harriet Nuwagaba-Biribonwoha, Wafaa M. El-Sadr, Jessica E. Justman

142  CHANGES IN HIV AND STI TESTING AND DIAGNOSES DURING THE COVID-19 PANDEMIC
9:58  Jennifer J. Chang, Qiaoling Chen, Rulin C. Hechter, Jodie Dionne-Odom, Katia Bruxvoort

143  CDC’S DIRECT-TO-CONSUMER DISTRIBUTION OF 100,000 HIV SELF-TESTS
10:06  Pollyanna R. Chavez, Brian Emerson, Emily Lilo, Jennie Johnston Gayden, Euna August, Christopher Voegeli, Revae Downey, Emily Pingel, Kevin P. Delaney
144 HIV SELF-TESTING UNCOVERS HIGH BURDEN OF HIDDEN INFECTIONS IN INDIA

10:22 LIVE QUESTIONS AND ANSWERS

10:40 INTRODUCTIONS

145 HIGH HIV SELF-TESTING OF MALE PARTNERS OF WOMEN LIVING WITH HIV IN RURAL SOUTH AFRICA
Dvora Joseph Davey, Kristin Wall, Nireshni Naidoo, Dhirisha Naidoo, Gugu Xaba, Claire Serrao, Silinganiso Chatikobo, Todd Malone, Kathryn Dovel

10:45 SIX-MONTH PrEP WITH HIV SELF-TESTING TO IMPROVE DELIVERY KENYA: A RANDOMIZED TRIAL
Kenneth Ngure, Katrina Ortblad, Peter A. Mogere, Ashley Bardon, Dorothy Mangale, Catherine Kiptinness, Stephen Gaku, Sarah Mbaire, Jacinta Nyokabi, Katherine K. Thomas, Nelly R. Mugo, Jared Baeten

11:09 LOW RISK OF ADVERSE EVENTS FOLLOWING ASSISTED PARTNER NOTIFICATION IN MOZAMBIQUE
Matthew R. Golden, Allend Mamudo, Ferruccio Vio, Erin Branigan, Zulmira Paredes, Adelina Maiela, Orvalho Augusto, Ateny Couto, Guita Amane, Noelia Chichecue, Joaquim Wate

11:17 LIVE QUESTIONS AND ANSWERS

Interactive Session-6 CHIMERIC ANTIGEN RECEPTORS (CARs): WHAT’S NEXT?

12:00 PM MT - 1:00 PM MT

Description: This session is intended to be engaging, lively, interactive, and scientifically fun. The session will include 4 rapid-fire presentations of 5 to 7 minutes each, followed by discussions and real-time interactions with the moderators, experts, and audience.

Target Audience: This session is directed to a broad audience of basic science experts and clinicians in the field of HIV virology and AIDS.

Level of Knowledge: It is assumed that the participants are familiar with many aspects of HIV pathogenesis and persistence and with the challenges of eliminating HIV reservoirs. Clinicians who attend should be familiar with HIV-associated malignancies, including B cell lymphomas.

Objectives: At the completion of the session, participants will be able to:
• Describe the basic science of a CAR and how it can function on diverse cell backgrounds to target HIV-infected and malignant cells
• List current challenges in maintaining functional CAR cells in vivo with respect to their expansion, persistence, and sustaining their function, and appreciating how these challenges are being addressed with ongoing basic and translational research
• Describe the active areas of research in the HIV/AIDS and cancer fields as well as clinical trials where CAR cellular therapy is having an impact on patient care or could have an impact in the future
Monday, March 29

12:00 SESSION OVERVIEW

12:05 NEW AND IMPROVED T CELL CARs FOR HIV ERADICATION OR CONTROL
James L. Riley, University of Pennsylvania, Philadelphia, PA, USA

12:10 GENERATING CAR T CELLS IN VIVO
Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

12:15 NATURAL KILLER CELL CARs: NEW APPROACHES TO CURE LEUKEMIA AND LYMPHOMA
Katy Rezvani, University of Texas MD Anderson Cancer Center, Houston, TX, USA

12:20 STIMULATING CARs WITH mRNA VACCINES
Benjamin Rengstl, BioNTech, Mainz, Germany

12:25 LIVE PANEL DISCUSSION

Interactive Session-7 HIV CONTROVERSIES: CASE-BASED APPROACH TO PATIENTS WHO ARE TREATMENT OR PREVENTION EXPERIENCED

Description: This session is intended to be engaging, lively, interactive, and scientifically fun. The session will include 3 case presentations, followed by a discussion of each case from the expert panel and answers to questions from the audience. The cases are focused on people with HIV who are treatment experienced in the context of therapy or preexposure prophylaxis (PrEP).

Target Audience: This session is directed to adult and pediatric HIV clinicians and clinical investigators as well as trainees in these areas.

Level of Knowledge: It is assumed that the participants are familiar with antiretroviral regimens commonly used for HIV treatment and prevention.

Objectives: At the completion of the session, participants will be able to:
- Describe new antiretroviral agents that now are or will soon be available for HIV treatment and HIV prevention
- Identify drug resistance risks of oral and long-acting PrEP and how they may impact HIV treatment of individuals who become infected during PrEP
- Design treatment regimens for people with HIV who have multidrug-resistant HIV

Moderators
Joseph J. Eron, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Hermione Lyall, Imperial College Healthcare NHS Trust, London, UK

CME
Panelists

Mina C. Hosseinipour, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Natella Rakhmanina, Children’s National Hospital, Washington, DC, USA

Annemarie M. Wensing, University Medical Center Utrecht, Utrecht, Netherlands

Timothy J. Wilkin, Weill Cornell Medicine, New York, NY, USA

Interactive Session-8  IMPACT OF VIRAL LOAD IN TRANSMISSION AND DISEASE PROGRESSION OF SARS-CoV-2 INFECTION

Description: This session is intended to be engaging, lively, interactive, and scientifically fun. The session will include 4 presentations of 8 minutes each, followed by a 20-minute panel discussion and interactions with the moderators, experts, and audience.

Target Audience: This session is directed to clinicians, epidemiologists, public health officials, and clinical virologists interested in the transmission of SARS-CoV-2 and the progression of COVID-19.

Level of Knowledge: It is assumed that the participants are familiar with the global epidemiology of COVID-19, the route of transmission of SARS-CoV-2, the clinical presentation of SARS-CoV-2 infection, data supporting the use of monoclonal antibodies and other antiviral treatments of SARS-CoV-2 infection, and data supporting the efficacy of vaccination.

Objectives: At the completion of the session, participants will be able to:

• Describe how the viral load of SARS-CoV-2 influences outcomes such as transmission and possibly virulence
• Assess whether monitoring viral load is useful in the clinical management of COVID-19
• Describe the impact of vaccination on viral kinetics during SARS-CoV-2 infection

Moderators

Jean-Michel Molina, University of Paris, Paris, France
Monica Gandhi, University of California San Francisco, San Francisco, CA, USA

12:00  SESSION OVERVIEW
12:02  ROLE OF VARIANTS AND VIRAL LOAD IN SARS-CoV-2 TRANSMISSION  
Arnaud Fontanet, Institut Pasteur, Paris, France

12:12  IS SARS-CoV-2 VIRAL LOAD ASSOCIATED WITH DISEASE PROGRESSION AND RESPONSE TO TREATMENT?  
Matthew Spinelli, University of California San Francisco, San Francisco, CA, USA

12:22  ARE NEW SARS-CoV-2 VARIANTS ASSOCIATED WITH MORE SEVERE DISEASE?  
Fiona Havers, Centers for Disease Control and Prevention, Atlanta, GA, USA

12:32  VIRAL LOAD KINETICS IN PARTIALLY OR FULLY VACCINATED INDIVIDUALS INFECTED WITH SARS-CoV-2  
Annelies Wilder-Smith, London School of Hygiene & Tropical Medicine, London, UK

12:42  LIVE PANEL DISCUSSION
### POSTER SESSIONS BY DAY

**MONDAY, FEBRUARY 14, 2022**

<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>158</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>160</td>
<td>MIGRATORY T CELLS ARE MORE SUSCEPTIBLE TO HIV-1 INFECTION VIA INCREASED VIRAL ENTRY</td>
<td>Paul G. Lopez, Oluwaseun E. Ajibola, Amélie Pagliuzza, Romaniya Zayats, Wan Hon Koh, Alon Herschhorn, Nicolas Chomont, Thomas T. Murooka</td>
</tr>
<tr>
<td>161</td>
<td>ACCUMULATION OF HIV-1 Env MUTATIONS LEADS TO HIGH-LEVEL RESISTANCE TO DOLUTEGRAVIR</td>
<td>Yuta Hikichi, Jennifer L. Groebner, Ann Wiegand, John W. Mellors, Mary F. Kearney, Eric O. Freed</td>
</tr>
<tr>
<td>162</td>
<td>N-GLYCOSYLATION SITE SIGNATURES OF HIV ENVELOPE IN POST-TREATMENT CONTROLLERS</td>
<td>Elmira Esmaeilzadeh, Behzad Etemad, Yijia Li, Lavine L. Christy, James Regan, Colline Wong, Elizabeth Connick, Paul Volberding, Michael Seaman, Jonathan Li</td>
</tr>
<tr>
<td>163</td>
<td>FUNCTIONALIZATION OF ENVELOPED PROTEIN NANOCAGES VIA DESIGNED TRANSMEMBRANE PROTEINS</td>
<td>Daniel Humphrys, Wesley I. Sundquist, Neil King, Ben Schmitz</td>
</tr>
<tr>
<td>164</td>
<td>MOLECULAR DETERMINANTS OF SARS-CoV-2 CELLULAR TROPISM IN VITRO</td>
<td>Maritza N. Puray-Chavez, Kyle M. LaPak, Shawn J. Mohammed, Dana Q. Lawson, Dennis Goldfarb, M. Ben Major, Sebla B. Kutluay</td>
</tr>
<tr>
<td>165</td>
<td>SPIKE MUTATION T403R ALLOWS BAT CORONAVIRUS RaTG13 TO USE HUMAN ACE2</td>
<td>Fabian Zech, Daniel Schniertshauer, Christoph Jung, Alexandra Herrmann, Arne Cordsmeier, Janis Müller, Jana Krueger, Sandra Heller, Steffen Stenger, Alexander Kleger, Timo Jacob, Karl-Klaus Conzelmann, Armin Ensser, Konstantin Sparrer, Frank Kirchhoff</td>
</tr>
<tr>
<td>166</td>
<td>D614G AND OTHER MUTATIONS ARE CRITICAL FOR FITNESS OF NOVEL SPIKE VARIANTS</td>
<td>Leonid Yurkovetskiy, Ann Dauphin, Matteo Bosso, Thomas Nyalile, Jeremy Luban</td>
</tr>
<tr>
<td>167</td>
<td>SARS-CoV-2 VARIANTS INCREASE KINETIC STABILITY OF OPEN SPIKE CONFORMATIONS</td>
<td>Ziwei Yang, Yang Han, Shilei Ding, Wei Shi, Tongqing Zhou, Andrés Finzi, Peter D. Kwong, Walther Mothes, Maolin Lu</td>
</tr>
<tr>
<td>168</td>
<td>MANNOSE-BINDING LECTIN (MBL) INHIBITS SARS-CoV-2 INFECTION AND REPLICATION IN VITRO</td>
<td>Isabel Pagani, Matteo Stravalaci, Daniela Cesana, Pierangelo Gallina, Nicoletta Pedemonte, Valeria Capurro, Nicola Clementi, Nicacio Mancini, Barbara Bottazzi, Alberto Mantovani, Elisa Vicenzi, Cecilia Garlanda</td>
</tr>
</tbody>
</table>
**Poster Session-B01  NONHUMAN PRIMATE MODELS OF HIV INFECTION**

**2:00 PM MT - 3:30 PM MT**

168 **VIRAL AND IMMUNE PREDICTORS OF TIME TO VIRAL REBOUND IN SHIV-INFECTED INFANT MACAQUES**


188 **IMPACT OF CD4 BINDING SITE bNAbs ON BARCODED TF-SHIV-D REBOUND IN MACAQUES AT ATI**

*Elise G. Viox*, Sadia Samer, Kevin Nguyen, Emily Lindemuth, Felicity Mampe, Steffen Docken, Mykola Pinkeych, M. Betina Pampena, Brandon Keele, Michael Betts, Miles P. Davenport, Mirko Piaidrini, Katharine J. Bar

190 **DEVELOPMENT OF VIRAL BIOMARKERS IN SHIV INFECTED NONHUMAN PRIMATES**

*Luca Sardo*, Guoxin Wu, Jessica Lewis, Carl J. Balibar, Paul Zuck, Daria Hazuda, Bonnie Howell

191 **ANTI-α4β7 ANTIBODY REDUCES INTESTINAL MYELOID CELL TOURNOVER IN SIV-INFECTED MACAQUES**

*Samuel D. Johnson*, Lindsey Knight, Omalla Olwenyi, Michellie Thurman, Siddappa N. Byrareddy

192 **INNATE IMPAIRMENT DURING SIV INFECTION ALTERS ZIKV VIRAL PATHOGENESIS**

Jennifer Tisoncik-Go, Thomas B. Lewis, Skyler Groenier, Daniel Newhouse, Kathleen M. Voss, Erin Broderick, Karina Wang, Naoto Iwayama, Chul Ahrens, Robert Murnane, Kathryn A. Guerriero, Michael Gale, Deborah H. Fuller, Megan A. O’Connor

**Poster Session-B02  SARS-CoV-2 PATHOGENESIS**

**2:00 PM MT - 3:30 PM MT**

193 **SARS-CoV-2 SPIKE PROTEIN DESTABILIZES MICROVASCULAR HOMEOSTASIS**

*Soumya Panigrahi*, Tamal Goswami, Brian Ferrari, Christopher J. Antonelli, Douglas A. Bazdar, Hannah Gilmore, Michael L. Freeman, Michael M. Lederman, Scott F. Sieg

194 **UNIQUE SARS-CoV-2 FURIN-CLEAVAGE SITE VARIANTS IN URINE OF SEVERE COVID-19 PATIENTS**

Tatiana Travieso, Sneha Mahesh, Kelly Hughes, Lingye Chen, Lyra B. Olson, Feng Gao, Bryan D. Kraft, Christina Wyatt, Mary Klotman, Maria Blasi

195 **GALECTIN-9 PROTECTS HUMANIZED ACE2-IMMUNOCOMPETENT MICE FROM SARS-CoV-2 INFECTION**

*Stephen T. Yeung*, Thomas A. Premeaux, Toshiro Niki, Satish Pillai, Kamal M. Khanna, Lishomwa Ndhlouvu
196 SARS-CoV-2 PLASMA VIREMIA AND DYSREGULATED IMMUNITY IN SEVERE COVID-19

Roberta Rovito, Valeria Bono, Matteo Augello, Camilla Tincati, Federica Mainoldi, Guillaume Beaudoin-Bussières, Silvia Bianchi, Mohamad Hadla, Vaibhav Yellenki, Stefano Casola, Elisa Borghi, André Finzi, Antonella D’Arminio Monforte, Giulia Marchetti

197 SARS-CoV-2 N-ANTIGEN SERA LEVELS ARE ASSOCIATED WITH COVID-19 PROGNOSTIC VALUE

Housssem R. Chenane, Reyene Menidjel, Samuel Lebourgeois, Cedric Louenan, Sarah Tubiana, Diane Descamps, Laurent Abel, Jérémy Guedj, Surbhi Malhotra, Samir Kumar-Singh, Jade Ghosn, Benoît Visseaux

198 SARS-CoV-2 RNAEMIA AS A BIOMARKER OF LOWER RESPIRATORY VIRAL LOAD IN COVID-19

Jana L. Jacobs, Asma Naqvi, Faraaz A. Shah, Bryan J. McVerry, Barbara Methé, Janet S. Lee, Alison Morris, Georgios D. Kitsios, William Bain, John W. Mellors

199 SARS-CoV-2–INFECTED MACAQUES EXHIBIT MICROBIAL TRANSLOCATION ACROSS INTESTINAL MUCOSA

Kelsie Brooks, Christine Nelson, Cynthia Aguilar, Charlotte Langner, Sophia Vrba, Alexandra Ortiz, Ornella Sortino, Kevin Vannella, Timothy Hoang, Mirko Paiardini, Daniel Chertow, Irini Sereti, Heather Hickman, Daniel Barber, Jason Brenchley

200 PULMONARY CMV REACTIVATION FOLLOWING SARS-CoV-2: IMPLICATIONS FOR IMMUNOPATHOLOGY

Jamin Roh, Peter A. Barry, Peter W. Hunt, Smita S. Iyer

208 INHIBITION OF HIV-1 INFECTION IN SICKLE CELL DISEASE

Sergei Nekhai, Namita Kumari, Asrar Ahmad, Marina Jerebtsova, Andrey I. Ivanov, Sharmin Diaz, James G. Taylor

209 THE GUT MICROBIOTA IMPACTS SUSCEPTIBILITY TO HIV

Danting Jiang, Ria Goswami, Sedem Dankwa, Sallie Permar, Neeraj K. Surana

210 EFdA OFFERS COMPLETE PROTECTION FROM REPEATED PENILE HIV CHALLENGES

Martina Kovarova, Sarah E. Wessel, Claire E. Johnson, Myron S. Cohen, J. Victor García-Martínez

211 VAGINAL PROTEOME ALTERATIONS ASSOCIATED WITH HIV ACQUISITION IN THE VOICE TRIAL

Christina Farr Zuend, Samantha Knodel, Laura Noél-Romas, Sausan Azzam, Marlón De Leon, Kateryna Kratzer, Zvahahaha Chirenje, Sharon L. Hillier, Jeanne Marrazzo, Adam D. Burgener

212 VAGINAL MICROBIOME PROFILES IN YOUNG WOMEN AT RISK FOR HIV INFECTION

Yiran Wang, Laura Noél-Romas, Michelle Perner, Samantha Horne, Sarah Hoger, Kenzie Birse, Christina Farr Zuend, Lyle R. McKinnon, Adam D. Burgener

213 STROMAL FIBROBLASTS FROM FEMALE GENITAL TRACT DIMINISH THE IN VITRO EFFICACY OF PrEP

Ashley F. George, Matthew McGregor, Jason Neidleman, Warner Greene, Nadia Roan
235 **STRUCTURAL CHARACTERIZATION OF DNA-ENCODED HIV VACCINES INDUCED NEUTRALIZING ANTIBODY**  
Ziyang Xu, Susanne Walker, Megan C. Wise, Neethu Chokkalingam, Mansi Purwar, Alan Moore, Jesper Pallesen, Daniel W. Kulp, David Weiner

236 **HIV VACCINE CANDIDATE EFFICACY MEDIATED BY CAMP-DEPENDENT EFFEROCYTOSIS AND V2-ADCC**  

237 **IMMUNOGENICITY AND PROPHYLACTIC EFFICACY OF ARENAVIRUS-BASED SIV VACCINE IN MACAQUES**  
Archana V. Boopathy, Bhawna Sharma, Daniela Deutschmann, Hoa Truong, Johnny Lee, Jeffrey Murry, Christian Callebaut, Romas Geleziunas, Wade Blair, Klaus Orlinger, Sarah Schmidt, Henning Lauterbach, Tariro Makadzange, Sarah Ahmad-Erber

238 **SAMT-247 SYNERGIIZES WITH ALVAC-BASED VACCINE TO PROTECT AGAINST SIVmac251 ACQUISITION**  
Mohammad Arif Rahman, Sabrina Helmold Hait, Isabela Silva de Castro, James D. Stamos, Ruth Hunegnaw, Melvin N. Doster, Tanya Hoang, Lisa M. Jenkins, David Venzon, Manjula Gunawardana, Marc Baum, Ettore Appella, Daniel H. Appella, Marjorie Robert-Guroff, Genoveffa Franchini

239 **IL-7 AND IL-15 IMPROVE HUMORAL RESPONSES OF A SHIV DNA VACCINE IN ANIMAL MODELS**  
Laury Anne Leroy, Alice Mac Donald, Aditi Kandlur, Deepanwita Bose, Peng Xiao, Jean Gagnon, François Villinger, Yahia CHEBLOUNE

240 **PROTECTION FROM A PATHOGENIC HETEROLOGOUS SIV BY ELITE CONTROLLERS OF SIVmac239ΔGY**  

Poster Session-D02  SARS-CoV-2 VACCINES  
2:00 PM MT - 3:30 PM MT

241 **TEMPORAL ASSOCIATIONS OF B AND T CELL IMMUNITY IN A 16-WEEK INTERVAL BNT162b2 REGIMEN**  
Manon Nayrac, Mathieu Dubé, Gérémy Sannier, Alexandre Nicolas, Alexandra Tazuz, Olivier Tastet, Shang Yu Gong, Lorie Marchitto, Nathalie Brassard, Guillaume Beaudoin-Bussières, Jonathan Richard, Cécile Tremblay, Valérie Martel-Laferrière, Andrés Finzi, Daniel E. Kaufmann

242 **A LONG-INTERVAL VACCINE REGIMEN LEADS TO STRONG HUMORAL RESPONSES AGAINST SARS-CoV-2**  
Alexandra Tazuz, Shang Yu Gong, Guillaume Beaudoin-Bussières, Lorie Marchitto, Annemarie Laumaea, Manon Nayrac, Gérémy Sannier, Renée Bazin, Jonathan Richard, Marceline Côté, Cécile Tremblay, Ralf Duerr, Valérie Martel-Laferrière, Daniel E. Kaufmann, Andrés Finzi
243 IMMUNE RESPONSES AFTER ChAdOx1 OR BNT162b2 BOOSTERS IN PRIMARY CORONAVAC VACCINATION
Watsamon Jantarabenjakul, Pimpayao Sodsai, Napaporn Chantasrisawad, Anusara Jitsatya, Chayapa Ruenjaiman, Jiratchaya Sophonph, Supaporn Wacharapluesadee, Thanyawee Puthanakit, Nattiya Hirankarn, Opass Putcharoen

244 INTRADERMAL AND INTRAMUSCULAR ADMINISTRATION OF THE BOOSTER COVID-19 VACCINATION
Suvimol Niyomnaitham, Somruedee Chatsiricharoenkul, Nasikarn Angkasekwina, Sansnee Senawong, Kulkanya Chokephaibulkit

245 DURABILITY AND BOOSTABILITY OF Ad26.COV2.S IN RHESUS MACAQUES
Xuan He, Abishek Chandrashekar, Jingyou Yu, Katherine McMahan, Frank Wegmann, Huahua Dan, Daniel Sellers, Jinyan Lin, Michelle Lifton, Hanne Andersen, Mark G. Lewis, Galit Alter, Hanneke Schultemarker, Roland Zahn, Dan Barouch

246 S mRNA PRIME S+ N DNA BOOST VACCINATION ELICITS ROBUST IMMUNE RESPONSES IN MICE
Adrian Rice, Mohit Verma, Emily Voigt, Peter Battisti, Sam Beaver, Kyle Dinkins, Shivani Mody, Wendy Higashide, Brett Morimoto, Elizabeth R. Gabitzsch, Jeffrey T. Safrit, Patricia R. Spilman, Christopher Fox, Corey Casper, Patrick Soon-Shiong

247 PROTECTIVE EFFICACY OF A GASTROINTESTINAL SARS-CoV-2 VACCINE
Jingyou Yu, Natalie Collins, Hanne Andersen, Christian Hofer, Donald S. Burke, Erica K. Barkei, Hannah King, Diane Bolton, Kayvon Modjarrad, Nelson L. Michael, Dan Barouch

248 LONG-TERM IMMUNOGENICITY AND EFFECTIVENESS OF CD40- TARGETING VACCINATION IN COVID-19
Véronique Godot, Lea Dupaty, Florence Picard, Ana Zarubica, Amandine Sansoni, Sylvain Cardinaud, Sandra Zurawski, Craig Fenwick, Mireille Centlivre, Mathieu Surenad, Christine Lacabarat, Giuseppe Pantaleo, Bernard Malissen, Gerard Zurawski, Yves Levy

249 ARMY LIPOSOMAL SPIKE FERRITIN NANOPARTICLE VACCINE INDUCES DURABLE IMMUNE RESPONSES

250 AAVCOVID: A SINGLE-DOSE, THERMOSTABLE COVID-19 VACCINE WITH DURABLE IMMUNOGENICITY
Nerea Zabaleta, Urja Bhatt, Cécile Herate, Pauline Maisonnasse, Jessica A. Chichester, Julio Sanmiguel, Cheikh Diop, David Maciorowski, James M. Wilson, Roger Le Grand, Luk H. Vandenberghe

251 SPIKE PLUS NUCLEOCAPSID VACCINE PROTECTS AGAINST SARS-CoV-2 DELTA INFECTION IN NHPs

252 INVESTIGATING CONSERVED SEQUENCE IN THE SARS-CoV-2 GENOME AS NOVEL VACCINE IMMUNOGEN
Gabriel Dagotto, John D. Ventura, David R. Martinez, Tochi Anioke, Benjamin S. Chung, Mazuba Siamatu, Julia Barrett, Jingyou Yu, Lisa H. Tostanoski, Alexandra Schaefer, Ralph Baric, Bette Korber, Dan Barouch
253 **ANTIGENICITY OF THE MU (B.1.621) AND A.2.5 SARS-CoV-2 SPIKES**

254 **OPTIMIZATION OF NONCODING REGIONS IMPROVES mRNA SARS-CoV-2 VACCINE IN NHPs**
Makda Gebre, Susanne Rauch, Nicole Roth, Jingyou Yu, Abishek Chandrashekar, Noe B. Mercado, Xuan He, Jinyan Liu, Katherine McMahan, Amanda Martinot, Xiaowen Liu, Mark G. Lewis, Stefan Mueller, Benjamin Petsch, Dan Barouch

255 **IgG GLYCOSYLATION PREDICTS COVID-19 DISEASE SEVERITY AND VACCINE ANTIBODY RESPONSE**
Michelle Ash, Pavan Bhimalli, Byoung-Kyu Cho, Basil Baby Mattamana, Stephanie Gambut, Imad Tarhoni, Cristina Fhied, Thomas Hope, Beverly Sha, Young Ah Goo, Lena Al-Harthi, Joao Mamede, Jeffrey Borgia, Neil Kelleher, Jeffrey Schneider

**Poster Session-D08 HIV IMMUNOLOGY: NK CELLS AND CYTOKINES**
2:00 PM MT - 3:30 PM MT

304 **SEX DIFFERENCES IN CYTOKINE PROFILES DURING SUPPRESSIVE ANTIRETROVIRAL THERAPY**
Christophe Vanpouille, Alan Wells, Timothy Wilkin, Jyoti S. Mathad, Sheldon Morris, Leonid Margolis, Sara Gianella

305 **DOWNREGULATION OF CD155 RESULTS IN HIV-1 RESTRICTION BY KIR2DLS5+ NK CELLS**

306 **THE ROLE OF ADAPTIVE NK CELLS DURING ACUTE HIV-1 INFECTION WITH DIFFERENT SUBTYPES**
Aljawharah Alrubayyi, Amin Hassan, Jonathan Hare, Jill Gilmour, Joakim Esbjörnsson, Eduard Sanders, Sarah Rowland-Jones, Dimitra Peppa

307 **CHARACTERIZATION OF NK CELLS IN ELITE CONTROLLERS LOSING HIV CONTROL**
Nerea Sánchez-Gaona, Ana Gallego Cortés, Antonio Astorga Gamaza, Norma Rallón, José M. Benito, Vicenç Falcó, Meritxell Genescà, Maria José Buzón

**Poster Session-D10 EBOLAVIRUS VACCINES**
2:00 PM MT - 3:30 PM MT

323 **PREVAC RCT: EFFECTS OF 3 EBOLA VACCINE STRATEGIES IN WEST AFRICAN ADULTS AND CHILDREN**
Mark Kieh, Laura Richert, Abdoul Habib Beavogui, Birgit Grund, Bailah Leigh, Eric D’Ortenzio, Seydou Doumbia, Samba Sow, Lisa Hensley, Yves Levy, Cliff Lane, Deborah Watson-Jones, James Neaton, Yazdan Yazdanpanah, for the PREVAC Study Team

324 **EBOLA VACCINE-INDUCED STRONG-BINDING ANTIBODY RESPONSES IN PEOPLE LIVING WITH HIV-1**
Thembi Mdluli, Suzanne Wollen-Roberts, Dominic Paquin-Proulx, Jay Hooper, Betty Mwesigwa, Josphat Kosgei, Janet Oyieko, Nyanda Ntinginya, Ilesh Jani, Michael Iroezindu, Lucy Ward, Kerstin Luhn, Cynthia Robinson, Julie Ake, Morgane Rolland
Poster Session-E03  INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND
2:00 PM MT - 3:30 PM MT

347 BRAIN PENETRANT CSF1R INHIBITOR REDUCES BRAIN VIRUS BURDEN IN SIV-INFECTED MACAQUES

348 COMBINATION OF PD-1 BLOCKADE AND AZD5582 THERAPY IN SIV+ MONKEYS
Bhrugu Yagnik, Sheikh A. Rahman, Gordon J. Freeman, Rafi Ahmed, Rama R. Amara

349 VIRAL AND BIOMARKER OUTCOMES OF AN ENGINEERED bNAb IN ART-SUPPRESSED PARTICIPANTS

350 DNA-ECD4-IG DECREASED HIV-1 RESERVOIR ON ART DELAYED VIRAL REBOUND IN HUMANIZED MICE
Zhe Yuan, Mansi Purwar, Opeyemi S. Adeniji, Ziyang Xu, Colin Hart, Kwasi Gyampoh, Guorui Zu, Abhijeet J. Kulkarni, Mohamed Abdel-Mohsen, David Weiner, Luis J. Montaner

351 EFFICACY OF Ad26/MVA + Env + VESATOLIMOD THERAPEUTIC VACCINATION IN RHEUS MACAQUES
John D. Ventura, Joseph P. Nkolola, Abishek Chandrashekar, Erica N. Borducchi, Jinyan Liu, David L. Hope, Victoria M. Giffin, Katherine McMahah, Romas Gelezunias, Jeffrey Murry, Mark G. Lewis, Maria G. Pau, Merlin Robb, Dan Barouche

352 BEAT2: peg-IFN-α2b + 3BNC117 AND 10-1074 KEEPS HIV AT <20 C/ML DURING 26 WEEK ATI

353 SMAC MIMETICS REACTIVATE HIV AND REDUCE THE VIRAL RESERVOIR IN HUMANIZED MICE
Jaspreet Jain, Tram N. Pham, Nicolas Bellini, Frédéric Dallaire, Thomas T. Murooka, Rémi Froment, Nicolas Chomont, Eric A. Cohen

354 INDUCIBLE RESERVOIR IN TISSUES, BUT NOT IN PERIPHERY, PREDICTS FUNCTIONAL CURE OF SIV
Adam J. Kleinman, Sindhuja Sivanandham, Ranjit Sivanandham, Paola Sette, Benjamin B. Policicchio, Cuiling Xu, Quentin Le Hingrat, Egidio Brocca-Cofano, Dongzhu Ma, Ivona Pandrea, Cristian Aperetrie

355 EFFECT OF HIGH-DOSE VITAMIN D3 ON THE HIV RESERVOIR: A RANDOMIZED CONTROLLED TRIAL
Matthew C. Pitman, Niamh Meagher, David J. Price, Ajantha Rhodes, Judy Chang, Barbara Scher, Brent Allan, Alan Street, James McMahon, Thomas A. Rasmussen, Paul U. Cameron, Jennifer Hoy, Stephen J. Kent, Sharon Lewin

356 CARD8 SENSITIZATION THROUGH DPP9 INHIBITION ENHANCES KILLING OF HIV-INFECTED CELLS
Kolin Clark, Qiankun Wang, Josh Kim, Liang Shan
357 HIV-1 VIRAL RESERVOIR DISRUPTION WITH PANOBINOSTAT AND IFN-α
Marie Armani-Tourret, Ciputra A. Hartana, Yelizaveta Rassadkina, Cecilia Gao, Katrina Shea, Amy Sbrolla, Xu Yu, Rajesh T. Gandhi, Daniel Kuritzkes, Mathias Lichterfeld

358 IMPACT OF INFLUENZA AND PNEUMOCOCCUS VACCINES ON CELLULAR HIV RNA TRANSCRIPTION
Sara Gianella, Alan Wells, Susanne May, Christy Anderson, Gemma Caballero, Laura Layman, Brianna Scott, Joseph Lonergan, Leticia Muttera, Liliana Harkness, Susan J. Little, Davey M. Smith

359 PHASE II CLINICAL TRIAL OF VEDOLIZUMAB AND ART IN SUBJECTS WITH NO PREVIOUS ART
Maria Reyes Jimenez Leon, Carmen Gasca-Capote, Cristina Roca-Oporto, Nuria Espinosa-Aguilera, Salvador Sobrino, Maria Fontillon, Immaculada Rivas-Jeremias, Karin Neukam, Jose German Sanchez-Hernandez, Raul Rigo-Bonnin, Antonio J. Cervera, Rosario Mesones, Pompeo Viciana, Luis Fernando Lopez Cortes, Ezequiel Ruiz-Mateos

360 CARD8 ACTIVATION BY HIV-1 PR TRIGGERS GSDMD-DEPENDENT AND -INDEPENDENT CELL DEATH
Qiankun Wang, Liang Shan

361 PROLONGED VIRAL SUPPRESSION BY IMMUNOTHERAPY WITH ANTI-HIV ANTIBODIES 3BNC117/10-1074

Poster Session-E04 CONTROLLERS AND POST-TREATMENT CONTROLLERS
2:00 PM MT - 3:30 PM MT

362 POST-TREATMENT CONTROLLERS LIMIT COMPLETED AND SPLICED HIV TRANSCRIPTS AFTER ATI
Adam Wedrychowski, Holly A. Martin, Sushama Telwater, Gayatri Nikhila Kadiyalah, Elizabeth Connick, Jeffrey Jacobson, David M. Margolis, Daniel J. Skiest, Paul Volberding, Frederick M. Hecht, Steven G. Deeks, Joseph K. Wong, Jonathan Li, Steven A. Yukl

363 IMMUNOLOGICAL AND GLYCOMIC CORRELATES OF TIME-TO-HIV-REBOUND IN VIREMIC CONTROLLERS
Yanhui Cai, Steven G. Deeks, Liao Zhang, Leila B. Giron, Jane Koshy, Zongbo Shang, Susan Guo, Christina de Vries, Elena Vendrane, Devi SenGupta, Mohamed Abdel-Mohsen, Jeffrey Wallin

364 POST-TREATMENT CONTROLLERS MAINTAIN A LIMITED INTACT RESERVOIR AFTER ART INTERRUPTION
Yijia Li, Behzad Efremad, Meghan Melberg, Radwa Sharaf, Wendy Hartogensis, Ronald J. Bosch, Jeffrey Jacobson, Elizabeth Connick, Paul Volberding, Daniel J. Skiest, David M. Margolis, Steven G. Deeks, Michael M. Lederman, Frederick M. Hecht, Jonathan Li

365 LIMITED EVOLUTION OF THE VIRAL RESERVOIR IN A NONHUMAN PRIMATE MODEL OF ELITE CONTROL
Kyle Rhodehouse, Mithra R. Kumar, Emily J. Fray, Christine M. Fennessey, Pyone Aye, Faith Schiro, Amitinder Kaur, Marissa D. Fahlberg, Lara A. Doyle-Meyers, Jeffrey D. Lifson, Brandon Keele, James Hoxie, Nicholas Maness, Janet Siliciano, Robert Siliciano
366 CD8 RECOGNITION OF AUTOLOGOUS VIRUS IN HIV-ELITE CONTROLLERS DESPITE ESCAPE MUTATIONS

Maria A Navarrete-Muñoz, Alejandro Calderón, Ricardo Ramos, África Holguín, Alfonso Cabello Übeda, Miguel Górgolás, José M. Benito, Norma Rallón

401 HIV-1 Nef IMPAIRS MYELIN AND DISRUPTS GLIAL CELLS IN THE CENTRAL NERVOUS SYSTEM

Jessica K. Schenck, Michael I. Bukrinsky, Robert H. Miller

402 NLRP3 INFLAMMASOME SIGNALING PATHWAY IS UPREGULATED IN BRAINS OF PEOPLE WITH HIV-1

Alice K. Min, Amara Plaza-Jennings, Susan Morgello, Schahram Akbarian, Talia H. Swartz

403 CONCOMITANT CARDIAC PATHOLOGY WITH ENCEPHALITIS IN SIV-INFECTED ANIMALS WITH AIDS

Kevin S. White, Joshua A. Walker, Patrick Autissier, Andrew Miller, Qingsheng Li, Rachel Burack, Woong-Ki Kim, Kenneth Williams

404 EVIDENCE OF BRAIN HYPOXIA IN NEUROPATHOLOGY OF SARS-CoV-2–INFECTED NONHUMAN PRIMATES

Ibolya Rutkai, Meredith G. Mayer, Linh Hellmers, Bo Ning, Zhen Huang, Nicholas Maness, Kasi Russell-Lodrigue, Tony Hu, Chad Roy, Robert Blair, Rudolf Bohm, Lara A. Doyle-Meyers, Jay Rappaport, Tracy Fischer

405 375W MUTATION ENHANCES CD4 BINDING AND CHANGES TROPISM IN SOME CLADES

Odette Verdejo-Torres, Tania Allin Vargas Pavia, Zhongming Mou, Paul R. Clapham, Maria Duenas Decamp

406 H/L-FERRITINS AND TIM-1 ASSOCIATED WITH NEUROCOGNITIVE FUNCTION IN PEOPLE WITH HIV

Harpreet Kaur, Kunling Wu, Robert Kalayjian, Frank Palella, Susan L. Koletar, Corrilynn O. Hileman, William Bush, Kristine Erlandsson, Ronald J. Ellis, Roger Bedimo, Babafemi O. Taiwo, Katherine Tassiopoulos, Asha R. Kallianpur, for the ACTG A5322 Study Team

407 CSF EXOSOME Aβ42 AND TAU/AB42 RATIO ASSOCIATED WITH COGNITIVE DISORDERS IN OLDER PWH

Debjani Guha, Vikas Misra, David Lorenz, Dana Gabuzda

408 HIGH PROTEIN CARBONYL LEVELS CORRELATE WITH ABNORMAL WHITE MATTER IN PEOPLE WITH HIV

409 INTRA-INDIVIDUAL STABILITY OF CSF BIOMarkers OVER 12 YEARS IN PEOPLE WITH HIV (PWH)

410 DECREASING CNS MYELOID ACTIVATION RELATES TO DECREASING NEURODEGENERATION IN HIV
Azin Tavasoli, Scott L. Letendre, Benjamin B. Gelman, Christina M. Marra, David Clifford, Susan Morgello, Jennifer Iudicello, Leah H. Rubin, Ronald J. Ellis

411 SERUM AND CSF ULTRASENSITIVE DETECTION OF NFL AND ALZHEIMER BIOMARKERS IN PLWH
Mattia Trunfio, Miriam Antonucci, Jessica Cusato, Daniela Vai, Daniele Imperiale, Antonio D’Avolio, Stefano Bonora, Giovanni Di Perri, Andrea Calcagno

412 ASSOCIATIONS BETWEEN PLASMA BIOMARKERS AND NEUROCOGNITION IN ART-TREATED PWH
Robert Kalayjian, Corrilynn O. Hileman, Ronald J. Ellis, Asha R. Kallianpur, Roger Bedimo, Kristine Erlandson, Susan L. Koletar, Babafemi O. Taiwo, Kunling Wu, Frank Palella, Katherine Tassiopoulos

413 SERUM NEUROFILAMENT AS A MARKER OF WHITE MATTER INJURY IN HIV DISEASE
Christina S. Meade, Sheri L. Towe, David M. Murdoch, Ryan P. Bell

414 PLASMA D-DIMER, A MARKER OF INFLAMMATION, IS INCREASED WITH POLYNEUROPATHY IN HIV
Ronald J. Ellis, David Clifford, Christina M. Marra, Ann C. Collier, Benjamin B. Gelman, Jessica Robinson-Papp, Scott L. Letendre, J Allen McCutchan, Robert K. Heaton

415 mtDNA HAPLOGROUPS AND COGNITIVE FUNCTION IN BLACK AND HISPANIC WOMEN WITH HIV

Poster Session-G01 WHAT’S NEW IN PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS
2:00 PM MT - 3:30 PM MT

429 IV PUSH ADMINISTRATION OF IBALIZUMAB: PHARMACOKINETICS, SAFETY, AND EFFICACY
Edwin DeJesus, Gary Richmond, Mezgebe Berhe, Anthony Mills, Tanya Schreibman, Charlotte-Paige Rolle, Kuei-Ling Kuo, Mohammed Zoghbi, Olivia G. Goss, Robert B. Cash, YingAn Lai, Martin Markowitz, Pedro M. Mesquita

430 DEEPHIV: DEEP LEARNING TO PREDICT DDI RELEVANCE FOR ARVs
Thao Pham, Mohamed Ghafoor, Justin Chiong, Dennis Wang, Marco Siccardi

431 PK & SAFETY OF DARUNAVIR/COBICISTAT WITH ONCE-WEEKLY ISONIAZID/RIFAPENTINE
Kristina M. Brooks, Alice K. Pau, Doris Swaim, Haden T. Bunn, Lilian Adejo, Charles A. Peloquin, Parag Kumar, Joseph A. Kovacs, Jomy M. George
432 ISLATRAVIR DOES NOT PROLONG QTC IN A THOROUGH QT STUDY IN HEALTHY PARTICIPANTS
Randolph P. Matthews, Yang Liu, Catherine Matthews, Kristin Butterfield, Terry O’Reilly, Selwyn A. Stoch, Marian Iwamoto

433 EVALUATION OF POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN ISLATRAVIR AND LENACAPAVIR
Haeyoung Zhang, Eva Mortensen, Martin Rhee, Luxi Cao, Aaron M. Share, John Ling, Ramesh Palaparthi

434 PHARMACOKINETICS OF LENACAPAVIR IN PARTICIPANTS WITH SEVERE RENAL IMPAIRMENT
Elijah Weber, Hiba Graham, Steve West, John Ling, Martin Rhee, Ramesh Palaparthi

435 REMOVAL OF DORAVIRINE BY HEMODIALYSIS IN HIV-INFECTED PATIENTS
Jose Molto, Fredzzia Graterol, Adrià Curran, Natalia Ramos, Arkaitz Imaz, Diego Sandoval, Francisco Perez, Lucia Bailon, Saye Khoo, Laura Else, Bonaventura Clotet

436 PHARMACOKINETICS OF DOLUTEGRAVIR AND BICTEGRAVIR IN OBESE PEOPLE LIVING WITH HIV
Mattia Berton, Sara Bettoni, Laurent Decosterd, Manuel Battegay, Matthias Cavassini, Felix Stader, Catia Marzolini

437 STUDY 31/A5349 POPULATION PHARMACOKINETIC ANALYSIS OF RIFAPENTINE AND MOXIFLOXACIN
Vincent Chang, Marc Weiner, Marjorie Z. Imperial, Nan Zhang, William Whitworth, Xia Byrant, Melissa Engle, Susan Dorm an, Payam Nahid, Susan Swindells, Richard E. Chaissen, Pheona Nsubuga, Kelly Dooley, Rada Savic, for the AIDS Clinical Trials Group and the Tuberculosis Trials Consortium

438 PHARMACOGENETICS OF BEDAQUILINE AND CLOFAZIMINE PLASMA CLEARANCE AMONG SOUTH AFRICANS

439 PHARMACOGENETICS OF DOLUTEGRAVIR PLASMA EXPOSURE AMONG SOUTH AFRICANS LIVING WITH HIV
Zinhle Cindi, Aida N. Kawuma, Gary Maartens, Roeland E. Wasmann, Paolo Denti, Lubbe Wiesner, Yuk Bradford, Francois Venter, Simiso M. Sokhela, Nomathembha Chandiwana, Marylyn D. Ritchie, David W. Haas, Phumla Sinxadi

Poster Session-H05 NOVEL AGENTS: INTRIGUING RESULTS
2:00 PM MT - 3:30 PM MT

498 DURABLE HUMAN HIV-SPECIFIC bNAb PRODUCTION 3 YEARS AFTER AAV8-MEDIATED GENE TRANSFER
Joseph P. Casazza, Evan M. Cale, Sandeep Narpala, Laura Novik, Galina V. Yamshchikov, Bob C. Lin, Janardan P. Pandey, Adrian McDermott, Mario R. Roederer, Alejandro Balazs, David Baltimore, Richard A. Koup, Julie E. Ledgerwood, John R. Mascola, for the VRC603 Team
499 MECHANISMS OF HOPEAPHENOL INHIBITION OF HIV PROVIRUS FOLLOWING DISCONTINUATION

500 INTRINSIC RESISTANCE OF HIV-2 AND SIV TO THE MATURATION INHIBITOR GSK2838232
Robert A. Smith, Dana N. Raugi, Robbie Nixon, Jennifer Song, Moussa Seydi, Geoffrey S. Gottlieb, for the University of Washington-Senegal HIV-2 Study Group

501 HIV-1 NONGROUP M PHENOTYPIC SUSCEPTIBILITY TO IBALIZUMAB (ANTI-CD4)
Lucie Poisson-Arnaud, Quentin Le Hingrat, Jean-Christophe Plantier, Elodie Alessandri-Gradt

432 ISLATRAVIR DOES NOT PROLONG QTc IN A THOROUGH QT STUDY IN HEALTHY PARTICIPANTS
Randolph P. Matthews, Yang Liu, Catherine Matthews, Kristin Butterfield, Terry O’Reilly, Selwyn A. Stoch, Marian Iwamoto

Poster Session-I01  PROFILING THE SENSITIVITY OF HIV TO NEUTRALIZING ANTIBODIES IN VIVO
2:00 PM MT - 3:30 PM MT

503 SUSCEPTIBILITY TO 3BNC117 AND 10-1074 IN ART-SUPPRESSED CHRONICALLY INFECTED PERSONS

504 PERFORMANCE OF A PHENOTYPE AND 2 GENOTYPE ALGORITHMS FOR bNAb SENSITIVITY PREDICTION
Marie H. Pahus, Jesper D. Gunst, Victor Ramos, Martin Tolstrup, Jacqueline D. Reeves, Christos Petropoulos, Michel Nussenzweig, Marina Caskey, Ole Søgaard

505 MUTATIONAL LANDSCAPE OF 10-1074 AND 3BNC117 SENSITIVITY IN A UK POPULATION WITH PHI
Penny Zacharopoulou, Lilian Nogueira, Thiago Oliveira, Helen Brown, Nicola Robinson, Sabine Kinloch-de Loes, Amanda Clarke, John Thornhill, Marina Caskey, Michel Nussenzweig, Julie Fox, Sarah Fidler, M. A. Ansari, John Frater, for the RIO and HEATHER Trial Investigators

Poster Session-I02  IMPACT OF HIV MUTATIONS ON FITNESS, DRUG RESISTANCE, AND TREATMENT RESPONSE
2:00 PM MT - 3:30 PM MT

506 EFFECT OF L74I POLYMORPHISM ON FITNESS OF HIV-1 SUBTYPE A6 RESISTANT TO CABOTEGRAVIR
Zixin Hu, Trevor Cordwell, Jerry Jeffrey, Daniel Kuritzkes

507 HOW MUTATIONS IN THE HIV-1 3’-POLYPURINE TRACT CONFER DOLUTEGRAVIR RESISTANCE
Jose Dekker, Bep Klaver, Ben Berkhout, Atze Das
ABSENCE OF CROSS-RESISTANCE TO LENACAPAVIR IN HIV ENTRY INHIBITOR-RESISTANT ISOLATES
Nicolas Margot, Vidula Naik, Laurie VanderVeen, Martin Rhee, Christian Callebaut

HIV DRUG RESISTANCE IN WOMEN RANDOMIZED TO DTG VS EFV OR TDF VS TAF IN PREGNANCY
Ceejay L. Boyce, Sean Brummel, Lauren Ziembia, Katie McCarthy, Kevin Knowles, Sheila Styrchak, Renee Browning, Nahida Chakhtoura, Sikkhullie Moyo, Tichaona Vhembo, Violet Korutaro, José H. Pilotto, Lameck Chinula, Shahn Lockman, Lisa M. Frenkel

A RANDOMIZED TRIAL OF DTG PLUS DRV/c AS A SWITCH STRATEGY IN SUBJECTS WITH MDR HIV-1
José Ramón Santos, Pere Domingo, Joaquín Portilla, Félix Gutiérrez, Arkaitz Imaiz, Helem H. Vilchez, Adrià Curran, Nieves Valcarce, Antoni Payeras, Enrique Bernal, Marta Montero, Miguel Ysusuki, Roger Paredes

LOW-LEVEL RESISTANCE MUTATIONS CORRELATE WITH HIV THERAPY FAILURE IN PREGNANT WOMEN

CHANGES IN THE HIV-1 3’-PPT IN PATIENTS FAILING DOLUTEGRAVIR IN BRAZIL
Jeroen J. van Kampen, Rob Gruters, Saye Khoo, Daniel Kuritzkes, Ricardo S. Diaz, James Hunter, Thibault Mesplede, David van de Vijver, Jolanda Voermans, Ben Berkhout, Atze Daas, Mauro Schechter

IMPACT OF NASH ON THE SURVIVAL OF PEOPLE LIVING WITH HIV
Juan Macías, Antonio Rivero-Juarez, Alejandro Gonzalez-Serna, Mario Frias, MARTA SANTOS, Ignacio Perez-Valero, Anaís Corman-Gomez, Antonio Rivero, Miguel Garcia-Deltoro, Luis M. Real, Juan A. Pineda

NONINVASIVE PREDICTION OF HEPATIC DECOMPENSATION IN PATIENTS WITH HIV
Amine Benmassaoud, Juan Macias, Anaís Corman-Gomez, Giovanni Guaraldi, Jovana Milic, Jürgen K. Rockstroh, Kathrin Van Bremen, Emmanuel Toschatzis, Akhilesh Mulay, Jennifer Price, Lucy J. Garvey, Dana Klabawi, Juan A. Pineda, Victor De-Ledinghen, Giada Sebastiani

NAFLD IS COMMON AND ASSOCIATED WITH CARDIOVASCULAR RISK IN REPRIEVE PARTICIPANTS
Carl J. Fichtenbaum, Heather J. Ribaudo, Jana Taron, Jorge T. Leon-Cruz, Netanya S. Utay, Ken Ho, Annie Luetkemeyer, Shobha Swaminathan, Carrie Johnston, Evelyne S. Fulda, Emma Kileel, Michael T. Lu, Steven Grinspoon, Jordan Lake, for the REPRIEVE Trial Investigators

FROM NAFLD TO MAFLD: IMPLICATIONS OF CHANGE IN TERMINOLOGY IN PWH
Giovanni Guaraldi, Jovana Milic, Stefano Renzetti, Federico Motta, Licia Gozzi, Adriana Cervo, Giulia Burastero, Vittorio Iadisernia, Bertrand Lebouché, Alshaima Alhinai, Marc Deschenes, Paolo Raggi, Stefano Calza, Cristina Mussini, Giada Sebastiani
522 THE PATHWAY OF NAFLD VS MAFLD TOWARD SIGNIFICANT FIBROSIS
Jovana Milic, Stefano Renzetti, Federico Motta, Licia Gozzi, Giulia Besutti, Giulia Burastero, Vittorio Iadisernia, Bertrand Lebouché, Alshaima Alhinai, Marc Deschenes, Stefano Calza, Cristina Mussini, Giada Sebastiani, Giovanni Guaraldi

523 HIGH INCIDENCE RATE OF CT-MEASURED NAFLD IN MEN WITH AND WITHOUT HIV INFECTION

524 DETERMINANTS OF LIVER STEATOSIS IN PEOPLE LIVING WITH HIV ON ANTIRETROVIRAL THERAPY
Carlotta Riebensahm, Annalisa Berzigotti, Bernard Surial, Huldrych F. Günthard, Philip Tarr, Hansjakob Furrer, André Rauch, Gilles Wandelier

525 CANNABIS USE AND HEPATIC STEATOSIS BY MRI-PDFF
Janet Diaz-Martinez, Javier A. Tamargo, Ivan Delgado-Enciso, Richard Ehman, Jun Chen, Kenneth E. Sherman, Leslie Seminario, Jupshy Jasmin, Marianna K. Baum, for the MASH Cohort

526 METABOLIC-ASSOCIATED FATTY LIVER DISEASE AND ITS ASSOCIATION WITH EPICARDIAL FAT
Win Min Han, Tanakorn Apornpong, Sasiwimol Ubolyam, Stephen J. Kerr, Anchalee Avihingsanon

527 NONOBSE NAFLD IS ASSOCIATED WITH HIGHER sCD14 CONCENTRATIONS IN ADULTS WITH HIV
Jordan Lake, Han Feng, Hongyu Miao, Paula Debroy, Anoma Somasunderam, Netanya S. Utay

Poster Session-K01 CANCER RISK, TREATMENT, AND EPIDEMIOLOGY
2:00 PM MT - 3:30 PM MT

552 DISTINCT CANCERS HAVE DISTINCT INFLAMMATORY PREDICTORS IN TREATED HIV

553 PROINFLAMMATORY GLYCOMIC DYSREGULATIONS PRECEDE CANCER ONSET DURING HIV INFECTION
Leila B. Giron, Jane Koshy, Jianyi Ding, David Lu, Geoffrey A. Feret, Ted Barrell, Alan Landay, Qin Liu, Robert Gross, Mohamed Abdel-Mohsen

554 USING NEXT-GENERATION SEQUENCING TO DETECT GENES RELATED TO CANCER IN WOMEN WITH HIV
Stephanie Jo, Alicia Golembieski, Dwayne Baxa

555 DELAYED ART LEADS TO IRREVERSIBLE DEPLETION OF SKIN AND MUCOSA RESIDENT MEMORY T CELL
Simona Saluzzo, Ram Vinay Pandey, Laura M. Gail, Lisa Kleissl, Johanna Strobl, Veronique Touzeau-Römer, Armin Rieger, Matthias Farlik, Wolfgang Weninger, Georg Stingl, Georg Stary
556  CD4+ AND RISK OF ADVERSE EVENTS IN PARTICIPANTS RECEIVING IMMUNOTHERAPY FOR CANCER
Thomas Odeny, Kathryn Lurain, Julius Strauss, Thomas S. Uldrick, Steven Fling, Elad Sharon, Anna K. Wright, James Gulley, Robert Yarchoan, Ramya Ramaswami

557  EXCESS MORTALITY ASSOCIATED WITH CANCER IN A PRIVATE HIV CARE PROGRAM IN SOUTH AFRICA
Yann Ruffieux, Hannes Mouton, Andreas D. Haas, Matthias Egger, Gary Maartens, Eliane Rohner

558  AGE AND CANCER INCIDENCE IN 5.2 MILLION PEOPLE LIVING WITH HIV IN SOUTH AFRICA
Yann Ruffieux, Mazvita Muchengeti, Victor Olago, Tafadzwa G. Dhokotera, Julia Bohlius, Matthias Egger, Elvira Singh, Eliane Rohner

559  TRENDS IN CANCER INCIDENCE IN DIFFERENT MODERN ART ERAS AMONG PEOPLE LIVING WITH HIV
Lauren Greenberg, for the RESPOND Cohort Consortium and the D:A:D Study

560  THE SOUTH AFRICAN HIV CANCER MATCH STUDY: COHORT PROFILE
Mazvita Muchengeti, Victor Olago, Matthias Egger, Tafadzwa G. Dhokotera, Elvira Singh, Julia Bohlius

Poster Session-L01  RISK FACTOR AND INFLAMMATORY MEDIATORS OF CARDIOVASCULAR DISEASE
2:00 PM MT - 3:30 PM MT

575  PREVALENCE AND CARDIOVASCULAR OUTCOME OF CLONAL HEMATOPOIESIS IN MEN LIVING WITH HIV

576  CLONAL HEMATOPOIESIS, INFLAMMATION, AND CORONARY ARTERY DISEASE IN PERSONS WITH HIV

577  SUBCLINICAL ATHEROSCLEROSIS AND IMMUNE ACTIVATION AMONG US FEMALES VS MALES WITH HIV
Markella V. Zanni, Borek Foldyna, Kenneth Williams, Tricia H. Burdo, Sara McCallum, Sara E. Looby, Patrick Autissier, Kathleen Fitch, Judith S. Currier, Michael T. Lu, Pamela S. Douglas, Heather J. Ribaudo, Steven Grinspoon, for the REPRIEVE Investigators

578  INFLAMMATORY CLUSTERS PREDICT MULTIMORBIDITY AND CVD IN PEOPLE WITH HIV ON ART

579  GDF15 IS A MARKER OF HIGH-RISK CORONARY Atherosclerotic PLAQUE IN PLWH
Léna Royston, Stéphane Isnard, Nils Perrin, John Lin, Brandon Fombuena, Manel Sadouni, Nicolas Chomont, Mohammad-Ali Jenabian, Benoit Trottier, Jean-Guy Baril, Carl Chartrand-Lefebvre, Cécile Tremblay, Madeleine Durand, Jean-Pierre Routy, for the Canadian HIV and Aging Cohort Study
580 ROLE OF RENIN-ANGIOTENSIN-ALDOSTERONE ACTIVATION IN ARTERIAL INFLAMMATION IN HIV
Grace Shen, Teressa S. Thomas, Allie R. Walpert, Kathleen Fitch, Christopher R. deFilippi, Gail K. Adler, Steven Grinspoon, Suman Srivinasa

581 STATIN USE IN ART-TREATED HIV REVEALS AN ALTERED MACROPHAGE TRANSCRIPTOMIC PROFILE
Jeeda Ismail, Cheryl M. Cameron, Manonmani Kumar, Banumathi Tamilselvan, Ken Riedl, Aya Cannon, Emily Bowman, Grace A. McComsey, Nicholas Funderburg, Mark J. Cameron

582 HIGH-SENSITIVE TROPONINS AND CORONARY CALCIUM SCORE IN OLDER ASIAN HIV
Pairoj Chattranukulchaisri, Sarawut Siwamogsatham, Hay Mar Su Lwin, Tanakorn Apornpong, Win Min Han, Sivapon Gatechompol, Opas Putcharoen, Anchalee Avihingsanon, for the HIV-NAT 006/207 Study Team

583 CORONARY FLOW RESERVE ON DTG/ABC/3TC AT BASELINE AND AFTER SWITCH TO BIC/FTC/TAF
Daniel M. Huck, Brittany Weber, Sean Parks, Sanjay Divakaran, Jennifer M. Brown, Courtney Bibbo, Leanne Barrett, Camden Bay, Laura Kogelman, Virginia A. Triant, Jacqueline Chu, Nina Lin, Kathleen Melbourne, Paul E. Sax, Marcelo Di Carli

Poster Session – M04  FRAILTY AND SLEEP DISTURBANCES
2:00 PM MT - 3:30 PM MT

615 ASSOCIATION OF PHENOTYPIC AGING WITH COMORBIDITIES, FRAILTY, AND INFLAMMATORY MARKER
Win Min Han, Tanakorn Apornpong, Sivapon Gatechompol, Sasiwimol Ubolyam, Stephen J. Kerr, Kristine Erlandson

616 L-FERRITIN AND TIM-1 ARE ASSOCIATED WITH FRAILTY MEASURES IN PEOPLE WITH HIV
Harpreet Kaur, Robert Kalyanjian, Kunling Wu, Katherine Tassiopoulos, Frank Palella, Babafemi O. Taiwo, William Bush, Corrilynn O. Hileman, Roger Bedimo, Susan L. Koletar, Ronald J. Ellis, Kristine Erlandson, Asha R. Kallianpur, for the ACTG A5322 Study Team

617 MUSCLE QUALITY AND PHYSICAL FUNCTION IN MEN WITH AND WITHOUT HIV
Jing Sun, Todd Brown, Susan Langan, Frank Palella, Jordan Lake, Lawrence A. Kingsley, Wendy Post, Kristine Erlandson, for the MACS/WIHS Combined Cohort Study

618 THE FUNCRAIL SCORE TO DISCRIMINATE FRAILTY IN OLDER ADULTS WITH HIV
Matilde Sánchez-Conde, Antonio Antela, Jorge Vergas, Margarita Ramírez, Pablo Ryan, Fernando Dronda, Maria José Galindo, Miguel Torralba, Maria Jesús Bustinduy, Alfonso Cabello Úbeda, Carmen Busca Arentzana, Isabel Machuca, Fatima Brañas

619 ASSOCIATION OF SLEEP DISRUPTION WITH KYNURENINE PATHWAY ACTIVATION IN WOMEN WITH HIV
Andrea C. Rogando, Kathleen Weber, Jiaqian Xing, Xiaonan Xue, Tsion Yohannes, Ralph Morack, Qibin Qi, Clary Clish, Kevin Bullock, Deborah Gustafson, Kathryn Anastos, Anjali Sharma, Helen J. Burgess, Audrey L. French
620 **SLEEP AND FRAILTY AMONG MEN WITH AND WITHOUT HIV**
Mary Clare C. Masters, Benjamin Barrett, Gypsysamber D’Souza, Joshua Hyong-Jin Cho, Sanjay R. Patel, Valentina Stosor, Naresh M. Punjabi, Frank Palella

621 **POOR SLEEP IS LINKED TO CVD RISK IN PLWH IN A SOUTHWESTERN US CLINIC**
Rita A. Bedrossian, Julia Fisher, Ryan Weltzer, Rachel Briggs, Anna C. Ressel, Marine Khachatryan, Jacob C. Matthews, Bao Q. Thai, Jagteshwar Tung, Michael Grandner, Freda Patterson, Elizabeth Connick

**Poster Session - M05  BIOMARKERS AND COMORBIDITIES**

622 **EXTERNAL VALIDATION OF BIOMARKER CLUSTERS BASED ON PROTEIN BIOMARKERS**
Nicholas Bakewell, Caroline Sabin, Nicki D. Doyle, Alejandro A. Garcia, Riya Negi, Frank A. Post, Jane Anderson, Jaime Vera, Marta Boffito, Lewis Haddow, Memory Sachikonye, Alan Winston, Patrick Mallon, Ken Kunisaki

623 **NETWORK ANALYSIS HIGHLIGHTS DIFFERENTIAL CLINICAL AND OMICS PROFILES IN HIV INFECTION**
Flora Mikaeloff, Marco Gelpi, Andreas D. Knudsen, Beate Vestad, Julie Høgh, Johannes R. Hov, Thomas Benfield, Daniel Murray, Marius Trøseid, Susanne D. Nielsen, Ujjwal Neogi

624 **EFFECT OF TENOFOVIR ON T-CELL MATURATIONAL SUBSETS IN LONG-TERM AVIREMIC HIV ADULTS**
Javier Rodriguez-Centeno, Andrés Esteban-Cantos, Julen Cadiñanos, Rocio Montejano, Natalia Stella-Ascariz, Rosa De Miguel, Beatriz Mena-Garay, Gabriel Saiz-Medrano, Belen Alejos, Maria Jimenez-Gonzalez, Jose I. Bernardino, Juan M. Castro-Alvarez, Berta Rodes, Jose R. Arribas

625 **TENOFOVIR ALAFENAMIDE IS ASSOCIATED WITH SHORTER TELOMERE LENGTH IN PEOPLE WITH HIV**
Upal Roy, Avery Matthews, Asante R. Kamkwala, Ankita Garg, Hansapani Rodrigo, David Clifford, Benjamin B. Gelman, Christina M. Marra, Susan Morgello, Leah H. Rubin, Donald Franklin, Robert K. Heaton, Yue Lin, Ronald J. Ellis, Scott L. Letendre

**Poster Session - N01  POSTACUTE SEQUELAE OF SARS-CoV-2 INFECTION**

626 **POST-ACUTE SEQUELAE OF SARS-CoV-2 IN NONHOSPITALIZED ACTIV-2 TRIAL PARTICIPANTS**
Teresa H. Evering, Busola Sanusi, Nikolaus Jilg, Eunice Yeh, Carlee B. Moser, David A. Wohl, Eric S. Daar, Paul Klekotka, Arzhang Cyrus Javan, Joseph J. Eron, Judith S. Currier, Michael Hughes, Davey M. Smith, Kara W. Chew, for the ACTIV-2/A5401 Study Team

627 **CLINICAL CONDITIONS ASSOCIATED WITH PASC IN KAISER PERMANENTE MID-ATLANTIC STATES**
628 PERSISTENT COVID-19 SYMPTOMS ARE HIGHLY PREVALENT 12 MONTHS AFTER HOSPITALIZATION
Catherine Chirouze, Delphine Bachelet, Jean sebastien Hulot, Minerva Cervantes-Gonzalez, Francois Goehringer, Adrien Lemaignen, Mylene Maillet, Pierre Delobel, Matthieu Revest, Xavier Duval, Cedric Laouenan, Jade Ghotan, for the French COVID Study Group and Investigators Group

629 CHEST CT BODY COMPOSITION CHANGES AT 3 AND 6 MONTHS AFTER SEVERE COVID-19 PNEUMONIA
Giulia Besutti, Jovana Milic, Giovanni Dolci, Marta Ottone, Marco Massari, Guido Ligabue, Filippo Monelli, Massimo Pellegrini, Efrem Bonelli, Paolo Giorgi Rossi, Giovanni Guaraldi

630 POST-COVID19 QUALITY OF LIFE: LOW SATISFACTION WITH PHYSICAL AND MENTAL HEALTH STATUS
Ilaria Mastrorosa, Carmela Pinnetti, Giulia Del Duca, Patrizia Lorenzini, Alessandra Vergori, Marta Camici, Anna Clelia Brita, Valentina Mazzotta, Pierangelo Chinello, Paola Mencarini, Maria Letizia Giancola, Amina Abdeddaim, Enrico Girardi, Francesco Vaia, Andrea Antonini

631 NEUROLOGIC AND IMMUNOLOGIC BIOMARKERS ASSOCIATED WITH POST-COVID NEUROLOGIC SYMPTOMS
Michael J. Peluso, Hannah M. Sans, Carrie A. Forman, Ahmed Chenna, Brandon C. Yee, John W. Winslow, Christos Petropoulos, Jeffrey N. Martin, John D. Kelly, Meredith Greene, Felicia C. Chow, Joanna Hellmuth, Timothy J. Henrich, Dave Glidden, Steven G. Deeks

Poster Session-004 NOVEL INSIGHTS IN CRYPTOCOCCAL MENINGITIS EPIDEMIOLOGY, TREATMENT, AND OUTCOMES

663 THE DREAMM PROJECT: EPIDEMIOLOGICAL FINDINGS AND CRYPTOCOCCAL MENINGITIS OUTCOMES
Cecelia Kanyama, Charles Kouanfack, Sayoki Mfinanga, Saulos Nyirenda, Aude Sturny-Leclere, Emma Beaumont, Sokoine Lesikari, Timothée Boyer-Chammard, Olivier Lortholary, Shabbar Jaffar, John Bradley, Sile Molloy, Tom Harrison, Angela Loyse, for the DREAMM Consortium

664 COST-EFFECTIVENESS OF THE AMBITION REGIMEN FOR HIV-ASSOCIATED CRYPTOCOCCAL MENINGITIS
Charles Muthoga, David S. Lawrence, David Meya, Henry Mwandumba, Cecelia Kanyama, Graeme Meintjes, Conrad Muzoora, Mosepele Mosepele, Chiratidzo E. Ndlovu, Tinevimbo Shiri, Shabbar Jaffar, Tom Harrison, Joseph N. Jarvis, Louis W. Niessen, for the AMBITION Study Group

665 RAPID SEMI-QUANTITATIVE ANTIGEN TESTING AND MORTALITY IN CRYPTOCOCCAL MENINGITIS
Tshepo B. Leeme, Kwana Lechiile, Cheusisime Kajanga, Melanie Moyo, Henry Mwandumba, Nabila Youssouf, Mosepele Mosepele, Tshepiso Mbangiwa, Alexandre Alanio, Aude Sturny-Leclere, Timothée Boyer-Chammard, Olivier Lortholary, David S. Lawrence, Tom Harrison, Joseph N. Jarvis
Poster Sessions Day 1

**Poster Session-005**  
**CMV AND FUNGAL OPPORTUNISTIC INFECTIONS**  
2:00 PM MT - 3:30 PM MT

<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>666</td>
<td>ACTG A5351S: EFFECT OF IMMUNE-MODULATORY INTERVENTIONS ON CMV REPLICATION DURING ART</td>
<td>Elizabeth Hastie, Carlee B. Moser, Xin Sun, Jeff L. Lennox, Priscilla Hsue, Ronald J. Bosch, Steven G. Deeks, Milenka Vargas, Michael M. Lederman, Peter W. Hunt, Timothy J. Henrich, Vincent Marconi, Sara Gianella</td>
</tr>
<tr>
<td>667</td>
<td>CYTOMEGALOVIRUS VIREMIA AS A RISK FACTOR FOR MORTALITY IN HIV-ASSOCIATED MENINGITIS</td>
<td>Caleb Skipper, Katherine Hullsiek, Kiiza Tadeo, Michael Okirwoth, Nelmary Hernandez-Alvarado, Claudia Fernandez-Alarcon, Emily Martyn, Jayne Ellis, Kenneth Ssebambulidde, Lillian Tugume, Edwin Nuwagira, Fiona Cresswell, David Meya, David R. Boulware, Mark R. Schleiss</td>
</tr>
<tr>
<td>668</td>
<td>CMV VIREMIA AND DISEASE IN VERY ADVANCED LATE PRESENTERS: AN ADVANZ-4 TRIAL SUBSTUDY</td>
<td>Paula Suanzes, Adrià Curran, Ferran Torres, Maria A. Marcos, Pere Domingo, Maria Saumoy, Roger Paredes, Christian Manzardo, Lluis Force, Eva Bonfill, Nuria Climent, Montserrat Plana, Vicenç Falcó, Jose M. Miro, for the Advanz-4 Study Group</td>
</tr>
<tr>
<td>669</td>
<td>A MORE INDIVIDUALIZED ANTIFUNGAL TREATMENT REGIMEN FOR MODERATE TO SEVERE HIV/PCP</td>
<td>Yingqiu Huang, Xiaoqing He, presented by Yaokai Chen</td>
</tr>
</tbody>
</table>

**Poster Session-P03**  
**EVOLVING INSIGHTS: MTCT RISK TO MATERNAL HEALTH**  
2:00 PM MT - 3:30 PM MT

<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>684</td>
<td>PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION</td>
<td>Jeanne Sibiude, Jerome Le Chenadec, Laurent Mandelbrot, Alexandre Hoctin, Catherine Dollfus, Albert Faye, Eida Bui, Emmanuelle Pannier Metzger, Jade Ghosn, Valérie Garrait, Véronique Avettrand-Fenoël, Pierre Frange, Josiane Warszawski, Roland Tubiana, for the ANRS-EPF Study Group</td>
</tr>
<tr>
<td>685</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>686</td>
<td>PBPK MODELING OF LONG-ACTING INJECTABLE CABOTEGRAVIR IN PREGNANCY</td>
<td>Shakir A. Atoyebi, Fazila S. Bunglawala, Nicolas Cottura, Maiara C. Montanha, Marco Siccardi, Catriona Waitt</td>
</tr>
<tr>
<td>687</td>
<td>PREGNANCY HEMOGLOBIN A1c AND GLUCOSE WITH DTG VS EFV, TDF VS TAF: IMPAACT 2010</td>
<td>Lameck Chinula, Evan Goldberg, Lauren Ziembta, Katie McCarthy, Chelsea Krotje, Kevin Knowles, Jyoti S. Mathad, Maria Leticia Santos Cruz, Risa M. Hoffman, Patrick Jean-Philippe, Tsungai Chipato, Deo Wabwire, Judith S. Currier, Shahin Lockman, Nahida Chakhtoura</td>
</tr>
</tbody>
</table>
688  WEIGHT GAIN WITH RALTEGRAVIR VS EFAVIRENZ DURING PREGNANCY  
Conrado M. Coutinho, Meredith Warshaw, Geraldo Duarte, Alice M. Stek, Avy Violari, Cristina B. Hofer, Jaime Deville, James S. Ngocho, José H. Pilotto, Mario D. Correa, Trevon Fuller, Nahida Chakhtoura, Mark Mirochnick, Esau Joao, for the NICHD P1081 Study Team

689  GESTATIONAL WEIGHT GAIN IN SOUTH AFRICAN PREGNANT WOMEN LIVING WITH HIV  
Hlengiwe P. Madlala, Landon Myer, Azetta Fisher, Mushu Matjila, Gregory Petro, Zandile Maqwatinini, Angela Bengtson

690  UNIQUE PROFILE OF INFLAMMATION AND IMMUNE ACTIVATION IN PREGNANT US WOMEN WITH HIV  
Stephanie Shiau, Denise Jacobson, Yanling Huo, Deborah Kacanek, Lynn M. Yee, David B. Williams, Lisa Haddad, Lena Serghides, Kathleen M. Powis, Paige L. Williams, Jennifer Jao, for the Pediatric HIV/AIDS Cohort Study

691  EPITOPES ASSOCIATED WITH ALTERED PATHOGENESIS IN VERTICAL HIV-1 TRANSMISSION  
Zak A. Yaffe, Kevin Sung, Jared Galloway, Ruth Nduati, Frederick Matsen IV, Julie Overbaugh

New Perspectives on the Health of Children Exposed to HIV in Utero  
2:00 PM MT - 3:30 PM MT

692  ASSOCIATION OF MATERNAL TDF-BASED ART WITH BONE MINERAL CONTENT IN BREASTFED INFANTS  
Tichaona Vhembo, Kristin Baltrusaitis, Camlin Tierney, Maxensia Owor, Sufia Dadhabhai, Avy Violari, Gerhard Theron, Dhayendre Moodley, Cynthia Mukwasi-Kahari, Kathleen George, John Shepherd, George K. Siberry, Renee Browning, Mary G. Fowler, Lynda Stranix-Chibanda

693  SIMILAR EARLY GROWTH IN HEU AND HUU INFANTS WITH MATERNAL ART OPTIMIZATION  
Maureen M. King’e, Irene Njuguna, Christine J. McGrath, Michelle Bulterys, Hellen Moraa, Alvin Onyango, Sarah Benki-Nugent, Dalton C. Wamalwa, Grace John-Stewart

694  MATERNAL IPT IN PREGNANCY AND GROWTH FALTERING AMONG HIV-EXPOSED UNINFECTED INFANTS  
Ashenafi S. Cherkos, Sylvia LaCourse, Daniel A. Enquobahrie, Grace Montepiedra, Carol Onyango, Blandina T. Mmbaga, Tichaona Vhembo, Gaerolwe Masheto, Gerhard Theron, Adriana Weinberg, Anita Gupta, Grace John-Stewart

695  PREDICTORS OF NEURODEVELOPMENT IN HIV-EXPOSED—UNINFECTED INFANTS  
Michelle Bulterys, Maureen M. King’e, Irene Njuguna, Daisy J. Chebet, Hellen Moraa, Jessica Dyer, Laurén Gomez, Melissa Gladstone, Christine J. McGrath, Anjuli D. Wagner, Dalton C. Wamalwa, Grace John-Stewart, Sarah Benki-Nugent

696  MITOCHONDRIAL PROTON LEAK IN INFANTS WITH IN UTERO HIV AND ART EXPOSURE IN BOTSWANA  
Poster Session Day 1

697 HEARING LOSS AND FETAL EXPOSURE TO ANTIRETROVIRAL DRUGS IN HIV-UNINFECTED CHILDREN
Peter Torre, Zhongli Zhang, Toinette Frederick, Murli Purswani, Howard J. Hoffman, Paige L. Williams, Tzy-Jyun Yao, for the Pediatric HIV/AIDS Cohort Study

698 Mtb INFECTION IN CHILDREN WITH AND WITHOUT HIV-EXPOSURE IN THE FIRST YEAR OF LIFE
Sylvia LaCourse, Jerphason O. Mecha, Jaclyn Escudero, Barbra A. Richardson, Elizabeth Maleche-Obimbo, Daniel Matemo, John Kinuthia, Grace John-Stewart

699 IDENTIFYING HIV-POSITIVE MOTHERS AND EXPOSED INFANTS IN MATERNAL CHILD SERVICES
Chloe A. Teasdale, Michelle Choy, Fatima Tsiouris, Eduarda Pimental de Gusmao, Etelvino Banqueiro, Nicole Flowers, Marilena Urso, Mirriah Vitale, Elaine J. Abrams

Poster Session-Q01 TIMING OF AND TESTING FOR HIV IN INFANTS, CHILDREN, AND YOUTH
2:00 PM MT - 3:30 PM MT

706 EVALUATION OF AN HIV-1/HIV-2 QUALITATIVE TEST FOR HIV EARLY INFANT DIAGNOSIS
Shuyi Li, Guoqing Zhang, Katrina Sleeman, Shon Nguyen, Demetrios Mathis, Heather Alexander, Clement Zeh

707 ESTIMATING TIME OF HIV-1 INFECTION IN INFANTS USING VIRAL SEQUENCE DIVERSITY
Magdalena Russell, Carolyn S. Fish, Sara Drescher, Noah Cassidy, Julie Overbaugh, Sarah Benki-Nugent, Jennifer Slyker, Dorothy Mbori-Ngacha, Rose Bosire, Dalton C. Wamalwa, Elizabeth Maleche-Obimbo, Grace John-Stewart, Frederick Matsen IV, Kara A. Lehman

708 COST OF AN HIV TEST-AND-TREAT STRATEGY AT BIRTH AND ITS EFFECT ON ART INITIATION
Kira Elsbernd, Issa Sabi, Joaquim Lequechane, Sirel Boniface, Chishamiso Mudenyanga, Chris W. Buck, Arlete Mamhume, Bindiya Meggi, Kassia Pereira, Mariana Müller, Till Bärnighausen, Michael Hoelscher, Arne Kroidl, Illes J. Zeh

709 VALIDATION OF A PEDIATRIC SCREENING TOOL TO IDENTIFY HIV-POSITIVE CHILDREN IN ZAMBIA

710 COMMUNITY-BASED, PEER-LED SRH SERVICES INCREASE COVERAGE IN AYP (YATHU YATHU TRIAL)
Mwelwa Phiri, Albertus Schaap, Lucheka Sigande, Rosemary Zulu-Phiri, Louis Mwape, Melvin Simuyaba, Sian Floyd, Sarah Fidler, Richard Hayes, Musonda Simwanga, Bernadette Hensen, Helen Ayles, for the Yathu Yathu Trial
**Poster Session-Q04  COMORBIDITIES AND COMPLICATIONS OF HIV AND ART IN CHILDREN AND YOUTH**  
2:00 PM MT - 3:30 PM MT

726 ESTIMATING ATHEROSCLEROTIC RISK IN SOUTH AFRICAN YOUTH WITH PERINATALLY ACQUIRED HIV  
Sana Mahtab, Lisa Frigati, Mothabisi Nyathi, Nana Akua Asafu-Agyei, Ntobeko Ntusi, Landon Myer, Heather Zar, Jennifer Jao

727 LONGITUDINAL CHANGES IN SUBCLINICAL VASCULAR DISEASE IN UGANDAN YOUTH WITH HIV  
Sahera Dirajjal-Fargo, Chenya Zhao, Abdus Sattar, Christine Karungi, Rashidah Nazzinda, Danielle Labbato, Nicholas Funderburg, Emmy Okello, Victor Musiime, Grace A. McComsey

728 MENTAL HEALTH AND TREATMENT OUTCOMES IN ADOLESCENTS LIVING WITH HIV IN WEST AFRICA  
Désiré Lucien Dahourou, Marc Harris Dassi Tchoupa Revegue, Marie-Sylvie N’Gbeche, Caroline Yonaba, Corinne Moh, Kouakou Kouadio, Patricia Nindjin, Karen Malatest, Jean-Claude Azani, Julie Jesson, Eulalie Kangah, Elisabeth Thio, Philippe Msellati, Valériane Leroy, for the IeDEA West-African Collaboration

729 MENTAL HEALTH DISORDERS IN HIV-POSITIVE ADOLESCENTS AND YOUTH: DATA FROM MOZAMBIQUE  
Francesco Di Gennaro, Anton Pozniak, Claudia Marotta, Lucy Ramirez, Hamilton Cardoso, Vasco Cintuaro, Natalia Chimundi, Andrea Azori, Izilda Chagurucu, Francesca Tognon, Giovanna De Meneghi, Edson Namarime, edoardo Occhi, Giovanni Putoto, Annalisa Saracino

730 PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE VERTICALLY HIV-INFECTED YOUTHS  
Itziar Carrasco, María Luisa Navarro, Sonia Alcolea, Antonio Olveira, Angel Lancharro, Maria Luisa Montes, Cristina Diez, Luis Escosa, Maria Jose Mellado, Carmen Busca Arenzana, Talía Sainz

731 WEIGHT GAIN AMONG ADOLESCENTS ON DOLUTEGRAVIR: A REAL CONCERN?  
Jesus Riscart, Eva Soria, Luis Prieto, Luis Escosa, Claudia Fortuny, Dolores Falcon, Antoinette Frick, Jose Tomas Ramos Amador, Matilde Bustillo, Maria Penin, Pilar Collado, María Luisa Navarro, Santiago Jiménez de Ory, Talía Sainz, for CORISPE

**Poster Session-R04  HIV CLUSTERS AND OUTBREAKS**  
2:00 PM MT - 3:30 PM MT

781 PRIORITIZING HIV-1 TRANSMISSION CLUSTERS FOR INTERVENTION: A PHYLOGENETIC APPROACH  
Rachel L. Miller, Angela McLaughlin, Richard Liang, Delphine Duahirwe, Anh Le, Chanson Brumme, Julio S. Montaner, Jeffrey B. Joy

782 PHYLOGENETIC TRACKING OF HIV EPIDEMIC GROWTH IN QUEBEC FROM 2014 TO 2020  
Bluma G. Brenner, Réjean Thomas, Isabelle Hardy, Ruxandra-Ilinca Ibanescu, Jean-Pierre Routy, Michel Roger, for the Montreal Primary HIV Infection Cohort
783 MOLECULAR ANALYSIS SUGGESTS LOW ONWARD HIV-1 TRANSMISSION AMONG MIGRANTS IN GREECE
Evangelia G. Kostaki, Stefanos Limnaios, Maria Chini, George Adamis, Vasileios Papastamopoulos, Anastasia Antoniadou, Simeon Metallidis, Vasileios Paparizos, Dimitrios Chatzidimitriou, Dimitra Paraskeva, Pagona Lagiou, Angelos Hatzakis, Gikas Magiorkinis, Lecimia Skoura, Dimitrios Paraskevis

784 DEEP LEARNING APPROACHES TO INFORM NETWORK-BASED HIV INTERVENTIONS AMONG PWID
Steven J. Clipman, Shruti H. Mehta, Shoba Mohapatra, Aylur K. Srikrishnan, Katie Zook, Priya Duggal, Saravanan Shanmugam, Paneerselvam Vandagopal, Muniratnam S. Kumar, Gregory M. Lucas, Carl Latkin, Sunil S. Solomon

785 HIGH HIV INCIDENCE AMONG PWID ON THE US/MEXICO BORDER DURING THE COVID-19 PANDEMIC
Britt Skaathun, Cho-Hee Shrader, Annick Borquez, Antoine Chaillon, Tetyana Vasylyeva, Irina Artamanova, Alicia Harvey-Vera, Gudelia Rangel, Steffanie Strathdee

786 MISSED OPPORTUNITIES: PREVENTION & CARE FOR PWID IN A WEST VIRGINIA HIV OUTBREAK
Robert A. Bonacci, Anne C. Moorman, Danae Bixler, McKenna Penley, Suzanne Wilson, Alana G. Hudson, Stephen Perez, Phillip P. Salvatore, Kathryn Curran, Rebecca Hershov, Alexandra M. Oster, Robert P. McClung, for the Kanawha County HIV Outbreak Investigation Team

Poster Session-R06 HIV EPIDEMIOLOGY 2:00 PM MT - 3:30 PM MT

797 GREEK MSM: 95-95-95 TARGET IS NOT ENOUGH TO MEET THE HIV INCIDENCE REDUCTION GOAL
Ilias Gountas, Kyriakos Souliotis, Georgios Nikolopoulos, Giota Touloumi

798 URBAN VERSUS RURAL ACHIEVEMENTS OF 90:90:90 TARGETS IN 12 AFRICAN COUNTRIES
Suhani Patel, Mansoor Farahani, Rachel Bray, Jessica E. Justman, Wafaa M. El-Sadr

799 AWARENESS OF HIV STATUS AMONG ADULTS LIVING WITH HIV IN 12 AFRICAN COUNTRIES
Ling Guo, Mansoor Farahani, Jessica E. Justman, Wafaa M. El-Sadr

800 DISCORDANT COUPLES’ KNOWLEDGE AND DISCLOSURE OF HIV STATUS IN 10 AFRICAN COUNTRIES
Mahad Magan, Mansoor Farahani, Rachel Bray, Dominique M. Reed, Jessica E. Justman, Wafaa M. El-Sadr

801 DIVERSE TIME TRENDS IN SEXUAL BEHAVIOR AFTER HIV DIAGNOSIS OVER 20 YEARS FOLLOW-UP
Kalongo Hamusonde, Dunja Nicca, Huldrych F. Günthard, Marcel Stöckle, Katharine E. Darling, Alexandra L. Calmy, Roger Kouyos, Andri Rauch, Luisa Salazar-Vizcaya, for the Swiss HIV Cohort Study

802 AUTHORSHIP INEQUALITIES IN GLOBAL HEALTH RESEARCH INITIATIVE
Veronika W. Skrivankova, Stefanie Hossmann, Carole Dupont, Morna Cornell, Marie Ballif, Matthias Egger
818 LIMIT OF DETECTION OF SARS-CoV-2 ANTIBODY ASSAYS
Evan Beck, Santosh Dhakal, Sharada Saraf, Reinaldo Fernandez, Owen R. Baker, Sabra L. Klein, Thomas Quinn, Oliver Laeyendecker

819 MSD V-PLEX SARS-CoV-2 ASSAY TO IDENTIFY VACCINATED AND INFECTED INDIVIDUALS
Evan Beck, Andrew Karaba, Xianming Zhu, Ruchee Shrestha, Aaron M. Milstone, Andrew Redd, Aaron Tobian, Evan M. Bloch, Emily Egbert, Joel Blankson, Yu-Hsiang Hsieh, Richard Rothman, Thomas Quinn, Oliver Laeyendecker

820 COMPARISON OF SARS-CoV-2 LIVE VIRUS NEUTRALIZATION AND SEROLOGIC IMMUNOA SAYS

821 DEVELOPMENT OF A HIGH-THROUGHPUT NGS WORKFLOW FOR SARS-CoV-2 WHOLE-GENOME SEQUENCING

822 ORAL SALIVA SWAB RT-PCR AS A FIT-FOR-PURPOSE DIAGNOSTIC TEST FOR COVID-19 IN CHILDREN
Cinta Moraleda, Sara Domínguez-Rodríguez, Juan Miguel Mesa, Paula García, Jose Antonio Alonso, Amanda Bermejo, Gema Sabrido, Leticia Martínez-Campos, María de la Serna, Arantxa Gonzalez, Álvaro Ballesteros, Juan Carlos Galán, Francisco Lorente, Alfredo Tagarro, for the EPICO-AEP Working Group

829 DIFFERENCES IN SEXUAL HEALTH CLINIC SERVICES BY AGE AND GENDER IN METROPOLITAN BOSTON
Anne M. Neilan, Yiqi Qian, Grace Chamberlin, Fatma M. Shebl, Kevin L. Ard

830 ASSESSING THE BENEFITS OF PREVENTION VERSUS CARE CONTINUUM INTERVENTIONS IN BALTIMORE
Melissa Schnure, Parastu Kasaie, David Dowdy, Maunank Shah, Ruchita Balasubramanian, Anthony T. Fojo

831 COST-EFFECTIVENESS OF HIV PrEP AMONG YOUNG MEN WHO HAVE SEX WITH MEN IN THE US
Alyssa K. Amick, G Ege Eskibozkurt, Sybil Hosek, Clare Flanagan, Raphael J. Landovitz, Kenneth Freedberg, Craig M. Wilson, Milton C. Weinstein, David Faltiel, Andrea Ciaramello, Anne M. Neilan

832 OUT-OF-POCKET PAYMENTS FOR PrEP DRUGS DECREASED ONLY MODESTLY IN 2021
Ya-Lin A. Huang, Weiming Zhu, Karen W. Hoover
833  PRESCRIPTIONS FOR BRAND AND GENERIC PrEP MEDICATIONS IN THE UNITED STATES
Duygu Islek, Weiming Zhu, Ya-Lin A. Huang, Karen W. Hoover

Weiming Zhu, Ya-Lin A. Huang, Athena Kourtis, Karen W. Hoover

835  EFFECT OF NAVIGATION ON LINKAGE TO HIV PREEXPOSURE PROPHYLAXIS AMONG US MSM
Anne A. Kimball, Weiming Zhu, Kashif Iqbal, Mary Tanner, Karen W. Hoover

836  ESTIMATING BENEFITS FROM USING ON-DEMAND ORAL PrEP BY MSM IN US: A MODELING STUDY
Sarah Stansfield, Mia Moore, Marie-Claude Boily, James Hughes, Deborah Donnell, Dobromir Dimitrov

837  PrEP INDICATIONS AND PrEP KNOWLEDGE, ACCESS, AND INTEREST AMONG INDIVIDUALS WITH HCV
Kristi C. Hill, Rachel Silk, Rahwa Eyasu, Onyinyechi Ogbumbadiugha, Emade Ebah, Amelia A. Cover, Ashley Davis, David Sternberg, Phyllis Bijole, Junfeng Sun, Henry Masur, Shyam Kotttilll, Sarah Kattakuzhy, Elana S. Rosenthal

838  PrEP LONG-TERM ENGAGEMENT AMONG MSM AND TGW IN LATIN AMERICA: THE ImPrEP STUDY
Valdilea Veloso, Ronaldo I. Moreira, Kelika A. Konda, Brenda Hoagland, Hamid Vega-Ramirez, Iuri C. Leite, Juan V. Guanira, Sergio Bautista-Arredondo, Heleen Vermander, Marcos R. Benedetti, Maria Pimenta, Thiago S. Torres, Beatriz Grinsztejn, Carlos F. Caceres, for the ImPrEP Study Group

839  DRUG RESISTANCE AND CLUSTERING PATTERNS AMONG PREVIOUS PrEP USERS WHO SEROCONVERTED
Angela McLaughlin, Junine Toy, Vincent Montoya, Paul Sereda, Jason Trigg, Amanda Granados, Sakshi Khanna, Chanson Brumme, Rolando Barrios, Julio S. Montaner, Jeffrey B. Joy

840  A RETROSPECTIVE ANALYSIS OF BONE LOSS IN EMTRICITABINE/TENOFOVIR THERAPY FOR HIV PrEP
Joseph C. Chang, Duy Do, Hector M. Delgado, An Huynh

841  TRENDS IN THE PREEXPOSURE PROPHYLAXIS CONTINUUM AMONG US LATINX MSM
Michael Barry, David Katz, Roxanne P. Kerani, Travis Sanchez, Jane J. Lee

869  TRENDS IN STI SCREENING DURING COVID-19 AND MISSED CASES AMONG ADOLESCENTS
Stephen Bonett, Daniel Teixeira da Silva, Danielle Petsis, Jungwon Min, Spandana Makeneni, Anjali Mahajan, Sarah M. Wood

870  STI TRANSMISSION DYNAMICS DURING THE COVID-19 PANDEMIC AMONG URBAN SEXUAL MINORITIES
Christina Schumacher, Nicole Thornton, Jessica Duchen, Carla Tilchin, Khalil Ghanem, Matthew M. Hamill, Carl Latkin, Anne Rompalo, Sebastian Ruhs, Adena Greenbaum, Jacky Jennings
**Poster Session-Y07  HIV AND SURVIVAL**

**CHARACTERISTICS OF DEATHS IN A PEPFAR HIV PROGRAM IN DEMOCRATIC REPUBLIC OF THE CONGO**
Dany Malaba, Michelle Selim, Paola Chanes-Mora, Hilary T. Wolf

**SURVIVAL AFTER HIV INFECTION IN THE ERA OF DECENTRALIZED DRUG DISTRIBUTION MODELS**
Amobi Onovo, David Onime, Jemeh Pius, Thomas Minior, Sena Woldetensay, Moses Katbi, Kaliwo Abiye, Adeeve Adegboye, Onyeka Igboelina, Chika Obiora-Okafo, Helina Meri, Rachel Goldstein

---

**Poster Session-Y08  COVID-19 AND HIV**

**TELEMEDICINE AND HIV CARE QUALITY MEASURES DURING THE COVID-19 PANDEMIC**
Mary Clare C. Masters, Juan Rivera, Mia Calamari, Katherine Wright, Patrick Janulis, Laura Rusie, Jacqueline Bannon, Patrick Milne, Shannon Galvin, Elena Molina, Lisa R. Hirschlhorn, Frank Paella, Rebecca N. Kumar, Cory Brown, Claudia Hawkins

**DID COVID-19 RESTRICTIONS IMPACT HIV TREATMENT AMONG MSM IN CHINA?**
Yinghui Sun, Weiran Zheng, Hui Li, Yanxiao Gao, Yuewei Zhan, Hui Chen, Yong Cai, Huachun Zhou

**PANDEMIC ERA CHANGES IN HIV/STI DIAGNOSES AND PrEP USE IN AN URBAN US HEALTH CENTER**
Kenneth H. Mayer, Sy Q. Gitin, Douglas Krakower, Chris H. Grasso, Katie Biello

**COVID-19–RELATED DISRUPTIONS IN THE HIV CARE CONTINUUM IN A LARGE URBAN COHORT OF PWH**
Amanda Castel, Shannon K. Barth, Michael A. Horberg, Jiayang Xiao, Anne Monroe, Alan E. Greenberg, for the DC Cohort Executive Committee

**SARS-CoV-2 VACCINATION: IMPACT ON HIV-1 RNA LEVELS AND ANTIBODY RESPONSE AMONG PLWH**
Vera Portillo, Pilar Ustero, Chiara Fedeli, Ianis Petignat, Ellen Cristina Mereles Costa, Adi Sulstarova, Cyril Jaksic, Sabine Yerly, Alexandra L. Calmy

**IMPACT OF COVID OUTBREAK ON PREVENTION AND CARE FOR HIV AND STIs AT A LARGE HOSPITAL**
Esteban Martinez, Elisa de Lazzari, Ivan Chivite, Ana Gonzalez-Cordon, Maria M. Mosquera, Montserrat Laguno, Jordi Bosch, Jose L. Blanco, Miriam Alvarez-Martínz, Berta Torres, Juan C. Hurtado, Josep Mallolas, Jose M. Miro, Maria A. Marcos

**CHARACTERIZING THE SCOPE AND DRIVERS OF THE IMPACT OF COVID-19 ON LOCAL HIV EPIDEMICS**
Anthony T. Fojo, Emma Wallengren, Melissa Schnure, Ruchita Balasubramanian, David Dowdy, Maunank Shah, Parastu Kasaie
944 HEALTHCARE ACCESS AMONG SOUTH AFRICAN YOUTH LIVING WITH & WITHOUT HIV DURING COVID-19
Danielle Giovenco, Audrey Pettifor, Stephanie Chung, Gina Itzikowitz, Yamkela Qaiya, Linda-Gail Bekker

945 COVID-19 AND THE HIV CARE CONTINUUM IN C3PNO COHORTS

946 IMPACT OF THE COVID-19 PANDEMIC ON HIV OUTPATIENT CARE AND VIRAL SUPPRESSION IN NYC
Shao Li Chaudhuri, Judith A. Aberg, Rachel Chasan, Emma Kaplan-Lewis, Keith Sigel

947 THE IMPACT OF THE COVID-19 LOCKDOWN ON HIV CARE CONTINUUM IN CHINA
Xinsheng Wu, Ganfeng Luo, Yuanyi Chen, Yi-Fan Lin, Yiguo Zhou, Yanxiao Gao, Yuewei Zhan, Huachun Zou

948 COVID-19 PANDEMIC IMPACT ON HIV PrEP PROGRAM ENGAGEMENT IN BRITISH COLUMBIA
Junine Toy, Cora Keeney, Raquel M. Espinoza, Wendy Zhang, Diana Kao, Erin Ready, Jason Trigg, Katherine J. Lepik, Mark Hull, Taylor McTilinden, Viviane D. Lima, Paul Sereda, David Moore, Rolando Barrios, Julio S. Montaner
TUESDAY, FEBRUARY 15, 2022

Poster Session-A02 IMMUNE CELL INFECTION AND RESPONSES
2:00 PM MT - 3:30 PM MT

170 RESTRICTED INFECTION OF MACROPHAGES BY SARS-CoV-2 INDUCES PROINFLAMMATORY RESPONSES

Sallieu Jalloh, Judith Olejnik, Jacob Berrigan, Ellen L. Suder, Annuurun Nisa, Sanjay Tyagi, Yuri Bushkin, Elke Mühlberger, Suryaram Gummuluru

171 NEUROPLIN-1 MEDIATES SARS-CoV-2 INFECTION OF ASTROCYTES PROMOTING NEURON DYSFUNCTION

Weili Kong, Mauricio Montano, Michael J. Corley, Ekram Wassim A. Helmy, Nadia Roan, Melanie M. Ott, Lishomwa Ndhlouvo, Warner Greene

172 GALECTIN-9 INDUCES SARS-CoV-2 REPLICATION AND INFLAMMATION IN AIRWAY EPITHELIAL CELLS

Li Du, Mohamed Bouzidi, Akshay Gala, Fred H. Deiter, Jean-Noël Billaud, Stephen T. Yeung, Prerna Dabrai, Jing Jin, Graham Simmons, Zain Y. Dossani, Toshiro Niki, Lishomwa Ndhlouvo, John Greenland, Satish Pillai

173 THE EFFECTS OF TYPE I & II IFNs DISCLOSE A ROLE FOR DOPAMINE IN SARS-CoV-2 INFECTION

Fiona Limanaqi, Gioia Cappelletti, Micaela Garziano, Sergio Strizzi, Claudia Vanetti, Claudio Fenizia, Daria Trabattoni, Mario Clerici, Mara Biasin

174 CHARACTERIZATION OF HIV AND SARS-CoV-2 COINFECTION: ROLE OF IL-10

Claudia Vanetti, Daria Trabattoni, Marta Stracuzzi, Antonella Amendola, Clara Fappani, Valeria Rubinacci, Claudio Fenizia, Mara Biasin, Anna Dighera, Irma Saulle, Francesco Ardizzone, Elisabetta Tanzi, Mario Clerici, Gian V. Zuccotti, Vania Giaconet

175 CHARACTERIZING MECHANISMS OF TRANSCRIPTIONAL CONTROL IN HIV-INFECTED MACROPHAGES

Rachel Van Duyne, Stephanie Matt, Alexis Brantly, Michael R. Nonnemacher, Peter J. Gaskill, Zachary A. Klase

Poster Session-B03 CORRELATES OF SARS-CoV-2 OUTCOMES
2:00 PM MT - 3:30 PM MT

201 IDENTIFICATION OF KEY BIOMARKERS FOR THE PREDICTION OF CRITICAL COVID-19 OUTCOMES

Laia Reverté Calvet, Elena Yeregui Etxeberria, Monsterrat Olona Cabases, Maria José Buzón, Anna Martí, Frederic Gómez-Bertomeu, Teresa Auguet, Clara Benavent-Bofill, Carme Boqué, Ezequiel Ruiz-Mateos, Maria Teresa Mestre, Francesc Vidal, Joaquín Peraire, Anna Rull, for the COVIDOMICS Study Group

202 MACHINE LEARNING ANALYSIS OF DNA METHYLATION IN COVID-19 DISEASE

Scott Bowler, Giorgos Papoutsoglou, Aristides Karanikas, Ioannis Tsamardinos, Michael J. Corley, Lishomwa Ndhlouvo

203 IMMUNE EXHAUSTION IS ASSOCIATED WITH PERSISTENT SARS-CoV-2 VIREMIA AND SEVERE DISEASE

204 CIRCULATING LEVELS OF TYPE I, TYPE II, AND TYPE III INTERFERONS AND COVID-19 SEVERITY
Alejandro A. Garcia, Riya Negi, Camille Heckmann, Grace Kenny

205 TGF-B2 IS ASSOCIATED WITH ASYMPTOMATIC/MILD SARS-CoV-2 INFECTION DURING PREGNANCY
Rachel Pope, Muhammad B. Latif, Gabriela Pacheco Sanchez, Meredith Gardner, Ruth Farrell, Kelly Gibson, Sarah O’Connell, Suprabhath Gajjala, Adrian McDermott, Robert Balderas, Michael Konstan, Mehul Suthar, Rafick-Pierre Sékaly, Susan Pereira Ribeiro

206 GDF-15 AS A PREDICTOR OF MORTALITY IN COVID-19: IMPLICATIONS FOR TREATMENT
Valeria Bono, Paola Ciceri, Matteo Sala, Lorenza Magagnoli, Roberta Rovito, Luisa Artioli, Mohamad Hadla, Vaibhav Yelenki, Antonella D’Arminio Monforte, Andrea Galassi, Camilla Tincati, Giulia Marchetti, Mario Cozzolino

207 ANGIOTENSIN II CAUSES T LYMPHOPENIA VIA REACTIVE OXYGEN SPECIES IN SEVERE COVID-19
Lucy Kundura, Sandrine Gimenez, Renaud Cezar, Sonia André, Yea-Lih Lin, Clément Mettling, Philippe Pasero, Laurent Muller, Pierre-Géraud Claret, Sandra Duvnjak, Paul Loubet, Albertotto, Tu-Anh Tran, Jérôme Estaquier, Pierre Corbeau

Poster Session-B05 HIV REPLICATION IN VIVO
2:00 PM MT - 3:30 PM MT

214 GERMINAL CENTER B CELLS AUGMENT HIV REPLICATION IN T FOLLICULAR HELPER CELLS
Matthew T. Ollerton, Joy Folkvord, David Parry, Elizabeth Connick

215 HIV DNA AND ACTIVATION DIFFER FOR LONG-LIVED CD4 CELLS IN LYMPH NODES AND PBMC ON ART
Christina Mallarino-Haeger, Maria Pino, Elise G. Viox, Amélie Pagliuzza, Sol del Mar Aldrete, Keith A. Delman, Michael C. Lowe, Nicolas Chomont, Vincent Marconi, Mirko Piaiardini

216 SINGLE-CELL ANALYSIS OF A HUMAN TONSIL EXPLANT HISTOCULTURE MODEL OF HIV-1 INFECTION
Connie A. Zhao, Tracey Freeman, Nadine Schrode, Sanjana Shroff, Benjamin Tweet, Robert Sebra, Kristin Beaumont, Talia H. Swartz

217 TEMSAVIR PROTECTS BYSTANDER CELLS FROM ADCC AND BLOCKS CYTOKINE BURST BY MONOCYTES

218 EFFECT OF HIV INFECTION AND ART INITIATION ON GENOME-WIDE DNA METHYLATION
Andrés Esteban-Cantos, Javier Rodriguez-Centeno, Juan C. Silla, Pilar Barruz, Fátima Sánchez, Gabriel Saiz-Medrano, Maria Jimenez-Gonzalez, Rosa De Miguel, Jose I. Bernardino, Rocio Montejano, Cédric Wallet, François Raffi, Berta Rodes, Jose R. Arribas, for NEAT001/ANRS143 Study Group

219 ESTROGEN EXPOSURE MAY ENHANCE TOLL-LIKE RECEPTOR 4 ACTIVATION IN HIV
Aaron E. Kettelhut, Emily Bowman, Janelle Gabriel, Manjusha Kulkarni, Jordan Lake, Nicholas Funderburg
<table>
<thead>
<tr>
<th>Session ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>D03</td>
<td>EVALUATING VIRUS-SPECIFIC CD8+ T CELLS FROM MULTIPLE ANATOMICAL SITES</td>
<td>Jennifer Simpson, Carly E. Starke, Carol Vinton, Alexandra Ortiz, Amy Ransier, Sam Darko, Daniel C. Douek, Jason Brenchley</td>
</tr>
<tr>
<td>256</td>
<td>CD8+ T-CELL REPROGRAMMING TO BOOST ANTI-HIV POTENTIAL</td>
<td>Federico Perdomo-Celis, Caroline Passaes, Stevven Volant, Faroudy Boufassa, Pierre De Truchis, Morgane Marcou, Katia Bourdic, Laurence Weiss, Corinne Jung, Christine Bourgeois, Cécile Goujard, Laurence Meyer, Michaela Müller-Trutwin, Olivier Lambotte, Asier Sáez-Cirión</td>
</tr>
<tr>
<td>257</td>
<td>CD8 RESPONSE TO HIV PROVIRUS IN ELITE CONTROLLERS IMPROVES EXPECTATIONS OF HIV CURE</td>
<td>Maria A. Navarrete-Muñoz, Jaime Valentin, José M Ligos, Alfonso Cabello Úbeda, Miguel Górgolas, José M. Benito, Norma Rallón</td>
</tr>
<tr>
<td>261</td>
<td>INVESTIGATING ANTIGEN-INDEPENDENT CD8+ T-CELL ENFORCEMENT OF HIV LATENCY</td>
<td>Talia M. Mota, Jared Weiler, Louise Leyre, Sandra Terry, Lynsay MacLaren Ehui, Avery Wimpelberg, Christopher M. Cannon, Sarah Henn, Erika Benko, Colin Kovacs, R. Brad Jones</td>
</tr>
<tr>
<td>262</td>
<td>HLA-II–ASSOCIATED VIRAL ADAPTATION IMPACTS CD4+ T-CELL RESPONSES IN HIV-1 VACCINES</td>
<td>Jacob K. Files, Sarah Sterrett, Timothy Fram, Nathan Erdmann, Anju Bansal, Paul Goepfert</td>
</tr>
<tr>
<td>264</td>
<td>HIV-SPECIFIC T-CELL FREQUENCIES AND FUNCTION AFTER ART DURING ACUTE OR EARLY HIV</td>
<td>Scott F. Sieg, Joseph A. Puleo, Lu Zheng, Brian Clagett, Javier R. Lama, Lawrence Fox, Jintanat Ananworanich, Kiat Ruxrungtham, Beatriz Grinsztejn, Roberto C. Arduino, Joseph J. Eron, John W. Mellors, Eric S. Daar, Trevor A. Crowell, for the AIDS Clinical Trials Group A5354 Study Team</td>
</tr>
</tbody>
</table>
266 TREATMENT INTERRUPTION AND T-CELL IMMUNITY IN ART-TREATED PRIMARY HIV INFECTION
Timothy L. Tipoe, Ane T. Ogbe, Helen Brown, Nicola Robinson, Ming J. Lee, Rebecca Hall, Claire Petersen, Heather Lewis, John Thornhill, Julienne Lwanga, Fiona Ryan, Julie Fox, Sarah Fidler, John Frater

267 PBMC TRANSCRIPTOME REVEALED A BENEFICIAL IMMUNE ACTIVATION AGAINST HIV-1 IN LGMD1F
Francisco Diez-Fuertes, Sara Rodríguez-Mora, Javier García-Pérez, Esther Calonge, Mercedes Bermejo, María Rosa López-Huertas, Mayte Coiras, José Alcamí

268 ASSOCIATIONS BETWEEN MATERNAL HIV AND INFANT IMMUNE ACTIVATION
Ceri Evans, Bernard Chasekwa, Jonathan Broad, Christie Noble, Kuda Mutasa, Sandra Rukobo, Margaret Govha, Patience Mushayanembwa, Florence D. Majo, Naume V. Tavengwa, Jean H. Humphrey, Robert Ntzini, Claire D. Bourke, Andrew J. Prendergast

269 IMPACT OF ANTIMICROBIALS ON PENILE IMMUNOLOGY: A RANDOMIZED CLINICAL TRIAL
Ronald Galiwango, Brenda Okech, Vineet Joag, Sandra Huijbner, Victoria M. Biribawa, Juliet Mpando, Moses Muwanga, Daniel Park, Tony Pham, Cindy Liu, Aaron Tobian, Lane Buchanan, Jessica Prodger, Rupert Kaul, for the APM Trial Group

270 COCAINE AND PERIPHERAL SEROTONIN DRIVE IMPAIRED T-CELL FUNCTION AND HIV PERSISTENCE
Mehul Sharma, Maggie Fu, Xuan Xu, Daniela Schlatzer, Rebeka Bordi, Susan Pereira Ribeiro, Jomuna Zeidan, Mark Chance, Marianna K. Baum, Rafick-Pierre Sékaly, Ashish A. Sharma

Poster Session-D09 SARS-CoV-2 IMMUNOLOGY: T CELLS, NK CELLS, AND CYTOKINES
2:00 PM MT - 3:30 PM MT

308 TGF-β SIGNALING PATHWAY SHAPES ADAPTIVE IMMUNITY IN EARLY SARS-CoV-2 INFECTION
Yulong Wei, Jack A. Collora, Runxia Liu, Jon Klein, Carolina Lucas, Akiko Iwasaki, Ya-Chi Ho, for the Yale IMPACT Team

309 SYSTEMATIC ANALYSIS OF INNATE IMMUNE ANTAGONISM OF SARS-CoV-2 AND ITS EVOLUTION

310 DETECTION OF CIRCULATING AND AIRWAY AUTOANTIBODIES TO IFN IN SEVERE COVID-19 PATIENTS
Federica Frasca, Mirko Scordio, Giuseppe Oliveto, Leonardo Sorrentino, Agnese Viscido, Camilla Bitossi, Alessandra Pierangeli, Luigi Celani, Giancarlo Cecarelli, Letizia Santinelli, Claudio M. Mastroianni, Gabriella D’Ettorre, Guido Antonelli, Carolina Scagnolari

311 DIFFERENTIAL IFN GENES EXPRESSION IN THE UPPER AIRWAYS OF CHILDREN AND ADULTS
Leonardo Sorrentino, Federica Frasca, Giuseppe Oliveto, Mirko Scordio, Agnese Viscido, Matteo Fracella, Fabio Midulla, Raffaella Nenna, Gabriella D’Ettorre, Giancarlo Cecarelli, Ombretta Turriziani, Massimo Gentile, Guido Antonelli, Alessandra Pierangeli, Carolina Scagnolari
312 DIFFERENTIALLY EXPRESSED IMMUNOLOGICAL GENES IN MILD AND SEVERE CASES OF COVID-19
Gabriel Gonzalez, Michael J. Carr, Alejandro A. Garcia, Rachel MacCann, John S. Lambert, Eoghlan De Barra, Eoin Feeney, Obada Yousif, Peter Doran, Alan Landay, Aoife G. Cotter, William W. Hall, Patrick Mallon

313 DIMENSIONALITY REDUCTION FOR STEPWISE ANALYSIS OF IMMUNE RESPONSE DYNAMICS IN COVID19
Elsa Brunet-Ratnasingham, Sacha Morin, Marjorie Labrecque, Lorie Marchitto, Amélie Pagliuza, Nathalie Brassard, David R. Morisson, Brent Richards, Madeleine Durand, Nicolas Chomont, Andrés Finzi, Matrine Tétreault, Guy Wolf, Daniel E. Kaufmann

314 T-CELL RESPONSE QUALITY TO ACUTE SARS-CoV-2 INFECTION, IMMUNE MEMORY, AND HCoV

315 IMPAIRED CYTOTOXIC IMMUNE RESPONSE AND EBV REACTIVATION IN PATIENTS WITH LONG COVID19
Lorena Vigón, Miguel Galán, Elena Mateos, Javier García-Pérez, Montserrat Torres, Sara Rodríguez-Mora, María Aranzazu Murciano-Antón, José Alcamí, Mayte Pérez-Olmeda, María Rosa López-Huertas, Mayte Coiras

316 SARS-CoV-2—SPECIFIC T CELLS ASSOCIATED WITH LUNG DYSFUNCTION IN LONG COVID-19
Katherine M. Littlefield, Renée Watson, Jennifer Schneider, Charles Neff, Eiko Yamada, Min Zheng, Thomas Campbell, Sarah Jolley, Andrew Fontenot, Brent Palmer

317 TCR SEQUENCING OF EPITOPE-SPECIFIC T CELLS FROM SARS-CoV-2 CONVALESCENT INDIVIDUALS

318 CROSS-RECOGNITION OF A CONSERVED CD4+ T-CELL EPITOPE PRESENT IN DIVERSE CORONAVIRUSES
Bezawit A. Woldemeskel, Arbor G. Dykema, Caroline C. Garliss, Saphira Cherfils, Kellie N. Smith, Joel Blankson

319 DEFINING IMMUNOGENIC PEPTIDES TARGETING SARS-CoV-2 VARIANTS OF CONCERN
Eunok Lee, Gabriel Duette, Gabriela Martins Costa Gomes, Katie Tungatt, Chloe Doyle, Ashley Lee, Vicki Stylianou, Rajiv Khanna, Keren Sandgren, Anthony Cunningham, Sarah Palmer

320 PREDICTING COVID-19 CLINICAL PROTECTIVE IMMUNITY FROM SARS-CoV-2 T-CELL RESPONSES
Amanda M. Buck, Darra Drucker, Michael J. Peluso, Steven G. Deeks, Rachel L. Rutishauser, Timothy J. Henrich, Amelia N. Deitchman

321 NATURAL KILLER CELL-MEDIATED ADCC IN SARS-CoV-2 INFECTION AND VACCINATION
Kerri Hagemann, Johannes Jung, Heike Hildebrandt, Stephan Menzel, Madeleine Bunders, Friedrich Koch-Nolte, Fabian Heinrich, Sven Peine, Julian Schulze Zur Wiesch, Thomas T. Brehm, Marylyn M. Addo, Marc Lütgehetmann, Marcus Altfeld
<table>
<thead>
<tr>
<th>Poster Session-E01</th>
<th>SINGLE-CELL ANALYSES OF HIV RESERVOIRS</th>
<th>2:00 PM MT - 3:30 PM MT</th>
</tr>
</thead>
<tbody>
<tr>
<td>322 DIVERGENT ADAPTIVE IMMUNE RESPONSES DEFINE 2 TYPES OF LONG COVID</td>
<td>Kervevan Jérôme, Isabelle Staropoli, Dorsaf SLAMA, Raphaël Jeger-Madiot, Delphine Planas, Marie-Pierre Pietri, Rémy Robinot, Faroudy Boufassa, Olivier Schwartz, Dominique Salmon, Lisa A. Chakrabarti</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Session-E01</th>
<th>SINGLE-CELL ANALYSES OF HIV RESERVOIRS</th>
<th>2:00 PM MT - 3:30 PM MT</th>
</tr>
</thead>
<tbody>
<tr>
<td>325 SINGLE-CELL IMAGING CORROBORATES THE LINK BETWEEN HIV INTEGRATION AND TRANSCRIPTION</td>
<td>Julie Janssens, Flore De Wit, Nagma Parveen, Frauke Christ, Zeger Debyser</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Session-E01</th>
<th>SINGLE-CELL PROFILING OF LEAKY LATENT HIV-1 RESERVOIRS IN ART-TREATED DONORS</th>
<th>2:00 PM MT - 3:30 PM MT</th>
</tr>
</thead>
<tbody>
<tr>
<td>326 SINGLE-CELL PROFILING OF LEAKY LATENT HIV-1 RESERVOIRS IN ART-TREATED DONORS</td>
<td>Mathieu Dubé, Nathalie Brassard, Rémi Fromentin, Gérémie Sannier, Gloria G. Delgado, Amélie Pagliuzza, Jean-Pierre Routy, Nicolas Chomont, Daniel E. Kaufmann</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Session-E01</th>
<th>SINGLE-CELL ANALYSES OF HIV RESERVOIRS</th>
<th>2:00 PM MT - 3:30 PM MT</th>
</tr>
</thead>
<tbody>
<tr>
<td>327 TRANSLATION-COMPETENT HIV RESERVOIRS ARE HIGHLY EXPANDED AND PHENOTYPICALLY DIVERSE</td>
<td>Caroline Dufour, Corentin Richard, Rémi Fromentin, Marion Pardons, Marta Massanella, Ben Murrell, Bertrand Routy, Jean-Pierre Routy, Nicolas Chomont</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Session-E01</th>
<th>SINGLE-CELL PROFILING OF LEAKY LATENT HIV-1 RESERVOIRS IN ART-TREATED DONORS</th>
<th>2:00 PM MT - 3:30 PM MT</th>
</tr>
</thead>
<tbody>
<tr>
<td>328 LONG-READ SEQUENCING ASSAY ALLOWS ACCURATE CHARACTERIZATION OF THE HIV-1 RESERVOIR</td>
<td>Laurens Lambrechts, Rita Verstraeten, Noah Bonine, Ytse Noppe, Marion Pardons, Basiel Cole, Lino Vandekerkhove</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Session-E01</th>
<th>SINGLE-CELL PROFILING OF LEAKY LATENT HIV-1 RESERVOIRS IN ART-TREATED DONORS</th>
<th>2:00 PM MT - 3:30 PM MT</th>
</tr>
</thead>
<tbody>
<tr>
<td>329 HIV-1 PROVIRUS-HOST CHROMATIN INTERACTIONS AT THE INTEGRATION SITE</td>
<td>Jack A. Collora, Sandra Springer, Yuval Kluger, Ya-Chi Ho</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Session-E01</th>
<th>SINGLE-CELL PROFILING OF LEAKY LATENT HIV-1 RESERVOIRS IN ART-TREATED DONORS</th>
<th>2:00 PM MT - 3:30 PM MT</th>
</tr>
</thead>
<tbody>
<tr>
<td>330 SINGLE-CELL MULTIOMICS ANALYSIS OF HIV RESERVOIR CELLS BY NOVEL T-TRACE APPROACH</td>
<td>Julie Frouard, Jason Neidleman, Rebecca Hoh, Steven G. Deeks, Warner Greene, Nadia Roan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Session-E01</th>
<th>SINGLE-CELL PROFILING OF LEAKY LATENT HIV-1 RESERVOIRS IN ART-TREATED DONORS</th>
<th>2:00 PM MT - 3:30 PM MT</th>
</tr>
</thead>
<tbody>
<tr>
<td>331 CD4+ T-CELL SUBSET-SPECIFIC DIFFERENCES IN HIV LATENCY ESTABLISHMENT</td>
<td>Eun Hye G. Kim, Lara Manganaro, Michael Schotsaert, Lubbertus C. Mulder, Viviana Simon</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Session-E06</th>
<th>DYNAMICS OF HIV RESERVOIRS AND VIRAL REBOUND</th>
<th>2:00 PM MT - 3:30 PM MT</th>
</tr>
</thead>
<tbody>
<tr>
<td>376 IMPACT OF TREATMENT INTERRUPTION ON COLONIC MUCOSA IN ACUTELY TREATED PARTICIPANTS</td>
<td>Alexandra Schuetz, Catherine Brands, David Morcock, Donn J. Colby, Trevor A. Crowell, Rungsun Rerknimit, Carlo Sacdalan, Suteeaporn Pinyakorn, Yuwadee Phuang-Ngern, Brandon Keele, Jeffrey D. Lifson, Jintanat Ananworanich, Denise C. Hsu, Claire Deleage, for the RV411/397 Study Groups</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Session-E06</th>
<th>DYNAMICS OF HIV RESERVOIRS AND VIRAL REBOUND</th>
<th>2:00 PM MT - 3:30 PM MT</th>
</tr>
</thead>
<tbody>
<tr>
<td>377 HIV-1 RESERVOIRS ESTABLISHED PRIOR TO THERAPY CONTRIBUTE TO REBOUND VIRUS</td>
<td>Katie Fisher, Xiao Qian Wang, Ashley Lee, Vincent Morcilla, Anneke de Vries, Eunok Lee, John-Sebastian Eden, Steven G. Deeks, Anthony Kelleher, Sarah Palmer</td>
<td></td>
</tr>
</tbody>
</table>
378  Vpr SHAPES THE PROVIRAL LANDSCAPE AND POLYCLONAL HIV-1 REACTIVATION PATTERNS IN VITRO  
Edmond Atindaana, Sarah Emery, Cleo Burnett, Jake Pitcher, Jeffrey M. Kidd, Alice Telesnitsky  

379  SIZE AND ACTIVITY OF THE HIV RESERVOIR PREDICT REBOUND TIMING AFTER ART INTERRUPTION  
Jonathan Li, Autumn Kittilson, Meghan Melberg, Elizabeth R. Wonderlich, Jennifer Kinslow, Evgenia Aga, Ronald J. Bosch, Robert Coombs, Steven G. Deeks, Rajesh T. Gandhi, Michael P. Busch, Alan Landay, Bernard J. Macatangay, Davey M. Smith, for the AIDS Clinical Trials Group A5345 Study Team  

380  DECAY KINETICS OF FREE VIRUS, INTACT & DEFECTIVE PROVIRUSES, & 2LTR CIRCLES ON ART  

381  FORMATION OF THE LONG-LIVED EARLY RESERVOIR IS PUNCTUATED BY EPISODIC SEEDING  

382  MEASURING HIV-1 RESERVOIR DYNAMICS DURING LONG-TERM ANTIRETROVIRAL THERAPY  
Thuy Nguyen, Mary E. Zipparo, Lindsey Adams, Shawn Hill, Matthew A. Adan, Erin Madeen, Chuen-Yen Lau, Frank Maldarelli  

383  HIV PROVIRUSES MIMIC THE CLONALITY OF HIGHLY EXPANDED CD4+ T CELLS IN PEOPLE ON ART  
Daniel B. Reeves, Danielle N. Rigau, Francesco R. Simonetti, Hao Zhang, Leah H. Rubin, Stephen Gange, Nadia Roan, Phyllis Tien, Joseph B. Margolick, Frederick M. Hecht, Steven G. Deeks, Joshua Schiffer, Janet Siliciano, Robert Siliciano, Annukka A. Antar  

384  PREDICTORS OF HIGH TOTAL AND INTACT HIV RESERVOIR AMONG CHILDREN WITH HIV IN KENYA  
Jillian Neary, Carolyn S. Fish, Noah Cassidy, Dalton C. Wamalwa, Agnes Langat, Evelyn Ngugi, Sarah Benki-Nugent, Hellen Moraa, Barbra A. Richardson, Jennifer Slyker, Dara A. Lehman, Grace John-Stewart  

385  PROVIRUSES WITH 5’-LEADER DELETIONS ARE A CAUSE OF NONSUPPRESSIBLE HIV-1 VIREMIA  
Francesco R. Simonetti, Jennifer A. White, Saif Yasin, Joseph Varriale, Milica Moskovljevic, Jiayi Duan, Kyle Rhodehouse, Andrei Gheorghe, Alison L. Hill, Hao Zhang, Christin Kilcrease, Christopher Hoffmann, Michael Summers, Janet Siliciano, Robert Siliciano  

386  INTACT HIV TRANSCRIPTS ARE RARE IN ART-SUPPRESSED INDIVIDUALS  
Holly A. Martin, Gayatri Nikhila Kadiyala, Sushama Telwatte, Adam Wedrychowski, Tsui-Hua Chen, Sara Moron-Lopez, Rebecca Hoh, Steven G. Deeks, Joseph K. Wong, Steven A. Yukl  

387  EARLY ANTIRETROVIRAL THERAPY REDUCES BUT DOES NOT ELIMINATE HIV DNA IN BLOOD  
Trevor A. Crowell, Justin Ritz, Lu Zheng, Asma Naqvi, Joshua Cyktor, Scott F. Sieg, Javier R. Lama, James F. Rooney, Lawrence Fox, Jintanat Ananworanich, Joseph J. Eron, Gert Van Zyl, John W. Mellors, Eric S. Daar, for the AIDS Clinical Trials Group A5354 Study Team  

---
388 INTACT NONINDUCIBLE PROVIRUSES ARE GENERATED DURING ACUTE HIV AND CAN PERSIST ON ART

389 EXPRESSION OF HIV-1 ANTI-SENSE TRANSCRIPTS IN DONORS ON ART
Rachel Sklutuis, Jennifer L. Groebner, Valerie F. Boltz, Wei Shao, Rui Li, Steven G. Deeks, Brandon Keele, Fabio Romero, Mary F. Kearney

390 EVALUATION OF GLIAL HIV RESERVOIRS USING A HUMANIZED BLOOD AND BRAIN MOUSE
Saumi Mathews, Edward Makarov, Lili Guo, Li Wu, Larisa Y. Poluektova, Santhi Gorantla

391 ALTERED MICROGLIAL GENOME STRUCTURE AND TRANSCRIPTION IN HIVE IMPACT HIV INTEGRATION
Amara Plaza-Jennings, Brandon Pratt, Benjamin K. Chen, Lotje De Witte, Susan Morgello, Hyejung Won, Schahram Akbarian

392 COMPARTMENTALIZED CLONAL EXPANSIONS OF CD8+ T CELLS IN CSF DURING ACUTE HIV INFECTION
Julie Mitchell, Caroline Subra, A Julian Pacheco Mendez, Faria Fatmi, Blake Colton, Supranee Buranapraditkun, Suteeraporin Pinyakorn, Carlo Sacdalan, Somporn Tipsuk, Nittaya Phanuphak, Denise C. Hsu, Sandhya Vasan, Serena S. Spudich, Lydie Trautmann, for the SEARCH010/RV254 Study Group

393 SIV-INFECTED CD4+ T CELLS CARRY VIRUS TO THE BRAIN
Howard S. Fox, Brenda M. Morsey, Meng Niu, Katay Emanuel, Benjamin G. Lamberty, Andrew J. Trease

394 MULTI-COMPARTMENT FRESH SINGLE-CELL STUDIES IN AN INTERNATIONAL HIV RESEARCH SETTING
Michael J. Corley, Supranee Buranapraditkun, Panadda Sawangsinth, Alexandra Schuetz, Sodsai Tovanabutra, Alina Pang, Shelli F. Farhadian, Nittaya Phanuphak, Carlo Sacdalan, Denise C. Hsu, Sandhya Vasan, Serena S. Spudich, Lishomwa Ndhloulou, for the RV254/SEARCH010 and RV304/SEARCH013 Study Group

Poster Session-F06 NEUROCOGNITION: PREDICTIONS, TRAJECTORIES, AND THERAPEUTICS
2:00 PM MT - 3:30 PM MT

422 ASSESSING HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH HIV AND COGNITIVE ISSUES
Kate Alford, Stephanie Daley, Sube Banerjee, Elizabeth Hamlyn, Daniel Trotman, Jaime Vera

423 PRESCRIBED DRUGS DISTINGUISH DATA-DRIVEN COGNITIVE PROFILES IN PEOPLE WITH HIV (PWH)
Raha Dastgheyb, Yanxun Xu, Alison Buchholz, Donald Franklin, Ronald J. Ellis, Susan Morgello, David Clifford, Benjamin B. Gelman, Christina M. Marra, Robert K. Heaton, David J. Moore, Scott L. Letendre, Qing Ma, Leah H. Rubin
67 CROI 2022

**Poster Sessions • Tuesday**

**Poster Sessions Day 2**

**CROI 2022**

---

424 **PREVALENCE AND CHARACTERISTICS OF HIV-ASSOCIATED STROKE IN A SOUTH AFRICAN SETTING**


425 **ABNORMAL COGNITIVE AGING IS DETECTED DESPITE CLINICALLY DEFINED COGNITIVE STABILITY**

Htein Linn Aung, Thomas Gates, Limin Mao, Bruce Brew, Krista J. Siefried, Andrew Carr, Lucette A. Cysique

426 **COGNITIVE PREDICTORS OF EVERYDAY FUNCTIONING IN THE WOMEN’S INTERAGENCY HIV STUDY**

David Vance, Pauline Maki, Danyang Yu, Raha Dastghheyb, Gayle Springer, Kathryn Anastos, Deborah Gustafson, Kathleen Weber, Derek M. Dykxhoorn, Joel Milam, Monica M. Diaz, Seble Kassaye, Drena Waldrop, Yanxun Xu, Leah H. Rubin

427 **A NOVEL COMORBIDITY INDEX PREDICTS COGNITIVE CHANGE IN PEOPLE WITH CHRONIC HIV**


428 **RECREATIVE DRUGS: NEW SUSPECTS IN HAND MYSTERY GAME**

Sophie Henrard, Nicola Trotta, Antonin Royai, Tim Coolen, Hichem Slama, Jean-Christophe Goffard, Serge Goldman, Xavier De Tiège

---

**Poster Session-G02  HIV PREVENTION AND MUCOSAL COMPARTMENT PHARMACOLOGY**

2:00 PM MT - 3:30 PM MT

440 **ANTI-INFECTIVES’ PENETRATION IN UPPER AND LOWER FEMALE GENITAL TISSUES**

Fan Wang, Olivia C. Namuju, Katelyn A. Pastick, Kizito Abdusalaamu, Usha Mishra, Lindsey B. Collins, David R. Boulware, Robert Lukande, David Meya, Melanie R. Nicol

441 **ORAL TDF/FTC PROVIDES EARLY MUCOSAL PROTECTION IN BOTH ON-DEMAND AND DAILY REGIMEN**

Sylvain Chawki, Audrey Gabassi, Mayssam El Mouhebb, Milad Taouk, Lambert Assoumou, Iris Bichard, Skander Benoethmane, Ali Amara, Rhonda Brand, Aaron Siegel, Lauriance Goldwirt, Ian McGowan, Dominique Costagliola, Jean-Michel Molina, Constance Delaugerre, for the PREVENIR Study

442 **PK/PD RESULTS OF CHAPS ORAL PREEXPOSURE PROPHYLAXIS TRIAL IN FORSKIN TISSUE**

Carolina Herrera, Laura Else, Emily Webb, Azure-Dee A. Pillay, Thabiso B. Seiphetlo, Limakatso Lebina, Jennifer Serwanga, Christian Callebaut, Robin Shattock, Francesca Chiodi, Clive Gray, Saye Khoo, Neil A. Martinson, Julie Fox, for the CHAPS Study Team

443 **ANAL SEX & TENOFOVIR DOUCHE SEQUENCE IMPACT COLORECTAL DISTRIBUTION OF HIV & DOUCHE**

Lynn N. Bertagnolli, Sandra Abdul Massih, Craig W. Hendrix, Sridhar Nimmagadda, Edward J. Fuchs
444 PHARMACOKINETIC STUDY OF ISLATRAVIR & ETONOGESTREL IMPLANTS IN MACAQUES
Michele B. Daly, Andres Wong-Sam, Linying Li, Archana Krovi, Gregory Gatto, Victoria Mrotz, Catalina Forero, Joy Gary, James Mitchell, Ariane Van der Straten, Walid Heneine, Gerardo García-Lerma, Charles Dobard, Leah Johnson

445 NEXT-GENERATION ISLATRAVIR/ETONOGESTREL/ETHINYL ESTRADIOL MPT INTRAVAGINAL RING
Isabella Young, Roopali Shrivastava, Rima Janusziewicz, Craig Sykes, Mackenzie L. Cottrell, Cynthia Cabrales, Angela Kashuba, David Katz, Richard Pyles, Kathleen L. Vincent, Rahima Benhabbour

446 LONG-ACTING DORAVIRINE FOR TREATMENT AND PREVENTION OF VAGINAL HIV TRANSMISSION
Martina Kovarova, Manse Kim, Sarah E. Wessel, J. Victor Garcia-Martinez

453 WITHDRAWN

454 PHASE-2 STUDY OF SAB-185, A POLYCLONAL ANTIBODY TREATMENT FOR COVID-19 IN ACTIV-2
Babafemi O. Taiwo, Kara W. Chew, Mark Giganti, David A. Wohl, Eric S. Daar, Maxine Olefsky, Rick Finnegan, Jake Miles, Arzhang Cyrus Javan, Jonathan Li, Judith S. Currier, Joseph J. Eron, Michael Hughes, Davey M. Smith, for the ACTIV-2/ACTG A5401 Study Team

455 MODELING REMDESIVIR ANTIVIRAL EFFICACY IN COVID-19 HOSPITALIZED PATIENTS
Guillaume Lingas, Nadège Néant, Alexandre Gaymard, Drifa Belhadi, Maya Hites, Dominique Costagliola, Yazdan Yazdanpanah, Florent Wallet, Amandine Gagneux-Brunon, France Mentré, Florence Ader, Charles Burdet, Jérémie Guedj, Maude Bouscambert-Duchamp, for the Discovery Study Group

456 SAFETY OF REMDESIVIR VS PLACEBO IN NONHOSPITALIZED PATIENTS WITH COVID-19
Bradon Webb, Godson Oguchi, Yessica Sachdeva, John Cafardi, Alan S Go, Kavita Juneja, Santosh Davies, Shuguang Chen, Chen-Yu Wang, Anu O. Osinusi, Frank Duff, Pablo Ryan, Carlos Vaca, Jorge Mera

457 EFFECTS OF CASIRIVIMAB + IMDEVIMAB ON SYMPTOM OUTCOMES IN OUTPATIENTS WITH COVID-19
Yuhuan Wang, Mohamed Hussein, Diana Rofail, Kuan-Ju Lin, Daniela J. Conrado, Kenneth C. Turner, Samit Ganguly, Hazem E. Hassan, Qian Huang, Zhichao Lyu, Hong Yan, Thomas Norton, Shazia Ali, John D. Davis, Nidal Al-Huniti

458 REMDESIVIR IN AN OUTPATIENT SETTING IMPROVES BIOMARKERS FOR PROGRESSION OF COVID-19
David Z. Pan, Pamela Odorizzi, Andre Schoenichen, Mazin Abdellghany, Shuguang Chen, Chris Blair, Henry N. Hultin, Scott D. Patterson, Anu O. Osinusi, Kavita Juneja, Jeffrey Wallin

Poster Session—Tuesday

Poster Session-H01 CLINICAL TRIALS OF THERAPY FOR SARS-CoV-2: ANTIMICROBIALS AND IMMUNE MODIFIERS
2:00 PM MT - 3:30 PM MT
A RANDOMIZED CONTROLLED TRIAL OF CAMOSTAT IN OUTPATIENTS WITH COVID-19
Nikolaus Jilg, Janet Nuttall, Atasi Jana, David Maislin, Susan Lewis, Bob Szurgot, Philip A. Hart

TDF/FTC FOR HIGH-RISK PATIENTS WITH COVID-19: THE PANCOVID RANDOMIZED CLINICAL TRIAL
María Velasco, Rocio Montejano, Gonzalo Sierra, Javier Queiruga, Patricia Martinez, Ané Goikoetxea, Angela Gutierrez, Miguel Torralba, Pablo Ryan, Pilar Vizcarra, Sofía Ibarra, María Jimenez-Gonzalez, Javier Marcos, Jose R. Arribas, for the PANCOVID Study Group

VIRAL KINETICS IN COVID-19 OUTPATIENTS TREATED WITH CASIRIVIMAB+IMDEVIMAB COMBINATION
Daniela J. Conrado, Kashyap Patel, Kuan-Ju Lin, Yuhuan Wang, Jiraganya Bholgsatiern, Mohamed A. Kamal, Kenneth C. Turner, Samit Ganguly, Hazem E. Hassan, Hong Yan, Cynthia Portal-Celhay, John D. Davis, Patrick F. Smith, Jérémie Guedj, Nidal Al-Huniti

A REAL-WORLD COMPARISON OF BAM/ETE VS CAS/IMD FOR COVID-19 CLINICAL PROGRESSION RISK
Valentina Mazzotta, Francesca Colavita, Patrizia Lorenzinì, Alessandro Cozzi-Lepri, Silvia Rosati, Ilaria Mastrotrosa, Eleonora Lalle, Claudia Cimaglia, Alessandra Vergori, Angela Corpollongo, Concetta Castilletti, Enrico Girardi, Francesco Vaia, Emanuele Nicastri, Andrea Antinori

BARICITINIB FOR HIGH-RISK PATIENTS WITH COVID-19: THE PANCOVID RANDOMIZED TRIAL
Alberto Borobia, Fernando de la Calle, Carlos Guijarro, Patricia González-Ruano, Marta Ibarrola, Marielena Ciudad, Ana Diaz-Brasero, Antonio de Pablo, Cristina Marcelo, Cristina Diez, Esperanza Merino, Vicente Estrada, María Novella Mena, Jose R. Arribas, for the PANCOVID Study Group

RECOVERY AND SURVIVAL IN COVID-19 RESPIRATORY FAILURE WHEN TREATED WITH AVIPTADIL

DO ALL CRITICALLY ILL COVID-19 PATIENTS BENEFIT FROM INTENSIFYING WITH TOCILIZUMAB?
Cristina Mussini, Alessandro Cozzi-Lepri, Jovana Milic, Andrea Cossarizza, Gianluca Cuomo, Adriana Cervo, Federica Carli, Sara Volpi, Giovanni Guaraldi

SARILUMAB PLUS STANDARD OF CARE (SOC) VERSUS SOC FOR SEVERE COVID-19 (ESCAPE STUDY)
Ilaria Mastrotrosa, Roberta Gagliardini, Francesco Vladimiro Segala, Annalisa Mondi, Patrizia Lorenzinì, Carlotta Cerva, Eleonora Taddì, Francesca Bai, Maria Maddalena Plazzi, Loredana Sarmatì, Emanuele Nicastri, Antonella D’Arminio Monforte, Fabrizio Palmieri, Antonella Cingolani, Andrea Antinori

CONVALESCENT PLASMA FOR OUTPATIENTS WITH EARLY COVID-19: A RANDOMIZED TRIAL
Arvind Gharbharan, Pere Millat-Martinez, Andrea Alemany, Casper Rokx, Corine H. Geurts van Kessel, Grigoris Papageourgiou, Carlijn Jordans, Marc Corbacho-Monné, Quique Bassat, Bonaventura Clotet, Bárbara Baro, Jaap Jan Zwaginga, Oriol Mitjà, Bart R. Rijnders, for the COMPILEhome Investigators
468 **ENPATORAN SAFETY AND EFFICACY IN COVID-19 PNEUMONIA: ANEMONETRial**
John McKinnon, Joel Santiaguel, Claudia Murta, Dongzi Yu, Mukhy Khursheed, Flavie Moreau, Sanjeev Roy, Amy Kao

469 **IMPACT OF TENOFOVIR ON SARS-CoV-2 INFECTION AMONG PEOPLE LIVING WITH HIV**
Daniel Kwakye Nomah, Juliana Reyes-Uruéña, Yesika Diaz, Sergio Moreno Fornés, Jordi Aciéton, Andreu Bruguera, Rosa M. Vivanco-Hidalgo, Jordi Casabona, Pere Domingo, Jordi Navarro, Arkaitz Imaz, Elisabet Deig, Gemma Navarro, Josep M Llibre, Jose M. Miro

---

**Poster Session-H02**

**NEW ANTIVIRALS FOR SARS-CoV-2: ACTIVITY IN VITRO AND IN VIVO**
2:00 PM MT - 3:30 PM MT

470 **PBI-0451 AN ORALLY ADMINISTERED 3CL PROTEASE INHIBITOR OF SARS-CoV-2 FOR COVID-19**
Brian P. Kearney, Andrew Plummer, Grushenka Wolfgang, David Turnquist, Mark R. Marshall, Mark Denison, Christian Schwabe, Uri Lopatin, Lee Arnold

471 **MOLNUPIRAVIR INCREASES RANDOM SARS-CoV-2 RNA ERRORS WITHOUT SELECTION FOR RESISTANCE**
Arthur Fridman, Nicholas J. Murgolo, Andy Liaw, Ying Zhang, Shunbing Zhao, Hong Wan, Alison Pedley, Min Xu, Daria Hazuda, Jay A. Grobler, Julie M. Strizki

472 **WITHDRAWN**

473 **GUNNERA PERPENSA ELLAGITANNINS SYNERGISTICALLY INHIBIT MULTIPLE SARS-CoV-2 VARIANTS**
Ian Tietjen, Luke Invernizzi, Phanankosi Moyo, Joel Cassel, Emery T. Register, Frederick Keeney, Joseph M. Salvino, Freddie J. Isaacs, Vinesh Maharaj, Luis J. Montaner

474 **INTERIM ANALYSIS OF A PHASE I STUDY OF PRTX007: SAFETY, PK, AND PD RESPONSE**
Charlotte R. Lemech, Curtis L. Scribner, Richard Daniels, James R. Appleman

475 **CETYLPYRIDINIUM CHLORIDE MOUTHWASHES TO REDUCE THE SHEDDING OF VIABLE SARS-CoV-2**
Jordana Muñoz-Basagoiti, Andrea Alemany, Daniel Perez-Zsolt, Dan Ouchi, Dalia Raich-Regué, Benjamin Trinité, Edwards Pradenas, Julià Blanco, Ruben León, Vanessa Blanc, Joan Gispert, Bonaventura Clotet, Oriol Mitjà, Núria Izquierdo-Users, for the CPC Study Group

476 **A NOVEL CLASS OF ANTIVIRAL COMPOUNDS WITH POTENT ACTIVITY AGAINST SARS-CoV-2**
David E. Gordon, Eugene Stavtsev, Anatolii Demchenko

477 **DESIGN OF NOVEL AND HIGHLY SELECTIVE SARS-CoV-2 MAIN PROTEASE INHIBITORS**
Joseph M. Salvino, Ian Tietjen, Adi Narayana Reddy R. Poli, Joel Cassel, Troy E. Messick, Emery T. Register, Frederick Keeney, Luis J. Montaner
478 EFFECT OF ASTODRIMER SODIUM AGAINST SARS-CoV-2 VARIANTS (A, B, F, Delta, K) IN VITRO
Philippe Gallay, Carolyn Luscombe, Winston Stauffer, Michael D. Bobardt, Graham Heery, Alex Castellarnau, Aynaz Seta, Jeremy R. Paull

Poster Session-I03 NEW TECHNOLOGIES TO DETECT HIV DRUG RESISTANCE
2:00 PM MT - 3:30 PM MT

513 TEMPORAL VARIABILITY OF MULTI-CLASS RESISTANT HIV-1 IN PROVIRAL DNA
Christian Hoffmann, Eva Wolf, Patrick Braun, Markus Bickel, Albrecht Stoehr, Silke Heldwein, Heribert Knechtem, Stefan Esser, Christoph Mayr, Christoph Wyen, Markus Mueller, Jan-Christian Wasmuth, Maximilian Münchhoff, Alexander Thielen, Martin Daemer

Poster Session-I04 TRANSMITTED HIV DRUG RESISTANCE
2:00 PM MT - 3:30 PM MT

514 COMPARATIVE ANALYSIS OF HIV-1 RNA AND ARCHIVED PROVIRAL HIV-1 DNA GENOTYPING
Noah C. Gaitan, Michelle L. D’Antoni, Rima K. Acosta, Susan J. Little, Antoine Chaillon

Poster Session-J02 HCV TREATMENT AND DISEASE
2:00 PM MT - 3:30 PM MT

515 POINT-OF-CARE URINE TENOFOVIR TESTING TO DETECT HIV DRUG RESISTANCE
Suzanne McCluskey, Katya Govender, John Adamson, Monica Gandhi, Matthew A. Spinelli, Mahommed-Yunus Moosa, Henry Sunpath, Pravikrishnhen Moodley, Melendhran Pillay, Selvan Pillay, Winnie R. Muyindike, Godfrey Masette, Bethany Hedd-Gauthier, Vincent Marconi, Mark Siedner

516 TRANSMITTED DRUG RESISTANCE TO INTEGRASE-BASED FIRST-LINE TREATMENT IN EUROPE
Adolfo De Salazar, Laura Viñuela, Ana Fuentes, Elisa Teyssou, Charlotte Charpentier, Sidonie Lambert-Niclot, Lavinia Fabeni, Carlo F. Perno, Dimitrios Paraskevis, Perpetua Gomes, Maria M. Santoro, Francesca Ceccherini-Silberstein, Anne Genevieve Marcelin, Federico Garcia, for the MeditRes HIV Collaboration

517 STATEWIDE TRENDS OF TRANSMITTED HIV-1 DRUG RESISTANCE IN RHODE ISLAND OVER 2004-2020
Vlad Novitsky, Jon Steingrimsson, Fizza S. Gillani, Mark Howison, Su Aung, Cindy Y. Won, Amy Brotherton, Rajeev Shah, Thomas Bertrand, Anna Civitarese, Katharine Howe, Utpala Bandy, Nicole Alexander-Scott, Joseph Hogan, Rami Kantor

528 EFFICACY & SAFETY OF RAVIDASVIR + SOFOSBUVIR IN HEPATITIS C: STORM-C-1 FINAL RESULTS
Soek-Siam Tan, Sombat Thanprasertsuk, Satawat Thongsawat, Nicolas Salvadori, Caroline Menêtrey, for the STORM-C-1 Research Team
529 TREATMENT WITH SOF/VEL/VOX IN HIV/HCV-COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAAs
Luz Martin Carbonero, Angela Gil-Martin, Teresa Aldázmiz-Echevarría, Vicente Estrada, Carlos Barros, Rebeca Font, Pablo Ryan, Carmen Quereda, Beatriz Alvarez, Rafael Micán, Juan Berenguer, Jorge Vergas, María Luisa Montes, Juan C. Lopez, for the Madrid-CoRe Study Group

530 ADHERENCE IN THE ACTG A5360 HCV MINIMAL MONITORING (MINMON) TRIAL
Leonard Sowah, Laura M. Smeaton, Irena Brates, Debika Bhattacharya, Benjamin Linas, Bruce Kreter, Sandra Wagner-Cardoso, Sunil S. Solomon, Mark S. Sulkowski, Gregory K. Robbins

531 IMPACT OF SVR WITH DAAaS IN COINFECTED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS
Teresa Aldázmiz-Echevarría, Juan Berenguer, Victor Hontañón, Chiara Fanciulli, Carmen Quereda, Carmen Busca Arenzana, Lourdes Domínguez, Cristina Hernandez Gutierrez, Jorge Vergas, Gabriel Gaspar, Lucio Jesús García-Fraile Fraile, Marta De Miguel, José M. Bellón, Juan González-García, for the GeSIDA 10318-Marathon Study Team

532 HIGHER MORTALITY OF PLWH CURED OF HCV BY DAAaS: RESULTS FROM THE ANRS-CO4-FHHD COHORT
Maria B. Requena, Sophie Grabar, Gilles Pialoux, Dominique Costagliola, Karine Lacombe

533 DIAGNOSIS OF ESOPHAGEAL VARICES IN VIRUS-RELATED ADVANCED CHRONIC LIVER DISEASE
Jordana Serero, Amine Zoughlami, Stephen E. Congly, Irene Zhao, Julie Zhu, Alnoor Ramji, Curtis Cooper, Philip Wong, Robert Bailey, Carla S. Coffin, Giada Sebastiani, for the Canadian HBV Network

534 HIV/HBV/HCV TRIPLE INFECTION, END-STAGE LIVER DISEASE, AND ALL-CAUSE MORTALITY
Amanda Mocroft, Adam Geressu, Charles Béguelin, Josep María Llibre, Jeffrey V. Lazarus, Janez Tomazic, Josep Maria Llibre, Jeffrey V. Lazarus, Janez Tomazic, Miloslav Parczewski, Johanna Brännström, Dalibor Sedlacek, Olaf Degen, Marc Van der Valk, Dzmitry Paduta, Lars Peters, for the EuroSIDA Study Group

535 IMPACT OF HCV CURE ON DEPRESSIVE SYMPTOMS IN THE HIV-HCV COINFECTED POPULATION
Gayatri J. Marathe, Erica E. Moodie, Marie-Josée Brouillette, Charlotte Lanièce Delaunay, Joseph Cox, Curtis Cooper, M. John Gill, Valérie Martel-Lafferrière, Neora Pick, Marie-Louise Vachon, Sharon Walmsley, Marina B. Klein, for the Canadian Co-infection Cohort

Poster Session-J03  HCV ELIMINATION AND CARE CASCADE
2:00 PM MT - 3:30 PM MT

536 HCV DIAGNOSIS PRECEDING AN HIV OUTBREAK AMONG PWID IN KANAWHA COUNTY, WV: 2019-2021
Alana G. Hudson, Robert A. Bonacci, Anne C. Moorman, McKenna Penley, Suzanne Wilson, Robert P. McClung, Jessica Hoffman, Erica Thomasson, Danae Bixler

537 THE HEPATITIS C CARE CONTINUUM IN THE DAA ERA AMONG TRANSGENDER WOMEN WITH HIV
Poster Sessions • Tuesday

538 PROGRESS TOWARD HCV MICROELIMINATION AMONG HIV-POSITIVE PATIENTS IN TAIWAN
Shu-Yuan Ho, Li-Hsin Su, Hsin-Yun Sun, Miao-Hui Huang, Yu-Shan Huang, Sung-Hsi Huang, Yi-Chia Huang, Wen-Chun Liu, Yi-Ching Su, Sui-Yuan Chang, Chien-Ching Hung

539 THE IMPACT OF COVID-19 ON HCV MICRO-ELIMINATION IN MSM IN GERMANY
Patrick Ingiliz, Thomas Lutz, Knud C. Schewe, Stefan Mauss, Stefan Christensen, Natasha Martin, Sonia Jain, Feng He, Michael Sabranski, Jukka Hartikainen, Markus Bickel, Jürgen K. Rockstroh, Christoph Boesecke

540 WITHDRAWN

541 PERFORMANCE OF HCV ANTIGEN ASSAY IN THE DIAGNOSIS OF ACUTE HCV INFECTION AMONG PLWH
Hsin-Yun Sun, Li-Hsin Su, Yi Ting Chen, Wen-Chun Liu, Yi-Ching Su, Yu-Chung Chuang, Yu-Shan Huang, Wan-Da Liu, Po-Liang Lu, Chien-Ching Hung, Ming-Lung Yu

542 HCV MICROELIMINATION AMONG PEOPLE LIVING WITH HIV IN SAN DIEGO: ARE WE ON TRACK?
Jaskaran S. Cheema, William C. Mathews, Adriane Wynn, Laura Bamford, Francesca Torriani, Lucas Hill, Amutha Rajagopal, Jeffrey Yin, Edward R. Cachay, Natasha Martin

561 PREVALENCE AND SEVERITY OF HPV-ASSOCIATED ANAL DISEASE IN PWH YOUNGER THAN 35
Keith Sigel, Michael M. Gaisa, Yuxin Liu

562 FACTORS ASSOCIATED WITH ANAL DYSPLASIA AMONG YOUNG MSM AND TW WITH HIV IN ATLANTA
Leah Loerinc, Amy Scheel, Amelia Thompson, Kristin Wall, Scott Gillespie, Molly McCallum, Lisa Flowers, Andres Camacho-Gonzalez

563 GENITAL AND ANAL CYTOLOGY: HPV COTESTING RESULTS FROM 381 WOMEN LIVING WITH HIV
Michael M. Gaisa, Kevin Weiss, Keith Sigel, Yuxin Liu

564 EVALUATING HPV TESTING FOR CERVICAL CANCER SCREENING IN 4 COUNTRIES’ HIV PROGRAMS
Jessica Joseph, Owen Demke, Lola Ameyan, Joseph Bitilinyu-Bango, Jibrin Kama, Marvin Lubega, Bernard Madzima, Tasimba Mhizha, Andrew Musoke, Timothy Tchereni, Shaukat Khan
Poster Session-K03  BASIC SCIENCE OF HPV, KSHV, AND HIV-ASSOCIATED LYMPHOMAS  
2:00 PM MT - 3:30 PM MT

565  IMMUNOLOGICAL BIOMARKERS ASSOCIATED WITH ANAL DYSPLASIA IN PEOPLE LIVING WITH HIV
Joaquin Burgos-Cibrian, Cristina Mancebo Pérez, Nuria Massana, Antonio Astorga Gamaza, Stefania Landolfi, Vicenç Falcó, Maria José Buzón, Meritxell Genescà

566  EXPRESSION OF IFN RECEPTORS IN ANAL CELLS FROM HIV-POSITIVE MEN DURING HPV INFECTION

567  HPV DIFFERENTLY HIJACKS ANAL INTERFERON RESPONSE IN HIV-POSITIVE AND HIV-NEGATIVE MSM
Eugenio Nelson Cavallari, Letizia Santinelli, Mirko Scordio, Federica Frasca, Giuseppe P. Innocenti, Luca Maddaloni, Gabriella De Girolamo, Giancarlo Ceccarelli, Claudio M. Mastroianni, Alessandra Pierangeli, Carolina Scagnolari, Gabriella D’Ettorre

568  WHOLE-GENOME SEQUENCING OF KSHV REVEALS EVIDENCE FOR 2 AFRICAN LINEAGES
Razia Moorad, Angelica Juarez, Justin T. Landis, Linda J. Pluta, Megan V. Perkins, Avery Cheves, Dirk P. Dittmer

569  IDENTIFICATION OF PROVIRAL INTEGRATIONS WITHIN HIV-ASSOCIATED B-CELL LYMPHOMAS
Michael P. Rist, Machika Kaku, Tyler Colson, Michael Freeman, John M. Coffin

Poster Session-L02  HYPERTENSION, HEART FAILURE, AND OTHER CARDIOVASCULAR DISEASE OUTCOMES  
2:00 PM MT - 3:30 PM MT

584  HIV INFECTION AND INCIDENT ABDOMINAL AORTIC ANEURYSM AMONG 143,327 VETERANS
Alexandra M. Filipkowski, Suman Kundu, Charles W. Alcorn, Joshua A. Beckman, Matthew Freiberg, Aaron W. Aday

585  HYPERTENSION CARE CASCADE DURING COVID IN VETERANS WITH HIV
Lewis S. Musoke, Sandra Woolson, Julie Schexnayder, Chris T. Longenecker, Elizabeth Strawbridge, Hayden Bosworth, Puja Van Epps

586  HYPERTENSION PREVALENCE AMONG PERSONS LIVING WITH HIV: ZAMBIA, JULY 2020–JUNE 2021
Jonas Hines, Jose Tomas Prieto, Sombo Fwoloshi, Peter Minchella, Cecilia Chitambala, Dalila Zachary, Megumi Itoh, Khozya D. Zymbo, Lloyd B. Mulenga, Simon Agolory

587  ATRIAL FIBRILLATION RISK FACTORS AMONG PATIENTS IN HIV CARE IN THE UNITED STATES
588 ELEVATED METHYLGLYOXAL TRIGGERS HEART FAILURE DURING HIV-1 INFECTION
Prasanta K. Dash, Fadhel Alomar, Jesse Cox, Bryan T. Hackfort, Howard S. Fox, Howard E. Gendelman, Santhi Gorantla, Keshore R. Bidasee

589 ACTIVATED MONOCYTES AND MYOCARDIAL FIBROSIS AMONG PERSONS WITH HIV IN SOUTH AFRICA
Tess Peterson, Muki Shey, Nomawethu Masina, Lye-Yeng Wong, Scott Shuldiner, Julian Wolfson, Stephen Jermy, Hadil Saad, Achita Singh, Mbalabu Lumbamba, Graeme Meintjes, Ntobeko Ntusi, Mpiko Ntsekhe, Jason Baker

590 IMPACT OF RHEUMATOLOGIC THERAPIES ON CARDIOVASCULAR OUTCOMES IN PEOPLE WITH HIV
Boghuma K. Titanji, Shumpei Nagatomi, Julia Gallini, Xiangqin Cui, Vincent Marconi

591 IMPAIRED RESPONSE OF MEMORY TREG TO HDL IS ASSOCIATED WITH HIGHER CARDIOVASCULAR RISK
Laura O. Atehortua, Carl J. Fichtenbaum, W. S. Davidson, Mirza Baig, Sarah Trentman, Claire A. Chougnet

592 ASSOCIATION OF IP-10 AND FAT ATTENUATION INDEX IN PWH AND CONTROLS WITHOUT CVD
Michael L. Freeman, Nivya George, Shana Burrows, Jean Jeudy, Pratik Patel, Daniela Moisi, Sarah E. Mitchell, Mariam Khabmaty, Kapil Sahara, Robert G. Weiss, Thomas Mathew, Michael M. Lederman, Shashwatee Bagchi

607 PROTEINURIA IS COMMON AMONG PEOPLE WITH HIV WITH CONTROLLED HIV VIREMIA
Edgar T. Overton, Amy Kantor, Kathleen Fitch, Paul M. Muntner, Mosepele Mosepele, Judith A. Aberg, Carl J. Fichtenbaum, Grace A. McComsey, Carlos Malvestutto, Michael T. Lu, Pamela S. Douglas, Steven Grinspoon, Heather J. Ribaudo, Christina Wyatt, for the REPRIVE Trial Investigators

608 APOL1 VARIANTS, SICKLE CELL TRAIT, AND KIDNEY FAILURE IN AFRICANS WITH HIV
Frank A. Post, Rachel K. Hung, Julie Fox, Burns Fiona, Andrew Ustianowski, Lisa Hamzah, Sarah Schoeman, Amanda Clarke, Caroline Sabin, Cheryl Winkler, for the GEN-AFRICA Study Group

609 PETRAM RESULTS: BONE TURNOVER CHANGES ON 18F-PET/CT AFTER A RANDOMIZED SWITCH TO TAF
Amelia E. Moore, James E. Burns, Deidre Sally, Ana Milinkovic, Georgios Krokos, Joemon John, Christopher Rookyard, Erica Pool, Richard Gilson, Alejandro Arenas-Pinto, Gary Cook, David Dunn, Glen Blake, Sarah L. Pett

610 ROSUVASTATIN WORSENS VITAMIN K2 STATUS WHICH IMPAIRS BENEFICIAL EFFECT ON BONE IN HIV
Jared C. Durieux, Sokratis N. Zisis, Christian F. Mouchati, Grace A. McComsey

611 HIV-ASSOCIATED COPD IS CHARACTERIZED BY INCREASED SMALL AIRWAYS DYSFUNCTION ON CT
Sarath Raju, Andrew Gearhart, Nicole L. Brown, Michael B. Drummond, Robert Brown, Meredith McCormack, Gregory D. Kirk
612 HIV AND TB DRIVE NONCOMMUNICABLE LUNG DISEASE IN URBAN WEST AFRICA
Douglas Fink, David Oladele, Abigail L. Slack, Oluwatosin Odubela, Tomiola Musari-Martins, Adaobi Ôkechukwu, Kemi Adetayo, Sola Opaneye, Rufai Abubakar, Agatha David, Shumonta Quaderi, Marc Lipman, John Hurst, Oliver Ezechi

613 HIV INFECTION DOES NOT EXPLAIN HIGHER NICOTINE METABOLISM IN PEOPLE WITH HIV (PWH)
Robert Gross, Warren B. Bilker, Xiaoyan Han, Michael Plankey, Deanna Ware, Mackey Friedman, Gypsamber D’Souza, Steven Wolinsky, Robert Schnoll, Rachel F. Tyndale, Rebecca L. Ashare

614 PREVALENCE OF ANEMIA AND RISK FACTORS IN PEOPLE WITH HIV IN THE MODERN ART ERA
Raynell Lang, M. John Gill, Richard Moore, Michael J. Silverberg, Amy Justice, Amanda Willig, Angel Mayor, Marina B. Klein, Michael A. Horberg, Kelly Gebo, Ronald J. Bosch, Laura Bamford, Jennifer S. Lee, Keri N. Althoff, for the North American AIDS Cohort Collaboration on Research and Design of IeDEA

612 HIV AND TB DRIVE NONCOMMUNICABLE LUNG DISEASE IN URBAN WEST AFRICA
Douglas Fink, David Oladele, Abigail L. Slack, Oluwatosin Odubela, Tomiola Musari-Martins, Adaobi Ôkechukwu, Kemi Adetayo, Sola Opaneye, Rufai Abubakar, Agatha David, Shumonta Quaderi, Marc Lipman, John Hurst, Oliver Ezechi

613 HIV INFECTION DOES NOT EXPLAIN HIGHER NICOTINE METABOLISM IN PEOPLE WITH HIV (PWH)
Robert Gross, Warren B. Bilker, Xiaoyan Han, Michael Plankey, Deanna Ware, Mackey Friedman, Gypsamber D’Souza, Steven Wolinsky, Robert Schnoll, Rachel F. Tyndale, Rebecca L. Ashare

614 PREVALENCE OF ANEMIA AND RISK FACTORS IN PEOPLE WITH HIV IN THE MODERN ART ERA
Raynell Lang, M. John Gill, Richard Moore, Michael J. Silverberg, Amy Justice, Amanda Willig, Angel Mayor, Marina B. Klein, Michael A. Horberg, Kelly Gebo, Ronald J. Bosch, Laura Bamford, Jennifer S. Lee, Keri N. Althoff, for the North American AIDS Cohort Collaboration on Research and Design of IeDEA

Poster Session-N02 NEUROCOGNITIVE MANIFESTATIONS OF COVID-19
2:00 PM MT - 3:30 PM MT

632 NEUROPSYCHOLOGIC PERFORMANCE FOLLOWING COVID-19: PREVALENCE AND PREDICTORS
Alessandra Vergori, Carmela Pinnetti, Giulia Del Duca, Anna Clelia Brita, Ilaria Mastorosara, Patrizia Lorenzini, Valentina Mazzotta, Marta Camicì, Pierangelo Cinello, Paola Mencarini, Maria Letizia Giancola, Amina Abdeddaim, Enrico Girardi, Francesco Vaia, Andrea Antinori

633 MENTAL HEALTH & ALCOHOL USE IN PEOPLE WITH & WITHOUT HIV BEFORE & DURING COVID-19
Sara Bares, Pamela May, Harlan Sayles, Renae Furl, Tony Wilson

634 QUINOLINIC ACID IS A BIOMARKER OF COVID-19–ASSOCIATED COGNITIVE IMPAIRMENT
Lucette A. Cysique, Sophia Bracken, Yasmin Allen-Davidian, Benjamin Heng, Sharron Chow, Mona Dehhaghi, Ananda Staats Pires, David Darley, Anthony Byrne, Anthony Kelleher, Greg Dore, Gail Matthews, Gilles Guillemin, Bruce Brew

635 CSF AND BLOOD ANALYSES IN PARTICIPANTS WITH POST-COVID-19 NEUropsychiatric symptoms
Lindsay S. McAlpine, Jennifer Chiarella, Hannah Walsh, Sharon Shin, Eunice Baik, Jennifer Yoon, Aroma Naeem, Michael Wilson, Samuel Pleasure, Christopher M. Bartley, Serena S. Spudich, Shelli F. Fairhadian, for the COVID Mind Study at Yale

Poster Session-O02 PHARMACOLOGIC RELATIONSHIPS ASSOCIATED WITH TB DRUGS AND OUTCOMES
2:00 PM MT - 3:30 PM MT

651 RIFABUTIN FORMULATION THAT DELIVERS DRUG 4 MONTHS PREVENTS AND TREATS Mtb INFECTION
Manse Kim, Claire E. Johnson, Alan A. Schmalstig, Ayano Annis, Sarah E. Wessel, Miriam Braunstein, J. Victor Garcia-Martinez, Martina Kovarova
652 **ISONIAZID AND RIFAMPIN PLASMA EXPOSURE ARE ASSOCIATED WITH TB TREATMENT OUTCOMES**

Lauren S. Poeltluk, Edward Acosta, David W. Haas, Brian Hachey, Gustavo Amorim, Marcelo Cordeiro-Santos, Afrânio L. Kritski, Marina C. Figueiredo, Leticia Linhares, Megan Turner, Felipe Ridolfi, Bruno B. Andrade, Valeria Cavalcanti Rolla, Timothy Sterling, for the RePORT Brazil Consortium

653 **ALCOHOL USE AND SUBOPTIMAL ADHERENCE TO ISONIAZID IN PERSONS WITH HIV AND LATENT TB**


654 **DOSE SELECTION OF RIFAPENTINE IN PEDIATRIC PATIENTS BASED ON PBPK MODELLING**

Maiara C. Montanha, Shakir A. Atoyebi, Fazila S. Bunglawala, Kamunkhwala Gausi, Hannah Kinvig, Paolo Denti, Marco Sicardi, Catriona Waitt

655 **CONCENTRATION-QT MODELING OF BEDAQUILINE, CLOFAZIMINE, AND PRETOMANID IN TB PATIENTS**

Mahmoud T. Abdelwahhab, Elin Svensson, Andreas Diacon, Almari Conradie, Morounfolu Olugbosi, Rodney Dawson, Gary Martens, Paolo Denti

656 **CLOFAZIMINE DRUG LEVELS AND CARDIAC TOXICITY IN CHILDREN WITH RIFAMPICIN-RESISTANT TB**

Ali M. Ali, Belen P. Solans, Jana Winckler, Anneke Hesseling, Heather Draper, Simon Schaal, Louvina van der Laan, Jennifer Hughes, Anthony Garcia-Prats, Rada Savic

**Poster Session-O03  TB EPIDEMIOLOGY, TREATMENT, AND IMPLEMENTATION SCIENCE**

**2:00 PM MT - 3:30 PM MT**

657 **SEX DIFFERENCES IN RATES OF TUBERCULOSIS IN PEOPLE WITH HIV IN RIO DE JANEIRO, BRAZIL**

Lelia H. Chaisson, Betina Durovni, Eileen P. Scully, Solange Cavalcante, Jonathan Golub, Richard E. Chaisson, Valeria Saraceni

658 **SEX DIFFERENCES IN LATENT TUBERCULOSIS INFECTION AMONG CLOSE CONTACTS IN BRAZIL**

Paul Y. Wada, Peter F. Rebeiyo, Allyson Guimaraes da Costa, Rebeca C. Araujo, Mariana Araujo-Pereira, Beatriz Barreto-Duarte, Alexandra B. Souza, Michael S. Rocha, Megan Turner, Valeria Cavalcanti Rolla, Afrânio L. Kritski, Marcelo Cordeiro-Santos, Bruno B. Andrade, Timothy Sterling, for the Regional Prospective Observational Research in Tuberculosis Brazil Consortium

659 **MODELING THE IMPACT OF HIV AND TB INTERVENTIONS ON SOUTH AFRICAN TB TRENDS: 1990-2019**

Mmamapudi Kubjane, Muhammad Osman, Rory Dunbar, Andrew Boullé, Leigh Johnson, for the Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine

660 **CLINICAL AND LABORATORY PREDICTORS OF TUBERCULOSIS RECURRENCE**

Sonya Krishnan, Nikhil Gupte, Shreyas Desmukh, Padma Priyadarshini, Sanjay Gaikwad, Vijay Vishwanathan, Madhusudan Barthwal, Amita Gupta, Hardy Kornfeld, Jonathan Golub, Vidya Mave, for the RePORT India Study Team
661 **PATIENT-LEVEL POOLED ANALYSIS OF STUDY 31/A5349, A STRATIFIED MEDICINE APPROACH**


662 **LATENT TB INFECTION TREATMENT ACCELERATES IMMUNE RECOVERY AMONG PLWH ON ART**

Eduarda Grinsztejn, Luciane Velasque, Sandra Wagner-Cardoso, Brenda Hoagland, Sandro Nazer, Beatriz Grinsztejn, Valdilea Veloso

---

660 **HIV AND SARS-CoV-2 INFECTION AMONG POSTPARTUM KENYAN WOMEN AND THEIR INFANTS**

Emily R. Begnel, Bhavna Chohan, Ednah Ojee, Judith A. Onyango, Prestone Owiti, LaRinda A. Holland, Barbra A. Richardson, Adam K. Khan, Rabia Maqsood, Efrem S. Lim, Dana A. Lehman, Jennifer Slyker, John Kinuthia, Dalton C. Wamalwa, Soren Gantt

661 **ADVERSE PREGNANCY OUTCOMES ASSOCIATED WITH COVID-19 INFECTION IN WESTERN KENYA**

Victor Akelo, Gregory Ouma, Joyce Were, Sammy Khagayi, Dickson Gethi, Richard Omore, Feiko ter Kuile, Marc Bulterys, Dickens Onyango, Beth A. T. Barr

662 **SARS-CoV-2 INFECTION AND PREGNANCY IN AFRICA: A 6-COUNTRY RETROSPECTIVE COHORT STUDY**


663 **LONGITUDINAL SARS-CoV-2 ANTIBODY RESPONSE IN PREGNANCY AND TRANSPLENTAL TRANSFER**

Sylvia LaCourse, Morgan Aurelio, Jaclyn Escudero, Sascha R. Ellington, Lauren B. Zapata, Margaret C. Snead, Viral Upadhyay, Krissy Yamamoto, Carol Salerno, Alex Greninger, Alisa Kachikis, Janet A. Enlund, Alison L. Drake

664 **IMMUNE SYSTEM PROFILE AND CYTOKINE LEVELS OF SARS-CoV-2 IN PREGNANCY AND NEWBORNS**

Elena Vázquez Alejo, Laura Tarancón-Diez, Itziar Carrasco, Sara Vigil-Vazquez, Mar Muñoz-Chapuli, Elena Rincón López, Jesús Saavedra-Lozano, Mar Santos Sebastián, Juan Antonio De León Luis, Manuel Sánchez-Luna, Maria Luisa Navarro, María Angeles Muñoz-Fernández

665 **NEUTRALIZING ANTIBODY RESPONSE AND TRANSPLENTAL TRANSFER IN COVID-19 IN PREGNANCY**

**Poster Session-P02**

**HIV, ART, AND PREGNANCY OUTCOMES: EPIDEMIOLOGY AND MECHANISMS**

2:00 PM MT - 3:30 PM MT

---

**676** IMPAACT 2032: REMDESVIR PK & SAFETY IN PREGNANT AND NON-PREGNANT WOMEN WITH COVID-19

**Kristina M. Brooks**, Kristin Baltrusaitis, Jeremiah Monmper, Elizabeth Greene, Frederic Bone, Kira Bacon, Rita Humeniuk, Dwight E. Yin, Nahida Chakhtoura, Alice M. Stek, Edmund Capparelli, Mark Mirochnick, Diana F. Clarke, Brookie M. Best, for the IMPAACT 2032 Study Team

---

**677** NEURAL TUBE DEFECTS AND PRENATAL EXPOSURE TO DOLUTEGRAVIR: UNITED STATES, 2008-2019

**Athena Kourtis**, Weiming Zhu, Margaret Lampe, Ya-Lin A. Huang, Karen W. Hoover

---

**678** BIRTH OUTCOMES FOLLOWING PRENATAL EXPOSURE TO DOLUTEGRAVIR: THE DOLomite-EPPICC STUDY

**Claire Thorne**, Karoline Aebi-Popp, Luminita Ene, Marco Floridina, Anna Maria Gamell, Marta Illan, Helen Peters, Anna Samarin, Leigh Ragone, Carlo Giaquinto, Vani Vannappagari, for the Dolomite-EPPICC Study Group

---

**679** RISK-BENEFIT TRADE-OFF FOR PREGNANCY AND INFANT OUTCOMES: DTG, EFV, TAF, AND TDF

**Sean Brummel**, Lauren Ziembka, Anne Coletti, Lameck Chinula, Chelsea Krotje, Renee Browning, Esau Joao, Mpho Raesi, James S. Ngocho, Linda Aupribul, Lynda Stranix-Chibanda, Roger L. Shapiro, Jeff Stringer, Shahin Lockman

---

**680** ADVERSE OUTCOMES IN SUBSEQUENT PREGNANCIES IN THE IMPAACT 2010 TRIAL

**Lee Fairlie**, Sean Brummel, Lauren Ziembka, Anne Coletti, Lameck Chinula, Roger L. Shapiro, Jeff Stringer, Renee Browning, Nahida Chakhtoura, Blandina T. Mmbaga, Tsungai P. Mhembre, Ayotunde Omoz-Oarhe, Beatrice Naggadya, Megshenee Naidoo, Shahin Lockman

---

**681** SOME InSTIs INDUCE TOXICITY AND DIFFERENTIATION IN HUMAN EMBRYONIC STEM CELLS

**Marie-Soleil R. Smith**, Ronil Patel, Lou Martineau, Helene C. Cote

---

**682** IMPACT OF MATERNAL HIV/HBV COINFECTION ON PREGNANCY AND INFANT OUTCOMES

**Flavia K. Matovu**, Camlin Tierney, Audrey Chang, Dhayendre Moodley, Vani Govender, Tichaona Vhembo, Kathleen George, Neaka Z. Mohtashemi, Philippa Musoke, Dingase Dula, Nahida Chakhtoura, Marion Peters, Mary G. Fowler, Judith S. Currier, Debika Bhattacharya

---

**683** HIV-RELATED DIFFERENCES IN PLACENTAL IMMUNOLOGY: DATA FROM THE PRACHITi COHORT

**Jyoti S. Mathad**, Ramesh Bhosale, Mallika Alexander, Shilpa Naik, Vandana Kulkarni, Lisa Marie Cranmer, Andrea Chalem, Jin Liu, Jun Lei, Anna Chudnovets, Anguo Liu, Rupak Shivakoti, Amita Gupta, Irina Burd
711 2-YEAR OUTCOME OF EARLY TREATED INFANTS IN SUB-SAHARAN AF RICA
Alfredo Tagarro, Sara Domínguez-Rodriguez, Louise Kuhn, Tacita Nhampossa, Kennedy Otowombe, Anita Janse van Rensburg, Nigel Klein, Maria Grazia Lain, Almoustapha I. Maiga, Camille Brehin, Carlo Giaquinto, Paolo Rossi, Pablo Rojo, for the EPICAL Consortium

712 HIV-1 RESERVOIR CELL EVOLUTION IN EARLY-TREATED CHILDREN IN BOTSWANA
Ciputra A. Hartana, Pilar García-Broncano, Yelizaveta Rassadkina, Xiaodong Lian, Chenyang Jiang, Kevin B. Einkauf, Sikhulile Moyo, Terence Mohammed, Comfort Maphorisa, Joseph Makhema, Ce Gao, Xu Yu, Daniel Kuritzkes, Roger L. Shapiro, Mathias Lichterfeld

713 DIFFERENTIAL CLEARANCE OF INTACT AND DEFECTIVE HIV DNA IN THE PEDIATRIC RESERVOIR

714 LOWER RESERVOIR CONTRIBUTION OF NAIVE VS MEMORY T CELLS IN PERINATAL HIV INFECTION
Adit Dhummakupt, Yuyang Huang, Joseph Szewczyk, Priya R. Khetan, Ya Chen, Hao Zhang, Bareng A. Nonyane, Thuy Anderson, Mareike Haaren, Vicki Tepper, Allison Agwu, Deborah Persaud

715 EARLY ANTIRETROVIRAL THERAPY IN NEONATES AND MATURATION OF THE GUT MICROBIOME
Louise Kuhn, Fan Li, Renate Strehlau, Nicole Tobin, Faeezah Patel, Stephanie Shiau, Shuang Wang, Elaine J. Abrams, Caroline T. Tiemessen, Grace M. Aldrovandi, for the LEOPARD Study Team

716 DNA METHYLATION SIGNATURES ASSOCIATED WITH HIV SUPPRESSION AFTER TREATMENT IN INFANTS
Stephanie Shiau, Ziyi Wang, Renate Strehlau, Ashraf Coovadia, Carmen Marsit, Shuang Wang, Michael T. Yin, Stephen M. Arpadi, Elaine J. Abrams, Louise Kuhn, for Neverest Study Team

717 THE SUBPHENOTYPES OF EARLY-TREATED CHILDREN LIVING WITH HIV-1
Sara Domínguez-Rodriguez, Alfredo Tagarro, Caroline Foster, Paolo Palma, Nicola Cotugno, Anita De Rossi, Annalisa Dalzini, Savita G. Pahwa, Eleni Nastouli, Kathleen Gärtner, Anne Genevieve Marcelin, Paolo Rossi, Carlo Giaquinto, Pablo Rojo, for the EPICAL Consortium

718 IS ROUTINE PCP PROPHYLAXIS NEEDED IN VERY EARLY-TREATED INFANTS WITH HIV?
Bryan S. Nelson, Camlin Tierney, Deborah Persaud, Jennifer Jao, Mark F. Cotton, Yvonne Bryson, Kira Bacon, Diane Costello, Charlotte Perlowski, Maria Leticia Santos Cruz, Jospahat Kosgei, Sai Majji, Dwight E. Yin, Ellen G. Chadwick, for the IMPAACT P1115 Team
740 COVID-19 IN CHILDREN: WORSENING OUTCOMES DURING DELTA VARIANT WAVE  
Christiana Smith-Anderson, Lori Silveira, Monika Jelic, Sean Lang, Shane Curran-Hays, Ye Ji Choi, JoEllen Fresia, Brian Carter, Shea Boyer, Lisa Abuogi

741 LONGITUDINAL STUDY OF ANTI SPIKE ANTIBODIES IN CHILDREN AFTER SARS-CoV-2 INFECTION  
Federica Frasca, Leonardo Sorrentino, Giuseppe Oliveto, Mirko Scordio, Matteo Fracella, Agnese Viscido, Fabio Midulla, Raffaella Nenna, Alessandra Febbo, Luigi Matera, Guido Antonelli, Carolina Scagnolari, Alessandra Pierangeli

742 HUMORAL AND CELLULAR RESPONSE TO mRNA SARS-CoV-2 VACCINATION IN HIV-INFECTED CHILDREN  
Jose Tomas Ramos Amador, Arantxa Berzosa Sanchez, Marta Illan, Alba Ruedas, Kauzar M. Mohamed Mohamed, Luis Prieto, Sara Guillén, Ignacio Callejas, Ana Belén Jiménez, Santiago Jiménez de Ory, Maria Luisa Navarro, Silvia Sanchez Ramon

743 BAMLANIVIMAB PLUS ETSEVIMAB FOR THE TREATMENT OF COVID-19 IN PEDIATRIC PATIENTS  
Himanshu P. Upadhyaya, Jenny Chien, Martin Bohm, Lisa Macpherson, Dipak R. Patel, Matthew M. Hufford, Mark Williams

744 REMDESVIR TREATMENT FOR COVID-19 IN HOSPITALIZED CHILDREN: CARAVAN INTERIM RESULTS  
Amina Ahmed, Pablo Rojo, Allison Agwu, David Kimberlin, Jaime Deville, Ana Mendez-Echevarria, Paul Sue, Luisa Galli, Zongbo Shang, Kavita Juneja, Henry N. Hulter, Charlotte Hedskog, Kathryn Kersey, William Muller, Flor Munoz

745 TREATMENTS FOR MIS-C IN CHILDREN: DISCHARGE, FEVER, AND SECOND-LINE THERAPIES  
Alfredo Tagarro, Sara Domínguez-Rodríguez, Juan Miguel Mesa, Cristina Epalza, Carlos Grasa, Maria Isabel Iglesias-Bouzas, Maria Fernández-Pascual, Jesús Saavedra, Beatriz Soto, Jacques G. Rivière, Victoria Fumadó, Leticia Martinez-Campos, álvaro Ballesteros, Cinta Moraleda, for the EPICO-AEP Working Group

746 ASYMPTOMATIC SARS-CoV-2 INFECTION IS EXTREMELY COMMON AMONG PEOPLE WITH HIV  
Isabelle R. Weir, Edgar T. Overtom, Markella V. Zann, Stephanie Fischinger, Kathleen Fitch, Judith A. Aberg, Carl J. Fichtenbaum, Gerald S. Bloomfield, Carlos Malvestutto, Sara McCallum, Pamela S. Douglas, Galit Alter, Heather J. Ribaudo, Steven Grinspoon, for the REPRIVE Trial Investigators

747 SARS-CoV-2 ANTIBODY CORRELATES AMONG PWID LIVING WITH AND WITHOUT HIV IN KENYA  
748 HIGHER COVID-19 POSITIVITY AND LOWER VACCINATIONS AMONG PEOPLE WHO USE DRUGS
Javier A. Tamargo, Janet Diaz-Martinez, Ivan Delgado-Ecino, Mary J. Trepka, David R. Brown, Nana A. Garba, Eneida Roldan, Yolangel Hernandez, Alileen M. Marty, Adriana Campa, Haley R. Martin, Jose A. Bastida Rodriguez, Yongjuin Huang, Marianna K. Baum, for the MASH Cohort

749 DAY-TO-DAY IMPACT OF COVID-19 ASSOCIATED WITH RISK OF OVERDOSE: C3PNO COHORT FINDINGS
Soroush Moallef, Becky L. Genberg, Kanna Hayashi, Shrutri H. Mehta, Jinocheol Choi, Kora DeBeck, Michele Kipke, Richard Moore, Marianna K. Baum, Steve Shoptaw, Pamina M. Gorbach, Brian Mustanski, Marjan Javanbakht, Sue Siminski, M. J. Milloy

750 SEROPREVALENCE AND RISK FACTORS FOR SARS-CoV-2 AMONG INCARCERATED ADULT MEN IN QUEBEC
Nadine Kronfli, Camille Dussault, Mathieu Maheu-Giroux, Alexandros Halavrezos, Sylvie Chalifoux, Jessica P. Sherman, Hyejin Park, Lina Del Balso, Matthew P. Cheng, Sebastien Poulin, Joseph Cox

751 RACIAL/ETHNIC AND NEIGHBORHOOD SOCIAL VULNERABILITY DISPARITIES IN COVID-19
Usama Bilal, Florence Momplaisir, Alina Schnake-Mahl, Kathleen Murphy, John Jemmott

752 ASSOCIATION BETWEEN THE NEIGHBORHOOD BUILT ENVIRONMENT AND COVID-19 HOSPITALIZATION
Sarah E. Rowan, Alessandro Rigolon, Jeremy Nemeth, Cory Husain, Brian Montague, Brenn Anderson-Gregson, Priyanka deSouza, Kristine Erlandson

753 A NATIONAL SEROPREVALENCE SURVEY OF SARS-CoV-2 ANTIBODIES IN SOUTH AFRICA: 2020-2021
Leickness C. Simbayi, Sizulu Moyo, Adrian Puren, Penny Moore, Samuel Manda, Nompuumelelo Zungu, Khangelani Zuma, Edmore Marinda, Sean Jooste, Tarylee Reddy, Lynn Morris, Amenea Goga, Musawenkosi Mabaso, Whadi-ah Parker, Inbarani Naidoo, for the NCAS Study Group

754 LOCAL-SCALE SPATIAL VARIABILITY IN SARS-CoV-2 SEROPREVALENCE IN AN INDIAN MEGACITY

755 PHYLODYNAMIC OF SARS-CoV-2 TRANSMISSION IN FRANCE: 2020

756 MAIN SARS-CoV-2 CIRCULATING VARIANTS IN SPAIN DURING THE FIRST YEAR OF THE PANDEMIC
Paloma Troyano-Hernández, Roberto Reinoso, África Holguín

757 MOLECULAR EPIDEMIOLOGY OF THE COVID-19 PANDEMIC IN CHICAGO
Ted Ling Hu, Lacy M. Simons, Egon A. Ozer, Ramon Lorenzo-Redondo, Judd F. Hultquist

758 CHARACTERISTICS AND OUTCOMES CHANGES IN COVID-19 INPATIENTS: A COMPARISON OF 4 WAVES
Martin Martinot, Magali Eyrify, Simon Gravier, Ciprian Ion, Mahsa Mohseni-Zadeh, Estelle Rougier, Jean-Claude Ongagna, Anais Henric, Anne Schieber, Christian Kempf
759 EFFICACY OF NATURAL IMMUNITY AGAINST REINFECTION WITH SARS-CoV-2 B.1.351 VARIANT
Laith J. Abu-Raddad, Hiam Chemaitelly, for the National Study Group for COVID-19 Epidemiology in Qatar

760 CLINICAL OUTCOME IN PEOPLE WITH COVID-19 BY HIV-STATUS: A NATIONWIDE REGISTER STUDY
Isabela Möller, Magnus Gisslen, Philippe Wagner, Pär Sparén, Anders Sönnerborg, Christina Carlander

787 EMPIRICAL ESTIMATES OF ADULT HIV INCIDENCE ACROSS 12 COUNTRIES IN SUB-SAHARAN AFRICA
Nora E. Rosenberg, Bonnie Shook-Sa, Mincen Liu, Lynda Stranix-Chibanda, Marcel Yotebieng, Nadia Sam-Agudu, Sam J. Phiri, Wilbroad Mutale, Linda-Gail Bekker, Manhattan E. Charurat, Jessica E. Justman, Benjamin Chi

788 EDUCATION AND HIV RISK: EVIDENCE FROM 12 SUB-SAHARAN AFRICAN COUNTRIES, 2015-2018
Elizabeth Gummerson, Daniela Quigee, Delivette Castor, Andrea Low

789 HEAVY RAINFALL IS ASSOCIATED WITH HIGHER HIV PREVALENCE ACROSS SUB-SAHARAN AFRICA
Karly Hampshire, Jason Nagata, Adrienne Epstein, Edwin D. Charlebois, Alexander C. Tsai, Denis Nash, Sheri D. Weiser

790 HIV RISK BEHAVIORS AMONG BLACK AND HISPANIC TRANSGENDER WOMEN IN THE UNITED STATES
Xinyi Li, Evelyn J. Olansky, Kathryn Lee, Janet Burnett, for the NHBS-Trans Study Group

791 GENDER IDENTITY, STIGMA, AND SEXUALLY TRANSMITTED INFECTIONS IN NIGERIA
Elyse LeeVan, Fengming Hu, Andrew Mitchell, Afoke Kokogho, Sylvia Adebajo, Haoyu Qian, Julie Ake, Merlin Robb, Manhattan E. Charurat, Stefan Baral, Rebecca G. Nowak, Trevor A. Crowell, for the TRUST/RV368 Study Group

792 PREVALENCE OF UNTREATED HIV AND HIV INCIDENCE AMONG OCCUPATIONAL GROUPS IN UGANDA
Victor O. Popoola, Joseph Kagaayi, Joseph Ssekasanvu, Robert Ssekubugu, Anthony Ndyanabo, Fred Nalugoda, Larry W. Chang, Godfrey Kigozi, Justin Lessler, Maria Waver, Donna Kabatesi, Lisa Mills, Steven J. Reynolds, David Serwadda, M. Kate Grabowski

Laura Platt, Fatma M. Shebl, Katherine K. Hsu, Kevin L. Ard, Catlainn Sionean, Johanna Chapin-Bardales, Bridget A. Bunda, Ingrid V. Bassett, Monina Klevens

794 SOURCES OF HIV TRANSMISSION IN THE ERA OF UNIVERSAL TEST AND TREAT: A MODELING STUDY
Adam Akullian, Joshua Herbeck, Anna Bershteyn
795 HIV INCIDENCE AND IMPACT OF INTERVENTIONS IN FEMALE SEX WORKERS IN MENA

796 ASSOCIATION THE HIV STATUS OF HOUSEHOLD HEAD AND THEIR YOUTHS IN 10 AFRICAN COUNTRIES
Matthew A. Weissberg, Mansoor Farahani, Rachel Bray, Jessica E. Justman, Wafaa M. El-Sadr

Poster Session-T03 HIV DIAGNOSTICS
2:00 PM MT - 3:30 PM MT

814 3-IN-1 RAPID BLOOD SELF-TESTING FOR HIV, HBV, AND HCV: ACCEPTABILITY AND FEASIBILITY
Nicolas Salvadori, Jullapong Achalapong, Chonlathorn Boontan, Surachet Arunothong, Woottichai Khamduang, Pornphimon Moolnoi, Sakorn Pornprasert, Sumeet Ongwandee, Jean Yves Mary, Gonzague Jourdain, Nicole Ngo-Giang-Huong, for the Napneung Project Team

815 INCREASE IN FALSE POSITIVE 4TH GENERATION HIV TESTS IN PATIENTS WITH COVID-19 DISEASE
Anita Shallal, Smitha Gudipati, Edward Peterson, Bernard Cook, Robert Tibbetts, Norman Markowitz

816 NEW MOLECULAR ASSAY BASED ON NANOTECHNOLOGY FOR THE EARLY DETECTION OF HIV-1 p24
Ana Rodriguez Galet, Sergio García López, Priscila Kosaka, África Holguín

817 INTERPRETATION OF HIV SELF-TEST RESULTS AMONG PrEP USERS IN KENYA
Peter A. Mogere, Ashley Bardon, Dorothy Mangale, Catherine Kiptinness, Richard Magara, Snaidah Ongachi, Sarah Mbaire, Stephen Gakuo, Nelly R. Mugo, Jared Baeten, Katrina Ortblad, Kenneth Nguere

Poster Session-V02 PrEP IN ADOLESCENTS AND PREGNANT PEOPLE
2:00 PM MT - 3:30 PM MT

842 A TOOL TO ASSESS HIV PREVENTION READINESS OF ADOLESCENT GIRLS AND YOUNG WOMEN

843 PrEP DISCONTINUATION AMONG ADOLESCENTS PrEP USERS IN BRAZIL
Diana R. Zeballos Rivas, Fabiane Soares, Laio Magno, Marcos Eustorgio, Leila Amorim, Dirceu Greco, Alexandre Grangeiro, Ines Dourado, for the PrEP1519 Brazil Study Group

844 ECOLOGICAL MOMENTARY ASSESSMENT TO EXPLORE THE POTENTIAL OF ON-DEMAND PrEP FOR YMSM
Lisa Hightow-Weidman, Zachary Soberano, Bryce Stamp, Kimberly Powers, Sybil Hosek, Jacob Stocks, Matthew Rosso, Alyssa Vecchio, Keith J. Horvath

845 PrEP USE PERSISTENCE AMONG KENYAN WOMEN WHO INITIATED PrEP DURING PREGNANCY
Jillian Pintye, John Kinuthia, Anna Larsen, Felix Abuna, Ben Ochieng, Nancy Ngumbau, Julia Dettinger, Laurén Gomez, Jessica E. Haberer, Grace John-Stewart, Jared Baeten
846 ORAL PrEP USE AMONG SOUTH AFRICAN WOMEN WITH PLANS FOR PREGNANCY
Lynn T. Matthews, Manjeetha Jaggernath, Yolandie Kriel, Christina Psaros, Patricia M. Smith, Kara Bennett, David R. Bangsberg, Craig W. Hendrix, Norma Ware, Jared Baeten, Kathleen E. Hurwitz, Jessica E. Haberer, Jennifer Smit

Brady W. Bennett, Sanjana Pampati, Marisol Valenzuela-Lara, Patrick S. Sullivan, Jodie L. Guest

848 EXTENDED-RELEASE NALTREXONE LOWERS INJECTION USE IN JUSTICE-INVOLVED PERSONS WITH HIV
Audun J. Lier, Nikhil Seval, Brent Vander Wyk, Angela Di Paola, Sandra Springer

849 SELF-START HOME PEPSE TO REDUCE UPTAKE TIME AND INCREASE PEPSE EFFICACY: RCT
Julie Fox, Julienne Lwanga, Achyuta Nori, Amanda Clarke, Ming J. Lee, Orla McQuillan, Lesedi M. Ledwaba-Chapman, Sana Mantori, Cassie Fairhead, Fiona Ryan, Yanzhong M. Wang, Anatole Menon Johansson, for HOME PEPSE

850 IMPLEMENTATION OF A POST-EXPOSURE PROPHYLAXIS HOTLINE IN WASHINGTON, DC
Megan Coleman, Jason Beverley, Annika Bergstrom, Kate Drezner, Rachel Harold, Michael Kharfen, Amanda B. Spence, Camilla Stanley, Ashlee Wimberly, Adam Visconti

851 RCT OF iTAB PLUS MOTIVATIONAL INTERVIEWING FOR PrEP ADHERENCE IN TRANSGENDER PERSONS
Sheldon Morris, Sonia Jain, Jill Blumenthal, Robert Bolan, Michael Dubé, Philip Henderson, Katya Corado, Feng He, Leah Burke, Peter Anderson, David J. Moore

Karen W. Hoover, Ya-Lin A. Huang, Weiming Zhu, Anne A. Kimball, Evelyn J. Olansky, Asa Radix

Maria Zlotorzynska, Weiming Zhu, Ya-Lin A. Huang, Kashif Iqbal, Mary Tanner, Karen W. Hoover

881 HIGH LEVEL OF HIV VIRAL SUPPRESSION IN UGANDAN MEN WITH URETHRITIS AND BACTERIAL STI
Evan Beck, Oliver Laeyendecker, Sharada Saraf, Annet Onzia, Johan H. Melendez, Peter Kyambahde, Tza-Huei Wang, Ethan Gough, Yukari C. Manabe, Matthew M. Hamill
882  HIV, ASYMPTOMATIC STI, AND THE RECTAL MUCOSAL IMMUNE ENVIRONMENT AMONG YOUNG MSM

883  SYPHILIS REINFECTIONS AMONG HIV+ AND HIV- PATIENTS: A RETROSPECTIVE STUDY
Giorgio Tiecco, Valentina Marchese, Samuele Storti, Melania Degli Antoni, Silvia Amadasi, Maurizio Gulletta, Francesca Viola, Emanuele Focà, Francesco Castelli, Maria Eugenia Quirós-Roldan

884  DOUBLE-DOSE ETONOGESTREL CONTRACEPTIVE IMPLANT OVERCOMES INTERACTION WITH EFAVIRENZ
Catherine A. Chappell, Mohammed Lamorde, Shadia Nakalema, Isabella Kyohairwe, Pauline Byakika-Kibwika, Leslie A. Meyn, Michelle Pham, Kimberly K. Scarsi

885  DISPARITIES IN PRENATAL SYPHILIS RISK AMONG PREGNANT WOMEN LIVING WITH HIV IN BRAZIL
Jessica L. Castilho, Fernanda F. Fonseca, Ahra Kim, Emilia M. Jalil, Andrea M. Beber, Valdiele Veloso, Carmen S. Domingues, Catherine McGowan, Angelica E. Miranda, Beatriz Grinsztejn, Adele S. Benzaken, Bryan Shepherd, Gerson Fernando M. Pereira, for the National Cohort Study of Dolutegravir and Pregnancy Outcomes in Brazil

886  SCREENING OF STIs IN PREGNANCY AND PREGNANCY OUTCOMES IN WOMEN WITH AND WITHOUT HIV
Dorothy C. Nyemba, Remco P. Peters, Andrew Medina-Marino, Jeffrey D. Klausner, Phuti Ngwepe, Landon Myer, Leigh Johnson, Dvora Joseph Davey

Poster Session-Y04  SUBSTANCE USE

2:00 PM MT - 3:30 PM MT

912  MAINTAINED ACCESS TO PREVENTION & CARE FOR PWID DESPITE COVID-19 IN HAIPHONG, VIETNAM
Delphine Rapoud, Duc Q. Nguyen, Tran T. Nguyen, Huong T. Duong, Oanh T. Khuat, Nicolas Nagot, Don C. Des Jarlais, Khue M. Pham, Vinh H. Vu, Didier Laureillard, Mai S. Le, Laurent Michel, Jean-Pierre Molès, Thanh T. Nham, Giang T. Hoang

913  SUBSTANCE USE AND HIV OUTCOMES AMONG PRISON RELEASEES IN ZAMBIA: A COHORT STUDY
Michael E. Herce, Helene J. Smith, Vivien Mai, Chilambwe Mwila, Mirriam Nanyangwe, Lillian Kasheka, Tina Kayumba, Yotam Lungu, Clement Moonga, Sisa Hatwiinda, Stewart E. Reid, Monde Muyoyeta

914  SUBSTANCE USE TREATMENT UTILIZATION AMONG WOMEN WITH AND AT RISK FOR HIV IN THE SOUTH
915 RANDOMIZED TRIAL OF PATIENT ACTOR TRAINING TO IMPROVE PrEP SERVICES FOR AGYW IN KENYA
Pamela Kohler, John Kinuthia, Anna Larsen, Felix Abuna, George Owiti, Joseph Sila, Tamara Owens, Valerie Kemunto, Harrison Lagat, Melissa Vera, Barbra A. Richardson, Jillian Pintye, Grace John-Stewart

916 PROJECTED IMPACT OF EXPANDED LONG-ACTING INJECTABLE PrEP USE ON LOCAL HIV EPIDEMICS
Ruchita Balasubramanian, Parastu Kasaie, Melissa Schnure, David Dowdy, Maunank Shah, Anthony T. Fojo

917 GET2PrEP3: RCT OF PROVIDER MESSAGING TO IMPROVE LINKAGE TO HIV PREVENTION SERVICES
Jason Zucker, Deborah A. Theodore, Caroline Carnevale, Eshiemomoh Osilama, Norman Archer, Lily Bonadonna, Elena Wadden, Nicholas Morley, Simian Huang, Kathrine Meyers, Alwyn Cohall, Peter Gordon, Delivette Castor, Magdalena E. Sobieszczyn

918 PrEP RATHER THAN COVID-19 INFLUENCED SEXUAL ACTIVITY AMONG MSM IN TOKYO
Daisuke Mizushima, Misao Takano, Yasuaki Yanagawa, Takahiro Aoki, Koji Watanabe, Shinichi Oka

919 SEXUAL HEALTHCARE USE, PrEP USE, AND THE INCIDENCE OF STI AMONG MSM DURING COVID-19
Feline De Il Court, Anders Boyd, Liza Coyer, Mark van den Elshout, Henry J. de Vries, Amy Matser, Elske Hoornenborg, Maria Prins

920 ACCEPTABILITY AND ELIGIBILITY FOR PrEP AMONG MEDICAL MALE CIRCUMCISION CLIENTS
Tendesayi Kufa-Chakezha, Ocean Tobaiwa, Sean M. Patrick, Khumbulani Moyo, Phil Dorrell, Nichola Lutchman, Erushka Pillay, Adrian Puren

921 HEALTH OF LONG-TERM PrEP USERS IN AUSTRALIA: FINDINGS FROM THE X-PLORE COHORT
Vincent J. Cornelisse, Dean Murphy, Michael Traeger, Mark Stoove, Brian Price, Edwina J. Wright, for the X-PLORE Study Team

922 DEFERRING CREATININE CLEARANCE TESTING TO SUPPORT PrEP UPTAKE IN YOUNG WOMEN
Craig J. Heck, Lara Lewis, Natasha Samsunder, Quarraisha Abdool Karim

923 A COMPARISON OF SELF-REPORTED PrEP ADHERENCE AND OBJECTIVE MEASURES IN KENYA
Ashley Bardon, Kenneth Nqure, Peter A. Mogere, Dorothy Mangale, David Chege, Catherine Kiptinness, Stephen Gakuuo, Sarah Mbaira, Peter Anderson, Nelly R. Mugo, Jared Baeten, Katrina Ortblad

924 PrEP ROLLOUT AND COVID-19 ARE IMPACTING COMMUNITY-BASED TESTING FOR HIV & OTHER STIs
Christoph Boesecke, Torben Kimhofer, Christopher Tocha, Oliver Schubert, Rainer Rybak, Klaus Kuhlen, Christoph Klaes, Jürgen K. Rockstroh

925 PrEP DISCONTINUATION AMONG WOMEN IN US COMMUNITY HEALTH CENTERS
Whitney Irie, Jonathan Todd, Kenneth H. Mayer, Elvin H. Geng, Douglas Krakower, Julia Marcus
926 USING SAFE SPACE MODEL TO SCALE UP HIV PREVENTION IN ADOLESCENT GIRLS AND YOUNG WOMEN
Andrew W. Wafula, Philip Masaulo, Jane Thiomi, Benard Ogony, Peris M. Nasimiyu, Paul Musingila, Carol Kambona

927 HIGH PrEP UPTAKE AND LOW HIV VIREMIA WHEN PrEP IS INTEGRATED INTO UGANDAN ART CLINICS
Renee Heffron, Timothy Muwonge, Dorothy Thomas, Florence Nambi, Lylliane Nakabugo, Joseph Kibuuka, Erika L. Feutz, Allison A. Meisner, Katherine K. Thomas, Norma Ware, Jane A. Simoni, Ingrid T. Katz, Herbert Kadama, Andrew Mujugira, for the Partners PrEP Program Team

928 PHARMACY-BASED PrEP INITIATION AND CONTINUATION IN KENYA: FINDINGS FROM A PILOT STUDY
Katrina Ortblad, Peter A. Mogere, Victor Omollo, Alexandria Kuo, Magdaline Asewe, Stephen Gakuo, Hilma N. Nakambale, Melissa Mugambi, Andy Stergachis, Josephine Odoyo, Elizabeth A. Bukusi, Kenneth Ngure, Jared Baeten

929 COST-EFFECTIVENESS OF A COLLABORATIVE DATA-TO-CARE INTERVENTION FOR HIV PREVENTION
Ram Shrestha, Robyn Fanfair, Liisa Randall, Crystal Lucas, Lisa Nichols, Nasima Camp, Kathleen Brady, Heidi Jenkins, Frederick Altice, Alfred DeMaria, Merceditas Villanueva, Paul Weidle

930 COGNITIVE BEHAVIORAL THERAPY FOR HIV & DEPRESSION: COST-EFFECTIVENESS IN SOUTH AFRICA
Aditya R. Gandhi, Emily P. Hyle, Justine Scott, Jasper S. Lee, Fatma M. Shebl, John Joska, Lena S. Andersen, Conall O’Cleirigh, Steven A. Safren, Kenneth Freedberg

931 AGRICULTURAL LIVELIHOOD INTERVENTION REDUCES HIV STIGMA: RESULTS FROM A CLUSTER RCT

932 PSYCHOSOCIAL FACTORS INTERACT WITH RACE DURING COUNTYWIDE PERSONALIZED HIV CARE
Michael J. Li, Brendon Chau, Wendy Garland, Sona Oksuzyan, Robert E. Weiss, Sae Rakada, Uyen Kao, Sung-Jae Lee, Steve Shoptaw

933 MENTAL HEALTH AND PrEP ADHERENCE AMONG MSM/NON-CISGENDER PEOPLE FROM LATIN AMERICA
Hamid Vega-Ramirez, Centli Guillén-Díaz-Barriga, Dulce Diaz, Kelika A. Konda, Thiago S. Torres, Oliver A. Elorreaga, Brenda Haagland, Juan V. Guirand, Marcos R. Benedetti, Sergio Bautista-Arredondo, Beatrix Grinsztejn, Carlos F. Caceres, Valdilea Veloso, for the ImPrEP Study Group

934 EFFECTS OF THE COVID-19 LOCKDOWN ON MENTAL HEALTH CARE USE IN PEOPLE LIVING WITH HIV
176 WITHDRAWN

177 SPECIFIC DETECTION AND REPLICATION KINETICS OF SARS-CoV-2 USING smRNA-FISH
Rajiv Pathak, Carolina Eliscovich, Updesh Dixit, Nacho Mena, Adolfo Garcia-Sastre, James M. Pullman, Robert H. Singer, Ganjam V. Kalpana

178 QUANTIFYING SARS-CoV-2 INFECTION KINETICS FROM UNVACCINATED AND VACCINATED PERSONS
Ruian Ke, Pamela Martinez, Rebecca L. Smith, Christopher B. Brooke

179 MUTATIONS IN PERSISTENT SARS-CoV-2 CASES
Lacy M. Simons, Judd F. Hulquist, Ramon Lorenzo-Redondo, Egon A. Ozer, Michael G. Ison, Chad J. Achenbach

180 ORF1 REGION OF SARS-CoV-2 GENOMIC RNA AS A PROMISING TARGET FOR siRNA-BASED THERAPY
Shubhankar Ambike, Cho-Chin Cheng, Martin Feuerherd, Domizia Baldassi, Stoyan Velkov, Gerald Burgstaller, Olivia M. Merkel, Thomas Michler

181 ROLE OF ACTIN REGULATORS IN HIV-1, IAV, & SARS-CoV-2 VIRUS-LIKE PARTICLES PRODUCTION
Manon Gourdelier, Peggy Merida, Jitendriya Swain, Delphine Muriaux

182 REDUCING HIV-1 HXB2 env GENE CpG FREQUENCY INCREASES VIRUS REPLICATION CAPACITY
Ana Jordan-Paiz, Sandra Franco, Miguel A. Martinez

183 UNRAVELING THE ANTVIRAL ACTIVITY OF PLITIDEPSIN BY ULTRASTRUCTURAL ANALYSIS
Martin Sachse, Raquel Tenorio, Isabel Fernández de Castro, Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Alejandro Losada, Pablo Avilés, Carmen Cuevas, Roger Paredes, Joaquim Segalés, Bonaventura Clotet, Júlia Vergara-Alert, Nuria Izquierdo-Useros, Cristina Risco, for the SARS-CoV-2 Study Team

184 REPURPOSING SINGLE-CELL RNA SEQ DATA TO QUANTIFY HIV SPLICING DURING LATENCY REVERSAL
Ann L. Emery, Jackson Peterson, Edward P. Browne, Ronald Swanstrom

185 HYDROGEN SULFIDE BLOCKS HIV REBOUND BY MAINTAINING CELLULAR REDOX HOMEOSTASIS
Virender K. Pal, Ragini Agrawal, Amit Singh

186 DEFECTIVE RNA-DIRECTED STRAND DISPLACEMENT DUE TO HIV-1 RIBONUCLEASE H INACTIVATION
Samara Martin Alonso, Dongwe Kang, Javier Martinez del Río, Joanna LuczkoWiak, Çağil Urhan, Estrella Frutos Beltrán, Xinyong Liu, Peng Zhan, Luis Menéndez Arias
187 INTERACTOME OF HIV PROTEINS AND THEIR HOST RNA INTERACTION PARTNERS
Tinus Schynkel, W. J. Van Snippenberg, Kimberly Verniers, Eric J. de Bony de Lavergne, Gwendolyn M. Jang, Nevan J. Krogan, Pieter Mestdagh, Linos Vandekerckhove, Wim Trypsteen

Poster Session-B06 OUTCOMES OF HIV INFECTION
2:00 PM MT - 3:30 PM MT

220 EXTENSIVE TRANSCRIPTIONAL PERTURBATIONS IN THE COLON VERSUS BLOOD DURING CHRONIC HIV
Stephanie Dillon, Kejun Guo, Emily Cooper, Cheyret Wood, Katerina Kechriss, Mario L. Santiago, Cara Wilson

221 GUT BARRIER INTEGRITY AND MICROBIOTA IN HIV PATIENTS RECEIVING ORAL BACTERIOTHERAPY
Leticia Santinelli, Giacomo Rossi, Giorgia Gioacchini, Ranieri Verin, Giuseppe P. Innocenti, Federica Frasca, Mirko Scordio, Francesca Lombardi, Alessandra Piccirilli, Stefano Fiorucci, Adriana Carino, Carolina Scagnolari, Giancarlo Ceccarelli, Claudio M. Mastroianni, Gabriella D’Ettorre

222 TNF-α AND IFN-Γ–PRODUCING CD4+ T CELLS MODULATE GUT REGENERATION IN HIV-1 INFECTION
Ana Jordan-Paiz, Martin E. Baumdick, Johannes Jung, Pia Fittje, Marcus Altfeld, Madeleine Bunders

223 HIV-INDUCED CELLULAR SENESCENCE IN PLWH IS DECREASED EX VIVO BY D+Q SENOLYTIC DRUGS
Nuria Climent, Víctor Casanova, María Jose Maleno, Andrea Rodríguez-Agustín, Sonsoles Sánchez-Palominos, Tania González, Carmen Hurtado, Esteban Martinez, Josep Mallolas, Juan Ambrosioni, Jose M. Miro, José Alcamí

224 REDUCED Nef BUT NOT Vpu FUNCTION IN AFRICAN LONG-TERM HIV SURVIVORS VS PROGRESSORS
Gisele Umviligihozo, Hua-Shian Hsieh, Jacklyn K. Mann, Steven W. Jin, Francis Mwimanzi, Hanwei Sudderuddin, Zabrina L. Brumme, Mark A. Brockman

225 IL-18 AND IL-3 IN EXTRACELLULAR VESICLES: BIOMARKERS FOR A DURABLE ELITE CONTROL

226 SURVIVAL AND DISEASE PROGRESSION IN ART-NAIVE LTNP WITH UNDETECTABLE HIV REPLICAION
Francisco Diez-Fuertes, Ruben A. Ayala-Suarez, Humberto Erick De La Torre-Tarazona, José Alcamí, Laura Capa

Poster Session-B07 HIV INFECTION AND INFLAMMATION
2:00 PM MT - 3:30 PM MT

227 METABOLIC SHIFTS POTENTIATE ACCELERATED AGING IN SUCCESSFUL LONG-TERM HIV TREATMENT
228 HIGH-THROUGHPUT TARGETED PLASMA PROTEOMICS SHOWS SYSTEMIC DYSREGULATION IN PWH ON ART
Nadira Vadaq, Vasiliki Matzaraki, Yue Zhang, Quirijn De Mast, Leo A. Joosten, Mihai Netea, Jingyuan Fu, Andre van der Ven

229 TARGETED INFLAMMATORY PLASMA PROTEOMICS SHOWS UPREGULATION OF DISTINCT PATHWAYS
Nadira Vadaq, Vasiliki Matzaraki, Lisa Van de Wijer, Louise van Eekeerden, Leo A. Joosten, Mihai Netea, Quirijn De Mast, Andre van der Ven

230 UPREGULATION OF INTERFERON-STIMULATED GENES PERSISTS DURING TREATED HIV-1 INFECTION
Yunqi Li, Cheryl M. Cameron, Banumathi Tamilselvan, Manonmani Kumar, Brian Richardson, Jared Baeten, Andrew Mujugira, Nelly R. Hugo, Connie L. Celum, Jairam R. Lingappa, Florian Hladik, Mark J. Cameron, Romel D. Mackelprang

231 INFLAMMATION AND IMMUNE ACTIVATION NOT DRIVEN BY ON-ART HIV-SPECIFIC IMMUNE RESPONSES

232 RECTAL TISSUE HIV RNA IS ASSOCIATED WITH SYSTEMIC INFLAMMATION IN PERSONS WITH HIV
Cecile D. Lahiri, Kehmiah Titaniq, Monica D. Reece, Ruby K. Taylor, Renata M. Shaw, Shelby Collins, Cyra C. Mehta, Jessica Ingersoll, Iggo Oteokun, Susan Pereira Ribeiro, Rafick-Pierre Sekaly, Christina Gavegno

233 LONGITUDINAL ASSOCIATION OF SYSTEMIC INFLAMMATION WITH FRAILTY IN HIV-INFECTED MEN
Weiying Zhang, Jay H. Bream, Sean Leng, Tricia Nilles, Huifen Li, Joseph B. Margolick

234 ASSOCIATION OF PLASMA BIOMARKERS WITH EARLY MORTALITY IN ADVANCED HIV INFECTION
Victor Riitho, Roisin Connan, Agnes Gwela, Josephine Namusanje, Ruth Nhema, Abraham Siika, James Hakim, Victor Musimu, James A. Berkley, Alexander Szubert, Nigel Klein, A S. Walker, Diana Gibb, Andrew J. Prendergast, for the REALITY Trial Team

271 LOSS OF TOLERANCE AND ANERGY IN HUMAN PERIPHERAL B CELLS DURING SARS-CoV-2 INFECTION
Moriah J. Castleman, Megan Stumpf, Nicholas Therrien, Brenda Martinez, Roberta Pelanda, Raul Torres

272 STRAIN-SPECIFIC SEROLOGICAL RESPONSE FOLLOWING SARS-CoV-2 VOC INFECTION
Karlijn van der Straten, Denise Guerra, Meliawati Poniman, Dirk Eggink, Marloes Grobben, Chantal Reusken, Hugo D. van Willigen, Elke Wynberg, Menno D. de Jong, Maria Prins, Tim Beaumont, Godelieve De Bree, Rogier W. Sanders, Marit J. van Gils
273 **SARS-CoV-2 NEUTRALIZING RESPONSE BEYOND 1 YEAR AFTER INFECTION**

Benjamin Trinité, Edwards Pradenas, Victor Urrea, Silvia Marfil, Ferran Tarrés-Freixas, Raquel Ortiz, Carla Rovirosa, Jorge Carrillo, Roger Paredes, Anna Chamorro, Ruth Toledo, Marta Massanella, Bonaventura Clotet, Julià Bianco

274 **ESTABLISHMENT OF AN ANTI-RBD THRESHOLD THAT PREDICTS ROBUST NEUTRALIZING ACTIVITY**


275 **HIGHER CORONAVIRUS ANTIBODY RESPONSES PREPANDEMIC IN AFRICA THAN IN THAILAND**

Yifan Li, Mélanie Merbah, Bradley Beckman, Thembi Mdulli, Heather Liu, Nittaya Phanuphak, Jonah Maswai, John Owuoth, Hannah Kibuuka, Michael Iroezindu, Emmanuel Bahemana, Sandhya Vasan, Julie Ake, Kayvon Modjarrad, Morgane Rolland

276 **PERSESTANCE OF SARS-CoV-2 ANTIBODIES IN CHILDREN AND ADULTS 1 YEAR AFTER INFECTION**

Costanza Di Chiara, Anna Cantarutti, Paola Costenaro, Chiara Cosma, Bonfante Francesco, Sandra Cozzani, Maria Raffaella Petrara, Francesco Carmona, Cecilia Liberati, Paolo Palma, Anita De Rossi, Mario Plebani, Carlo Giaquinto, Andrea Padoan, Daniele Donà

277 **IMMUNOAGONIST CONVERTS CMV-SPECIFIC T CELLS INTO MORE POTENT HIV-SPECIFIC CAR-T CELLS**

Hang Su, Christopher Hiner, Moriah Rabin, Danica Lee, Stephanie Sabido, Scott J. Garforth, Jianhua Zheng, Kim Anthony-Gonda, Boro Dropulić, Steven C. Almo, Harris Goldstein

278 **PRECLINICAL STUDIES TOWARD A PHASE I/IIA TRIAL USING ANTI-HIV DuoCAR-T CELL THERAPY**

Kim Anthony-Gonda, Alex Ray, Yuge Wang, Hang Su, Ariele Block, Danica Lee, Sarah Kleinsorge-Block, Jane Reese, Marcos de Lima, Dimitar S. Dimitrov, Rimas Orentas, Steven G. Deeks, Harris Goldstein, Boro Dropulic

279 **CD64 GENE-MODIFIED PRIMARY NK CELLS LOADED WITH ANTI-HIV bNAbS TRIGGER HIGH ADCC**

Costin Tomescu, Hong Kong, Meizan Lai, James L. Riley, Luis J. Montaner

280 **TARGETING SIGLEC IMMUNE CHECKPOINTS POTENTIATE NK CLEARANCE OF HIV-INFECTED CELLS**

Opeyemi S. Adenijii, Leticia Kuri-Cervantes, Chenfei Yu, Ziyang Xu, Glen Chew, Costin Tomescu, Ashley F. George, Nadia Roan, Lishomwa Ndhlovu, Qin Liu, Kar Muthumani, David Weiner, Michael Betts, Han Xiao, Mohamed Abdel-Mohsen

281 **IMMUNE RESPONSES FOLLOWING ANTI-PD-1 MONOCLONAL ANTIBODY INFUSION IN PERSONS WITH HIV**

Bernard J. Macatangay, Cynthia Gay, Ashley McKhann, Ronald J. Bosch, Chanelle Wimbish, Patrick Mehta, Raymond Cha, Kendall F. Moseley, Cheryl Jennings, Danielle Campbell, Elizabeth Miller, Randall Tressler, Daniel Kuritzkes, Joseph J. Eron, David W. Hardy
282 CDK INHIBITORS IMPACT HIV-1 SUSCEPTIBILITY BY MODULATING IN VIVO IMMUNOLOGIC RESPONSE
Lucía Gutiérrez Chamorro, Eudald Felip, Ifeanyi J. Ezeonwumelu, Bonaventura Clotet, Mireia Margelí, Ester Ballana

283 PROMOTING RESIDENT MEMORY CD8+ T-CELL PHENOTYPES TO ENHANCE HIV RESERVOIR ELIMINATION
Sebastián G. Kuguel, Nuria Massana, Jon Cantero-Pérez, Marina Suppi, Judith Grau-Expósito, Josep Castellví, Laura Mañalich-Barrachina, Cristina Centeno-Mediavilla, Jordi Navarro, Adrià Curran, Vicenç Falcó, Maria José Buzón,Meritxell Genescà

284 INCLUDING Env IN AN HIV THERAPEUTIC VACCINE BLUNTS Gag/Pol-SPECIFIC T-CELL RESPONSES
Kara W. Chew, Emma Reuschel, Mansi Purwar, Megan C. Wise, Nilu Goonetilleke, Elizabeth R. Wonderlich, Faraz Zaidi, Drew Frase, Jean Boyer, Laurent Humeau, Rafick-Pierre Sékaly, David Weiner, Dave Glidden, Steven G. Deeks, Rachel L. Rutishauser

285 CONSERVED-REGION MVA VACCINES REDIRECT HIV T-CELL IMMUNODOMINANCE IN PWH ON ART
Nilu Goonetilleke, Yinyin Xu, Shahryar Samir, Ann Marie Weideman, Sallay Kallon, Joanna Warren, Maria Abad, Alison Crook, Lawrence Fox, Michael Hudgens, David M. Margolis, Tomas Hanke, JoAnn D. Kuruc, Cynthia Gay, for the M&M Study Team

286 DENDRITIC CELL VACCINATION AGAINST HIV ALTERS NK CELL FREQUENCY AND PHENOTYPE
Thessa Laeremans, Cynthia Lungu, Sabine Den Roorover, Sigrid D’Haese, Rob Gruters, Sabine D. Allard, Joeri L. Aerts

287 EX VIVO ASSAY PREDICTS HIV-1 SUPPRESSION BY bNAbs INFUSED IN A PHASE I CLINICAL TRIAL
Sabrina Helmold Hait, Sarah E. Lovelace, Emily E. Coates, Grace Chen, Martin R. Gaudinski, Ro Shauna Rothwell, Eileen Donaghy, Joanna Roa, Carl J. Fichtenbaum, Jorge Santana, Rachel Presti, Pablo Tebas, Julie E. Ledgerwood, Amarendra Pegu, John R. Mascola

288 ChAdOx1 nCoV-19 VACCINATION IN PWH: IMMUNE RESPONSES TO SARS-CoV-2, VOCs, AND HCoVs
Ane T. Ogbe, Matthew Pace, Mustapha Bittaye, Stephanie Longet, Tom Tipton, Wanwisa Dejnirattisai, Katie J. Ewer, Gavin R. Screaton, Sarah C. Gilbert, Miles Caroll, Andrew J. Pollard, Sarah Fidler, Julie Fox, Teresa Lambe, John Frater

289 HIGH SEROCONVERSION RATE AND DELTA NEUTRALIZATION IN PLWHIV VACCINATED WITH BNT162b2
Valérie Pourcher, Lisa Belin, Cathia Soulie, Michelle Rosenzwajg, Stéphane Marot, Karine Lacombe, Nadia Valin, Gilles Pialoux, Ruxandra Calin, Roland Tubiana, Marc Antoine Valantin, David Klatzmann, Vincent Calvez, Noémie Simon-Tillaux, Anne Genevieve Marcelin
290 HOW HIV MODULATES THE SAFETY AND IMMUNOGENICITY OF THE BNT162b2 COVID-19 VACCINE
Ludovica Ferrari, Lorenzo Piermatteo, Federica Caldara, Eleonora Andreassi, Ada Bertoli, Harrison Austin, Diletta Meloni, Elisabetta Teti, Mirko Compagno, Marco Iannetta, Francesca Ceccherini-Silberstein, Loredana Sarmati, Massimo Andreoni, Anna Maria Geretti, for the PTVAX Study

291 DURABILITY OF SARS-CoV-2 mRNA VACCINE IMMUNE RESPONSE IN PLWH WITH ADVANCED DISEASE
Stefania Cicalini, Alessandra Vergori, Alessandro Cozzi-Lepri, Silvia Meschi, Veronica Bordoni, Simone Lanini, Daniele Lapa, Davide Mariotti, Lidya De Pascale, Veronica D’aquilla, Concetta Castilletti, Chiara Agrati, Enrico Girardi, Francesco Vaia, Andrea Antinori

292 SARS-CoV-2 VACCINE IMMUNOGENICITY IN PLWH IN THE NETHERLANDS
Kathryn S. Hensley, Marlou Jongkees, Corine H. Geurts van Kessel, Virgil A. Dalm, Jan G. den Hollander, Wouter F W Bierman, Eliane M. Leyten, Emile F. Schippers, Heidi S. Ammerlaan, Marc Van der Valk, Bart J. Rijnders, Kees Brinkman, Anna Roukens, Casper Rokx, for the COVIH Study Group

293 IMMUNOGENICITY TO COVID-19 mRNA VACCINE BOOSTER SHOT IN PLWH BY CURRENT CD4+ COUNT
Alessandra Vergori, Stefania Cicalini, Alessandro Cozzi-Lepri, Giulia Matusali, Veronica Bordoni, Simone Lanini, Francesca Colavita, Eleonora Cimini, Roberta Iannazzo, Lidya De Pascale, Concetta Castilletti, Chiara Agrati, Enrico Girardi, Francesco Vaia, Andrea Antinori, for the HIV-VAC Study Group

294 ALTERED FEATURES OF B AND T CELL RESPONSES TO BNT162 VACCINE IN HEMODIALYSIS PATIENTS
Alexandre Nicolas, Gérémy Sannier, Lorie Marchitto, Manon Nayrac, Nathalie Brassard, Shilei Ding, Alexandra Tauzin, Mathieu Dubé, Cécile Tremblay, Valérie Martel-Laferrière, Rémi Goupil, William Beaubien-Souligny, Andrés Finzi, Rita Suri, Daniel E. Kaufmann

295 ANTIBODY RESPONSE TO SARS-CoV-2 VACCINES AND IMMUNODEFICIENCY: A RANDOMIZED TRIAL
Frédérique Chammartin, Benjamin Speich, Irene A. Abela, Patrizia Amico, Marcel Stöckle, Anne L. Eichenberger, Macé M. Schuurmans, Thomas Müller, Michael Tamm, Huldrych F. Günthard, Michael T. Koller, Alexandra Trkola, Matthias Briel, Katharina Kusejko, Heiner C. Bucher

296 ANTIBODIES IN SOLID ORGAN TRANSPLANT RECIPIENTS 6 MONTHS AFTER BNT162b2 VACCINATION
Sebastian Hamm, Dina Leth Møller, Laura Pérez-Álós, Rasmus Bo Hasselbalch, Zitta Barrella Harboe, Ruth Frikke-Schmidt, Sisse R. Ostrowski, Michael Perch, Søren Schwartz Sørensen, Allan Rasmussen, Henning Bundgaard, Peter Garred, Kasper Karmark Iversen, Susanne D. Nielsen, for VACCIM

297 HUMORAL RESPONSE TO SARS-CoV-2 mRNA VACCINE IN HEART TRANSPLANT RECIPIENTS
Valentine M. Ferré, Zohra Brouk, Heloise Flamant, Caroline Kernéis, Charlotte Charpentier, Vanja Da Silva, Constance Verdonk, Eric Vicaut, Luc De Chaisemartin, Diane Descamps, Nadhira Houhou-Fidouh, Richard Dorent
298 **IMMUNE PARAMETERS ASSOCIATED WITH LOWER SARS-CoV-2 VACCINATION RESPONSE IN OLD PEOPLE**

Joana Vitalle Andrade, Alberto L. Perez-Gomez, Maria Reyes Jimenez Leon, Carmen Gasca-Capote, Sara Bachiller, Francisco José Ostos, Inmaculada Rivas-Jeremias, Maria del Mar Silva-Sanchez, Anabel Ruiz-Mateos, Luis Fernando Lopez Cortes, Mohammed Rafii-El-Idrissi Benhnia, Ezequiel Ruiz-Mateos

**Poster Session-D07** SARS-CoV-2 IMMUNE THERAPY
2:00 PM MT - 3:30 PM MT

299 **DUAL MONOCLONAL ANTIBODIES IN COVID-19 PATIENTS: CLINICAL AND VIROLOGICAL EFFICACY**

Valentine M. Ferré, Nathan Peiffer-Smadja, Laura Kramer, Aicha Kanté, Margaux Debarge, Christophe Choquet, Romain Coppée, Donia Bouzid, Jonathan Messika, Jennifer Le Grand, Michael Thy, Solen Kernéis, Diane Descamps, Benoît Visseaux, Jade Ghosn

300 **IN VIVO EFFICACY OF ENGINEERED ACE2-Fc IN PREVENTING LETHAL SARS-CoV-2 INFECTION**

Yaozong Chen, Lulu Sun, Irfan Ullah, Guillaume Beaudoin-Bussières, Andrew Hederman, William D. Tolbert, Rebekah Sherburn, Dung N. Nguyen, Priti Kumar, Margaret E. Ackerman, Walther Mothes, Andrés Finzi, Pradeep D. Uchil, Frank J. Gonzalez, Marzena Pazgier

301 **A FC-ENHANCED NON-NEUTRALIZING ANTIBODY DELAYS SARS-CoV-2—INDUCED DEATH IN MICE**

Guillaume Beaudoin-Bussières, Yaozong Chen, Irfan Ullah, Jérémie Prévost, William D. Tolbert, Kelly Symmes, Shilei Ding, Mehdi Benlarbi, Fei Zhou, Edwin Pozharski, Priti Kumar, Walther Mothes, Pradeep D. Uchil, Marzena Pazgier, Andrés Finzi

302 **REAL-LIFE USE OF HIGH-DOSE ANAKINRA IN COVID-19 PATIENTS TREATED WITH REMDESIVIR**

Roberta Monardo, Andrea Mastrangelo, Laura Galli, Alessandro Tomelleri, Vincenzo Spagnuolo, Chiara Oltolini, Giacomo Ponta, Corrado Campochiaro, Lorenzo Dagna, Giulio Cavalli, Fabio Ciceri, Paola Cinque, Paolo Scarpellini, Antonella Castagna, Marco Ripa

303 **METHYLPREDNISOLONE PULSES IN HOSPITALIZED PATIENTS WITH SEVERE COVID-19 PNEUMONIA**

Giovanni Dolci, Carlo Salvarani, Marco Massari, Gabriella L. Mariani, Massimo Costantini, Franco Merlo, Pierluigi Viale, Stefano Nava, Emanuele A. Negr, Chiara Barbieri, Luisa Savoldi, Mariagrazia Catanoso, Luca Boni, Nicola Facciolongo, for the RCT-MP-COVID19 Study Group

**Poster Session-E02** MECHANISMS OF HIV LATENCY: MAINTENANCE AND REVERSAL
2:00 PM MT - 3:30 PM MT

332 **GLUTAMINOLYSIS ALTERS CD4+ T-CELL IMMUNOMETABOLISM AND INHIBITS HIV TRANSCRIPTION**

Leila B. Giron, Toshitha Kannan, Jane Koshy, Clovis S. Palmer, Alan Landay, Andrew Kossenkov, Mohamed Abdel-Mohsen

333 **IDENTIFICATION OF THE HIV-1 Ast RNA DOMAINS INVOLVED IN PROMOTING VIRAL LATENCY**

Rui Li, Kaveh Daneshvar, Biplob Paul, Michelle Pleet, Rachel Barclay, Isabella Caico, Zahra Gholizadeh, Mohd Shameel Iqbal, Fatah Kashanchi, Alan Mullen, Fabio Romerio
Poster Session Day 3

334 HIV LATENCY REVERSAL VIA IAP ANTAGONISM AND TARGETED BET BROMODOMAIN INHIBITION
Shane D. Falcinelli, Jackson Peterson, Anne-Marie Turner, David Irlebeck, Samuel Raines, Katherine James, Cameron Sutton, Anthony Sanchez, Edward P. Browne, Richard M. Dunham, Nancie Archin, David M. Margolis

335 HIV-INDUCED TYPE I INTERFERONS PROMOTE VIRAL LATENCY IN INFECTED MACROPHAGES
Timothy Hanley, Laura J. Martins, Vicente Planelles

336 SMYDS ACTIVATES HIV-1 TRANSCRIPTION AND IS UPREGULATED BY Tat AND USP11
Daniela Boehm, Victor L. Lam, Melanie M. Ott

337 CIRCADIAN-MODULATING COMPOUNDS INDuce HIV REACTIVATION FROM LATENTLY INFECTED CELLS
Jared Stern, Jennifer Zerbato, Ajantha Rhodes, Sharon Lewin, Michael Roche

338 PHARMACOLOGIC CONTROL OF CD4+ T-CELL PROLIFERATION TO TARGET HIV-1 PERSISTENCE
Emily A. Innis, Callie Levinger, Matthew A. Szaniawski, Elizabeth S. Williams, José Alcamí, Alberto Bosque, Joshua Schiffer, Mayte Coiras, Adam Spivak, Vicente Planelles

339 IRF7 REGULATES HIV-1 LATENCY REVERSAL INDEPENDENT OF CYTOKINE SIGNALING BLOCKADE
Ifearnyi J. Ezeonwumelu, Edurne Garcia-Vidal, Bruna Oriol-Tordera, Marta Ruiz-Riol, André Gohr, Marta Massanella, Bonaventura Clotet, Roger Badia, Eva Riveira-Muñoz, Estel Ballana

340 NFκB BINDING MOTIF GENOTYPES IN PROVIRAL PROMOTERS ACROSS HIV-1 SUBTYPES
Ha Eun Lim, Pragya Khadka, Erika Benko, Colin Kovacs, Ronald Galiwango, Paul Buule, Tatdeo Kityamuweesi, Andrew Redd, Steven J. Reynolds, Thomas Quinn, Jessica Prodger, R. Brad Jones, Guinevere Q. Lee

341 IDENTIFICATION OF SYNERGISTIC COMBINATIONS OF HIV SILENCING PROMOTING FACTORS
Zichong Li, Warner Greene, for the Hope Collaboratory

342 miRNA-103 MODULATES CCR5 AND AFFECTS ESTABLISHMENT OF HIV-1 LATENCY IN CD4+ T CELLS
Nicolas Bellini, Robert Lodge, Tran N. Pham, Jaspreet Jain, Cécile Tremblay, Jean-Pierre Routy, Alon Herschhorn, Thomas T. Murooka, Eric A. Cohen

343 POTENT TARGETED ACTIVATOR OF CELL KILL (TACK) MOLECULES ELIMINATE HIV-INFECTED CELLS
Carl J. Balibar, Daniel J. Klein, Beata Zamlynny, Tracy L. Diamond, Zhiyu Fang, Carol Cheney, Marina Bukhtiyarova, Yangi Su, Min Xu, Abdellatif ElMarrouni, John F. Fay, Shih Lin Goh, Daria Hazuda, Bonnie Howell, Antonella Converso

344 GENOME-WIDE CRISPR INHIBITION SCREEN IDENTIFIES A NEW HIV-1 SILENCING FACTOR SLTM
Rachel Kim, Savannah F. Pedersen, Jack A. Collora, Ya-Chi Ho

345 DASATINIB PREVENTS HIV INFECTION OF MACROPHAGES AND REDUCE THE INFLAMMATORY POTENTIAL
Sara Rodríguez-Mora, Guiomar Casado, Lorena Vigón, Juan Cantón De Seoane, Fernando Ramos-Martin, Miguel Cervero, María Aranzazu Murciano-Antón, Adam Spivak, José Alcamí, Vicente Planelles, Mayte Coiras
346 CRISPR-Cas9–MEDIATED EXONIC DISRUPTION DELIVERED BY LNP FOR HIV-1 ELIMINATION
Mahmudul Hasan, Jonathan Herskovitz, Milankumar Patel, Farah Shahjbin, Bhavesh D. Kevadiya, Howard E. Gendelman

367 HIV ENVENOLE DIVERSITY AND SENSITIVITY TO bnAbs ACROSS STAGES OF ACUTE AND EARLY HIV
Laurie VanderVeen, Brian Moldt, Lisa Selzer, Jiani Li, PC Parvangada, Jintanat Ananworanich, Trevor A. Crowell, Joseph J. Eron, Eric S. Daar, Richard H. Haubrich, Romas Gelezunienas, Joshua Cytoker, John W. Mellors, Christian Callebaut, for the AIDS Clinical Trials Group A5354 Study Team

368 FUNCTIONAL MDSCs ARE MAINTAINED DURING ART AND PRECLUDE HIV-1 RESERVOIR REACTIVATION
Ana Gallego Cortés, Carla Serra, Judith Grau-Expósito, Joan Rey Cano, Jordi Navarro, Adrià Curran, Joaquin Burgos-Cibrian, Paula Suanzes, Vicenç Falcó, Meritxell Genesca, Maria José Buzón

369 ROVER: REDIRECTOR OF VACCINE-INDUCED EFFECTOR RESPONSES FOR HIV-1 TARGET CELL KILLING
Christina V. Konrad, Emma F. Iversen, Jesper D. Gunst, Ida Monrad, Lars Østergaard, Ole Søgaard, Mariane H. Schleimann, Martin Tolstrup

370 TARGETED DELIVERY OF BCL2 INHIBITORS SENSTIZES HIV+ CELLS TO ELIMINATION BY CTL
Andrea Gramatica, Ozgun Kocabiyik, Rachel S. Resop, Ali Danesh, Dennis C. Copertino, Alberto Bosque, Darrell Irvine, R. Brad Jones

371 THE LATENT SIV RESERVOIR IS ESTABLISHED INDEPENDENT OF CYTOTOXIC T LYMPHOCYTE CONTROL
Maura Statzu, Andrew Wong, Julia B. McBrien, Jin Wang, Miles P. Davenport, Brandon Keele, Thomas H. Vanderford, Ann Chahroudi, Mirko Paiardini, Guido Silvestri, Deanna Kulpa

372 AUTOLOGOUS NEUTRALIZATION OF HIV RESERVOIR OUTGROWTH IS STABLE OVER TIME DURING ART
Joseph Varriale, Subul Beg, Natalie McMyln, Kwan Pui Chan, Francesco R. Simonetti, Kenneth Lynn, Pablo Tebas, Ian Frank, Karam Mounzer, Katharine J. Bar, Michael Seaman, Robert Siliciano, Janet Siliciano

373 SARS-CoV-2 mRNA VACCINATION EXPOSES LATENT HIV TO Nef-SPECIFIC CD8+ T CELLS
Eva Stevenson, Sandra Terry, Dennis C. Copertino, Louise Leyre, Adam R. Ward, Pragya Khadka, Kevin Bernard, Grant Ellsworth, Carrie Johnston, Marina Caskey, Christian Gaebler, Timothy Wilkin, Guinevere Q. Lee, R. Brad Jones

374 HOHDBt SYNERGIZES WITH IL-15 TO ENHANCE THE CYTOTOXIC CAPACITY OF HIV-SPECIFIC CTL
Dennis C. Copertino, Carissa Stover, Amanda Macedo, Alberto Bosque, R. Brad Jones

375 ALTERED CELL CYCLING AND APOPTOSIS IN COLONIC MUCOSA OF IMMUNOLOGICAL NONRESPONDERS
Mari Kaarboe, Mingyi Yang, Malin H. Meyer-Myklestad, Arvid V. Sundaram, Asle W. Medhus, Birgitte Stiksrud, Anne Ma Dyhröl-Riise, Dag Kvale, Johannes R. Hov, Marius Trøseid, Pål Aukrust, Magnan Bjarås, Dag Henrik Reikvam
ART: EFFICACY, SWITCHES, AND TOXICITY
2:00 PM MT - 3:30 PM MT

395 PHARMACOGENETICS OF THE LATE-ONSET Efavirenz Neurotoxicity Syndrome (LENS)
Roland van Rensburg, Sam Nightingale, Naeem Brey, Christine H. Albertyn, Tracy Kellermann, Jantjie J. Taljaard, Tonya M. Esterhuizen, Phumla Sinxadi, Eric Decloedt

396 CORRELATIONS OF UNDETECTABLE HIV DNA 96 WEEKS AFTER ART INITIATION DURING ACUTE HIV
Gunn Pungpapong, Phillip Chan, Denise C. Hsu, Carlo Sacdalan, Somchai Sreepleanjan, Peeriya Pruksakaew, Suteeraporn Pinyakorn, Bohyung Yoon, Sandhya Vasan, Sodsai Tovanabutra, Nittaya Phanuphak, Robert Paul, Nicolas Chomont, Serena S. Spudich, for the RV254 Study Group

397 EFFECT OF ART TREATMENT ON MACROPHAGE ACCUMULATION IN THE CNS WITH SIV
Zoey K. Wallis, Cecily Midkiff, Xavier Alverez, Kevin S. White, Patrick Autissier, Addison Q. Amadeck, Soon Ok Kim, Cinar Sumer, Yiwei Wang, Maia Jakubowski, Andrew Miller, Kenneth Williams

398 Efavirenz Plasma Levels, Cognition, and Central Nervous System Side Effects
Alice Ranzani, Francesco Castelli, Antonio Di Biagio, Antonella D’Arminio Monforte, Antonio D’Avolio, Alessandro Soria, Francesca Bai, Emanuele Focà, Lucia Taramasso, Andrea Calcagno, Paolo Bonfanti, Giuseppe Lapadula

399 REVERSIBILITY OF CENTRAL NERVOUS SYSTEM ADVERSE EVENTS IN COURSE OF ART
Lucia Taramasso, Giancarlo Orofino, Elena D. Ricci, Barbara Menzaghi, Giuseppe V. De Socio, Nicola Squillace, Giordano Madeddu, Francesca Vichi, Benedetto M. Celesia, Chiara Molteni, Filippo Del Puente, Eleonora Sarchi, Goffredo Angioni, Antonio Cascio, Paolo Bonfanti

400 IMPACT OF INTEGRASE STRAND TRANSFER INHIBITORS ON COGNITION IN THE HAILO COHORT
Jane O’Halloran, Charles Goss, Mansi Agarwal, Sarah Cooley, Kunling Wu, Rachel Presti, Beau M. Ances, Katherine Tassiopoulos, Kristine Erlandson

NEUROIMAGING PROFILING AND OUTCOMES
2:00 PM MT - 3:30 PM MT

416 EFFECTS OF AIR POLLUTANTS ON NEUROIMAGING MEASURES DIVERGE BY HIV STATUS
Julie K. Wisch, Ruth Alemu, Sarah Cooley, Anna H. Boerwinkle, Alexander Rosenow, Beau M. Ances

417 DECREASED MYELIN CONTENT AND COGNITIVE PERFORMANCE IN ADULTS WITH PERINATAL HIV
Payal B. Patel, Alyssa Vecchio, Lydia Barakat, Thor Wagner, Ann J. Melvin, Jennifer Chiarella, Shannon Kolind, Michael Hoff, Adam Dvorak, Irene Vavasour, Serena S. Spudich, Christina M. Marra, Robert Paul, Swati Rane

418 CHILDHOOD TRAUMA MODIFIES BRAIN MORPHOLOGY AND COGNITION IN PEOPLE WITH HIV
**Poster Sessions • Wednesday**

**Poster Sessions Day 3**

**CROI 2022**

---

**419** **BRAIN VOLUMETRICS DIFFER BY FIEBIG STAGE IN ACUTE INFECTION**

_Jacob Bolzenius, Napapon Sailsata, Andrew Belden, Phillip Chan, Carlo Sacdalan, Julie Ake, Somchalee Sreepleanjan, Khunthalee Benjapornpong, Denise C. Hsu, Sandhya Vasan, Torie Tsuei, Serena S. Spudich, Victor Valcour, Robert Paul, for the SEARCH 010/RV254 and SEARCH 013/RV304 Study Teams_

---

**420** **INCREASED PHYSICAL STRENGTH IS ASSOCIATED WITH IMPROVED BRAIN INTEGRITY IN OLDER PLWH**

_Sarah Cooley, Brittany Nelson, Alexander Rosenow, Beau M. Ances_

---

**421** **MACHINE LEARNING QUANTIFIES ACCELERATED WHITE MATTER AGING IN PERSONS WITH HIV**

_Kalen Petersen, Jeremy Strain, Sarah Cooley, Florin Vaida, Beau M. Ances_

---

**Poster Session-G03** **FROM FORMULATION TO DRUG EXPOSURE TO ADHERENCE: IMPORTANT PRINCIPLES IN PHARMACOLOGY**

_2:00 PM MT - 3:30 PM MT_

---

**447** **EVG/COBI/FTC/TAF TABLETS DISSOLVED IN TAP WATER NEAR BIOEQUIVALENT WITH WHOLE TABLETS**

_Craig W. Hendrix, Edward J. Fuchs, Mark Marzinke, Sandra Abdul Massih, Jennifer Breakey, Sasha Beselman, Ian McNicholl, Adriana Andrade_

---

**448** **TRANSFORMATION OF DOLUTEGRAVIR INTO A YEAR-LONG PARENTERAL PRODRUG FORMULATION**

_Suyash Deodhar, Brady Stillman, Aditya Bade, Brandon Hanson, Bhagya Dyavar Shetty, Nagsen Gautam, JoEllyn McMillan, Morgan Johnston, Michellie Thurman, Yazen Alnouti, Samuel M. Cohen, Bhavesh D. Kevadiya, Siddappa N. Byrareddy, Benson J. Edagwa, Howard E. Gendelman_

---

**449** **IMPACT OF HYALURONIDASE ON LONG-ACTING DRUG RELEASE PHARMACOKINETICS IN MURINE MODELS**

_Henry Pertinez, Amit Kaushik, Paul Curley, Usman Arshad, Eman El-Khateeb, Si-Yang Li, Charles W. Flexner, Eric Nuermberger, Andrew Owen, Nicole C. Ammerman_

---

**450** **POSTMORTEM TISSUE SAMPLING TO DESCRIBE EXPOSURE OF 8 ANTI-INFECTIVES IN THE BRAIN**


---

**451** **TENOFOVIR URINE POINT-OF-CARE TEST PREDICTS VIREMIA AND DRUG RESISTANCE DURING ART**

_Lucas E. Hermans, Chijioke N. Umunakkwe, Samanta T. Lalla-Edward, Shane Hebel, Francois Venter, Hugo A. Tempelman, Annemarie Wensing_

---

**452** **NOVEL PHASE II TRIAL DESIGN WITH STRATIFIED MEDICINE PRINCIPLES FOR TREATMENT OF TB**

_Marjorie Z. Imperial, Vincent Chang, Payam Nahid, Susan Swindells, Gustavo E. Velásquez, Rada Savic, Patrick P. Phillips_
479 LONG-ACTING CABOTEGRAVIR + RILPIVIRINE EVERY 2 MONTHS: ATLAS-2M WEEK 152 RESULTS

480 SWITCHING TO A nRTI-FREE 2-DRUG REGIMEN (2DR): A SUB-ANALYSIS OF THE DUALIS STUDY
Malte B. Monin, Christiane Cordes, Schneider Jochen, Hans-Jürgen Stellbrink, Stefan H. Scholtten, Björn Jensen, Heiko Jessen, Wilfried Obst, Petra Spornraeft-Ragaller, Pavel Khaykin, Annamaria Balogh, Eva Wolf, Helen Binder, Christoph Spinner, Christoph Boesecke

481 ARCHIVED RESISTANCE AND RESPONSE TO <40 C/ML & TND: DTG/3TC FDC AT WEEK 48 IN SALSA
Mark Underwood, Olayemi Osiyemi, Rafael Rubio, Laurent Hocqueloux, Norma Porteiro, Olaf Degen, James Oyee, Joe Horton, Chris Parry, Ruolan Wang, Myoorn Sithamparanathan, Jean A. Van Wyk, Brian Wynne, Choy Man, Elizabeth Blair

482 2DR VS 3DR INTEGRASE INHIBITOR-BASED REGIMENS INITIATION AND CD4+/CD8+ RATIO RECOVERY
Javier Martínez-Sanz, Raquel Ron, Elena Moreno, Matilde Sánchez-Conde, Alfonso Muriel, María Rivero, José-Ramón Blanco, Enrique Bernal, Miguel de Zárraga, Maria José Galindo, Eva Poveda, Gloria Samperiz, Santiago Moreno, Sergio Serrano-Villar, for the Cohort of the Spanish HIV/AIDS Research Network

483 MULTIMICS PLASMA PROFILE OF SWITCHING FROM 3DR TO DOLUTEGRAVIR PLUS LAMIVUDINE
Anna Rull, Elisa de Lazzari, Eugenia B. Negredo, Pere Domingo, Juan M. Tiraboschi, Esteve Ribera, Nadia Abdulghani, Verónica Alba, Consuelo Viladés, Joaquin Peraire, Jose M. Gatel, Jose L. Blanco, Francesc Vidal, Esteban Martinez, for the DOLAM Study Group

484 LOW-LEVEL HIV REPLICATION FOR DTG/3TC VS TAF-BASED REGIMEN IN TANGO THROUGH WEEK 144
Ruolan Wang, Nisha George, Mounir Ait-Khaled, Andrew Tomlinson, James Oyee, Thomas Lutz, Olayemi Osiyemi, Miguel Górgolas, Riya Moodley, Brian Wynne, Myoorn Sithamparanathan, Mark Underwood

485 SWITCHED VERSUS RECYCLED nRTIs IN PI-BASED SECOND-LINE REGIMENS IN EAST AFRICA
Suzanne McCluskey, Beverly Musick, Arvind Kaimal, Francesca Odhiamba, Lameck Diero, Winnie R. Muyindike, Rita Lyamuya, Samson Okumu, Mark Siedner, Kara Woolfs-Kaloustian, Constantin Yiannoutsos

486 RESUPPRESSION AFTER VIROLOGICAL FAILURE IN DOLUTEGRAVIR AND EFAVIRENZ-BASED REGIMENS
Kaitlyn Mccan, Francois Venter, Eric Delaporte, Simiso M. Sokhela, Charles Kounfack, Godspower Akpomiemie, M. Mpoudi-Etame, Angela Tembo, Tamara Tovar Sanchez, P. Omgbase Bassega, Ambar Qavi, Andrew Hill
487  48-WEEK OUTCOMES AFTER PROGRAMMATIC TRANSITION TO DOLUTEGRAVIR IN UGANDA


488  EFFICACY OF TENOFOVIR-LAMIVUDINE-DOLUTEGRAVIR FOR INITIAL AND FIRST-LINE SWITCH ART

Cissy Kityo, Caitlyn McCarthy, Michael Hughes, Catherine Godfrey, Carole Wallis, Urvi Parikh, Sarita Shah, Yukari C. Manabe, George K. Siberry, Isaac Tsikhutsu, Elizabeth Woolley, John W. Mellors, Charles W. Flexner, James Hakim, for the AIDS Clinical Trials Group A5381/The Hakim Study Team

489  WITHDRAWN

490  PREDICTORS OF VIRAL SUPPRESSION FOLLOWING ENHANCED ADHERENCE COUNSELING: VISEND TRIAL

Danielle C. Engamba, C. William Wester, Melody M. Mutinta, Alepalli P. Kumar, Bob Chirwa, Getrude Phiri, Edford Sinkala, Davies Kampamba, Mpanji Siwingwa, Nyuma Mbewe, Aggrey Mweemba, Sombo Fwoloshi, Andrew Hill, Lloyd B. Mulenga, Lameck Chirwa

491  LONG-ACTING LENACAPAVIR IN PEOPLE WITH MULTIDRUG RESISTANT HIV-1: WEEK 52 RESULTS

Onyema Ogbuagu, Sorana Segal-Maurer, Cynthia Brinson, Ploenchan Chetchotisakd, Kenneth Lichtenstein, Joseph McGowan, Andrew A. Wiznia, Kimberly Workowski, Hui Wang, Nicolas Margot, Hadas Dvory-Sobol, Martin Rhee, Jared Baeten, Jean-Michel Molina

Poster Session-H04  FIRST-LINE THERAPY, LOW-LEVEL VIREMIA, AND ADHERENCE

2:00 PM MT - 3:30 PM MT

492  FEASIBILITY AND VIRAL RESPONSE TO TREATING ACUTE/EARLY HIV IN A MULTINATIONAL STUDY

Eric S. Daar, Justin Ritz, Lu Zheng, Jintanat Ananworanich, Cecelia Kanyama, Susan J. Little, Susan E. Cohn, Sharon A. Riddler, Ann C. Collier, Robert Coombs, Lawrence Fox, Javier R. Lama, Trevor A. Crowell, for the AIDS Clinical Trials Group (ACTG) A5354 Study Team

493  LONG-TERM OUTCOMES OF DOLUTEGRAVIR AND EFAVIRENZ-400 AS FIRST-LINE ART IN CAMEROON

Mireille Mpoudi Ngole-Etame, Tamara Tovar Sánchez, Pierrette Omgba-Basega, Justin Désiré Olinga, Eric Mimbe, Michel Foalem, Raphaël Pelloquin, Marie Varloteaux, Marcel Tongo, Martine Peeters, Jacques Reynes, Alexandra L. Calmy, Eric Delaporte, Charles Kouanfack, for the NAMSAL ANRS 12313 Study Group

494  B/F/TAF 5-YEAR OUTCOMES IN TREATMENT-NAIVE ADULTS

David A. Wohl, Anton Pozniak, Kimberly Workowski, Debbie Hagins, Eric S. Daar, Chloe L. Orkin, Ellen Koenig, Karam Mounzer, Samir Gupta, Hailin Huang, Rima K. Acosta, Jason Hindman, Jared Baeten, Hal Martin, Paul E. Sax
495 HIV-1 RNA DECAY IN SEMEN AND RECTUM WITH DTG PLUS 3TC VERSUS BIC/FTC/TAF
Arkaitz Imaz, Sofia Scevola, Jordi Niubo, Pere Domingo, Guillermo Verdejo, Adrià Curran, Vicens Diaz de Brito, Juan M. Tiraboschi, Sandra Morenila, Benito Garcia-Vidal, Irene Soriano, Daniel Podzamczer

496 ANTIRETROVIRAL THERAPY ADHERENCE IN MEDICARE FEE-FOR-SERVICE BENEFICIARIES WITH HIV
Pengxiang Li, Girish Prajapati, Zhi Geng, Vrushabh P. Ladage, Jean M. Arduino, Dovie L. Watson, Robert Gross, Jaipa A. Doshi

497 LOW-LEVEL VIREMIA AND VIROLOGICAL FAILURE IN HIV ANTIRETROVIRAL THERAPY
An Jing, Lao Yunfei, Tang Songyuan, Dong Xingqi, Lou Jingcheng, Li Tianshu

Poster Session-J04 HBV EPIDEMIOLOGY, TREATMENT, AND PREVENTION
2:00 PM MT - 3:30 PM MT

543 REGIONAL VARIATION IN HBV PREVALENCE IN PEOPLE LIVING WITH HIV IN BOTSWANA
Bonolo B. Phinius, Motswedi Anderson, Irene Gobe, Margaret Mokomane, Sharon Mutenga, Molly Pretorius Holme, Tendai Gaolathe, Mompati Mmalane, Roger L. Shapiro, Joseph Makhema, Shahin Lockman, Vlad Novitsky, Max Essex, Sukhileile Moyo, Simani Gaseitsiwe

544 A RANDOMIZED TRIAL OF HBV REVACCINATION IN MSM BORN IN THE NEONATAL VACCINATION ERA
Yi-Chia Huang, Hsin-Yun Sun, Chia-Wen Li, Sung-Hsi Huang, Wen-Chun Liu, Yi-Ching Su, Sui-Yuan Chang, Wen-Chien Ko, Chien-Ching Hung

545 A LONG-ACTING TENOFOVIR PRODRUG SUPPRESSES HBV REPLICATION FOR OVER 3 MONTHS
Srijanee Das, Weimin Wang, Denise A. Cobb, Murali Ganesan, Franchesca G. Fonseca, Mohammad Ullah Nayan, Suyash Deodhar, Brandon Hanson, Edward Makarov, Howard E. Gendelman, Natalia A. Osna, Benson J. Edagwa, Larisa Y. Poluektova

546 LOW RATES OF HEPATITIS B VACCINATION AMONG HIV PATIENTS
Mamta K. Jain, Karen J. Vigil, Onkar Kshirsagar, Laura A. Hansen, Barbara S. Taylor, Mae Thamer

547 HEPATITIS B RNA AND CORE-RELATED ANTIGEN IN HIV-HBV COINFECTION
Kasha P. Singh, Jennifer Zerbato, Wei Zhao, Danny K. Wong, Gavin Cloherty, Jeffrey Gersch, Hugh Mason, Ajantha Rhodes, Peter Revill, Anchalee Avihingsanon, Jennifer Audsley, Man-Fung Yuen, Sharon Lewin

548 NEW HEPATITIS B INFECTION AMONG HIV PATIENTS: WHO IS AT RISK?
Mamta K. Jain, Karen J. Vigil, Onkar Kshirsagar, Laura A. Hansen, Barbara S. Taylor, Mae Thamer
103 CROI 2022

**Poster Session-J05**  
**EXPRESSION AND PATHOGENESIS OF LIVER DISEASE**  
2:00 PM MT - 3:30 PM MT

---

549  
**ETIOLOGY OF LIVER DISEASE IN ADULTS WITH HIV IN LOW- AND MIDDLE-INCOME COUNTRIES**  
Marie K. Plaisy, Albert Minga, Gilles Wandeler, Alain Attia, Renee De Waal, Jeremy Ross, Niha Samala, Sonia Salvi, Mark H. Kuniholm, Gad Murenzi, Hugo Perrazo, Antoine Jaquet, for iDeA

550  
**SINGLE-CELL ANALYSIS OF THE LIVER IN HIV REVEALS PROFIBROTIC MONOCYTES/MACROPHAGES**  
Christopher Oetheimer, Michael S. Wallace, Alex S. Genshaft, Ira Fleming, Mike Villet, Lai Ping Wong, Michael L. Dadoine, Eliana T. Epstein, Adaeze Obinelo, Ashraf Thabet, Alex K. Shalek, Ruslan Sadreyev, Gregory K. Robbins, Raymond T. Chung, Nadia Alatrakchi

---

551  
**CD4/CD8 RATIO ≥0.5 IS A RISK FACTOR OF ACUTE REJECTION IN HIV-INFECTED LT RECIPIENTS**  
Sandra Silva Arrieta, Lucia Serrano, Antonio Rafecas, Christian Manzardo, Jesus Fortun, Marino Blanes, Magdalena Salcedo, Itxarone Bilbao, Elisa Cordero, Santos Del Campo, Asuncion Moreno, Antonio Rimola, Christian Brander, Jose M. Miro, for the FIPSE HIV-LT Investigators

---

**Poster Session-K04**  
**KAPOSI SARCOMA TREATMENT AND HTLV**  
2:00 PM MT - 3:30 PM MT

---

570  
**ROLE OF SOCIAL SUPPORT IN DIAGNOSIS AND TREATMENT OF HIV-ASSOCIATED KAPOSI SARCOMA**  
Rhea Singh, Sigrid Collier, Aggrey Semeere, Helen Byakwaga, Miriam Laker-Oketta, Mc Monhon, Linda Chemtai, Merridy Grant, Lisa Butler, Ingrid V. Bassett, Samson Kiprono, Toby Maurer, Jeffrey N. Martin, Naftali Busakhala, Esther Freeman

571  
**CHARACTERISTICS OF PATIENTS ADMITTED TO THE ICU WITH KSHV-ASSOCIATED DISEASES**  
Megan E. Hansen, Ralph Mangusan, Kathryn Lurain, Thomas Odeny, Jomy M. George, Crystal Lu, Maura Manion, Anaida Widell, Irene Kwede, Denise Whitby, Thomas S. Uldrick, Robert Yarchoan, Ramya Ramaswami

572  
**POMALIDOMIDE INDUCES T-CELL ACTIVATION AND DECREASES SENESCENCE IN KAPOSI SARCOMA**  
Kathryn Lurain, Mark Polizzotto, Laurie T. Krug, Kathleen M. Wyvill, Ramya Ramaswami, Robert Yarchoan, Thomas S. Uldrick, Irini Sereti

573  
**RISK AND PROTECTIVE FACTORS ASSOCIATED TO HTLV-1 MOTHER-TO-CHILD TRANSMISSION**  
Gabriela S. Prates, Arthur Paiva, Tatiane Assone, Rosa Marcusso, Jerusa V. Smith, Augusto Penalva, Jorge Casseb

574  
**HTLV ADULT T-CELL LEUKEMIA/LYMPHOMA: A RETROSPECTIVE STUDY IN FRENCH GUIANA 2009-2019**  
Karim Abdelmoumen, Kinan D. Alsibai, Mathieu Nacher, Jean-Michal Cauvin, N’Detodji-Bill Wankpo, Pauline Naudion, Caroline Misslin-Tritsch, Felix Djossou, Antoine Gessain, Lionel Galicier, Olivier Hermin, Florin Santa, Pierre Couppie, Jean-Pierre Droz, Loic Epelboin
593 PREDICTED IMPACT OF ART SWITCH ON BODY MASS INDEX AMONG WOMEN WITH HIV

594 InStI-RELATED BODY COMPOSITION DIFFERENCES IN CHRONICALLY INFECTED MLWH

595 PHARMACOGENETICS OF WEIGHT GAIN AFTER SWITCH TO INTEGRASE INHIBITOR-BASED REGIMENS
David W. Haas, Kunling Wu, Katherine Tassiopoulos, Todd Hulgan, Jordan Lake, John Koethe, Todd Brown, Michael Leonard, Sara Bares, David Samuels, Kristine Erlandson, for the AIDS Clinical Trials Group

596 WEIGHT CHANGE FOLLOWING SWITCH TO DOLUTEGRAVIR IN RURAL KENYA
Matthew D. Hickey, Erick Wafula, Lucas Godoy Garraza, Sabina Ogachi, Gordon Orori, Richard O. Adele, Maya L. Petersen, Diane V. Havlir, Laura B. Balzer, James Ayiekio

597 MACHINE LEARNING ALGORITHM TO PREDICT >5% WEIGHT GAIN IN PWH SWITCHING TO InStI
Giovanni Guaraldi, Federico Motta, Jovana Milic, Sara Barbieri, Licia Gozzi, Emanuele Aprire, Michela Belli, Maria Venuta, Gianluca Cuomo, Federica Carli, Giovanni Dolci, Vittorio Iadisernia, Giulia Burastero, Cristina Mussini, Federica Mandreoli

598 48-WEEK BODY COMPOSITION CHANGES IN PLWH SWITCHING FROM 3DR TO DTG + 3TC: DOLAM STUDY
Esteban Martinez, Elisa de Lazzari, Adrià Curran, Pere Domingo, Eugenia B. Negredo, Nadia Abdulghani, Jose M. Gatell, Jose L. Blanco, for the DOLAM Study Group

599 ADIPOCYTE DIFFERENTIATION AND ANTIRETROVIRAL DRUGS: AN IN VITRO MODEL
Maria Aurora Carleo, Angelica Perna, Pietro Rosario, Silvia Mascolo, Angela Lucariello, Giulia Palmiero, Viviana Rizzo, Anna Maria Rossmoando, Alfonso Baldi, Antonio De Luca, Paolo Maggi, Vincenzo Esposito

600 METABOLIC PERTURBATIONS BY INTEGRASE INHIBITORS IN DIFFERENTIATED HUMAN ADIPOCYTES
R. Taylor Pickering, Kaitlin M. Soden, Archana Asundi, Nina Lin

601 DOLUTEGRAVIR REVERSIBLY INDUCES MITOCHONDRIAL FRAGMENTATION AND TOXICITY IN VITRO
Loic C. Caloren, Abhinav Ajaykumar, Tetiana Povsheda, Anthony Hsieh, Marie-Soleil R. Smith, Pierre Becquart, Jacqueline A. Quandt, Judy M. Wong, Helene C. Cote
Poster Session-M02  METABOLIC COMPLICATIONS
2:00 PM MT - 3:30 PM MT

602 LIPIDOMICS PROFILE OF METABOLIC SYNDROME IN WELL-TREATED PEOPLE LIVING WITH HIV
Sofie O. Villumsen, Rui Benfeitas, Andreas D. Knudsen, Marco Gelpi, Julie Høgh, Magda T. Thomsen, Daniel Murray, Ujjwal Neogi, Susanne D. Nielsen

603 WEEK-48 METABOLIC HEALTH AFTER SWITCH TO DTG/3TC VS CAR BY BASELINE REGIMEN: SALSA
Debbie Hagins, Cristina Mussini, Fujie Zhang, Princy N. Kumar, Laurent Hocqueloux, Nuria Espinosa-Aguilera, Christoph Wyen, James Oyee, Lori A. Gordon, Gilda Bontempo, Brian Wynne, Elizabeth Blair, Mounir Ait-Khaled, Jean A. Van Wyk

604 AGE AND OBESITY AS RISK FACTORS FOR DIABETES IN AFRICANS WITH HIV
Lisa Hamzah, Amelia Oliveira, Claire Norcross, Zoe Ottaway, Julie Fox, Burns Fiona, Andrew Ustianowski, Sarah L. Pett, Sarah Schoeman, Amanda Clarke, Caroline Sabin, Louise Goff, Frank A. Post, Cheryl Winkler, for the GEN-AFRICA Study Group

605 CO-OCCURRING OBESITY AND HIV ARE NOT ASSOCIATED WITH DIABETES MELLITUS IN SOUTH AFRICA
Itai M. Magodoro, Mongiwethu N. Dungeni, Alison C. Castle, Shakespear Mureyani, Mark J. Siedner

606 FEMINIZING HORMONAL THERAPIES WORSEN CARDIOMETABOLIC PROFILES IN TRANSGENDER WOMEN
Jordan Lake, Han Feng, Hongyu Miao, Paula Debroy, Katherine McGowan, Sabina Haberlen, Wendy Post, Shalender Bhasin, Matthew Budoff, Todd Brown

Poster Session-N03  COVID-19: MISCELLANEOUS CLINICAL AND THERAPEUTIC ISSUES
2:00 PM MT - 3:30 PM MT

636 TOCILIZUMAB (BIOSIMILAR) USE IN CYTOKINE STORM OF SEVERE COVID-19 PNEUMONIA

637 THE IMPACT OF COVID-19 TREATMENTS ON PATIENT OUTCOMES: A PROBABILISTIC VIEW

638 ALTERED GUT MICROBIOTA AND RESPIRATORY DYSFUNCTION 3 MONTHS AFTER SEVERE COVID-19
Beate Vestad, Thor Ueland, Tørø V. Lerum, Tuva B. Dahl, Kristian Holm, Andreas Barratt-Due, Anne Ma Dyrhol-Riise, Birgitte Stiksrud, Hedda B. Hoel, Bente Halvorsen, Annika E. Michelsen, Ole H. Skjønsberg, Pål Aukrust, Johannes R. Hov, Marius Trøseid
Introduction to Section:

**Poster Sessions Day 3**

**CROI 2022**

**106**

**Poster Sessions • Wednesday**

---

**639 CAPSULE ENDOSCOPY FINDINGS IN PATIENTS WITH SEVERE SARS-CoV-2 INFECTION: PILOT STUDY**


Montes de Oca, Santiago Ávila-Ríos

**640 HIV AND SARS-CoV-2 INFECTION AND OUTCOMES IN THE MID-ATLANTIC US**

Amanda B. Spence, Sameer Desale, Jennifer Lee, Princy N. Kumar, Xu Huang, Stanley E. Cooper, Stephen Fernandez, Seble Kassaye

**641 USE OF CORTICOSTEROIDS TO MANAGE HOSPITALIZED PATIENTS WITH COVID-19 IN ZAMBIA**

Peter Minchella, Sombo Fwoloshi, Duncan Chanda, Davies Kampamba, Megumi Itoh, Khozya D. Zyanbo, Jonas Hines, Suilanji Sivile, Simon Agolory, Lloyd B. Mulenga

**642 VARIABLES ASSOCIATED WITH HOSPITALIZATION DUE TO COVID-19 IN PEOPLE LIVING WITH HIV**

Fernanda Rombini, **Jamile Ballivian**, Diego Cecchini, Liliana Calanni, Fabricio Morales, Elena Obieta, Laura Morganti, Claudia Migazzi, Maria L. Yantorno, Maria Marta Greco, Rosana Cuini, Martin Hojman, Diana Pinto, Isabel Casseti, for the COVIDARE Study Team

**643 ZINC DEFICIENCY IS INDEPENDENTLY ASSOCIATED WITH INCREASED COVID-19 DISEASE SEVERITY**

Christian F. Mouchati, Sokratis N. Zisis, Jared C. Durieux, Sarah Scott, Beth Smith, Danielle Labbato, Grace A. McComsey

**644 MENSTRUATION IRREGULARITIES AMONG REPRODUCTIVE-AGE WOMEN DURING THE COVID-19 PANDEMIC**

Emily M. Cherenack, Ana S. Salazar, Patricia Raccamarich, Violeta J. Rodriguez, Alejandro Mantero, Sophia F. Gerard, Marissa Maddalon, Deborah Jones Weiss, Nichole R. Klatt, Maria L. Alcaide

---

**Poster Session-O01  NOVEL MYCOBACTERIAL DIAGNOSTICS AND BIOMARKERS**

2:00 PM MT - 3:30 PM MT

---

**645 CRISPR-DETECTED CELL-FREE DNA FOR PEDIATRIC TB DIAGNOSIS AND TREATMENT RESPONSE**

Sylvia LaCourse, Zhen Huang, Joshua Stern, Jaclyn Escudero, Lisa Marie Cranmer, Irene Njoguna, Elizabeth Maleche-Obimbo, Dalton C. Wamalwa, Christopher Lyon, Grace John-Stewart, Tony Hu

**646 MYCOBACTERIA-SPECIFIC CD4 T CELLS IN CHILDREN LIVING WITH HIV BEFORE AND AFTER ART**


**647 POTENTIAL USE OF URINE LF-LAM IN DIAGNOSING ACTIVE TB IN THAI HIV-POSITIVE ADULTS**

Chawisar Janekrongtham, Rangsima Lolekha, Anchalee Avihingsanon, Nporn Ariyothai, Rom Luengwattanapon, Patsaya Mookleemas, Chonticha Kittinunvorakoon, Chuenkamol Sethaputra, Supannee Jirairiyavej, Sasiwimol Uboylam, Chris Fujitnirun, Sureerat Watcharasuwanseere, Thitisant P. Na Ayuthaya, Sanny Northbrook, Cheewanan Lertpiriyasuwat
648 HIGHLY PERFORMANT MULTIPLEX PCR FOR TB AND NTM INFECTIONS IN PERSONS WITH HIV
Yeya dit Sadio Sarro, Bassirou Diarra, Bocar Baya, Ousmane Kodio, Fanta Sanogo, Djakaridja Daniogo, Ibrahim B. Diallo, Mohamed Toloufoudi, Chad J. Achenbach, Seydou Doumbia, Babafemi O. Taiwo, Robert Murphy, Sally M. McFall, Mamoudou Maiga

649 BLOOD-BASED PATHOGEN AND HOST BIOMARKER SIGNATURES THAT PREDICT TB TREATMENT OUTCOMES
Marjorie Z. Imperial, George Sigal, Anu Mathew, Leah Jarlsberg, Patrick P. Phillips, Jon Jacobs, Mingyu Wang, Tatiana Plisova, Christopher Campbell, J. Lucian Davis, William Whitworth, Jeff Sc chorey, David Lewinsohn, Rada Savic, Payam Nahid

650 IMPAIRED DLCO CORRELATES WITH REDUCED TOTAL LUNG GLYCOLYSIS AFTER TB TREATMENT
Patrick De Marie C. Katoto, Sandra Mukasa, Karen Wolmarans, Antoneta Mashinyira, Reto Guler, Friedrich Thiemenmann

Poster Session-P05 HIV INFECTION AND PREVENTION IN PREGNANCY
2:00 PM MT - 3:30 PM MT

700 EVALUATION OF CAB-LA SAFETY AND PK IN PREGNANT WOMEN IN THE BLINDED PHASE OF HPTN 084
Sinead Delany-Moretlwe, James Hughes, Xu Guo, Brett Hanscom, Craig W. Hendrix, Jennifer Farrior, Rebecca H. Berhanu, Alex R. Rinehart, Susan L. Ford, James F. Rooney, Adeola Adeyeye, Raphael J. Landovitz, Myron S. Cohen, Mina C. Hosseinpour, Mark Marzinke

701 RECENT HIV INFECTION AMONG PREGNANT WOMEN FROM 2 NATIONAL SURVEYS IN SOUTH AFRICA
Selamawit A. Woldesenbet, Mireille Cheyip, Tendesayi Kufa-Chakezha, Carl Lombard, Samuel Manda, Kassahun Ayalew, Adrian Puren

702 HIV TEST-POSITIVITY IN PREGNANT AND POSTNATAL WOMEN RETESTED IN NAMPULA, MOZAMBIQUE
Chloe A. Teasdale, Michelle Choy, Fatima Tsiouris, Eduarda Pimental de Gusmao, Etelvino Banqueiro, Nicole Flowers, Marilena Urso, Mirriah Vitale, Elaine J. Abrams

703 PREGNANCY IN WOMEN WITH HIV IN A TUBERCULOSIS-PREVENTIVE THERAPY TRIAL
Priya Singh, Lawrence Moulton, Grace Link Barnes, Amita Gupta, Reginah Msandiwa, Richard E. Chaisson, Neil A. Martinson

704 PrEP CONTINUATION AND OBJECTIVE ADHERENCE IN PREGNANT/POSTPARTUM SOUTH AFRICAN WOMEN
Dvora Joseph Davey, Dorothy C. Nyemba, Rufaro Mvududu, Nyiko Mashele, Linda-Gail Bekker, Pamina M. Gorbach, Thomas J. Coates, Lubbe Wiesner, Jennifer Norman, Landon Myer

705 PREGNANCY AND BIRTH OUTCOMES IN PrEP-EXPOSED & UNEXPOSED PREGNANT SOUTH AFRICAN WOMEN
Dvora Joseph Davey, Dorothy C. Nyemba, Rufaro Mvududu, Nyiko Mashele, Linda-Gail Bekker, Pamina M. Gorbach, Thomas J. Coates, Landon Myer
**Poster Session-Q03**  REAL-WORLD OUTCOMES IN PEDIATRICS  
2:00 PM MT - 3:30 PM MT

719 **SEVERE IMMUNE SUPPRESSION AND RETENTION AMONG INFANTS IN SOUTH AFRICA**  
Gabriela E. Patten, Nosisa Sipambo, Karl-Günter Technau, Jonathan Euvrard, Nathan Ford, Mary-Ann Davies

720 **HIGH PREVALENCE OF HIV DRUG RESISTANCE AMONG NEWLY DIAGNOSED CHILDREN 0-18 MONTHS**  

721 **LIVING: 48-WEEK DATA ON LPV/r PELLETS IN 990 CHILDREN IN RESOURCE-LIMITED SETTINGS**  
Dalton C. Wamalwa, Victor Musieme, Adeodata R. Kekitinwa, Juliet Mwangwa-Amumpaire, Rachel N. Musoke, Joseph K. Mbutia, Elizabeth Maleche-Obimbo, Winstone M. Nyandiko, Elizabeth A. Bukusi, Maja Weisser, Nzovu Ulenga, Mariama Diallo, Vishal Goyal, Alistair Swanson, for the LIVING Study Team

722 **HIGH DRUG RESISTANCE AND NEED FOR ART CHANGE IN CHILDREN WITH VIRAL FAILURE IN KENYA**  

723 **EBV AND CMV VIREMIA PREDICT INCREASED MORTALITY IN HOSPITALIZED CHILDREN WITH HIV**  
Lasata Shrestha, Irene Njuguna, Donghoon Lee, Elizabeth Maleche-Obimbo, Michael Boeckh, Emily R. Begnel, Daisy J. Chebet, Judith A. Onyango, Lisa Marie Cranmer, Meei-Li Huang, Barbra A. Richardson, Grace John-Stewart, Dalton C. Wamalwa, Jennifer Slyker

724 **PEDIATRIC AND ADOLESCENT RETENTION TRENDS ACROSS AGE BANDS DURING COVID-19 PANDEMIC**  
Ziyanda T. Makaba, Claire Serrao, Zamazama P. Shelembe, Refilwe Mosome, Vimbainasheshe Siguaxe, Dhirisha Naidoo

725 **IMPACT OF ECONOMIC EMPOWERMENT ON ART ADHERENCE IN HIV-POSITIVE ADOLESCENTS IN UGANDA**  
Samuel Kizito, Prosocovia Nabunya, Flavia Namuwonge, Josephine Nabayinda, Joshua Kiyangi, Jennifer Nattabi, Fred Ssewamala

---

**Poster Session-Q05**  PK, SAFETY, AND ACCEPTABILITY OF NEW AGENTS FOR CHILDREN AND YOUTH  
2:00 PM MT - 3:30 PM MT

732 **EXTENDED SAFETY AND PK OF ANTI-HIV MONOCLONAL Ab VRC07-523LS IN HIV-EXPOSED INFANTS**  
Coleen K. Cunningham, Edmund Capparelli, Elizabeth J. McFarland, Petronella Muresan, Charlotte Perlowski, Dwight E. Yin, Jack Meye, Sai Majji, Lynette Purdue, Paul A. Harding, Adrian McDermott, John R. Mascola, Barney S. Graham, for the IMPAACT P1112 Team
733  SUBOPTIMAL LOPINAVIR EXPOSURE ON 8-HOURLY LPV/r 4:1 IN HIV/TB-COINFECTED CHILDREN  
Chishala Chabala, Anna Turkova, Monica Kapasa, Kristen C. Lebeau, Kevin M. Zimba, Lubbe Wiesner, Khozya D. Zyambo, Louise C. Choo, Chalilwe Chungu, Joyce C. Lungu, Angela M. Crook, Veronica Mulenga, Diana Gibb, Helen McIlleron, for the SHINE Trial Team

734  TAF/TFV PHARMACOKINETICS WHEN GIVEN WITH PI/InSTI ART IN THE CHAPAS-4 PEDIATRIC TRIAL  
Hylke Waalewijn, Alexander Szebert, Lubbe Wiesner, Chishala Chabala, Mutsa Bwakura-Dangarembizi, Shafic Makumbi, Joan Nangiya, Vivian Mumbiro, Veronica Mulenga, Victor Musiime, David M. Burger, Diana Gibb, Helen McIlleron, Angela Colbers, for CHAPAS4

735  PHARMACOKINETICS OF ABACAVIR IN AFRICAN CHILDREN <14 KG DOSED PER WHO WEIGHT-BANDS  

736  PHARMACOKINETICS/SAFETY OF DTG, ABC/3TC DISPERSIBLE TABLETS IN THAI CHILDREN <20 KG  
Athiporn Premgamone, Suvaporn Anugulruengkitt, Noppadol Wacharachaisurupol, Chayapa Phasomsap, Monta Tawan, Thidarat Jupimai, Chutima Saisaengjan, Yardpirono Tawon, Tim R. Cressey, Thanyawee Puthanakit

737  IMPAACT 2019: PK & SAFETY OF DISPERSIBLE ABC/DTG/3TC IN CHILDREN WITH HIV 6 TO <14 KG  
Kristina M. Brooks, Jennifer Kiser, Yasha Rani, Gaerolwe Masheto, Faezech Patel, Iris Mustich, Barbara Heckman, Mark Lojacono, Dwight E. Yin, Sai Majji, Hardik Chandasana, Helena Rabie, Patricia Flynn, for the IMPAACT 2019 Study Team

738  SAFETY AND PK OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE IN ADOLESCENTS  

739  ADOLESCENT AND PARENT EXPERIENCES WITH LONG-ACTING INJECTABLES IN THE MOCHA STUDY  

761  LIFE EXPECTANCY AFTER HIV DIAGNOSIS: UNITED STATES, 2008-2018  
Azfar-E-Alam Siddiqi, Anna Satcher Johnson, Angela Hernandez, Xiaohong Hu, Ruiguang Song

762  SURVIVAL AMONG HIV-POSITIVE VETERANS BEFORE AND AFTER THE VA OPT-OUT TESTING POLICY  
Kartavya J. Vyas, Vincent Marconi, Jodie L. Guest
763  MORTALITY RATES WITH OR WITHOUT InSTI THERAPY IN SUBGROUPS OF PWH: 2009-2018

764  ASSOCIATIONS OF MODERN INITIAL ANTIRETROVIRAL DRUG REGIMENS WITH ALL-CAUSE MORTALITY
Adam Trickey, Lei Zhang, Suzanne M. Ingle, Antonella Castagna, Piotr Cichon, Pere Domingo, Sophie Grabar, Mina Psychogiu, Marta Rava, Peter Reiss, Christopher T. Rentsch, Melchor Riera, Michael J. Silverberg, Caroline Sabin, Jonathan A. Sterne

765  REDUCTIONS IN MORTALITY RISK AFTER STARTING ART IN 2010-2019 VERSUS 1995-2003
Lei Zhang, Suzanne M. Ingle, M. John Gill, Arvand Sighem, Robert Zangerle, Enrico Girardi, Matthias Cavassini, Greer Burkholder, Derek D. Satre, George Adams, Amy Justice, Sophie Grabar, John Koethe, Heidi Crane, Jonathan A. Sterne

766  EXCESS LIFE-YEARS LOST ASSOCIATED WITH HOSPITALIZATION FOR MENTAL ILLNESS
Yann Ruffieux, Mpho Tlali, Anja E. Wettstein, Gary Maartens, John Joska, Morna Cornell, Leigh Johnson, Nicky Maxwell, Veronika W. Skrivankova, Mary-Ann Davies, Matthias Egger, Andreas D. Haas

767  PLASMA RENALASE AND ALL-CAUSE MORTALITY IN PEOPLE WITH AND WITHOUT HIV
John Chang, Kaku So-Armah, Xiaojia Guo, Amy Justice, Gary Desir

768  CARE AND VIRAL SUPPRESSION AFTER HIV DIAGNOSIS IN US METROPOLITAN AREAS: 2019
Shacara Johnson Lyons, Anna Satcher Johnson, Jianmin Li

769  HIV CARE OUTCOMES AMONG FOREIGN-BORN PERSONS WITH DIAGNOSED HIV INFECTION: 2019
Tebitha Mawokomatanda, Sonia Singh, Eduardo Valverde

770  DECLINE IN CD4+ COUNTS AND RISK OF SEVERE MORBIDITY IN PLHIV AFTER INITIATING cART
Maria Choufany, Laurence Weiss, Alain Makinson, Hélène Roul, Jean-Michel Livrozet, Valérie Pourcher, Giovanna Melica, Christophe Rioux, Jean-Paul Viard, Esaïe Marshall, Sophie Grabar, Dominique Costagliola

771  EFFECT OF AIDS DRUG ASSISTANCE PROGRAM VARIABILITY ON TIMELY ART & VIRAL SUPPRESSION

772  THE IMPACT OF CHURN ON HIV OUTCOMES IN A SOUTHERN UNITED STATES CLINICAL COHORT
Srínivas Nithin Gopalsamy, Vincent Marconi, Wendy S. Armstrong, Jonathan A. Colasanti
773  CHARACTERIZING GEOSPATIAL MOBILITY AMONG PLWH IN TENNESSEE AND ITS IMPACT ON HIV CARE
Aima A. Ahonkhai, Aihua Bian, Natalie Robbins, Laurie Maurer, Kate Clouse, Leslie Pierce, Jessica M. Perkins, Steven A. Wernke, Bryan Shepherd, Meredith R. Brantley

774  LATINOS WITH HIV IN DC: AN INTERSECTIONAL APPROACH EXPLORING HIV HEALTH OUTCOMES
Leah Varga, Morgan Byrne, Marinella Temprosa, Michael A. Horberg, Carlos Rodriguez-Diaz, Anne Monroe, Amanda Castel, for the DC Cohort Executive Committee

775  EFFECT OF SOCIAL DETERMINANTS OF HEALTH ON UNCONTROLLED HIV INFECTION
Jason S. Melo, Nancy A. Hessol, Sharon Pipkin, Ling Hsu

776  MENTAL HEALTH DISORDERS IN PEOPLE WITH HIV AND THE EFFECTS ON THE HIV CARE CONTINUUM

777  PATTERNS OF SUBSTANCE USE AND MENTAL HEALTH SYMPTOMS AMONG PEOPLE WITH HIV IN CARE

778  IMPACT OF METHAMPHETAMINE USE ON VIRAL LOAD BY GENDER AMONG PEOPLE WITH HIV
Rob J. Fredericksen, Robin M. Nance, Lydia N. Drumright, Bridget M. Whitney, Stephanie A. Ruderman, Jimmy Ma, Andrew W. Hahn, Edward R. Cachay, Geetanjali Chander, Jeffrey M. Jacobson, Kenneth H. Mayer, Sonia Napravnik, Amanda Willig, Heidi Crane

779  VIRAL SUPPRESSION BY 3 MONTHS OF DIAGNOSIS AS AN INDICATOR OF PROGRESS IN HIV CARE
Sierra Upton, Irina Tabidze, Jeff Lauritsen, Mark S. Dworkin

780  VIRAL SUPPRESSION AMONG PERSONS ENROLLED IN HIV RECENT INFECTION SURVEILLANCE: ZAMBIA
Zaena Tessema, Elyssa Stoops, Aaron Shibemba, Lumbani Phiri, Simon Agolory, Kennedy Nkwemw, Samuel Yingst, Dailes Nsofwa, Leigh Tally, Peter Minchella, Melissa Arons, Canditira Mclemore, Kemb N. Lee

Poster Session-T01 DETECTING RECENT INFECTIONS
2:00 PM MT - 3:30 PM MT

803  ANALYSIS OF RECENT INFECTION AMONG PERSONS NEWLY DIAGNOSED WITH HIV IN NIGERIA
Moses Katbi, Adefisayo Adedoyin, Amobi Onovo, Adeoye Adegoye, Rachel Goldstein, Helina Meri, Angela Agwewe, Pamela Gado, Amalchukwu Ukae, David Onime

804  EVALUATION OF HIV-1 RECENCY ASSAYS AMONG PROSPECTIVELY OBSERVED HIV-1 SEROCONVERSIONS
Stephanie Cox, Christoph Carter, Alex Kintu, Christian Callebaut, Jared Baeten, Moupali Das
805 NEAR-UNIVERSAL COVERAGE OF RECENT HIV TESTING IN RURAL UGANDA: POPULATION-BASED STUDY
Holly Nishimura, Ruth Young, Joseph G. Rosen, Nora S. West, Joseph Ssekasanvu, Robert Ssekubugu, Fred Nalugoda, Gertrude F. Nakigozi, Steven J. Reynolds, Larry W. Chang, David Sserwadda, Joseph Kagaayi, M. Kate Grabowski

Poster Session-T02 UNDERSTANDING AND STRENGTHENING HIV DIAGNOSIS AND MONITORING
2:00 PM MT - 3:30 PM MT

806 HIGH POSITIVITY AMONG CLIENTS OF A VIRTUAL HIV TESTING STRATEGY IN INDIA

807 FACEBOOK ADVERTISEMENTS COST PER NEW HIV DIAGNOSIS USING ROUTINE AND TARGETED MODELS
John Hanna, Ank Nijhawan, Christoph U. Lehmann, Richard Medford

808 INTEGRATION OF HIV AND HCV SERVICES WITH MEDICATION FOR OPIOID USE DISORDER IN THE US
Eshan U. Patel, Becky L. Genberg, Xianming Zhu, Noa Krawczyk, Shruti H. Mehta, Aaron Tobian

809 PARTNER VIOLENCE, DISTRESS, AND HIV TESTING IN HETEROSEXUALLY ACTIVE ADULTS IN THE US
Cassandra O. Schember, Susan Cha, Meredith R. Brantley, Peter F. Rebeiro, Samantha A. Mathieson, Jack Marr, April Pettit, for the National HIV Behavioral Surveillance Study Group

810 HIV DIAGNOSIS AND LINKAGE TO CARE IN PARTNERS OF KEY POPULATION IN NIGERIA
Amobi Onovo, Kalaiwo Abiye, Angela Agweye, Godwin Emmanuel, Olivia Keiser

811 CHARACTERISTICS OF HEALTH FACILITIES ASSOCIATED WITH LOW HIV VIRAL LOAD COVERAGE

812 PATIENT-COLLECTED DRIED BLOOD SPOTS PROVIDE ACCURATE MEASUREMENT OF HIV VIRAL LOAD
Torin T. Schaafsma, Katherine K. Thomas, Heidi Van Rooyen, Maryam Shahmanesh, Stephen Asimwe, Meighan K rows, Philip Joseph, Thu lani Ngubane, Kombi Sausi, Nsika Sithole, Jared Baeten, Connie L. Celum, Alastair Van Heerden, Ru Anne Barnabas, for the DO ART Study Team

813 INCREASED KNOWLEDGE OF HIV STATUS AMONG YOUTH: RESULTS OF YATHU YATHU RANDOMIZED TRIAL
Bernadette Hensen, Sian Floyd, Mwelwa Phiri, Albertus Schaap, Lucheka Sigande, Melvin Simuyaba, Lawrence Mwenge, Rosemary Zulu-Phiri, Louis Mwape, Sarah Fidler, Richard Hayes, Musonda Simwinga, Helen Ayles
823  UTILITY OF COVID-19 POINT-OF-CARE ANTIGEN TESTS IN LOW-MIDDLE INCOME SETTINGS

Ameena Goga, Elizabeth S. Mayne, Kubashni Woebere, Simbarashe Takuva, Duduzile Nsibande, Molebogeng Lekalakala, Shameem Jaumdally, Portia Mutevedzi, Helena Vreede, Brodie Daniels, Clement Kufe, Keertan Dheda, Kamy Chetty, Glenda E. Gray, for the SA COVID-19 POC Study Team

824  POINT-OF-CARE ANTIBODY TESTS FOR COVID-19: FIELD-BASED PERFORMANCE, SOUTH AFRICA

Ameena Goga, Elizabeth S. Mayne, Kubashni Woebere, Simbarashe Takuva, Duduzile Nsibande, Molebogeng Lekalakala, Shameem Jaumdally, Portia Mutevedzi, Helena Vreede, Brodie Daniels, Clement Kufe, Keertan Dheda, Kamy Chetty, Glenda E. Gray, for the SA COVID-19 POC Study Team

825  PERFORMANCE OF SARS-CoV-2 ANTIBODY ASSAYS IN A NATIONAL SEROSURVEY IN SOUTH AFRICA


826  PREPANDEMIC SARS-CoV-2 SEROPOSITIVITY AMONG PREGNANT WOMEN: ZAMBIA, 2017-2018

Mpanji Siwingwa, Jonas Hines, Sombo Fwoloshi, Samuel Yingst, Peter Minchella, Adam Wolkon, Gershon Chongwe, Simon Agolory, Lloyd B. Mulenga

827  SARS-CoV-2 RAPID ANTIGEN DIAGNOSTICS: COMBINED ANALYSIS OF 8 MATHEMATICAL MODELS

Karla Therese L. Sy, Joshua M. Chevalier, Alvin X. Han, Sarah J. Girdwood, Mariet Benade, Megan Hansen, Naushin Huq, Amy Toporowski, Anna Bershteyn, Colin A. Russell, Brooke Nichols, for the ACT-Accelerator Rapid Antigen Diagnostic Modelling Consortium

828  ESTIMATION OF SARS-CoV-2 CUMULATIVE INCIDENCE: AN APPLICATION OF MIXTURE MODELING

Rifa Khan, Matt Hitchings, Eshan U. Patel, Aylur K. Srikrishnan, Mark Anderson, K. S. Kumar, Amy Wesolowski, Syed H. Iqbal, Mary A. Rodgers, Shruti H. Mehta, Gavin Cloherty, Derek A. Cummings, Sunil S. Solomon

854  EFFECT OF ANTIMICROBIALS ON PENILE BACTERIAL DENSITY AND FORESKIN INFLAMMATION

Tony Pham, Ronald M. Galiwango, Daniel Park, Juan Enrique Salazar, Brenda Okech, Victoria M. Biribawa, Juliet Mpendo, Moses Muwanga, Aaron Tobian, Jessica Prodger, Rupert Kaul, Cindy Liu, for the APM Trial Group

855  IN SITU FORMING IMPLANTS WITH CABOTEGRAVIR FOR ULTRA-LONG-ACTING PrEP

856  **PHASE I TRIAL OF SUBCUTANEOUS ADMINISTERED VRC07-523LS AND PGT121**  
Sharana Mahomed, Nigel Garrett, Edmund Capparelli, Farzana Osman, Tanuja Gengiah, Derseree Archary, Cheryl Baxter, Penny Moore, Quarraisha Abdool Karim, Dan Barouch, Patricia E. Fast, John R. Mascola, Julie E. Ledgerwood, Lynn Morris, Salim S. Abdool Karim

857  **A PHASE I CLINICAL TRIAL WITH A CONSENSUS SEQUENCE-BASED NATIVE-LIKE HIV-1 Env TRIMER**  
Emma Reiss - Stafford, Mathieu A. Claireaux, Karlijn van der Straten, Guistiniano V. Kerster, Wouter Oljhoek, Neeltje A. Kootstra, Rob Hurks, Antje Heit, Dietmar Katinger, Robin Shattock, Marit J. van Gils, Rogier W. Sanders, Godelieve De Bree

858  **TAF/EVG DUAL-COMPARTMENT INSERT EFFICACY AGAINST RECTAL SHIV TRANSMISSION IN MACAQUES**  
Natalia Makarova, Tyana Singletary, M. M. Peet, James Mitchell, Angela Holder, Chuong Dinh, Maria Mendoza, Yi Pan, Walid Heneine, Gerardo Garcia-Lerma, Meredith Clark, James Smith, Gustavo Doncel

859  **EXPECTATIONS OF PREVENTIVE BENEFITS & HIV-RELATED RISK BEHAVIORS IN HPTN069/ACTG5305**  
Jeremy Sugarman, Brian Weir, Chen Dun, Roy M. Gulick, Timothy Wilkin, Kenneth H. Mayer, Marybeth McCauley, Kevin P. Weinfurt

860  **LONG-ACTING LENACAPAVIR PROTECTS AGAINST INTRAVENOUS CHALLENGE WITH SIMIAN-TROPIC HIV**  

---

**Poster Session-V05  COVID-19 TRACING, VACCINES, AND EFFECT OF TDF ON COVID-19 SEVERITY**  
**2:00 PM MT - 3:30 PM MT**

861  **EVALUATION OF THE COVID-19 CONTACT TRACING PROGRAM IN KING COUNTY, WA, USA**  
Hannah N. Collins, Matthew R. Golden, Rachel W. Kubiak, Tigran Avoundsian, Eli Kern, Elizabeth Meacham, Megan Baldwin, Sarah Stewart, Julia Hood

862  **WITHDRAWN**

863  **SARS-CoV-2 VACCINE EFFECTIVENESS FOR IN-HOSPITAL MORTALITY: ZAMBIA, 2021**  
Jonas Hines, Duncan Chanda, Peter Minchella, Sombo Fwoloshi, Megumi Itoh, Davies Kampamba, Khozya D. Zヤムbo, Suilanji Sивile, Francis D. Mwansa, Kennedy Malama, Simon Agolory, Lloyd B. Mulenga

864  **STOPCoV: SAFETY AND EFFICACY OF PREVENTATIVE COVID VACCINES**  
Sharon Walmsley, Leah Szadkowski, Rosemarie Clarke, Rizani Ravindran, Anne-Claude Gingras, for the STOPCoV Research Team
865  PROPORTION OF PLWH NOT VACCINATED FOR COVID-19 IN ITALY AND PREDICTORS

Alessandro Tavelli, Stefania Cicalini, Diletta Barbanotti, Spinello Antinori, Daniela Segala, Giovanni Guarialdi, Marta Guastavigna, Claudia Lazzaretti, Massimo Puoti, Francesca Ceccherini-Silberstein, Antonella Castagna, Enrico Girardi, Antonella D’Arminio Monforte, Andrea Antinori, for the Icona Study Group

866  EFFECTIVENESS OF COVID-19 VACCINATION AMONG PEOPLE LIVING WITH HIV DURING AN OUTBREAK

Kuan-Yin Lin, Pei-Ying Wu, Wang-Da Liu, Hsin-Yun Sun, Chien-Ching Hung, Shan-Chwen Chang

867  TENOFOVIR DISOPROXIL FUMARATE AND SEVERITY OF COVID-19 IN PEOPLE WITH HIV INFECTION

Julia Del Amo, Rosa Polo, Santiago Moreno, Esteban Martinez, Alfonso Cabello Úbeda, José A. Iribarren, Adrià Curran, Juan Macias, Marta Montero, Carlos Dueñas, Ana Mariño, Asun Diaz, Jose R. Arribas, Inma Jarrín, Miguel Hernán

868  HUMORAL IMMUNE RESPONSE AFTER COVID-19 VACCINATION IN PEOPLE LIVING WITH HIV

Linda Wittkop, Paul Loubet, Mathieu Chaclouni, Karine Lacombe, Valérie Pourcher, Alain Makinson, Pierre-Olivier Girodet, David Chirio, Maeva Lefebvre, Catherine Mutter, Xavier De Lamballerie, Julie Longobardie, Axel Levier, Jean-Daniel Lelièvre, Odile Launay

**Poster Session-X02  THE TANGLED WEB: SEXUAL AND REPRODUCTIVE HEALTH AND HIV RISK**

2:00 PM MT - 3:30 PM MT

872  SEXUAL HEALTH CLINIC OUTCOMES AND PrEP LINKAGE IN A LARGE URBAN EMERGENCY DEPARTMENT

Aniruddha Hazra, Ruby Massey, Michelle Moore, Damaris Garcia, Richard Rodgers, Jessica Schmitt

873  DISCORDANT SYPHILIS ANTIBODY TESTING AND HIV RISK IN THE BRONX, NEW YORK

Nisha M. Patel, Uriel R. Felsen, Martin F. Packer, Mindy S. Ginsberg, Eric A. Meyerowitz

874  INNATE IMMUNITY PREDICTORS OF HIV RISK LINKED TO GENITAL HERPES


875  GENITAL MICROBIOME AND TENOFOVIR LEVELS IN TRANSGENDER MEN AND CISWOMEN ON ORAL PrEP

Jill Blumenthal, Mackenzie L. Cottrell, Sheldon Morris, Maile Y. Karris, Stephen A. Rawlings, Leah Burke, Sara Gianella, Antoine Chaillon

876  IMPACT OF NONAVALENT ANTI-HPV VACCINATION ON ORAL PAPILLOMAVIRUS INFECTION

Roberto Rossotti, Alice Nava, Chiara Baiguera, Maria C. Moioli, Diana Fantì, Federico D’Amico, Elvira Inglese, Daniele Calzavara, Chiara Vismara, Simona Bosso Lasco, Andrea M. Tamburini, Massimo Cernuschi, Francesco Scaglione, Massimo Puoti
877  A RISK SCORE TO FACILITATE TARGETED STI DIAGNOSTIC TESTING IN YOUNG KENYAN WOMEN
Victor Omollo, Pamela Murnane, Renee Heffron, Lara Kidoguchi, Zachary O. Kwen, Elizabeth A. Bukusi, Connie L. Celum, Craig R. Cohen

878  BACTERIAL VAGINOSIS PRIOR TO AND DURING FIRST PREGNANCY IN KENYAN AGYW AT RISK OF HIV
Lynda M. Oluch, Alison C. Roxby, Nelly R. Mugo, Kenneth Ngure, Kenneth Tapia, Bhavna Chohan, Catherine Kiptinness, Anna Wald, Stacy Selke, Melody Wang, Murugi Micheni, Stephen Gakuo, Edith Kimani, Linet Makena

879  HIV-ASSOCIATED IMMUNE BIOMARKERS IN WOMEN AND GIRLS FOLLOWING SEXUAL VIOLENCE

880  INCREASED HIV TARGET CELLS IN FGT DURING FOLLICULAR PHASE OF HIV SERONEGATIVE WOMEN
Sakthivel Govindaraj, Tyree Staple, Gina Bailey Herring, Marisa R. Young, Christina Mehta, Alicia K. Smith, Lisa Haddad, Vijayakumar Velu

887  IMPROVING TIME TO VIRAL SUPPRESSION: 5 YEARS POST-IMPLEMENTATION OF RAPID ART START

888  INCREASED HIV VIRAL SUPPRESSION DURING COVID-19 AMONG US URBAN PEOPLE WITH HIV
Matthew A. Spinelli, Noelle LeTourneau, Dave Glidden, Ling Hsu, Matthew D. Hickey, Elizabeth Imbert, Mireya Arreguin, Jennifer Jain, Jon J. Oskarsson, Susan P. Buchbinder, Mallory Johnson, Diane V. Havlir, Katerina Christopoulos, Monica Gandhi

889  WITHDRAWN

890  LINKAGE TO CARE AND TIME TO VIRAL SUPPRESSION IN PWH IN SPAIN: 2004-2020
Belen Alejos, Cristina Diez, Maria Jose Galindo, Juan C. Lopez, Victoria Hernando, Oskar Ayerdí, Maria M. Alonso, Vicente Estrada, Juan A. Pineda, Alvaro Mena, Maria Novella Mena, David Dalmau, Inma Jarrín, Juan Berenguer, for the Cohort of the Spanish AIDS Research Network

891  RCT OF A MULTISECTORAL AGRICULTURAL INTERVENTION TO IMPROVE HIV AND HEALTH OUTCOMES
892 VIRAL LOAD MONITORING IN PUBLIC SECTOR CLINICS IN RURAL SOUTH AFRICA
Collins Iwuji, Lusanda Mazibuko, Meg Osler, Tshwaraganaang Modise, Dickman Garea, Siphephelo Dlamini, Patrick Gabela, Nompumelelo Khoza, Thabani Mtshali, Mark Siedner, Kathy Baisley, Andrew Boulie, Kobus Herbst

893 INNOVATION TO ACHIEVE THE SECOND 95 AMIDST COVID-19 IN KEY POPULATION IN NIGERIA
Bolanle Oyeledun, Obioma Azurunwa, Christian Onyia, Collins Irmiangihe, Francis Ogirima, Eznine Akinola, Pius Izere-Christopher, Inyang Ayo, Evelyn Ureye, Emeka Kanebi

894 GENERIC DARUNAVIR AND DOLUTEGRAVIR ARE COST-EFFECTIVE IN SECOND-LINE ART
Jennifer Campbell, Janne Estill, Zachary Panos, Joseph Harwell, Marta Prescott, Paul Domanico, Carolynn Amole

895 TRANSITIONING WOMEN TO PREFERRED TLD REGIMEN IS LAGGING IN SUB-SAHARAN AFRICA
Neha Shah, Allahna Esber, Nicole Dear, Sean Cavannaugh, Michael Iroezinu, Emmanuel Bahemana, Hannah Kibuuka, John Owuoth, Jonah Maswai, Valentine Singoei, Trevor A. Crowell, Christina Polyak, Julie Ake, for the AFRICOS Study Group

Poster Session-Y02 HIV INCIDENCE, TESTING, AND LINKAGE
2:00 PM MT - 3:30 PM MT

896 HIV TEAMS AS TOOL TO IMPROVE THE HIV TESTING CASCADE IN HOSPITALS: #AWARE.HIV PROJECT
Carlijn Jordans, Kathryn S. Hensley, Jeroen J. van Kampen, Femke P. Mollema, Elisabeth H. Gisolf, Rachida El Moussaoui, Gonneke Hermanides, Anna Roukens, Robert-Jan Sips, Zoltán Szlávik, Renee N. Finkenflügel, Bart J. Rijnders, Annelies Verbon, Casper Roxx, for the #aware.hiv Project Group

897 PARTNER TESTING WITH HIV SELF-TEST DISTRIBUTION BY UGANDAN PREGNANT WOMEN WITH HIV
Andrew Mujugira, Gabrielle Stein, Agnes Nakyanzi, Jade Boyer, Deborah Donnell, Faith Naddungu, Paul Ssendiwala, Juliet Kyomugisha, Juliet Eron, Michelle Bulterys, Monisha Sharma, Monique A. Wyatt, Norma Ware, Connie L. Celum

898 CONTRIBUTIONS TO THE DECLINE IN HIV INCIDENCE AMONG GBM IN THE UK: A MODELLING STUDY
Valentina Cambiano, Fiona Lampe, Alec Miners; Sheena McCormack, Noel Gill, Graham Hart, Kevin Fenton, Marc Thompson, Gus Cairns, Valerie Delpeche, Alison Rodger, Andrew N. Phillips

Poster Session-Y03 RETENTION AND VIRAL SUPPRESSION
2:00 PM MT - 3:30 PM MT

899 HIV CARE OUTCOMES BY PLACE OF BIRTH AMONG HISPANIC/LATINO PERSONS WITH HIV INFECTION
Sonia Singh, Tebitha Mawokomatanda, Eduardo Valverde

900 FIDELITY OF UNIVERSAL HIV TEST AND TREATMENT (UTT) IMPLEMENTATION IN SOUTH AFRICA
Jabulani Ncayiyana, Radoslaw Panczak, Per Von Groote, Matthias Egger
901 IMPACT OF AGING IN HIV ON COVID-19 OUTCOMES VIA A MATCHED STUDY
Siyuan Guo, Jiajia Zhang, Xueying Yang, Sharon Weissman, Bankole A. Olatosi, Rena Patel, Xiaoming Li

902 SIMILAR SHORT-TERM OUTCOMES WITH SAME-DAY ART INITIATION VS RAPID ART INITIATION
Yi-Chia Huang, Chia-Jui Yang, Yuan-Ti Lee, Hsin-Yun Sun, Chin-Shiang Tsai, Nan-Yao Lee, Po-Huang Liu, Hung-Jen Tang, Chen-Hsiang Lee, Chi-Ying Lin, Chien-Ching Hung, for the Taiwan HIV Study Group

903 RETENTION IN HIV CARE IN RURAL SOUTH AFRICA USING DATA HARMONIZATION APPROACHES
Collins Iwuji, Kathy Baisley, Dickman Gareta, Theresa Smit, Mark Siedner, Kobus Herbst

904 WITHDRAWN

905 RETURN TO CARE AFTER INTERRUPTION IN TREATMENT IN SOUTH-CENTRAL UGANDA
Alice Kisakye, Edward N. Kankaka, Joseph Kabanda, Bill Elur, Rose B. Nakitoyo, Steven J. Reynolds, M. Kate Grabowski, Maria Wawer, Ronald Gray, Larry W. Chang, Fred Nalugoda, Gertrude F. Nakigozi, Joseph Kagaayi, David Serwadda

906 SPATIAL HETEROGENEITY IN TREATMENT INTERRUPTION AND RETURN IN HIV PROGRAM IN UGANDA
Edward N. Kankaka, Alice Kisakye, Francis X. Wasswa, Fred Nalugoda, Joseph Kabanda, Grace Namayanja, Steven J. Reynolds, M. Kate Grabowski, Maria Wawer, Ronald Gray, Larry W. Chang, Gertrude F. Nakigozi, Joseph Kagaayi, David Serwadda

907 IMPACT OF BRAZILIAN HEALTH POLICIES ON GENDER/AGE GAPS IN HIV TREATMENT INDICATORS
Felipe Krakauer, Julie Somogyi, Fernanda M. Rick, Alexandre A. Ferreira, Vivian I. Avelino-Silva

908 POSITIVE PATHWAYS: IMPLEMENTATION TRIAL FOR HIV RETENTION IN CARE
Michael Wohlfeiler, Rachel P. Weber, Laurence Brunet, Jennifer S. Fusco, Christine Uranaka, Quateka Cochran, Monica Palma, Tammeka Evans, Carl Millner, Gregory P. Fusco

909 MODELING THE IMPACT AND COST-EFFECTIVENESS OF INTERVENTIONS FOR RETENTION IN HIV CARE
Anna Bershteyn, Lise Jamieson, Hae-Young Kim, Masabho P. Milali, Edinah Mudimu, Debra ten Brink, Rowan Martin-Hughes, Sherrie L. Kelly, Andrew N. Phillips, Loveleen Bans-Matharu, Valentina Cambiano, Paul Revill, Gesine Meyer-Rath, Brooke Nichols

910 LONGITUDINAL ANALYSIS OF ADAP UTILIZATION: 2008-2018
Kathleen A. McManus, Andrew Strumpf, Brian Sun, Amber Steen, Tim Horn, Auntré Hamp, Amy Killelea, Olivia Liu, Elizabeth T. Rogawski McQuade
911 VIRAL LOAD BEFORE SWITCHING TO DOLUTEGRAVIR & ASSOCIATION WITH HIV TREATMENT OUTCOMES

Matthew L. Romo, Jessie Edwards, Aggrey Semeere, Beverly Musick, Mark Urassa, Francesca Odhiambo, Lameck Diero, Charles Kasozi, Gad Murenzi, Patricia Lelo, Annette H. Sohn, Kara Wools-Kaloustian, Denis Nash, for IeDEA
POSTER SESSIONS BY CATEGORY

Note, abstracts that were submitted in categories designated with the letters C, S, U, and W were integrated into other sessions.

A. Virology of HIV or SARS-CoV-2
   A01 INFECTION AND ENVELOPE (Monday)
   A02 IMMUNE CELL INFECTION AND RESPONSES (Tuesday)
   A03 VIRUS REPLICATION AND HOST FACTORS (Wednesday)

B. Pathogenesis of HIV or SARS-CoV-2: Human Studies and Animal Models
   B01 NONHUMAN PRIMATE MODELS OF HIV INFECTION (Monday)
   B02 SARS-CoV-2 PATHOGENESIS (Monday)
   B03 CORRELATES OF SARS-CoV-2 OUTCOMES (Tuesday)
   B04 HIV TRANSMISSION (Monday)
   B05 HIV REPLICATION IN VIVO (Tuesday)
   B06 OUTCOMES OF HIV INFECTION (Wednesday)
   B07 HIV INFECTION AND INFLAMMATION (Wednesday)

C. HIV-Associated Tumor Viruses

D. Host Immune Responses, Vaccines, and Immunotherapies: HIV or SARS-CoV-2
   D01 HIV VACCINES (Monday)
   D02 SARS-CoV-2 VACCINES (Monday)
   D03 HIV IMMUNOLOGY: T CELLS (Tuesday)
   D04 SARS-CoV-2 IMMUNOLOGY: B CELLS AND ANTIBODIES (Wednesday)
   D05 HIV IMMUNE THERAPY (Wednesday)
   D06 SARS-CoV-2 VACCINE RESPONSES IN SPECIAL POPULATIONS (Wednesday)
   D07 SARS-CoV-2 IMMUNE THERAPY (Wednesday)
   D08 HIV IMMUNOLOGY: NK CELLS AND CYTOKINES (Monday)
   D09 SARS-CoV-2 IMMUNOLOGY: T CELLS, NK CELLS, AND CYTOKINES (Tuesday)
   D10 EBOLAVIRUS VACCINES (Monday)

E. HIV Reservoirs, Latency, and Curative Strategies Including Therapeutic Vaccines and Gene Therapy
   E01 SINGLE-CELL ANALYSES OF HIV RESERVOIRS (Tuesday)
   E02 MECHANISMS OF HIV LATENCY: MAINTENANCE AND REVERSAL (Wednesday)
   E03 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL REBOUND (Monday)
   E04 CONTROLLERS AND POST-TREATMENT CONTROLLERS (Monday)
   E05 IMMUNE PRESSURES ON THE HIV RESERVOIR (Wednesday)
   E06 DYNAMICS OF HIV RESERVOIRS AND VIRAL REBOUND (Tuesday)

F. Neuropathogenesis and Neurologic Complications of HIV, SARS-CoV-2, or Both in Adults
   F01 CNS RESERVOIRS, REGULATION, AND ESCAPE (Tuesday)
   F02 ART: EFFICACY, SWITCHES, AND TOXICITY (Wednesday)
   F03 HIV, SIV, AND SARS-CoV-2 NEUROPATHOGENESIS MODELING (Monday)
   F04 BLOOD AND CSF BIOMARKERS OF BRAIN INTEGRITY AND FUNCTION (Monday)
   F05 NEUROMAGING PROFILING AND OUTCOMES (Wednesday)
   F06 NEUROCOGNITION: PREDICTIONS, TRAJECTORIES, AND THERAPEUTICS (Tuesday)
G. Clinical Pharmacology in Adults
G01 WHAT'S NEW IN PHARMACOKINETICS, PHARMACOGENETICS, AND DRUG INTERACTIONS (Monday)
G02 HIV PREVENTION AND MUCOSAL COMPARTMENT PHARMACOLOGY (Tuesday)
G03 FROM FORMULATION TO DRUG EXPOSURE TO ADHERENCE: IMPORTANT PRINCIPLES IN PHARMACOLOGY (Wednesday)

H. Antiviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy, and Effectiveness Studies in HIV or SARS-CoV-2 in Adults
H01 CLINICAL TRIALS OF THERAPY FOR SARS-CoV-2: ANTIVIRALS AND IMMUNE MODIFIERS (Tuesday)
H02 NEW ANTIVIRALS FOR SARS-CoV-2: ACTIVITY IN VITRO AND IN VIVO (Tuesday)
H03 ANTIRETROVIRAL THERAPY IN EXPERIENCED PATIENTS: SUSTAIN OR REGAIN SUPPRESSION (Wednesday)
H04 FIRST-LINE THERAPY, LOW-LEVEL VIREMIA, AND ADHERENCE (Wednesday)
H05 NOVEL AGENTS: INTRIGUING RESULTS (Monday)

I. Resistance of HIV or SARS-CoV-2 to Small Molecules and Antibodies in Adults
I01 PROFILING THE SENSITIVITY OF HIV TO NEUTRALIZING ANTIBODIES IN VIVO (Monday)
I02 IMPACT OF HIV MUTATIONS ON FITNESS, DRUG RESISTANCE, AND TREATMENT RESPONSE (Monday)
I03 NEW TECHNOLOGIES TO DETECT HIV DRUG RESISTANCE (Tuesday)
I04 TRANSMITTED HIV DRUG RESISTANCE (Tuesday)

J. Hepatitis Viruses and Liver Complications in Adults
J01 FATTY LIVER: NAFL, MAFL, AND NASH (Monday)
J02 HCV TREATMENT AND DISEASE (Tuesday)
J03 HCV ELIMINATION AND CARE CASCADE (Tuesday)
J04 HBV EPIDEMIOLOGY, TREATMENT, AND PREVENTION (Wednesday)
J05 EXPRESSION AND PATHOGENESIS OF LIVER DISEASE (Wednesday)

K. AIDS-Related Malignancies
K01 CANCER RISK, TREATMENT, AND EPIDEMIOLOGY (Monday)
K02 CERVICAL CANCER AND ANAL CANCER: PREVALENCE AND SCREENING (Tuesday)
K03 BASIC SCIENCE OF HPV, KSHV, AND HIV-ASSOCIATED LYMPHOMAS (Tuesday)
K04 KAPOSI SARCOMA TREATMENT AND HTLV (Wednesday)

L. Cardiovascular Complications of HIV Infection and Antiretroviral Therapy
L01 RISK FACTOR AND INFLAMMATORY MEDIATORS OF CARDIOVASCULAR DISEASE (Monday)
L02 HYPERTENSION, HEART FAILURE, AND OTHER CARDIOVASCULAR DISEASE OUTCOMES (Tuesday)

M. Other Complications of HIV Infection and Antiretroviral Therapy in Adults
M01 WEIGHT GAIN AND ADIPOSE TISSUE BIOLOGY (Wednesday)
M02 METABOLIC COMPLICATIONS (Wednesday)
M03 OTHER COMORBIDITIES (Tuesday)
M04 FRAILTY AND SLEEP DISTURBANCES (Monday)
M05 BIOMARKERS AND COMORBIDITIES (Monday)

N. Clinical Complications of COVID-19 Disease in Adults
N01 POSTACUTE SEQUELAE OF SARS-CoV-2 INFECTION (Monday)
N02 NEUROCOGNITIVE MANIFESTATIONS OF COVID-19 (Tuesday)
N03 COVID-19: MISCELLANEOUS CLINICAL AND THERAPEUTIC ISSUES (Wednesday)
O. Tuberculosis and Other Opportunistic Infections, Including the Impact of HIV or SARS-CoV-2 in Adults

O01 NOVEL MYCOBACTERIAL DIAGNOSTICS AND BIOMARKERS (Wednesday)
O02 PHARMACOLOGIC RELATIONSHIPS ASSOCIATED WITH TB DRUGS AND OUTCOMES (Tuesday)
O03 TB EPIDEMIOLOGY, TREATMENT, AND IMPLEMENTATION SCIENCE (Tuesday)
O04 NOVEL INSIGHTS IN CRYPTOCOCCAL MENINGITIS EPIDEMIOLOGY, TREATMENT, AND OUTCOMES (Monday)
O05 CMV AND FUNGAL OPPORTUNISTIC INFECTIONS (Monday)

P. Maternal and Fetal HIV or SARS-CoV-2: Transmission, Prevention, Treatment, Pregnancy, and Postpartum Maternal Health

P01 COVID-19 IN MOTHERS AND THEIR CHILDREN (Tuesday)
P02 HIV, ART, AND PREGNANCY OUTCOMES: EPIDEMIOLOGY AND MECHANISMS (Tuesday)
P03 EVOLVING INSIGHTS: MTCT RISK TO MATERNAL HEALTH (Monday)
P04 NEW PERSPECTIVES ON THE HEALTH OF CHILDREN EXPOSED TO HIV IN UTERO (Monday)
P05 HIV INFECTION AND PREVENTION IN PREGNANCY (Wednesday)

Q. HIV, SARS-CoV-2, or Both in Infants, Children, and Adolescents

Q01 TIMING OF AND TESTING FOR HIV IN INFANTS, CHILDREN, AND YOUTH (Monday)
Q02 EARLY TREATMENT AND HIV RESERVOIRS IN CHILDREN (Tuesday)
Q03 REAL-WORLD OUTCOMES IN PEDIATRICS (Wednesday)
Q04 COMORBIDITIES AND COMPLICATIONS OF HIV AND ART IN CHILDREN AND YOUTH (Monday)
Q05 PK, SAFETY, AND ACCEPTABILITY OF NEW AGENTS FOR CHILDREN AND YOUTH (Wednesday)
Q06 ALL THINGS COVID-19 IN CHILDREN (Tuesday)

R. Epidemiology of HIV in Adults

R01 SARS-CoV-2 EPIDEMIOLOGY (Tuesday)
R02 FACTORS ASSOCIATED WITH SURVIVAL IN PEOPLE WITH HIV (Wednesday)
R03 HIV CARE OUTCOMES (Wednesday)
R04 HIV CLUSTERS AND OUTBREAKS (Monday)
R05 RISK FACTORS FOR HIV ACQUISITION AND TRANSMISSION (Tuesday)
R06 HIV EPIDEMIOLOGY (Monday)

S. Epidemiology of COVID-19


T01 DETECTING RECENT INFECTIONS (Wednesday)
T02 UNDERSTANDING AND STRENGTHENING HIV DIAGNOSIS AND MONITORING (Wednesday)
T03 HIV DIAGNOSTICS (Tuesday)
T04 ADVANCES IN SARS-CoV-2 DIAGNOSTICS (Monday)
T05 APPLYING SARS-CoV-2 TESTS IN PRACTICE (Wednesday)

U. COVID-19 Testing: New Diagnostics for Virus, Viral Variants, and Antibodies; Testing in Various Populations; and Scale-Up
V. HIV Prevention Interventions in Adults
   V01 PrEP: SERVICES, COST-EFFECTIVENESS, BONE LOSS, AND ARV RESISTANCE (Monday)
   V02 PrEP IN ADOLESCENTS AND PREGNANT PEOPLE (Tuesday)
   V03 HIV PREVENTION: NALTREXONE, PEP, AND PrEP FOR TRANSGENDER PEOPLE (Tuesday)
   V04 EARLY PHASE STUDIES OF HIV VACCINES, bNabs, AND NEXT-GENERATION PrEP (Wednesday)
   V05 COVID-19 TRACING, VACCINES, AND EFFECT OF TDF ON COVID-19 SEVERITY (Wednesday)

W. COVID-19 Prevention Interventions in Adults

X. Contraception, Sexually Transmitted Infections, and Reproductive Health in Adults
   X01 SEXUAL AND REPRODUCTIVE HEALTH IN THE TIME OF COVID-19 (Monday)
   X02 THE TANGLED WEB: SEXUAL AND REPRODUCTIVE HEALTH AND HIV RISK (Wednesday)
   X03 THE PLOT THICKENS: SEXUAL AND REPRODUCTIVE HEALTH ISSUES IN PEOPLE WITH HIV (Tuesday)

Y. Implementation and Scale-Up of Prevention and Treatment for HIV and Impact of COVID-19 on HIV-Related Programs
   Y01 VIRAL LOAD MEASUREMENT AND SUPPRESSION (Wednesday)
   Y02 HIV INCIDENCE, TESTING, AND LINKAGE (Wednesday)
   Y03 RETENTION AND VIRAL SUPPRESSION (Wednesday)
   Y04 SUBSTANCE USE (Tuesday)
   Y05 HIV PREVENTION (Tuesday)
   Y06 MENTAL HEALTH AND STIGMA (Tuesday)
   Y07 HIV AND SURVIVAL (Monday)
   Y08 COVID-19 AND HIV (Monday)

With the virtual nature of the conference, the symposia sessions have been scheduled for the following week on February 22, 23, and 24.
LIVE SYMPOSIA SESSIONS BY DAY

TUESDAY, FEBRUARY 22, 2022

**Symposium-1  GETTING INTO SHAPE: A DEEPER LOOK AT VIRAL MATURATION**

**Target Audience:** This session is directed to persons interested in the process of HIV maturation.

**Level of Knowledge:** It is assumed that the participants are familiar with the basic steps of HIV replication.

**Objectives:** At the completion of the session, participants will be able to:
- Describe the role of intasomes in proviral integration
- Describe the principles of the HIV assembly and maturation process
- Describe the composition, structure, and function of the HIV capsid

**Conveners**

Theodora Hatziioannou, The Rockefeller University, New York, NY, USA
Frank Kirchhoff, Ulm University Medical Center, Ulm, Germany

<table>
<thead>
<tr>
<th>Session No.</th>
<th>Title</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>51</td>
<td>HIV-1 MATURATION - NEW VIEWS OF AN EXTRAORDINARY METAMORPHOSIS</td>
<td>8:30 AM MT</td>
</tr>
<tr>
<td>52</td>
<td>NEW ROLE FOR INTEGRASE IN VIRAL MATURATION</td>
<td>8:50 AM MT</td>
</tr>
<tr>
<td>53</td>
<td>STRUCTURE, ASSEMBLY, AND FUNCTIONAL ROLE OF THE INTASOME IN HIV REPLICATION</td>
<td>9:10 AM MT</td>
</tr>
<tr>
<td>54</td>
<td>LIVE QUESTIONS AND ANSWERS</td>
<td>9:30 AM MT</td>
</tr>
</tbody>
</table>

**Symposium-2  INFANT POSTNATAL PROPHYLAXIS: WHY BOTHER?**

**Target Audience:** This session is directed to clinicians, epidemiologists, pharmacologists, and virologists who are interested in postnatal HIV prophylaxis.

**Level of Knowledge:** It is assumed that the participants are familiar with the fundamentals of mother-to-child transmission of HIV.

**Objectives:** At the completion of the session, participants will be able to:
- Describe how postnatal prophylaxis works
- List the complexities of prevention strategies and where improvements could be made
- Recognize different possible strategies for postnatal prophylaxis in the future
Symposia Day 1

Symposia Sessions • Tuesday

54 SETTING THE STAGE: POSTNATAL PROPHYLAXIS TO REDUCE NEW PEDIATRIC INFECTIONS
Claire Thorne, University College London, London, UK

10:15

55 ANTIRETROVIRALS FOR PREVENTION: FROM ADULTS TO BABIES
Martina Penazzato, World Health Organization, Geneva, Switzerland

10:35

56 SPEED DIALING NEONATES TO THE IDEAL POSTNATAL PROPHYLAXIS REGIMEN
Adrie Bekker, Stellenbosch University, Cape Town, South Africa

10:55

11:15 LIVE QUESTIONS AND ANSWERS

57 PREPARING FOR THE PLATE OF PREVENTION OPTIONS: HOW CAN WE DELIVER?
Hyman Scott, San Francisco Department of Public Health, San Francisco, CA, USA

12:00

58 BUILDING BACK BETTER: PUBLIC HEALTH SYSTEMS, PUBLIC TRUST, AND THE PrEP PIPELINE
Kenyon Farrow, PrEP4ALL, New York, NY, USA

12:20

59 APPLYING LESSONS ON EFFICACY AND AUTONOMY FROM CONTRACEPTION TO PrEP
Dominika Seidman, University of California San Francisco, San Francisco, CA, USA

12:40

1:00 LIVE QUESTIONS AND ANSWERS

Symposium-3 BRINGING CHOICE TO HIV PREVENTION
12:00 PM MT - 1:30 PM MT

Target Audience: This session is directed to researchers, clinicians, and translational scientists interested in the delivery of choices of methods for HIV prevention and how the uptake of these can be improved.

Level of Knowledge: It is assumed that the participants are familiar with recent developments in the development of HIV prevention modalities.

Objectives: At the completion of the session, participants will be able to:

• Describe new HIV prevention options and the issues around their delivery
• Identify factors that influence the uptake of new prevention options
• Identify strategies that can be used in service delivery to increase uptake of new prevention technologies

Conveners
Sharon L. Hillier, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
James A. McIntyre, Anova Health Institute, Johannesburg, Gauteng, South Africa
Symposium-4  THE HIV RESERVOIR: CREATION, SELECTION, MAINTENANCE, AND REVERSAL
8:30 AM MT - 10:00 AM MT

Target Audience: This session is directed to scientists and clinicians who are interested in understanding the mechanisms by which HIV persists during antiretroviral therapy.

Level of Knowledge: It is assumed that the participants are familiar with the concepts of HIV persistence and latency.

Objectives: At the completion of the session, participants will be able to:
• Explain the concept of intact and defective proviruses
• Describe the mechanisms by which some proviruses are selected after prolonged therapy and the dynamics of the HIV reservoir
• Describe novel approaches used to target and eliminate latent and replication-competent HIV

Conveners
Katharine J. Bar, University of Pennsylvania, Philadelphia, PA, USA
Nicolas Chomont, Université de Montréal, Montreal, Canada

107  THE HIV-1 PROVIRAL LANDSCAPE: WHAT HAVE WE LEARNED?
8:30
Sarah Palmer, The Westmead Institute for Medical Research, Westmead, Australia

108  ROLE OF SELECTION PRESSURES AND IMMUNE RESPONSES IN SHAPING THE PERSISTENT RESERVIOR
8:50
Francesco R. Simonetti, The Johns Hopkins University, Baltimore, MD, USA

109  NOVEL IMMUNOTHERAPY-BASED CURE INTERVENTIONS
9:10
Mirko Paiardini, Emory University, Atlanta, GA, USA

9:30  LIVE QUESTIONS AND ANSWERS

Symposium-5  TUBERCULOSIS: NEW STRATEGIES IN THE TREATMENT OF THE WORLD’S OLDEST EPIDEMIC
10:15 AM MT - 11:45 AM MT

Target Audience: This session is directed to researchers, clinicians, epidemiologists, and public health professionals familiar with tuberculosis and its pathogenesis, epidemiology, complications, treatment, and prevention.

Level of Knowledge: It is assumed that the participants are familiar with the basic principles of epidemiology, treatment, and prevention of drug-susceptible and drug-resistant tuberculosis.

Objectives: At the completion of the session, participants will be able to:
• Describe new data related to regimens and strategies to shorten treatment duration for drug-susceptible and drug-resistant tuberculosis
• Identify factors associated with treatment success with shorter course regimens for treatment of drug-susceptible and drug-resistant tuberculosis
• Identify promising new or novel agents under investigation for the treatment of tuberculosis
Symposia Sessions • Wednesday

110  TREATMENT SHORTENING FOR DRUG-SUSCEPTIBLE TB: WHERE ARE WE AND WHAT’S NEXT?  
10:15  
Susan Dorman, Medical University of South Carolina, Charleston, SC, USA

111  A NEW ERA FOR TREATMENT OF MULTI-DRUG RESISTANT TUBERCULOSIS  
10:35  
David Moore, London School of Hygiene & Tropical Medicine, London, UK

112  THE PROMISE OF NEW DRUGS AND LONG-ACTING INJECTABLES FOR TB TREATMENT AND PREVENTION  
10:55  
Eric L. Nuermberger, The Johns Hopkins University, Baltimore, MD, USA

11:15  LIVE QUESTIONS AND ANSWERS

Symposium-6  SEXUALLY TRANSMITTED INFECTIONS: REVERSING THE TIDE  
12:00 PM MT - 1:30 PM MT

Target Audience: This session is directed to clinicians, researchers, and public health professionals interested in the state of the science and epidemiology of sexually transmitted infections (STIs).

Level of Knowledge: It is assumed that the participants are familiar with basic terminology and science for STIs.

Objectives: At the completion of the session, participants will be able to:
- Describe the current epidemiology of STIs in the United States
- Describe the underlying science behind STI vaccine development and evaluation
- Describe the current state of the science for several STI vaccines
- Explain the core science and practical issues behind preexposure prophylaxis (PrEP) for STIs
- List the current STIs and antimicrobial agents being evaluated for STI PrEP

Conveners
Connie L. Celum, University of Washington, Seattle, WA, USA
Jonathan Mermin, Centers for Disease Control and Prevention, Atlanta, GA, USA

113  THE STATE OF STI EPIDEMICS AND RESPONSE IN THE UNITED STATES  
12:00  
Leandro Mena, Centers for Disease Control and Prevention, Atlanta, GA, USA

114  CURRENT AND FUTURE RESEARCH IN STI VACCINES  
12:20  
Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
115  SEXUALLY TRANSMITTED INFECTIONS
12:40  PROPHYLAXIS, IS THIS THE ANSWER?
Elizabeth A. Bukusi, Kenya Medical Research Institute, Nairobi, Kenya

1:00  LIVE QUESTIONS AND ANSWERS
THURSDAY, FEBRUARY 24, 2022

Symposium-7  IMMUNE PROTECTION IN THE FIELD: RAISING THE STAKES  CME
8:30 AM MT - 10:00 AM MT

Target Audience: This session is directed to clinicians and scientists who are interested in understanding the implications of recent advances in HIV prevention, and where the field is headed.

Level of Knowledge: It is assumed that the participants are familiar with the principles of passive and active vaccination for the prevention of HIV and other diseases.

Objectives: At the completion of the session, participants will be able to:
• Assess the current state of the HIV passive immunity field
• Explain the promise and limitations of mRNA vaccines
• Describe the recent progress in antibody germline targeting HIV immunogens

Conveners
Penny Moore, University of the Witwatersrand, Johannesburg, South Africa
Huldrych F. Günthard, University Hospital Zurich, Zurich, Switzerland

149 LESSONS LEARNED FROM THE AMP TRIAL: IS THE GLASS HALF FULL?
8:30
Carolyn Williamson, University of Cape Town, Cape Town, South Africa

150 PUSHING THE ENVELOPE: mRNA VACCINES FOR COVID-19, HIV AND OTHER PATHOGENS
8:50
Drew Weissman, University of Pennsylvania, Philadelphia, PA, USA

151 JUMP-STARTED IMMUNE RESPONSE: NOW, HOW TO TEACH BREADTH?
9:10
William R. Schief, Scripps Research Institute, La Jolla, CA, USA

9:30 LIVE QUESTIONS AND ANSWERS

Symposium-8  HIV AND AGING  CME
10:15 AM MT - 11:45 AM MT

Target Audience: This session is directed to clinical and translational researchers studying HIV and aging and multi-morbidity in people with HIV.

Level of Knowledge: It is assumed that the participants are familiar with the increased burden of age-related multimorbidity in people with HIV.

Objectives: At the completion of the session, participants will be able to:
• Identify age-related complications that are (and are not) increased in people with HIV as well as the spectrum of morbidity in people who start antiretroviral therapy early versus late
• Identify basic mechanisms that might mediate the increased burden of age-related morbidity in people with HIV
• Identify measures of frailty and how they can be integrated into clinical trials
Convener
Peter W. Hunt, University of California San Francisco, San Francisco, CA, USA

Panelists
Jules Levin, National AIDS Treatment Advocacy Project, New York, NY, USA
Venita Ray, Positive Women’s Network, Oakland, CA, USA

152 CLINICAL EPIDEMIOLOGY OF AGING AND COMORBIDITY WITH HIV INFECTION: A GLOBAL PERSPECTIVE
10:15
Mark Siedner, Harvard Medical School, Boston, MA, USA

153 POTENTIAL BIOLOGIC MECHANISMS OF AGING IN HIV
10:35
Nicholas Funderburg, The Ohio State University, Columbus, OH, USA

154 INTEGRATING FRAILTY AND FUNCTIONAL OUTCOMES INTO CLINICAL TRIALS
10:55
Kristine Erlandson, University of Colorado, Denver, CO, USA

11:15 LIVE QUESTIONS AND ANSWERS

Symposium-9 HIV PREVENTION IN SPECIAL POPULATIONS
12:00 PM MT - 1:30 PM MT

Target Audience: This session is directed to physicians, physician assistants, nurse practitioners, registered nurses, and other clinical decision-makers involved in HIV prevention care and research.

Level of Knowledge: It is assumed that the participants have a solid, working knowledge of HIV prevention and disease management.

Objectives: At the completion of the session, participants will be able to:
• Describe the unique challenges and barriers to HIV prevention success experienced in key populations (people who use drugs, transgender persons, and sex workers)
• Describe the current state of the science on approaches to HIV prevention among these key populations
• List the clinical best practices as well as research and current data gaps in HIV prevention for these key populations

Conveners
Jessica E. Justman, Columbia University, New York, NY, USA
Raphael J. Landovitz, University of California Los Angeles, Los Angeles, CA, USA

155 A COMPREHENSIVE APPROACH TO HIV PREVENTION IN PEOPLE WHO USE SUBSTANCES
12:00
Adam W. Carrico, University of Miami, Miami, FL, USA
156 12:20 TAILORING HIV PREVENTION STRATEGIES FOR THE UNIQUE NEEDS OF TRANSGENDER AND NONBINARY PEOPLE
Sari L. Reisner, Brigham and Women’s Hospital, Boston, MA, USA

157 12:40 HIV PREVENTION APPROACHES TAILORED TO INDIVIDUALS ENGAGED IN SEX WORK
Frances M. Cowan, Liverpool School of Tropical Medicine, Harare, Zimbabwe

1:00 LIVE QUESTIONS AND ANSWERS
# ABSTRACT PROCESS

## Scientific Categories

### Basic Science

<table>
<thead>
<tr>
<th>A.</th>
<th>Virology of HIV or SARS-CoV-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.</td>
<td>Pathogenesis of HIV or SARS-CoV-2: Human Studies and Animal Models</td>
</tr>
<tr>
<td>C.</td>
<td>HIV-Associated Tumor Viruses</td>
</tr>
<tr>
<td>D.</td>
<td>Host Immune Responses, Vaccines, and Immunotherapies: HIV or SARS-CoV-2</td>
</tr>
<tr>
<td>E.</td>
<td>HIV Reservoirs, Latency, and Curative Strategies Including Therapeutic Vaccines and Gene Therapy</td>
</tr>
<tr>
<td>F.</td>
<td>Neuropathogenesis and Neurologic Complications of HIV, SARS-CoV-2, or Both in Adults</td>
</tr>
</tbody>
</table>

### Clinical

<table>
<thead>
<tr>
<th>G.</th>
<th>Clinical Pharmacology in Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>H.</td>
<td>Antiviral Therapy: Pre-Clinical Data, Randomized Trials, Efficacy, and Effectiveness Studies in HIV or SARS-CoV-2 in Adults</td>
</tr>
<tr>
<td>I.</td>
<td>Resistance of HIV or SARS-CoV-2 to Small Molecules and Antibodies in Adults</td>
</tr>
<tr>
<td>J.</td>
<td>Hepatitis Viruses and Liver Complications in Adults</td>
</tr>
<tr>
<td>K.</td>
<td>AIDS-Related Malignancies</td>
</tr>
<tr>
<td>L.</td>
<td>Cardiovascular Complications of HIV Infection and Antiretroviral Therapy</td>
</tr>
<tr>
<td>M.</td>
<td>Other Complications of HIV Infection and Antiretroviral Therapy in Adults</td>
</tr>
<tr>
<td>N.</td>
<td>Clinical Complications of COVID-19 Disease in Adults</td>
</tr>
<tr>
<td>O.</td>
<td>Tuberculosis and Other Opportunistic Infections, Including the Impact of HIV or SARS-CoV-2 in Adults</td>
</tr>
<tr>
<td>P.</td>
<td>Maternal and Fetal HIV or SARS-CoV-2: Transmission, Prevention, Treatment, Pregnancy, and Postpartum Maternal Health</td>
</tr>
<tr>
<td>Q.</td>
<td>HIV, SARS-CoV-2, or Both in Infants, Children, and Adolescents</td>
</tr>
</tbody>
</table>

### Epidemiology/Public Health

<table>
<thead>
<tr>
<th>R.</th>
<th>Epidemiology of HIV in Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>S.</td>
<td>Epidemiology of COVID-19</td>
</tr>
<tr>
<td>U.</td>
<td>COVID-19 Testing: New Diagnostics for Virus, Viral Variants, and Antibodies; Testing in Various Populations; and Scale-Up</td>
</tr>
<tr>
<td>V.</td>
<td>HIV Prevention Interventions in Adults</td>
</tr>
<tr>
<td>W.</td>
<td>COVID-19 Prevention Interventions in Adults</td>
</tr>
<tr>
<td>X.</td>
<td>Contraception, Sexually Transmitted Infections, and Reproductive Health in Adults</td>
</tr>
<tr>
<td>Y.</td>
<td>Implementation and Scale-Up of Prevention and Treatment for HIV and Impact of COVID-19 on HIV-Related Programs</td>
</tr>
</tbody>
</table>

For more information, visit the CROI Abstract Categories webpage. Note, abstracts that were submitted in categories designated with the letters C, S, U, and W were integrated into other categories.
Presenter Responsibilities
Visit the Invited Presenter, Oral Abstract Presenter, and Poster Presenter webpages for information regarding presenter responsibilities.

Abstract Review Process
For information, visit the Abstract Guidelines and Submission webpage.

Statistics for Abstracts
General Abstracts Submitted ............................................ 1508
General Abstracts Accepted .............................................. 860
General Oral Abstracts Accepted ......................................... 92
General Poster Abstracts Accepted ....................................... 768
Late-Breaking Abstracts Submitted .......................................... 72
Late-Breaking Abstracts Accepted .......................................... 38
Late-Breaking Oral Abstracts Accepted .................................... 17
Late-Breaking Poster Abstracts Accepted ................................. 21
Total Abstracts Submitted ........................................... 1580
Total Abstracts Accepted .............................................. 898

Abstracts Related to SARS-CoV-2 or Special Study Populations
SARS-CoV-2 ............................................................ 214
Adolescents ............................................................. 48
Men Who Have Sex With Men (MSM) .................................... 94
People Who Inject Drugs (PWID) ......................................... 39
Transgender Men or Women .............................................. 37
Women ........................................................................ 130

Authors have noted specific populations as the focus of their study, if applicable.
INDEX OF STUDIES RELATED TO WOMEN

The following index lists abstracts that the authors have noted women or women’s issues as the focus of the study. This index was developed for attendees with an interest in these issues. We encourage you to refer to the Virtual Program for other presentations that may address this subject.

MONDAY, FEBRUARY 14, 2022

27 UNIVERSAL HEPATITIS C VIRUS SCREENING IN PREGNANCY: THE JUICE IS WORTH THE SQUEEZE
28 HBIG-FREE STRATEGY TO PREVENT HBV MOTHER-TO-CHILD TRANSMISSION: ANRS TA PROHM STUDY
29 THE IMPACT OF COVID-19 ON ADVERSE BIRTH OUTCOMES IN BOTSWANA BY HIV STATUS
37 GUT MICROBIOTA, PLASMA METABOLOMICS, AND ATHEROSCLEROSIS IN HIV INFECTION
41 HPV GENOTYPING IN STUDY OF ADJUNCTIVE VACCINE FOR TREATMENT OF CERVICAL DYSPLASIA
193 SARS-CoV-2 SPIKE PROTEIN DESTABILIZES MICROVASCULAR HOMEOSTASIS

211 VAGINAL PROTEOME ALTERATIONS ASSOCIATED WITH HIV ACQUISITION IN THE VOICE TRIAL
212 VAGINAL MICROBIOME PROFILES IN YOUNG WOMEN AT RISK FOR HIV INFECTION
213 STROMAL FIBROBLASTS FROM FEMALE GENITAL TRACT DIMINISH THE IN VITRO EFFICACY OF PrEP
304 SEX DIFFERENCES IN CYTOKINE PROFILES DURING SUPPRESSIVE ANTIRETROVIRAL THERAPY
352 BEAT2: peg-IFN-α2b + 3BNC117 AND 10-1074 KEEPS HIV AT <20 C/ML DURING 26 WEEK ATI
410 DECREASING CNS MYELOID ACTIVATION RELATES TO DECREASING NEURODEGENERATION IN HIV
415 MtDNA HAPLOGROUPS AND COGNITIVE FUNCTION IN BLACK AND HISPANIC WOMEN WITH HIV

509 HIV DRUG RESISTANCE IN WOMEN RANDOMIZED TO DTG VS EFV OR TDF VS TAF IN PREGNANCY
511 LOW-LEVEL RESISTANCE MUTATIONS CORRELATE WITH HIV THERAPY FAILURE IN PREGNANT WOMEN
512 CHANGES IN THE HIV-1 3'-PPT IN PATIENTS Failing Dolutegravin IN BRAZIL
520 NAFLD IS COMMON AND ASSOCIATED WITH CARDIOVASCULAR RISK IN REPRIEVE PARTICIPANTS
554 USING NEXT-GENERATION SEQUENCING TO DETECT GENES RELATED TO CANCER IN WOMEN WITH HIV
577 SUBCLINICAL ATHEROSCLEROSIS AND IMMUNE ACTIVATION AMONG US FEMALES VS MALES WITH HIV
578 INFLAMMATORY CLUSTERS PREDICT MULTIMORBIDITY AND CVD IN PEOPLE WITH HIV ON ART

619 ASSOCIATION OF SLEEP DISRUPTION WITH KYNURENINE PATHWAY ACTIVATION IN WOMEN WITH HIV
684 PERINATAL HIV-1 TRANSMISSION IN FRANCE: U=U FOR MOTHERS ON ART FROM CONCEPTION
WITHDRAWN

685  PBPK MODELING OF LONG-ACTING INJECTABLE CABOTEGRAVIR IN PREGNANCY
686  PREGNANCY HEMOGLOBIN A1c AND GLUCOSE WITH DTG VS EFV, TDF VS TAF: IMPAACT 2010
688  WEIGHT GAIN WITH RALTEGRAVIR VS EFAVIRENZ DURING PREGNANCY
689  GESTATIONAL WEIGHT GAIN IN SOUTH AFRICAN PREGNANT WOMEN LIVING WITH HIV
690  UNIQUE PROFILE OF INFLAMMATION AND IMMUNE ACTIVATION IN PREGNANT US WOMEN WITH HIV
695  PREDICTORS OF NEURODEVELOPMENT IN HIV-EXPOSED–UNINFECTED INFANTS
699  IDENTIFYING HIV-POSITIVE MOTHERS AND EXPOSED INFANTS IN MATERNAL CHILD SERVICES
710  COMMUNITY-BASED, PEER-LED SRH SERVICES INCREASE COVERAGE IN AYP (YATHU YATHU TRIAL)
729  MENTAL HEALTH DISORDERS IN HIV-POSITIVE ADOLESCENTS AND YOUTHS: DATA FROM MOZAMBIQUE
731  WEIGHT GAIN AMONG ADOLESCENTS ON DOLUTEGRAVIR: A REAL CONCERN?
782  PHYLOGENETIC TRACKING OF HIV EPIDEMIC GROWTH IN QUEBEC FROM 2014 TO 2020
829  DIFFERENCES IN SEXUAL HEALTH CLINIC SERVICES BY AGE AND GENDER IN METROPOLITAN BOSTON
941  SARS-COV-2 VACCINATION: IMPACT ON HIV-1 RNA LEVELS AND ANTIBODY RESPONSE AMONG PLWH
942  IMPACT OF COVID OUTBREAK ON PREVENTION AND CARE FOR HIV AND STIs AT A LARGE HOSPITAL

TUESDAY, FEBRUARY 15, 2022

65  HIV-1 REMISSION WITH CCR5Δ32Δ32 HAPLO-CORD TRANSPLANT IN A US WOMAN: IMPAACT P1107
77  PK OF DOSE-ADJUSTED EMERGENCY CONTRACEPTION WITH RIFAMPICIN THERAPY IN ACTG A5375
80  LONG-ACTING INJECTABLE FOR PREVENTION OF HIV AND UNPLANNED PREGNANCY
82  PHASE I PK, SAFETY, AND ACCEPTABILITY STUDY OF A 90-DAY TENOFOVIR VAGINAL RING
86  COUNTERFACTUAL ESTIMATION OF CAB-LA EFFICACY AGAINST PLACEBO USING EXTERNAL TRIALS
88  CHOICE AND ADHERENCE TO DAPIVIRINE RING OR ORAL PrEP BY YOUNG AFRICAN WOMEN IN REACH
90  DETECTING RECENT HIV INFECTIONS IN OUTPATIENT DEPARTMENTS: A MULTI-COUNTRY ANALYSIS
92  THE IMPACT OF FREE ANTIRETROVIRAL THERAPY FOR NONCITIZEN PREGNANT WOMEN IN BOTSWANA
106  TREATMENT OF ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS TO PREVENT ANAL CANCER
205  TGF-B2 IS ASSOCIATED WITH ASYMPTOMATIC/MILD SARS-CoV-2 INFECTION DURING PREGNANCY
262  INVESTIGATING ANTIGEN-INDEPENDENT CD8+ T-CELL ENFORCEMENT OF HIV LATENCY
A NOVEL COMORBIDITY INDEX PREDICTS COGNITIVE CHANGE IN PEOPLE WITH CHRONIC HIV

ANTI-INFECTIVES’ PENETRATION IN UPPER AND LOWER FEMALE GENITAL TISSUES

PROGRESS TOWARD HCV MICROELIMINATION AMONG HIV-POSITIVE PATIENTS IN TAIWAN

PREVALENCE AND SEVERITY OF HPV-ASSOCIATED ANAL DISEASE IN PWH YOUNGER THAN 35

GENITAL AND ANAL CYTOLOGY: HPV COTESTING RESULTS FROM 381 WOMEN LIVING WITH HIV

EVALUATING HPV TESTING FOR CERVICAL CANCER SCREENING IN FOUR COUNTRY’S HIV PROGRAMS

IMPAIRED RESPONSE OF MEMORY TREG TO HDL IS ASSOCIATED WITH HIGHER CARDIOVASCULAR RISK

SEX DIFFERENCES IN LATENT TUBERCULOSIS INFECTION AMONG CLOSE CONTACTS IN BRAZIL

HIV AND SARS-CoV-2 INFECTION AMONG POSTPARTUM KENyan WOMEN AND THEIR INFANTS

ADVERSE PREGNANCY OUTCOMES ASSOCIATED WITH COVID-19 INFECTION IN WESTERN KENYA

SARS-CoV-2 INFECTION AND PREGNANCY IN AFRICA: A 6-COUNTRY RETROSPECTIVE COHORT STUDY

LONGITUDINAL SARS-CoV-2 ANTIBODY RESPONSE IN PREGNANCY AND TRANSPLACENTAL TRANSFER

IMMUNE SYSTEM PROFILE AND CYTOKINE LEVELS OF SARS-CoV-2 IN PREGNANCY AND NEWBORNs

NEUTRALIZING ANTIBODY RESPONSE AND TRANSPLACENTAL TRANSFER IN COVID-19 IN PREGNANCY

IMPAACT 2032: REMdesivir PK & SAFETY IN PREGNANT AND NON-PREGNANT WOMEN WITH COVID-19

NEURAL TUBE DEFECTS AND PRENATAL EXPOSURE TO DOLUTEGRAVIR: UNITED STATES, 2008-2019

BIRTH OUTCOMES FOLLOWING PRENATAL EXPOSURE TO DOLUTEGRAVIR: THE DOLOMITE-EPPICC STUDY

RISK-BENEFIT TRADE-OFF FOR PREGNANCY AND INFANT OUTCOMES: DTG, EFV, TAF, AND TDF

ADVERSE OUTCOMES IN SUBSEQUENT PREGNANCIES IN THE IMPAACT 2010 TRIAL

SOME InSTIs INDUCE TOXICITY AND DIFFERENTIATION IN HUMAN EMBRYONIC STEM CELLS

IMPACT OF MATERNAL HIV/HBV COINFECTION ON PREGNANCY AND INFANT OUTCOMES

HIV-RELATED DIFFERENCES IN PLACENTAL IMMUNOLOGY: DATA FROM THE PRACHITI COHORT

DAY-TO-DAY IMPACT OF COVID-19 ASSOCIATED WITH RISK OF OVERDOSE: C3PNO COHORT FINDINGS

EMPIRICAL ESTIMATES OF ADULT HIV INCIDENCE ACROSS 12 COUNTRIES IN SUB-SAHARAN AFRICA

EDUCATION AND HIV RISK: EVIDENCE FROM 12 SUB-SAHARAN AFRICAN COUNTRIES, 2015-2018

HIV INCIDENCE AND IMPACT OF INTERVENTIONS IN FEMALE SEX WORKERS IN MENA

AUTHORSHIP INEQUALITIES IN GLOBAL HEALTH RESEARCH INITIATIVE
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A TOOL TO ASSESS HIV PREVENTION READINESS OF ADOLESCENT GIRLS AND YOUNG WOMEN</td>
<td>842</td>
</tr>
<tr>
<td>PrEp USE PERSISTENCE AMONG KENyan WOMEN WHO INITIATED PrEp DURING PREGNANCY</td>
<td>845</td>
</tr>
<tr>
<td>ORAL PrEp USE AMONG SOUTH AFRICAN WOMEN WITH PLANS FOR PREGNANCY</td>
<td>846</td>
</tr>
<tr>
<td>GEOGRAPHIC CLUSTERING AND PROGRESS IN PrEp USE AMONG WOMEN IN THE US: 2012-2019</td>
<td>847</td>
</tr>
<tr>
<td>DOUBLE-DOSE ETONOgestREL CONTRACEPTIVE IMPLANT OVERCOMES INTERACTION WITH EFAVIRENZ</td>
<td>848</td>
</tr>
<tr>
<td>DISPARITIES IN PRENATAL SYphilIS RISK AMONG PREGNANT WOMEN LIVING WITH HIV IN BRAZIL</td>
<td>849</td>
</tr>
<tr>
<td>SCREENING OF STIs IN PREGNANCY AND PREGNANCY OUTCOMES IN WOMEN WITH AND WITHOUT HIV</td>
<td>850</td>
</tr>
<tr>
<td>SUBSTANCE USE TREATMENT UTILIZATION AMONG WOMEN WITH AND AT RISK FOR HIV IN THE SOUTH</td>
<td>914</td>
</tr>
<tr>
<td>RANDOMIZED TRIAL OF PATIENT ACTOR TRAINING TO IMPROVE PrEp SERVICES FOR AGYw IN KENya</td>
<td>923</td>
</tr>
<tr>
<td>DEFERRING CREATININE CLEARANCE TESTING TO SUPPORT PrEp UPTAKE IN YOUNG WOMEN</td>
<td>924</td>
</tr>
<tr>
<td>PrEp DISCONTINUATION AMONG WOMEN IN US COMMUNITY HEALTH CENTERS</td>
<td>925</td>
</tr>
</tbody>
</table>

WEDNESDAY, FEBRUARY 16, 2022

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHASE IIB EFFICACY TRIAL OF MOSAIC HIV-1 VACCINE REGIMEN IN AFRICAN WOMEN: IMBOKODO</td>
<td>121</td>
</tr>
<tr>
<td>Dolutegravir With Recycled nRTis IS NONINFERIOR TO PI-BASED ART: VISEND TRIAL</td>
<td>135</td>
</tr>
<tr>
<td>CDC’S DIRECT-TO-CONSUMER DISTRIBUTION OF 100,000 HIV SELF-TESTS</td>
<td>143</td>
</tr>
<tr>
<td>HIV SELF-TESTING UNCOVERS HIGH BURDEN OF HIDDEN INFECTIONS IN INDIA</td>
<td>144</td>
</tr>
<tr>
<td>HIGH HIV SELF-TESTING OF MALE PARTNERS OF WOMEN LIVING WITH HIV IN RURAL SOUTH AFRICA</td>
<td>145</td>
</tr>
<tr>
<td>SIX-MONTH PrEp WITH HIV SELF-TESTING TO IMPROVE DELIVERY KENYA: A RANDOMIZED TRIAL</td>
<td>146</td>
</tr>
<tr>
<td>SURVIVAL AND DISEASE PROGRESSION IN ART-NAïVE LTNP WITH UNDETECTABLE HIV-REPLICATION</td>
<td>226</td>
</tr>
<tr>
<td>METABOLIC SHIFTS POTENTIATE ACCELERATED AGING IN SUCCESSFUL LONG-TERM HIV TREATMENT</td>
<td>227</td>
</tr>
<tr>
<td>LOSS OF TOLERANCE AND ANERGY IN HUMAN PERIPHERAL B CELLS DURING SARS-CoV-2 INFECTION</td>
<td>271</td>
</tr>
<tr>
<td>PROMOTING RESIDENT MEMORY CD8+ T-CELL PHENOTYPES TO ENHANCE HIV RESERVOIR ELIMINATION</td>
<td>283</td>
</tr>
<tr>
<td>SARS-CoV-2 mRNA VACCINATION EXPOSES LATENT HIV TO Nef-SPECIFIC CD8+ T CELLS</td>
<td>373</td>
</tr>
<tr>
<td>EVG/Cobi/FTC/Taf TABLETS DISSOLVED IN TAP WATER NEAR BIOEQUIVALENT WITH WHOLE TABLETS</td>
<td>447</td>
</tr>
<tr>
<td>RESUPPRESSION AFTER VIROLOGICAL FAILURE IN Dolutegravir AND Efavirenz-BASED REGIMENS</td>
<td>486</td>
</tr>
<tr>
<td>PREDICTORS OF VIRAL SUPPRESSION FOLLOWING ENHANCED ADHERENCE COUNSELING: VISEND TRIAL</td>
<td>490</td>
</tr>
<tr>
<td>B/F/TAF FIVE-YEAR OUTCOMES IN TREATMENT-NAïVE ADULTS</td>
<td>494</td>
</tr>
</tbody>
</table>
573  RISK AND PROTECTIVE FACTORS ASSOCIATED TO HTLV-1 MOTHER-TO-CHILD TRANSMISSION

593  PREDICTED IMPACT OF ART SWITCH ON BODY MASS INDEX AMONG WOMEN WITH HIV

598  48-WEEK BODY COMPOSITION CHANGES IN PLWH SWITCHING FROM 3DR TO DTG + 3TC: DOLAM STUDY

644  MENSTRUATION IRREGULARITIES AMONG REPRODUCTIVE-AGE WOMEN DURING THE COVID-19 PANDEMIC

700  EVALUATION OF CAB-LA SAFETY AND PK IN PREGNANT WOMEN IN THE BLINDED PHASE OF HPTN 084

701  RECENT HIV INFECTION AMONG PREGNANT WOMEN FROM 2 NATIONAL SURVEYS IN SOUTH AFRICA

702  HIV TEST-POSITIVITY IN PREGNANT AND POSTNATAL WOMEN RETESTED IN NAMPULA, MOZAMBIQUE

703  PREGNANCY IN WOMEN WITH HIV IN A TUBERCULOSIS-PREVENTIVE THERAPY TRIAL

704  PrEP CONTINUATION AND OBJECTIVE ADHERENCE IN PREGNANT/POSTPARTUM SOUTH AFRICAN WOMEN

705  PREGNANCY AND BIRTH OUTCOMES IN PrEP-EXPOSED & UNEXPOSED PREGNANT SOUTH AFRICAN WOMEN

719  SEVERE IMMUNE SUPPRESSION AND RETENTION AMONG INFANTS IN SOUTH AFRICA

736  PHARMACOKINETICS/SAFETY OF DTG, ABC/3TC DISPERSIBLE TABLETS IN THAI CHILDREN <20 KG

763  MORTALITY RATES WITH OR WITHOUT InSTI THERAPY IN SUBGROUPS OF PWH: 2009-2018

770  DECLINE IN CD4+ COUNTS AND RISK OF SEVERE MORBIDITY IN PLHIV AFTER INITIATING cART

778  IMPACT OF METHAMPHETAMINE USE ON VIRAL LOAD BY GENDER AMONG PEOPLE WITH HIV

813  INCREASED KNOWLEDGE OF HIV STATUS AMONG YOUTH: RESULTS OF YATHU YATHU RANDOMIZED TRIAL

856  PHASE I TRIAL OF SUBCUTANEOUSLY ADMINISTERED VRC07-523LS AND PGT121

859  EXPECTATIONS OF PREVENTIVE BENEFITS & HIV-RELATED RISK BEHAVIORS IN HPTN069/ACTG5305

867  TENOFOVIR DISOPROXIL FUMARATE AND SEVERITY OF COVID-19 IN PEOPLE WITH HIV INFECTION

872  SEXUAL HEALTH CLINIC OUTCOMES AND PrEP LINKAGE IN A LARGE URBAN EMERGENCY DEPARTMENT

874  INNATE IMMUNITY PREDICTORS OF HIV RISK LINKED TO GENITAL HERPES

875  GENITAL MICROBIOME AND TENOFOVIR LEVELS IN TRANSGENDER MEN AND CISWOMEN ON ORAL PrEP

877  A RISK SCORE TO FACILITATE TARGETED STI DIAGNOSTIC TESTING IN YOUNG KENYAN WOMEN

878  BACTERIAL VAGINOSIS PRIOR TO AND DURING FIRST PREGNANCY IN KENYAN AGYW AT RISK OF HIV
879  HIV-ASSOCIATED IMMUNE BIOMARKERS IN WOMEN AND GIRLS FOLLOWING SEXUAL VIOLENCE

880  INCREASED HIV TARGET CELLS IN FGT DURING FOLLICULAR PHASE OF HIV SERONEGATIVE WOMEN

895  TRANSITIONING WOMEN TO PREFERRED TLD REGIMEN IS LAGGING IN SUB-SAHARAN AFRICA

897  PARTNER TESTING WITH HIV SELF-TEST DISTRIBUTION BY UGANDAN PREGNANT WOMEN WITH HIV

907  IMPACT OF BRAZILIAN HEALTH POLICIES ON GENDER/AGE GAPS IN HIV TREATMENT INDICATORS
The following index list presenting authors as of January 17, 2022. Changes to presenting authors after that date are not reflected.
<table>
<thead>
<tr>
<th>Author</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baggs, Matthew</td>
<td>205</td>
</tr>
<tr>
<td>Baker, Kyle</td>
<td>173</td>
</tr>
<tr>
<td>Bakshi, Surjit S.</td>
<td>740</td>
</tr>
<tr>
<td>Bal, Paranjoy</td>
<td>802</td>
</tr>
<tr>
<td>Balcet, Carmen</td>
<td>625</td>
</tr>
<tr>
<td>Baldis, Giada</td>
<td>96</td>
</tr>
<tr>
<td>Balinski, Orest</td>
<td>308</td>
</tr>
<tr>
<td>Balko, Seteia</td>
<td>579</td>
</tr>
<tr>
<td>Balmes, Jonathan</td>
<td>958</td>
</tr>
<tr>
<td>Balslev, Tine</td>
<td>811</td>
</tr>
<tr>
<td>Balsley, David</td>
<td>745</td>
</tr>
<tr>
<td>Baluk, Ryan</td>
<td>465</td>
</tr>
<tr>
<td>Baluni, Srikant</td>
<td>778</td>
</tr>
<tr>
<td>Barna, Orsolya</td>
<td>368</td>
</tr>
<tr>
<td>Baroni, Andreas</td>
<td>236</td>
</tr>
<tr>
<td>Bartlett, Benjamin</td>
<td>518</td>
</tr>
<tr>
<td>Bartolome, Francesco</td>
<td>776</td>
</tr>
<tr>
<td>Bartolome, Giorgio</td>
<td>326</td>
</tr>
<tr>
<td>Bartolome, Giancarlo</td>
<td>734</td>
</tr>
<tr>
<td>Bartolome, Michael</td>
<td>559</td>
</tr>
<tr>
<td>Bartolome, Simon</td>
<td>657</td>
</tr>
<tr>
<td>Bartolome, Thomas</td>
<td>596</td>
</tr>
<tr>
<td>Barzaghi, Giuseppe</td>
<td>319</td>
</tr>
<tr>
<td>Baschuka, Zdenko</td>
<td>741</td>
</tr>
<tr>
<td>Bastian, Jutta</td>
<td>32</td>
</tr>
<tr>
<td>Bastien, Anne-Marie</td>
<td>759</td>
</tr>
<tr>
<td>Basu, Aditya</td>
<td>354</td>
</tr>
<tr>
<td>Basu, Anjali</td>
<td>91</td>
</tr>
<tr>
<td>Basu, Dipak</td>
<td>23</td>
</tr>
<tr>
<td>Basu, Prashant</td>
<td>28</td>
</tr>
<tr>
<td>Basu, Pratin</td>
<td>476</td>
</tr>
<tr>
<td>Basu, Pratipriya</td>
<td>206</td>
</tr>
<tr>
<td>Basu, Satish</td>
<td>37</td>
</tr>
<tr>
<td>Basu, Shashikant</td>
<td>759</td>
</tr>
<tr>
<td>Basu, Uday</td>
<td>708</td>
</tr>
<tr>
<td>Basham, Suresh</td>
<td>849</td>
</tr>
<tr>
<td>Bashir, Ali</td>
<td>78</td>
</tr>
<tr>
<td>Bashir, Alisha</td>
<td>337</td>
</tr>
<tr>
<td>Bashir, Aruna</td>
<td>356</td>
</tr>
<tr>
<td>Bashir, Fazil</td>
<td>663</td>
</tr>
<tr>
<td>Bashir, Hardikruti</td>
<td>723</td>
</tr>
<tr>
<td>Bashir, Jayati</td>
<td>619</td>
</tr>
<tr>
<td>Bashir, Kalpan</td>
<td>743</td>
</tr>
<tr>
<td>Bashir, Kapil</td>
<td>908</td>
</tr>
<tr>
<td>Bashir, Kavyasree</td>
<td>542</td>
</tr>
<tr>
<td>Bashir, Preeti</td>
<td>865</td>
</tr>
<tr>
<td>Bashir, Rakhi</td>
<td>695</td>
</tr>
<tr>
<td>Bashir, Sanjiv</td>
<td>549</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>530</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>939</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>671</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>772</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>579</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>368</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>465</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>657</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>745</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>745</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>326</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
<tr>
<td>Bashir, Shobhit</td>
<td>559</td>
</tr>
</tbody>
</table>
van Rensburg, Roland 395
van Santen, Daniela K. 73
Vance, David 426
VanBerk, Laurie 367
Vanetti, Claudia 174
Varga, Leah 774
Variale, Joseph 372
Vázquez Alejo, Elena 674
Veenhuis, Rebecca T. 129
Vega-Ramirez, Hamid 933
Veloso, Valdilea 838
Ventura, John D. 351
Verdegue-Jones, Odette 405
Vergori, Alessandra 293, 632
Verma, Mohit 246
Vestad, Beate 638
Vhembo, Tichaona 692
Vigón, Lorena 315
Vixo, Else G. 189
Visseaux, Benoit 197, 755
Vitalle Andrade, Joana 298
Volpe, Karen E. 415
Vyas, Kartavya J. 762
-W-
Waalewijn, Hylke 734
Wada, Paul Y. 658
Wafulu, Andrew W. 926
Walker-Sperling, Victoria E.K. 63
Wallace, Michael S. 550
Walls, Zoey K. 397
Walmsley, Sharon 864
Wang, Fan 440
Wang, Qiankun 360
Wang, Ruolan 484
Wang, Yiran 212
-Wang, Yuhuan 457
Wang, Zheng 37
Ward, Adam R. 231
Watson, Eric S. 627
Webb, Bradon 456
Weber, Elijah 434
Wedrychowski, Adam 362
Wei, Yulong 308
Weinberger, Leor 472
Weisberg, Matthew A. 796
Weiser, Sheri D. 931
Wettstein, Anja E. 934
White, Jennifer A. 380
White, Kevin S. 403
Williams, Mark 743
Wittkop, Linda 868
Wohl, David A. 494
Wohlfelder, Michael 908
Woldemokel, Bezawit A. 318
Woldemokel, Selamawit A. 701
Wu, Vincent H. 66
Wu, Xiaoheng 947
-X-
Xu, Ziyang 235
-Y-
Yaffe, Zak A. 691
Yagnik, Bhruig 348
Yazdanpanah, Yazdan 323
Yeung, Stephen T. 195
Young, Isabella 80
Young, Ruth 91
Yu, Jingyou 247
Yuan, Zhe 350
Yurkovetskiy, Leonid 166
-Z-
Zabaleta, Nerea 250
Zablocki-Thomas, Laurent D. 347
Zacharopoulou, Penny 505
Zanni, Markella V. 577
Zaunders, John 126
Zeballos Rivas, Diana Reyna. 843
Zech, Fabian 165
Zewdie, Kidist Belay. 87
Zhang, Haoyoung 433
Zhang, Lei 765
Zhang, Weijie 233
Zhao, Connie A. 216
Zhong, Shuntai 45
Zhu, Weiming 834, 853
Ziegler, Joseph 42
Zucker, Jason 917
### SCHEDULE AT A GLANCE

**CROI 2022 Schedule**

**February 12-16 (with symposia)**

#### Live Symposium Program • February 12 - 16, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Saturday, February 12, 2022</th>
<th>Sunday, February 13, 2022</th>
<th>Monday, February 14, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>W-1 SCOTT M. HAMMER WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES (8:30 AM - 12:30 PM)</td>
<td>OPENING SESSION (8:30-10:45 AM)</td>
<td>P.1 MONDAY (8:30 - 9:45 AM)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MARTIN DELANEY PRESENTATION</td>
<td>HIV NON-RESIDUAL MODELS IN PATHOGENESIS AND CURING CHILDREN UNINFECTED ACTION</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WE'RE STILL HERE: HIV, AGING, AND THE INVISIBLE GENERATION</td>
<td>ORAL ABSTRACT SESSION (11:45 AM)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BERNARD FIELDS LECTURE</td>
<td>0-1 TARGETS VIRAL INFECTIOUSNESS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VACCINE STRATEGIES FOR HIV-1 AND COVID-19</td>
<td>0-2 MATERNAL-NEWBORN SARS-CoV2 MODELS FOR STUDIES OF VIRUS BIOLOGY</td>
</tr>
<tr>
<td>9:45 AM</td>
<td></td>
<td>N’GALY-MANN LECTURE</td>
<td>0-3 MALIGNANCIES AND COVID-19 INFECTION STRATEGIES FOR HIV-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HIV RESEARCH: GENERATING EVIDENCE TO ADVANCE PUBLIC HEALTH POLICIES IN BRAZIL</td>
<td>0-4 EVOLVING HIV AND COVID-19</td>
</tr>
<tr>
<td>11:00 AM</td>
<td></td>
<td></td>
<td>CONCURRENT TECHNICAL WORKSHOPS (11:00 AM - 1:00 PM)</td>
</tr>
<tr>
<td>12:00 PM</td>
<td></td>
<td>W-2 FRONTERS IN LABORATORY TECHNOLOGIES</td>
<td>CONCURRENT SESSIONS (12:00 - 1:00 PM)</td>
</tr>
<tr>
<td>12:30 PM</td>
<td></td>
<td>W-3 CASE-BASED LIVER WORKSHOP</td>
<td>CONCURRENT SYMPOSIA SESSIONS (12:00 - 1:00 PM)</td>
</tr>
<tr>
<td>1:00 PM</td>
<td></td>
<td>W-4 CLINICAL TRIAL DESIGN AND ANALYSIS</td>
<td>11 VIRAL SURVIVAL STRATEGIES IN THE TREATMENT OF THE COVID-19 EPIDEMIC</td>
</tr>
<tr>
<td>1:15 PM</td>
<td></td>
<td></td>
<td>12 COVID-19: CONSENSUS AND CONTROVERSY</td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
<td></td>
<td>HIV, SIV, AND SARS-CoV-2 PATHOGENESIS, PERSISTENCE, AND MODELS FOR STUDIES OF VIRUS BIOLOGY</td>
</tr>
<tr>
<td>3:30 PM</td>
<td></td>
<td></td>
<td>13 (COVID-19) MANDATORY PRESENT, FORWARD</td>
</tr>
<tr>
<td>3:30 PM</td>
<td></td>
<td></td>
<td>NETWORKING SESSIONS FOR NEW INVESTIGATORS</td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
<td></td>
<td>LIVE CHAT SESSIONS WITH POSTER PRESENTERS</td>
</tr>
</tbody>
</table>

#### Live Symposia Program • February 22 - 24, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Tuesday, February 22, 2022</th>
<th>Wednesday, February 23, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM</td>
<td>CONSECUTIVE SYMPOSIA SESSIONS (8:30 AM - 1:30 PM)</td>
<td>CONSECUTIVE SYMPOSIA SESSIONS (8:30 AM - 1:30 PM)</td>
</tr>
<tr>
<td>10:15 AM</td>
<td>5-1 GETTING INTO SHAPE: A DEEPER LOOK AT VIRAL MATURATION (8:30 - 10:00 AM)</td>
<td>5-4 THE HIV RESERVOIR: CREATION, MAINTENANCE, AND REVERSAL (8:30 - 9:45 AM)</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>5-2 INFANT POSTNATAL PROPHYLAXIS: WHY BOTHER? (10:15 - 11:45 AM)</td>
<td>5-5 TUBERCULOSIS: NEW STRATEGIES FOR THE WORLD’S OLDEST INFECTION (8:30 - 9:45 AM)</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>5-3 BRINGING CHOICE TO HIV PREVENTION (12:00 - 1:30 PM)</td>
<td>5-6 SEXUALLY TRANSMITTED DISEASES (8:30 - 9:45 AM)</td>
</tr>
</tbody>
</table>
**Schedule at a Glance**

*This is a summary of the schedule for February 22, 23, and 24.*

<table>
<thead>
<tr>
<th>February 14, 2022</th>
<th>Tuesday, February 15, 2022</th>
<th>Wednesday, February 16, 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PLENARY SESSION (8:30 AM)</strong></td>
<td><strong>P-2</strong> <strong>TUESDAY PLENARY SESSION (8:30- 9:30 AM)</strong></td>
<td><strong>P-3</strong> <strong>WEDNESDAY PLENARY SESSION (8:30 - 9:30 AM)</strong></td>
</tr>
<tr>
<td><strong>HUMAN PRIMATE STUDIES, VIRUS INFECTION, IMMUNE RESPONSES, AND PATHOGENESIS: AN INTERACTIVE SESSION (9:45 - 11:00 AM)</strong></td>
<td><strong>NEW INSIGHTS INTO HIV RNA BIOLOGY</strong></td>
<td><strong>NEW ANTIRETROVIRALS AND THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 - 11:45 AM)</strong></td>
<td><strong>P-1</strong> <strong>MONDAY NETWORKING SESSIONS FOR NEW INVESTIGATORS (1:15 - 1:55 PM)</strong></td>
<td><strong>P-4</strong> <strong>WEDNESDAY NETWORKING SESSIONS FOR NEW INVESTIGATORS (1:15 - 1:55 PM)</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 - 11:45 AM)</strong></td>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 - 11:45 AM)</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>0-10 IMMUNE RESPONSES TO HIV AND SARS-CoV-2 IN TREATMENT, PREVENTION, AND PATHOGENESIS</strong></td>
<td><strong>0-01 CROSSING THE CNS BORDER: HIV, SV, AND SARS-CoV-2</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>0-11 SHIFTING PARADIGMS IN HIV TREATMENT AND DISEASE PROGRESSION OF SARS-CoV-2 INFECTION</strong></td>
<td><strong>0-12 HIV ANTIVIRALS AND OUTCOMES</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>CONCURRENT INTERACTIVE SESSIONS (12:00 - 1:00 PM)</strong></td>
<td><strong>CONCURRENT INTERACTIVE SESSIONS (12:00 - 1:00 PM)</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>CONVERSATION: HIV AND THE WAY TO HEALTH (8:30 - 9:30 AM)</strong></td>
<td><strong>CONVERSATION: HIV AND THE WAY TO HEALTH (8:30 - 9:30 AM)</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>CONVERSATION: HIV AND THE WAY TO HEALTH (8:30 - 9:30 AM)</strong></td>
<td><strong>CONVERSATION: HIV AND THE WAY TO HEALTH (8:30 - 9:30 AM)</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>LONG COVID: FROM BENCH TO BEDSIDE AND BEYOND</strong></td>
<td><strong>LONG COVID: FROM BENCH TO BEDSIDE AND BEYOND</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
<tr>
<td><strong>ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
<td><strong>WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF HIV TREATMENT AND PREVENTION</strong></td>
</tr>
</tbody>
</table>
| **ORAL ABSTRACT SESSIONS (9:45 -11:45 AM)** | **WHAT WOULD YOU LIKE TO HAVE BEEN IN THE FUTURE OF H